{"5d3cad66ff27b7d70f1895c653f79d63379af069": [["Poliovirus Sabin 1, 2, and 3 strains were obtained from the late B. Rombaut (Vrije Universiteit Brussels, Brussels, Belgium) .", [["Poliovirus Sabin 1", "ORGANISM", 0, 18], ["Poliovirus Sabin", "SPECIES", 0, 16], ["Poliovirus Sabin 1", "SPECIES", 0, 18], ["Poliovirus Sabin", "TEST", 0, 16]]], ["Human rhinoviruses 2 and 14 were a kind gift of Joachim Seipelt (Medical University of Vienna, Austria).", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human rhinoviruses", "SPECIES", 0, 18], ["Human rhinoviruses", "TEST", 0, 18]]], ["ERAV (NM11/67) was kindly provided by David Rowlands and Toby Tuthill (University of Leeds, United Kingdom).", [["ERAV", "GENE_OR_GENE_PRODUCT", 0, 4]]], ["Virus titers were determined by endpoint titration according to the method of Reed and Muench and expressed as 50% cell culture infective doses (CCID 50 ).", [["cell", "ANATOMY", 115, 119], ["Virus", "ORGANISM", 0, 5], ["cell", "CELL", 115, 119], ["Virus titers", "TEST", 0, 12]]]], "PMC7113990": [["IntroductionIn hospitals and dental clinics, the major risk of infection for healthcare workers and dental professionals is the transmission from patients, through contaminated instruments or pieces of equipment and the hospital surroundings.[12] In hospital-acquired infections, surgical site infections (SSIs) and dental clinics play a role in more than 20% of infections.[34] It is by the Centre for Disease Control and Prevention that 2.7% of surgical procedures are complicated by patient working areas because of the presence of various infections.[5] With over 6 billion microbes/ml of saliva colonizing in every individual's oral cavity, the dental clinic is an axis of microbial pursuit.", [["site", "ANATOMY", 289, 293], ["oral cavity", "ANATOMY", 633, 644], ["infection", "DISEASE", 63, 72], ["infections", "DISEASE", 268, 278], ["surgical site infections", "DISEASE", 280, 304], ["SSIs", "DISEASE", 306, 310], ["infections", "DISEASE", 363, 373], ["infections", "DISEASE", 543, 553], ["patients", "ORGANISM", 146, 154], ["patient", "ORGANISM", 486, 493], ["saliva", "ORGANISM_SUBSTANCE", 593, 599], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 633, 644], ["patients", "SPECIES", 146, 154], ["patient", "SPECIES", 486, 493], ["infection", "PROBLEM", 63, 72], ["acquired infections", "PROBLEM", 259, 278], ["surgical site infections (SSIs", "PROBLEM", 280, 310], ["infections", "PROBLEM", 363, 373], ["Disease Control", "TREATMENT", 403, 418], ["surgical procedures", "TREATMENT", 447, 466], ["various infections", "PROBLEM", 535, 553], ["saliva colonizing", "PROBLEM", 593, 610], ["infection", "OBSERVATION", 63, 72], ["infections", "OBSERVATION", 268, 278], ["infections", "OBSERVATION", 294, 304], ["infections", "OBSERVATION", 363, 373], ["various", "OBSERVATION_MODIFIER", 535, 542], ["infections", "OBSERVATION", 543, 553], ["oral cavity", "ANATOMY", 633, 644], ["microbial pursuit", "OBSERVATION", 678, 695]]], ["To maintain international guidelines and precautions for infection control, various protective measures have been taken to control the contamination of the dental clinics and to protect the patient and the dental personal.", [["infection", "DISEASE", 57, 66], ["patient", "ORGANISM", 190, 197], ["patient", "SPECIES", 190, 197], ["international guidelines", "TREATMENT", 12, 36], ["precautions", "TREATMENT", 41, 52], ["infection control", "TREATMENT", 57, 74], ["various protective measures", "TREATMENT", 76, 103]]], ["The significant part of infection control is the clinician's mouth mask which acts as a strike to microorganisms from the touch of possibly contaminated hands to the contaminated aerosols due to routine ultrasonic scaling and high-speed handpieces.[67]IntroductionSpooner JL in 1967 in his review mentioned that Weaver and Capps were the first who described in 1915 that face masks are effective against contagious disease as well as cross infections.[8] In the dental clinics, the dentist mouth mask, major protective equipment comes in direct closeness to the patient and is an area of significant concentration of the aerosol but the literature available showed that the surgical mouth mask might not be sufficient to protect the person from air-borne pathogens and might also be the origin of various air-borne and droplet infection.[910] Hence, the present study was conducted to assess the bacterial and fungal presence and their prevalence over the contaminated surgical mask in dental practice.Subjects and MethodsThis study was conducted to assess the bacterial and fungal contamination and their prevalence on 240 used surgical face masks (face mask earloop triple-layered non-woven polypropylene) from 130 dental personnel during the 2 months period from September to November 2019.", [["mouth", "ANATOMY", 61, 66], ["mouth", "ANATOMY", 490, 495], ["mouth", "ANATOMY", 683, 688], ["infection", "DISEASE", 24, 33], ["infections", "DISEASE", 440, 450], ["infection", "DISEASE", 827, 836], ["polypropylene", "CHEMICAL", 1193, 1206], ["mouth", "ORGANISM_SUBDIVISION", 61, 66], ["hands", "ORGANISM_SUBDIVISION", 153, 158], ["mouth", "ORGANISM_SUBDIVISION", 490, 495], ["patient", "ORGANISM", 562, 569], ["mouth", "ORGAN", 683, 688], ["patient", "SPECIES", 562, 569], ["person", "SPECIES", 733, 739], ["infection control", "TREATMENT", 24, 41], ["'s mouth mask", "TREATMENT", 58, 71], ["contaminated hands", "PROBLEM", 140, 158], ["routine ultrasonic scaling", "TEST", 195, 221], ["high-speed handpieces", "TREATMENT", 226, 247], ["contagious disease", "PROBLEM", 404, 422], ["cross infections", "PROBLEM", 434, 450], ["the dentist mouth mask", "TREATMENT", 478, 500], ["major protective equipment", "TREATMENT", 502, 528], ["the aerosol", "TREATMENT", 617, 628], ["the surgical mouth mask", "TREATMENT", 670, 693], ["air-borne pathogens", "PROBLEM", 745, 764], ["various air-borne", "PROBLEM", 797, 814], ["droplet infection", "PROBLEM", 819, 836], ["the present study", "TEST", 850, 867], ["the bacterial and fungal presence", "PROBLEM", 892, 925], ["the contaminated surgical mask", "TREATMENT", 952, 982], ["This study", "TEST", 1022, 1032], ["the bacterial and fungal contamination", "PROBLEM", 1057, 1095], ["surgical face masks", "TREATMENT", 1129, 1148], ["face mask", "TREATMENT", 1150, 1159], ["triple-layered non-woven polypropylene", "TREATMENT", 1168, 1206], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["infection", "OBSERVATION", 24, 33], ["speed handpieces", "OBSERVATION", 231, 247], ["air-borne", "OBSERVATION", 805, 814], ["droplet infection", "OBSERVATION", 819, 836], ["surgical mask", "OBSERVATION", 969, 982], ["fungal contamination", "OBSERVATION", 1075, 1095]]], ["The participants of the study were of both genders aged 20 to 40 years, and have voluntarily participated and gave the signed consent form.", [["participants", "SPECIES", 4, 16], ["the study", "TEST", 20, 29]]], ["The study was conducted with the ethical approval of the ethical committee.", [["The study", "TEST", 0, 9]]], ["A cross-sectional survey was conducted using a self-administered questionnaire, consisting of seven questions used to assess the knowledge and practice of participants regarding the use of mouth mask.Subjects and MethodsThe 130 dental clinic participants were working from different departments such as: Department of oral medicine and radiology, department of oral and maxillofacial surgery, department of pedodontics, department of endodontics, department of periodontics, and dental emergency room of the college.", [["mouth", "ANATOMY", 189, 194], ["oral", "ANATOMY", 318, 322], ["oral", "ANATOMY", 361, 365], ["mouth", "ORGANISM_SUBDIVISION", 189, 194], ["oral", "ORGANISM_SUBDIVISION", 318, 322], ["oral", "ORGANISM_SUBDIVISION", 361, 365], ["participants", "SPECIES", 155, 167], ["participants", "SPECIES", 242, 254], ["mouth mask", "TREATMENT", 189, 199], ["maxillofacial", "ANATOMY", 370, 383]]], ["Their used surgical masks maximum of 30 min duration, which were 240 in total, were collected in sterile zip lock pouches to culture and analysis of the bacterial and fungal counts on the inside and outside surface of the mouth masks.", [["pouches", "ANATOMY", 114, 121], ["surface", "ANATOMY", 207, 214], ["mouth", "ANATOMY", 222, 227], ["mouth", "ORGANISM_SUBDIVISION", 222, 227], ["surgical masks", "TREATMENT", 11, 25], ["sterile zip lock pouches", "TREATMENT", 97, 121], ["culture", "TEST", 125, 132], ["analysis", "TEST", 137, 145], ["the bacterial", "PROBLEM", 149, 162], ["fungal counts", "TEST", 167, 180], ["the mouth masks", "TREATMENT", 218, 233], ["bacterial", "OBSERVATION_MODIFIER", 153, 162], ["fungal counts", "OBSERVATION", 167, 180], ["mouth", "ANATOMY", 222, 227]]], ["Inside and outside surface of the mouth masks were separated by sterile technique and put in a sterile container consisting of trypticase soy broth for 25 min.", [["surface", "ANATOMY", 19, 26], ["mouth", "ANATOMY", 34, 39], ["the mouth masks", "TREATMENT", 30, 45], ["sterile technique", "TREATMENT", 64, 81], ["a sterile container", "TREATMENT", 93, 112], ["trypticase soy broth", "TREATMENT", 127, 147], ["mouth", "ANATOMY", 34, 39]]], ["A spread plate method was used for determining total bacterial and fungal counts.", [["A spread plate method", "TREATMENT", 0, 21], ["total bacterial and fungal counts", "PROBLEM", 47, 80], ["fungal counts", "OBSERVATION", 67, 80]]], ["General bacteria of the specimen are cultivated in a plate count agar (PCA) and general fungi of the specimen are cultivated in a Sabouraud 4% dextrose agar (SDA).", [["specimen", "ANATOMY", 24, 32], ["specimen", "ANATOMY", 101, 109], ["dextrose agar", "CHEMICAL", 143, 156], ["dextrose", "CHEMICAL", 143, 151], ["General bacteria of the specimen", "PROBLEM", 0, 32], ["a plate count agar", "TEST", 51, 69], ["general fungi", "TEST", 80, 93], ["bacteria", "OBSERVATION", 8, 16]]], ["The plates were incubated at 37\u00b0C for 48 h to get the bacterial counts, and incubated at room temperature for 7 days for fungal counts.", [["the bacterial counts", "TEST", 50, 70], ["fungal counts", "TEST", 121, 134]]], ["With the method given by Larone 1995, preliminarily identification of microorganism's species present was done by Gram's stain and microscopic morphology (lactophenol cotton blue) of the isolated bacteria and fungi was performed.[11] After incubation, the bacterial and fungal colonies were counted and calculated to express as colony-forming unit/m3 (cfu/m3) by a formula as follows:Subjects and MethodsTotal counts (colony-forming unit/m3 or cfu/m3) = [Total colonies \u00d7 1000]/250Subjects and MethodsCollected data of the study were analyzed using Statistical Package for Social Sciences (SPSS) software version 17 using descriptive frequency method.", [["colonies", "ANATOMY", 277, 285], ["lactophenol cotton blue", "CHEMICAL", 155, 178], ["fungal colonies", "CELL", 270, 285], ["microorganism's species", "PROBLEM", 70, 93], ["Gram's stain", "TEST", 114, 126], ["microscopic morphology", "TEST", 131, 153], ["lactophenol cotton blue", "TREATMENT", 155, 178], ["the isolated bacteria", "PROBLEM", 183, 204], ["fungi", "PROBLEM", 209, 214], ["incubation", "TREATMENT", 240, 250], ["the bacterial and fungal colonies", "TEST", 252, 285], ["colony", "TEST", 328, 334], ["Total counts", "TEST", 404, 416], ["Total colonies", "TEST", 455, 469], ["the study", "TEST", 519, 528], ["descriptive frequency method", "TREATMENT", 622, 650], ["bacteria", "OBSERVATION", 196, 204], ["bacterial", "OBSERVATION_MODIFIER", 256, 265], ["fungal colonies", "OBSERVATION", 270, 285]]], ["Results are represented as frequency and percentage to estimate the prevalence of antimicrobial agents present in the samples as well the responses of participants.", [["samples", "ANATOMY", 118, 125], ["participants", "SPECIES", 151, 163], ["antimicrobial agents", "TREATMENT", 82, 102]]], ["Mean and standard deviation (SD) for describing bacterial and fungal counts were analyzed using the paired t-test and to compare between the mean of microbial contamination on the outside and inside areas of used masks.ResultsA total of 240 used surgical masks were collected in the present study from 130 dental professionals from various departments to assess the bacterial and fungal contamination.", [["Mean", "TEST", 0, 4], ["standard deviation (SD)", "PROBLEM", 9, 32], ["bacterial and fungal counts", "PROBLEM", 48, 75], ["the paired t-test", "TEST", 96, 113], ["microbial contamination", "PROBLEM", 149, 172], ["surgical masks", "TREATMENT", 246, 260], ["the bacterial and fungal contamination", "PROBLEM", 362, 400], ["standard deviation", "OBSERVATION", 9, 27], ["fungal counts", "OBSERVATION", 62, 75], ["fungal contamination", "OBSERVATION", 380, 400]]], ["Out of 130 participants, 73 were males and 57 were females.", [["participants", "ORGANISM", 11, 23], ["participants", "SPECIES", 11, 23]]], ["Questionnaire variables analysis revealed that 66.9% of participants wear their mouth-masks while working at chair-side and about 33% wear them all the time.", [["participants", "ORGANISM", 56, 68], ["mouth", "ORGANISM_SUBDIVISION", 80, 85], ["participants", "SPECIES", 56, 68], ["Questionnaire variables analysis", "TEST", 0, 32]]], ["67.6% of the study participants keep their mouth masks in the instrument trays, while 19.2% in their clinic working apron pockets.", [["mouth", "ANATOMY", 43, 48], ["participants", "ORGANISM", 19, 31], ["mouth", "ORGANISM_SUBDIVISION", 43, 48], ["participants", "SPECIES", 19, 31], ["the study", "TEST", 9, 18]]], ["85.3% participant responded that mouth-mask can cause cross-contamination when touched.", [["mouth", "ANATOMY", 33, 38], ["mouth", "ORGANISM_SUBDIVISION", 33, 38], ["participant", "SPECIES", 6, 17], ["mask", "TREATMENT", 39, 43], ["cross-contamination", "PROBLEM", 54, 73]]], ["In the present study, 42.3% participant attempted cases without a mouth mask and about 26.9% stated that they have exchanged their mouth-masks with others.", [["mouth", "ANATOMY", 66, 71], ["mouth", "ANATOMY", 131, 136], ["mouth", "ORGANISM_SUBDIVISION", 66, 71], ["mouth", "ORGANISM_SUBDIVISION", 131, 136], ["participant", "SPECIES", 28, 39], ["the present study", "TEST", 3, 20], ["a mouth mask", "TREATMENT", 64, 76]]], ["16.1% of participants stated that a mouth-mask can be disposed along with the normal household waste [Table 1].ResultsAll bacterial and fungal species were identified in samples by their morphological appearance and biochemical reaction characteristics.", [["mouth", "ANATOMY", 36, 41], ["samples", "ANATOMY", 170, 177], ["participants", "ORGANISM", 9, 21], ["samples", "CANCER", 170, 177], ["participants", "SPECIES", 9, 21], ["a mouth-mask", "TREATMENT", 34, 46], ["All bacterial and fungal species", "PROBLEM", 118, 150], ["bacterial", "OBSERVATION_MODIFIER", 122, 131], ["fungal species", "OBSERVATION", 136, 150], ["biochemical reaction", "OBSERVATION", 216, 236]]], ["Table 2 results revealed that out of 240 samples collected, bacterial species was predominated by Staphylococci species 26.35% followed by Pseudomonas 17.82% and Streptococci 15.50%.", [["samples", "ANATOMY", 41, 48], ["Pseudomonas 17.82", "SPECIES", 139, 156], ["bacterial species", "PROBLEM", 60, 77], ["Staphylococci species", "PROBLEM", 98, 119], ["Pseudomonas", "TEST", 139, 150], ["Streptococci", "TEST", 162, 174], ["bacterial species", "OBSERVATION", 60, 77], ["Staphylococci species", "OBSERVATION", 98, 119]]], ["Aspergillus fungal species was also present in 6.97%.ResultsIn the present study, results stated that the mean \u00b1 SD of bacterial contamination on the inside area of the used masks was 48 \u00b1 26 cfu/ml/piece and 180 \u00b1 110 cfu/ml/piece from the outside area.", [["Aspergillus fungal species", "ORGANISM", 0, 26], ["Aspergillus fungal species", "PROBLEM", 0, 26], ["the present study", "TEST", 63, 80], ["bacterial contamination", "PROBLEM", 119, 142], ["fungal species", "OBSERVATION", 12, 26], ["bacterial contamination", "OBSERVATION", 119, 142]]], ["It was significantly different, P < 0.001.", [["significantly", "OBSERVATION_MODIFIER", 7, 20], ["different", "OBSERVATION_MODIFIER", 21, 30]]], ["The used surgical masks from dental department personnel working outpatient dental department had relatively higher bacterial contamination than the other dental departments.", [["relatively higher bacterial contamination", "PROBLEM", 98, 139]]], ["[Table 3] For fungal contamination, mean \u00b1 SD on the outside area of the used masks was significantly higher than the inside area 14 \u00b1 6 and 32 \u00b1 13 cfu/ml/piece, P < 0.001.", [["fungal contamination", "PROBLEM", 14, 34], ["mean", "TEST", 36, 40], ["significantly", "OBSERVATION_MODIFIER", 88, 101], ["higher", "OBSERVATION_MODIFIER", 102, 108]]], ["The used surgical masks from dental personnel working in the outpatient dental department had relatively higher fungal contamination than the other dental departments [Table 4].DiscussionIn dental clinics, it has been assumed that bloodborne pathogens such as hepatitis B virus and hepatitis C virus can be transmitted through the inhalation of blood products in the aerosol, which obtain their main entry inside the body via the microabrasion in the mucosa of the airway.[12] In 1969 Micik, proposed the term \u201caerosol\u201d and \u201csplatter\u201d in the dental clinics, which has a capacity to produce numerous health risks, among which tuberculosis and severe acute respiratory syndrome are considered fatal.[1314]DiscussionIn the present study, a cross-sectional questionnaire revealed that the study participants were not properly aware of the proper usage of mouth mask in clinical practice.", [["blood", "ANATOMY", 345, 350], ["body", "ANATOMY", 417, 421], ["mucosa", "ANATOMY", 451, 457], ["airway", "ANATOMY", 465, 471], ["mouth", "ANATOMY", 851, 856], ["hepatitis B", "DISEASE", 260, 271], ["hepatitis C", "DISEASE", 282, 293], ["tuberculosis", "DISEASE", 625, 637], ["acute respiratory syndrome", "DISEASE", 649, 675], ["hepatitis B virus", "ORGANISM", 260, 277], ["hepatitis C virus", "ORGANISM", 282, 299], ["blood", "ORGANISM_SUBSTANCE", 345, 350], ["body", "ORGANISM_SUBDIVISION", 417, 421], ["mucosa", "MULTI-TISSUE_STRUCTURE", 451, 457], ["airway", "MULTI-TISSUE_STRUCTURE", 465, 471], ["mouth", "ORGANISM_SUBDIVISION", 851, 856], ["hepatitis B virus", "SPECIES", 260, 277], ["hepatitis C virus", "SPECIES", 282, 299], ["participants", "SPECIES", 791, 803], ["hepatitis B virus", "SPECIES", 260, 277], ["hepatitis C virus", "SPECIES", 282, 299], ["surgical masks", "TREATMENT", 9, 23], ["relatively higher fungal contamination", "PROBLEM", 94, 132], ["bloodborne pathogens", "PROBLEM", 231, 251], ["hepatitis B virus", "PROBLEM", 260, 277], ["hepatitis C virus", "PROBLEM", 282, 299], ["blood products", "TREATMENT", 345, 359], ["the aerosol", "TREATMENT", 363, 374], ["severe acute respiratory syndrome", "PROBLEM", 642, 675], ["the study", "TEST", 781, 790], ["mouth mask", "TREATMENT", 851, 861], ["surgical masks", "OBSERVATION", 9, 23], ["higher", "OBSERVATION_MODIFIER", 105, 111], ["fungal contamination", "OBSERVATION", 112, 132], ["body", "ANATOMY_MODIFIER", 417, 421], ["microabrasion", "OBSERVATION", 430, 443], ["mucosa", "ANATOMY", 451, 457], ["airway", "ANATOMY", 465, 471], ["tuberculosis", "OBSERVATION", 625, 637], ["severe", "OBSERVATION_MODIFIER", 642, 648], ["acute", "OBSERVATION_MODIFIER", 649, 654], ["respiratory syndrome", "OBSERVATION", 655, 675]]], ["Most of the participants have claimed to change mouth mask after every case but storage habit was not adequate and keeping mouth mask in instrument trays and working apron pockets causes external contamination, the main reason for a microbial load on the outer surface of a mouth mask.", [["mouth", "ANATOMY", 48, 53], ["mouth", "ANATOMY", 123, 128], ["outer surface", "ANATOMY", 255, 268], ["mouth", "ANATOMY", 274, 279], ["participants", "ORGANISM", 12, 24], ["mouth", "ORGANISM_SUBDIVISION", 48, 53], ["mouth", "ORGANISM_SUBDIVISION", 123, 128], ["outer surface", "CELLULAR_COMPONENT", 255, 268], ["mouth", "ORGANISM_SUBDIVISION", 274, 279], ["participants", "SPECIES", 12, 24], ["mouth mask", "TREATMENT", 48, 58], ["mouth mask in instrument trays", "TREATMENT", 123, 153], ["working apron pockets", "PROBLEM", 158, 179], ["external contamination", "PROBLEM", 187, 209], ["a mouth mask", "TREATMENT", 272, 284], ["external contamination", "OBSERVATION", 187, 209]]], ["Studies done by Banu et al. and Vargese et al. stated that white coat pockets harbor various bacteria which can lead to infections in the clinical working area.[1516] Monalisa et al. in their study found that 47% of participants reported keeping their mouth mask in instrument trays while 44% store mouth mask in apron pockets, which was consistent with the present study.[17]DiscussionIn dental clinics, the usage of ultrasonic scaler tips which produces 300 colony forming units/cubic feet of bacteria and burs of high-speed handpieces is considered as the main source of aerosol production.[1518] Mareeswari et al. stated that microorganisms which are commonly present in the dental clinic working contaminated surfaces may include Gram-positive Streptococcus spp., Staphylococcus spp., and Gram-negative Pseudomonas spp., E. coli, and Aspergillous spp.[7] Most of the micro-organisms isolated from the used surgical mouth mask were potentially pathogenic and Gram-positive bacteria were isolated in majority of number from the present study which remains consistent with the study done by Pospero et al. where total bacteria from the dental professional face mask and from the contaminated surfaces in the dental clinics had 42% of Streptococcus species, 41% of Staphylococcus, and 17% of Gram-negative bacteria.[19]DiscussionThe present study was performed for the assessment of bacterial and fungal contamination on the used surgical masks among dental professionals.", [["mouth", "ANATOMY", 252, 257], ["mouth", "ANATOMY", 299, 304], ["colony", "ANATOMY", 460, 466], ["mouth", "ANATOMY", 920, 925], ["infections", "DISEASE", 120, 130], ["Streptococcus species", "DISEASE", 1236, 1257], ["participants", "ORGANISM", 216, 228], ["mouth", "ORGANISM_SUBDIVISION", 252, 257], ["mouth", "ORGANISM_SUBDIVISION", 299, 304], ["Gram-", "GENE_OR_GENE_PRODUCT", 735, 740], ["Streptococcus spp.", "ORGANISM", 749, 767], ["Staphylococcus spp.", "ORGANISM", 769, 788], ["Gram", "GENE_OR_GENE_PRODUCT", 794, 798], ["Pseudomonas spp.", "ORGANISM", 808, 824], ["E. coli", "ORGANISM", 826, 833], ["Aspergillous spp", "ORGANISM", 839, 855], ["mouth", "ORGANISM_SUBDIVISION", 920, 925], ["Streptococcus species", "ORGANISM", 1236, 1257], ["Gram", "GENE_OR_GENE_PRODUCT", 1293, 1297], ["participants", "SPECIES", 216, 228], ["Streptococcus spp.", "SPECIES", 749, 767], ["Staphylococcus spp.", "SPECIES", 769, 788], ["Pseudomonas spp.", "SPECIES", 808, 824], ["E. coli", "SPECIES", 826, 833], ["Streptococcus spp.", "SPECIES", 749, 767], ["Staphylococcus spp.", "SPECIES", 769, 788], ["Pseudomonas spp.", "SPECIES", 808, 824], ["E. coli", "SPECIES", 826, 833], ["Studies", "TEST", 0, 7], ["white coat pockets harbor various bacteria", "PROBLEM", 59, 101], ["infections", "PROBLEM", 120, 130], ["their study", "TEST", 186, 197], ["their mouth mask in instrument trays", "TREATMENT", 246, 282], ["apron pockets", "PROBLEM", 313, 326], ["the present study", "TEST", 354, 371], ["ultrasonic scaler tips", "TREATMENT", 418, 440], ["bacteria", "PROBLEM", 495, 503], ["high-speed handpieces", "TREATMENT", 516, 537], ["aerosol production", "PROBLEM", 574, 592], ["microorganisms", "PROBLEM", 630, 644], ["Gram-positive Streptococcus spp.", "PROBLEM", 735, 767], ["Staphylococcus spp.", "PROBLEM", 769, 788], ["Gram", "TEST", 794, 798], ["negative Pseudomonas spp.", "PROBLEM", 799, 824], ["E. coli", "PROBLEM", 826, 833], ["Aspergillous spp", "PROBLEM", 839, 855], ["the micro-organisms", "PROBLEM", 868, 887], ["surgical mouth mask", "TREATMENT", 911, 930], ["potentially pathogenic", "PROBLEM", 936, 958], ["Gram-positive bacteria", "PROBLEM", 963, 985], ["the present study", "TEST", 1027, 1044], ["the study", "TEST", 1075, 1084], ["total bacteria", "PROBLEM", 1114, 1128], ["the dental professional face mask", "TREATMENT", 1134, 1167], ["Streptococcus species", "PROBLEM", 1236, 1257], ["Staphylococcus", "PROBLEM", 1266, 1280], ["Gram-negative bacteria", "PROBLEM", 1293, 1315], ["The present study", "TEST", 1330, 1347], ["the assessment", "TEST", 1366, 1380], ["bacterial and fungal contamination", "PROBLEM", 1384, 1418], ["surgical masks", "TREATMENT", 1431, 1445], ["pockets", "OBSERVATION_MODIFIER", 70, 77], ["infections", "OBSERVATION", 120, 130], ["bacteria", "OBSERVATION", 495, 503], ["speed handpieces", "OBSERVATION", 521, 537], ["aerosol production", "OBSERVATION", 574, 592], ["microorganisms", "OBSERVATION", 630, 644], ["negative Pseudomonas", "OBSERVATION_MODIFIER", 799, 819], ["E. coli", "OBSERVATION", 826, 833], ["Aspergillous spp", "OBSERVATION", 839, 855], ["micro-organisms", "OBSERVATION", 872, 887], ["positive bacteria", "OBSERVATION", 968, 985], ["consistent with", "UNCERTAINTY", 1059, 1074], ["total", "OBSERVATION_MODIFIER", 1114, 1119], ["bacteria", "OBSERVATION", 1120, 1128], ["negative bacteria", "OBSERVATION", 1298, 1315], ["fungal contamination", "OBSERVATION", 1398, 1418]]], ["The disposable surgical mouth masks were at first developed to strain aerosols containing microorganisms discharged from the mouth and nose, and probably to shield the human respiratory system from fine airborne particles that are known to be linked with various respiratory disorders.[2] Normally surgical mouth mask is developed to prevent microorganisms from the nose and oral cavity of the dental operator from spreading to others.", [["mouth", "ANATOMY", 24, 29], ["mouth", "ANATOMY", 125, 130], ["nose", "ANATOMY", 135, 139], ["respiratory", "ANATOMY", 263, 274], ["mouth", "ANATOMY", 307, 312], ["nose", "ANATOMY", 366, 370], ["oral cavity", "ANATOMY", 375, 386], ["respiratory disorders", "DISEASE", 263, 284], ["mouth", "ORGANISM_SUBDIVISION", 125, 130], ["nose", "ORGANISM_SUBDIVISION", 135, 139], ["human", "ORGANISM", 168, 173], ["mouth", "ORGAN", 307, 312], ["nose", "ORGANISM_SUBDIVISION", 366, 370], ["oral cavity", "ORGANISM_SUBDIVISION", 375, 386], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["The disposable surgical mouth masks", "TREATMENT", 0, 35], ["strain aerosols containing microorganisms", "PROBLEM", 63, 104], ["various respiratory disorders", "PROBLEM", 255, 284], ["Normally surgical mouth mask", "TREATMENT", 289, 317], ["microorganisms from the nose", "PROBLEM", 342, 370], ["mouth", "ANATOMY", 125, 130], ["nose", "ANATOMY", 135, 139], ["respiratory system", "ANATOMY", 174, 192], ["airborne particles", "OBSERVATION", 203, 221], ["respiratory disorders", "OBSERVATION", 263, 284], ["surgical", "OBSERVATION_MODIFIER", 298, 306], ["mouth mask", "OBSERVATION", 307, 317], ["microorganisms", "OBSERVATION", 342, 356], ["nose", "ANATOMY", 366, 370], ["oral cavity", "ANATOMY", 375, 386]]], ["However, surgical mouth mask is not well designed to filter particles of some infectious agents, especially M. tuberculosis.[9] In the present study, bacteria and fungi were significantly more in number on the outer surface of contaminated used surgical mask which was found similar to study done by Luksamijarulkul et al. with the presence of bacteria and fungi on outer surface of mask 166 \u00b1 199 cfu/ml/piece and 34 \u00b1 18 cfu/ml/piece, P < 0.001 respectively.[2] In 1998 Kretzer and Larson stated that some used mask behaviors probably increased the microbial contamination on the masks.[20] Therefore, it is suggested that surgical masks could filter most of microorganism from the environment of dental clinics.", [["mouth", "ANATOMY", 18, 23], ["outer surface", "ANATOMY", 210, 223], ["outer surface", "ANATOMY", 366, 379], ["tuberculosis", "DISEASE", 111, 123], ["mouth", "ORGAN", 18, 23], ["M. tuberculosis", "ORGANISM", 108, 123], ["outer surface", "CELLULAR_COMPONENT", 210, 223], ["outer surface", "CELLULAR_COMPONENT", 366, 379], ["M. tuberculosis", "SPECIES", 108, 123], ["M. tuberculosis", "SPECIES", 108, 123], ["surgical mouth mask", "TREATMENT", 9, 28], ["some infectious agents", "TREATMENT", 73, 95], ["M. tuberculosis", "PROBLEM", 108, 123], ["the present study", "TEST", 131, 148], ["bacteria", "PROBLEM", 150, 158], ["fungi", "PROBLEM", 163, 168], ["surgical mask", "TREATMENT", 245, 258], ["study", "TEST", 286, 291], ["bacteria", "PROBLEM", 344, 352], ["fungi", "PROBLEM", 357, 362], ["mask", "TEST", 383, 387], ["P", "TEST", 437, 438], ["Larson", "TREATMENT", 484, 490], ["the masks", "TREATMENT", 578, 587], ["surgical masks", "TREATMENT", 625, 639], ["microorganism", "PROBLEM", 661, 674], ["infectious", "OBSERVATION", 78, 88], ["tuberculosis", "OBSERVATION", 111, 123], ["surgical mask", "OBSERVATION", 245, 258], ["bacteria", "OBSERVATION", 344, 352], ["fungi", "OBSERVATION", 357, 362], ["increased", "OBSERVATION_MODIFIER", 537, 546]]], ["Luksamijarulkul et al. in their study found that the majority of isolates are Staphylococcus aureus (41%) and Pseudomonas species(38%) similar to the present study, and the most isolatedfungi were Aspergillus species(44%) and Penicillum species(25%) from the isolated incubated colonies, while in our study, only Aspergillus spp. was present as fungal colony.[2]DiscussionGram-positive Streptococci, coagulase-negative Staphylococci, and Aspergillous fungithatare common microorganism in dental clinics have increased risk of cross-infection to patients with prosthetic devices, intravascular catheters, and immune-compromised patients.[20] The American Conference of Governmental Industrial Hygienists (ACGIH) suggested that the optimal level of bacterial counts or fungal counts in the indoor air of any patient working areas should be less than 500 cfu/m3.[21] However, World Health Organization proposed that the microbial counts in the medical and dental patient operating places should be less than 300 cfu/m3 and for individuals or patients with immune-suppression, it should be less than 100 cfu/m3.[22232425]Declaration of patient consent ::: ConclusionThe authors certify that they have obtained all appropriate participant consent forms.", [["colonies", "ANATOMY", 278, 286], ["colony", "ANATOMY", 352, 358], ["intravascular", "ANATOMY", 579, 592], ["Staphylococcus aureus", "DISEASE", 78, 99], ["Aspergillus species", "DISEASE", 197, 216], ["immune-suppression", "DISEASE", 1053, 1071], ["Staphylococcus aureus", "ORGANISM", 78, 99], ["Aspergillus species", "ORGANISM", 197, 216], ["Penicillum species", "ORGANISM", 226, 244], ["Aspergillus spp", "ORGANISM", 313, 328], ["Gram-positive Streptococci", "SIMPLE_CHEMICAL", 372, 398], ["patients", "ORGANISM", 545, 553], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 579, 592], ["patients", "ORGANISM", 627, 635], ["patient", "ORGANISM", 806, 813], ["patient", "ORGANISM", 960, 967], ["patients", "ORGANISM", 1039, 1047], ["patient", "ORGANISM", 1132, 1139], ["Staphylococcus aureus", "SPECIES", 78, 99], ["patients", "SPECIES", 545, 553], ["patients", "SPECIES", 627, 635], ["patient", "SPECIES", 806, 813], ["patient", "SPECIES", 960, 967], ["patients", "SPECIES", 1039, 1047], ["patient", "SPECIES", 1132, 1139], ["Staphylococcus aureus", "SPECIES", 78, 99], ["Aspergillus spp", "SPECIES", 313, 328], ["Aspergillous fungithatare", "SPECIES", 438, 463], ["their study", "TEST", 26, 37], ["Staphylococcus aureus", "PROBLEM", 78, 99], ["Pseudomonas species", "PROBLEM", 110, 129], ["the present study", "TEST", 146, 163], ["Aspergillus species", "PROBLEM", 197, 216], ["Penicillum species", "PROBLEM", 226, 244], ["the isolated incubated colonies", "PROBLEM", 255, 286], ["our study", "TEST", 297, 306], ["Aspergillus spp", "PROBLEM", 313, 328], ["fungal colony", "PROBLEM", 345, 358], ["Gram-", "TEST", 372, 377], ["Streptococci", "TEST", 386, 398], ["coagulase", "TEST", 400, 409], ["Staphylococci", "PROBLEM", 419, 432], ["Aspergillous fungithatare common microorganism", "PROBLEM", 438, 484], ["prosthetic devices", "TREATMENT", 559, 577], ["intravascular catheters", "TREATMENT", 579, 602], ["bacterial counts", "TEST", 747, 763], ["fungal counts", "TEST", 767, 780], ["the microbial counts", "TEST", 913, 933], ["immune-suppression", "TREATMENT", 1053, 1071], ["Staphylococcus aureus", "OBSERVATION", 78, 99], ["Aspergillus species", "OBSERVATION", 197, 216], ["incubated colonies", "OBSERVATION", 268, 286], ["Aspergillus spp", "OBSERVATION", 313, 328], ["fungal colony", "OBSERVATION", 345, 358], ["negative Staphylococci", "OBSERVATION", 410, 432], ["prosthetic devices", "OBSERVATION", 559, 577], ["intravascular catheters", "OBSERVATION", 579, 602]]], ["In the form, the participants have given their consent for their images and other clinical information to be reported in the journal.", [["participants", "ORGANISM", 17, 29], ["participants", "SPECIES", 17, 29], ["their images", "TEST", 59, 71]]], ["The participants understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.Financial support and sponsorship ::: ConclusionNil.Conflicts of interest ::: ConclusionThere are no conflicts of interest.", [["participants", "SPECIES", 4, 16], ["no", "UNCERTAINTY", 269, 271], ["conflicts", "OBSERVATION", 272, 281]]]], "a75e09e0c2d66b9a44c296e9e448a9cbf6053140": [["| INTRODUCTIONFor persons with coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there appears to be a strong relationship between being an individual with overweight or obesity and the risks of hospitalization and needing treatment in intensive care units (ICUs).", [["coronavirus disease", "DISEASE", 31, 50], ["COVID-19", "CHEMICAL", 57, 65], ["acute respiratory syndrome coronavirus", "DISEASE", 88, 126], ["overweight", "DISEASE", 218, 228], ["obesity", "DISEASE", 232, 239], ["persons", "ORGANISM", 18, 25], ["SARS-CoV-2", "ORGANISM", 130, 140], ["persons", "SPECIES", 18, 25], ["severe acute respiratory syndrome coronavirus", "SPECIES", 81, 126], ["SARS-CoV-2", "SPECIES", 130, 140], ["coronavirus disease", "PROBLEM", 31, 50], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 77, 126], ["obesity", "PROBLEM", 232, 239], ["treatment", "TREATMENT", 285, 294], ["severe", "OBSERVATION_MODIFIER", 81, 87], ["acute", "OBSERVATION_MODIFIER", 88, 93], ["respiratory syndrome", "OBSERVATION", 94, 114], ["obesity", "OBSERVATION", 232, 239]]], ["Emerging literature suggests that adults with obesity under the age of 60 are more likely to be hospitalized.", [["obesity", "DISEASE", 46, 53], ["adults", "ORGANISM", 34, 40], ["obesity", "PROBLEM", 46, 53]]], ["1 The COVID-19 pandemic has occurred at a time when the prevalence of individuals with overweight/obesity is increasing in virtually all countries globally.", [["overweight/obesity", "DISEASE", 87, 105], ["The COVID", "TEST", 2, 11], ["overweight/obesity", "PROBLEM", 87, 105], ["obesity", "OBSERVATION", 98, 105], ["increasing", "OBSERVATION_MODIFIER", 109, 119]]], ["In fact, almost all countries today have a prevalence of individuals with overweight/obesity greater than 20%.", [["overweight/obesity", "DISEASE", 74, 92], ["overweight/obesity", "PROBLEM", 74, 92], ["obesity", "OBSERVATION", 85, 92]]], ["[2] [3] [4] To date, no country has experienced a reduction in the prevalence of individuals with overweight/obesity.| INTRODUCTIONIn addition, policy responses for mitigating COVID-19 are creating major economic hardships.", [["overweight/obesity", "DISEASE", 98, 116], ["overweight/obesity", "PROBLEM", 98, 116], ["obesity", "OBSERVATION", 109, 116]]], ["The COVID-19 pandemic has brought to all countries the need to restrict movement, implement social distancing and impede economic activities across a broad spectrum of nonessential occupations.", [["The COVID", "TEST", 0, 9]]], ["These adjustments have caused food system problems, including changes in food consumption and physical activity patterns, and remote telework environments that may exacerbate current trends in the prevalence of individuals with obesity, while another effect will be to increase the proportion food insecure and also those stunted and malnourished.", [["obesity", "DISEASE", 228, 235], ["food system problems", "PROBLEM", 30, 50], ["obesity", "PROBLEM", 228, 235], ["obesity", "OBSERVATION", 228, 235]]], ["These changes have long-lasting implications beyond the mitigation of the current SARS-CoV-2 spread and may be detrimental to people's health.| INTRODUCTIONThe association between individuals with excessive body fat, especially visceral adipose tissue; individuals with obesity; major cardiometabolic problems, ranging from hypertension to cardiovascular disease to type 2 diabetes (T2D); and a number of cancers is strong.", [["body fat", "ANATOMY", 207, 215], ["visceral adipose tissue", "ANATOMY", 228, 251], ["cardiovascular", "ANATOMY", 340, 354], ["cancers", "ANATOMY", 405, 412], ["SARS", "DISEASE", 82, 86], ["obesity", "DISEASE", 270, 277], ["cardiometabolic problems", "DISEASE", 285, 309], ["hypertension", "DISEASE", 324, 336], ["cardiovascular disease", "DISEASE", 340, 362], ["type 2 diabetes", "DISEASE", 366, 381], ["T2D", "DISEASE", 383, 386], ["cancers", "DISEASE", 405, 412], ["people", "ORGANISM", 126, 132], ["body fat", "TISSUE", 207, 215], ["visceral adipose tissue", "TISSUE", 228, 251], ["cancers", "CANCER", 405, 412], ["people", "SPECIES", 126, 132], ["the current SARS", "PROBLEM", 70, 86], ["excessive body fat", "PROBLEM", 197, 215], ["especially visceral adipose tissue", "PROBLEM", 217, 251], ["obesity", "PROBLEM", 270, 277], ["major cardiometabolic problems", "PROBLEM", 279, 309], ["hypertension", "PROBLEM", 324, 336], ["cardiovascular disease", "PROBLEM", 340, 362], ["type 2 diabetes (T2D)", "PROBLEM", 366, 387], ["cancers", "PROBLEM", 405, 412], ["may be", "UNCERTAINTY", 104, 110], ["visceral", "ANATOMY_MODIFIER", 228, 236], ["adipose tissue", "ANATOMY", 237, 251], ["obesity", "OBSERVATION", 270, 277], ["hypertension", "OBSERVATION", 324, 336], ["cardiovascular disease", "OBSERVATION", 340, 362], ["diabetes", "OBSERVATION", 373, 381], ["cancers", "OBSERVATION", 405, 412], ["strong", "OBSERVATION_MODIFIER", 416, 422]]], ["[5] [6] [7] [8] The underlying metabolic and inflammatory factors of individuals with obesity also play a considerable role in the manifestation of severe lung diseases.", [["lung", "ANATOMY", 155, 159], ["obesity", "DISEASE", 86, 93], ["lung diseases", "DISEASE", 155, 168], ["[5] [6] [7] [8]", "SIMPLE_CHEMICAL", 0, 15], ["lung", "ORGAN", 155, 159], ["inflammatory factors", "PROTEIN", 45, 65], ["The underlying metabolic and inflammatory factors", "PROBLEM", 16, 65], ["obesity", "PROBLEM", 86, 93], ["severe lung diseases", "PROBLEM", 148, 168], ["metabolic", "OBSERVATION_MODIFIER", 31, 40], ["inflammatory", "OBSERVATION_MODIFIER", 45, 57], ["obesity", "OBSERVATION", 86, 93], ["severe", "OBSERVATION_MODIFIER", 148, 154], ["lung", "ANATOMY", 155, 159], ["diseases", "OBSERVATION", 160, 168]]], ["Susceptibility to acute respiratory distress syndrome (ARDS), the primary cause of COVID-19 mortality, is significantly greater among individuals with obesity.", [["acute respiratory distress syndrome", "DISEASE", 18, 53], ["ARDS", "DISEASE", 55, 59], ["obesity", "DISEASE", 151, 158], ["acute respiratory distress syndrome", "PROBLEM", 18, 53], ["ARDS", "PROBLEM", 55, 59], ["COVID", "TEST", 83, 88], ["obesity", "PROBLEM", 151, 158], ["acute", "OBSERVATION_MODIFIER", 18, 23], ["respiratory distress syndrome", "OBSERVATION", 24, 53], ["greater", "OBSERVATION_MODIFIER", 120, 127], ["obesity", "OBSERVATION", 151, 158]]], ["9 Importantly, being an individual with obesity independently increases the risk of influenza morbidity and mortality, 10 most likely through impairments in innate and adaptive immune responses.", [["obesity", "DISEASE", 40, 47], ["influenza", "DISEASE", 84, 93], ["obesity", "PROBLEM", 40, 47], ["influenza morbidity", "PROBLEM", 84, 103], ["obesity", "OBSERVATION", 40, 47], ["influenza", "OBSERVATION", 84, 93]]], ["11 Potentially the vaccines developed to address COVID-19 will be less effective for individuals with obesity due to a weakened immune response.| INTRODUCTIONIn this paper, we first highlight the epidemiological data that provide insight into the relationship between being an individual with overweight/individuals with obesity and COVID-19, undertaking when possible meta-analyses of the published data.", [["COVID-19", "CHEMICAL", 49, 57], ["obesity", "DISEASE", 102, 109], ["overweight", "DISEASE", 293, 303], ["obesity", "DISEASE", 321, 328], ["COVID-19", "CHEMICAL", 49, 57], ["the vaccines", "TREATMENT", 15, 27], ["COVID", "TEST", 49, 54], ["obesity", "PROBLEM", 102, 109], ["a weakened immune response", "PROBLEM", 117, 143], ["obesity", "PROBLEM", 321, 328], ["COVID", "TEST", 333, 338]]], ["We provide an overview of the current understanding of how individuals with obesity affect the immunological and physiological response to SARS-CoV-2.| INTRODUCTIONWe follow this with a discussion of the issues of income distribution, food insecurity and the major dietary shifts we are seeing globally.", [["obesity", "DISEASE", 76, 83], ["SARS", "DISEASE", 139, 143], ["food insecurity", "DISEASE", 235, 250], ["obesity affect", "PROBLEM", 76, 90]]], ["Our discussion includes dietary and activity issues linked with COVID-19 that might exacerbate individuals with obesity and some of the potential policies that can address this issue.| BACKGROUND: THE GLOBAL PREVALENCE OF INDIVIDUALS WITH OVERWEIGHT AND OBESITYThe prevalence of individuals with overweight/obesity is at an all-time high and is increasing across the globe.", [["obesity", "DISEASE", 112, 119], ["overweight/obesity", "DISEASE", 296, 314], ["individuals", "ORGANISM", 279, 290], ["COVID", "TREATMENT", 64, 69], ["obesity", "PROBLEM", 112, 119], ["OBESITY", "PROBLEM", 254, 261], ["overweight/obesity", "PROBLEM", 296, 314], ["OBESITY", "OBSERVATION", 254, 261], ["obesity", "OBSERVATION", 307, 314], ["increasing", "OBSERVATION_MODIFIER", 345, 355], ["globe", "ANATOMY", 367, 372]]], ["This is true not only in higher income countries but also in low-and middle-income countries with high levels of undernutrition leading to the double burden of malnutrition.", [["undernutrition", "DISEASE", 113, 127], ["malnutrition", "DISEASE", 160, 172], ["high levels of undernutrition", "PROBLEM", 98, 127], ["the double burden of malnutrition", "PROBLEM", 139, 172], ["malnutrition", "OBSERVATION", 160, 172]]], ["4, 12 Few low-and middle-income countries have a prevalence of individuals with overweight/obesity less than 20% among their adult populations.", [["overweight/obesity", "DISEASE", 80, 98], ["overweight/obesity", "PROBLEM", 80, 98], ["Few", "OBSERVATION_MODIFIER", 6, 9], ["low", "OBSERVATION_MODIFIER", 10, 13], ["middle", "ANATOMY_MODIFIER", 18, 24], ["obesity", "OBSERVATION", 91, 98]]], ["Figure 1 shows a map of the world in the 1990s and the late 2010s.| BACKGROUND: THE GLOBAL PREVALENCE OF INDIVIDUALS WITH OVERWEIGHT AND OBESITYA large proportion of the populations in higher income countries are overweight or obese.", [["a map", "TEST", 15, 20], ["obese", "PROBLEM", 227, 232], ["large", "OBSERVATION_MODIFIER", 146, 151], ["proportion", "OBSERVATION_MODIFIER", 152, 162], ["populations", "OBSERVATION_MODIFIER", 170, 181], ["obese", "OBSERVATION", 227, 232]]], ["As Figure 1 shows, few higher income countries have adult populations with a prevalence of overweight/obese less than 70%.", [["overweight/obese", "DISEASE", 91, 107], ["obese", "PROBLEM", 102, 107], ["few", "OBSERVATION_MODIFIER", 19, 22], ["higher", "OBSERVATION_MODIFIER", 23, 29]]], ["This prevalence is not declining in any country.", [["not", "UNCERTAINTY", 19, 22], ["declining", "OBSERVATION_MODIFIER", 23, 32]]], ["In higher income countries, the prevalence of individuals with overweight/obesity was already high in the 1990s, and it has continued to increase.", [["overweight/obesity", "DISEASE", 63, 81], ["individuals", "ORGANISM", 46, 57], ["overweight/obesity", "PROBLEM", 63, 81], ["obesity", "OBSERVATION", 74, 81]]], ["In fact, larger portions of their populations have become individuals with morbid obesity with body mass indexes (BMIs) over 35-40 kg m \u22122 .", [["body", "ANATOMY", 95, 99], ["morbid obesity", "DISEASE", 75, 89], ["body", "ORGANISM_SUBDIVISION", 95, 99], ["morbid obesity", "PROBLEM", 75, 89], ["body mass indexes", "PROBLEM", 95, 112], ["BMIs", "TEST", 114, 118], ["larger", "OBSERVATION_MODIFIER", 9, 15], ["portions", "OBSERVATION_MODIFIER", 16, 24], ["morbid", "OBSERVATION_MODIFIER", 75, 81], ["obesity", "OBSERVATION", 82, 89], ["body", "OBSERVATION_MODIFIER", 95, 99], ["mass", "OBSERVATION", 100, 104]]], ["In low-and middle-income countries outside of Latin America and a number of small islands, the growth in individuals with overweight/obesity has occurred primarily in the past several decades from 1990 to 2020 which we and many others have documented.", [["overweight/obesity", "DISEASE", 122, 140], ["small islands", "PROBLEM", 76, 89], ["overweight/obesity", "PROBLEM", 122, 140], ["low", "OBSERVATION_MODIFIER", 3, 6], ["middle", "ANATOMY_MODIFIER", 11, 17], ["small", "OBSERVATION_MODIFIER", 76, 81], ["islands", "OBSERVATION", 82, 89], ["growth", "OBSERVATION_MODIFIER", 95, 101], ["obesity", "OBSERVATION", 133, 140]]], ["2, 3, [13] [14] [15] [16] Further, evidence shows that >70% of the individuals with overweight/obesity live in low-or middle-income countries, and as country economies grow, the burden of individuals with obesity shifts to the poor.", [["overweight/obesity", "DISEASE", 84, 102], ["obesity", "DISEASE", 205, 212], ["3, [13] [14] [15] [16]", "SIMPLE_CHEMICAL", 3, 25], ["overweight/obesity", "PROBLEM", 84, 102], ["obesity shifts", "PROBLEM", 205, 219], ["obesity", "OBSERVATION", 95, 102], ["obesity", "OBSERVATION", 205, 212]]], ["[17] [18] [19] In the Middle East and Latin America, the prevalence of rates of individuals with obesity are among the highest in the world.| BACKGROUND: THE GLOBAL PREVALENCE OF INDIVIDUALS WITH OVERWEIGHT AND OBESITYTwo related factors are equally important.", [["obesity", "DISEASE", 97, 104], ["obesity", "PROBLEM", 97, 104], ["OVERWEIGHT AND OBESITYTwo related factors", "PROBLEM", 196, 237], ["Middle", "ANATOMY_MODIFIER", 22, 28], ["obesity", "OBSERVATION", 97, 104], ["highest", "OBSERVATION_MODIFIER", 119, 126]]], ["First, we are finding that much of the BMI increase accompanies an increase in central adiposity proxied by waist circumference at all ages compared with the amount of such adiposity one or two decades earlier.", [["waist", "ORGANISM_SUBDIVISION", 108, 113], ["the BMI", "PROBLEM", 35, 42], ["central adiposity", "PROBLEM", 79, 96], ["waist circumference", "TEST", 108, 127], ["such adiposity", "PROBLEM", 168, 182], ["increase", "OBSERVATION_MODIFIER", 67, 75], ["central adiposity", "OBSERVATION", 79, 96]]], ["[20] [21] [22] Second, across the globe, the economically poor are more prone to develop obesity than are the rich.", [["obesity", "DISEASE", 89, 96], ["obesity", "PROBLEM", 89, 96], ["globe", "ANATOMY", 34, 39], ["obesity", "OBSERVATION", 89, 96]]], ["[17] [18] [19] 23 F I G U R E 1 Prevalence of overweight and obesity based on 1990s and late 2010s weight and height data| EPIDEMIOLOGICAL RELATIONSHIPS: INDIVIDUALS WITH OVERWEIGHT AND OBESITY AND COVID-19This review study is exempted from IRB review, and there was no public or patient involvement.| Literature retrievalWe examined PubMed, Google Scholar, MedRxiv, BioRxiv, Wanfang (for Chinese literature) and other literature search engines (e.g., China National Knowledge Infrastructure Data and ICNARC) to systematically review all publications in Chinese or English that include data on COVID-19 and BMI or individuals with obesity.", [["overweight", "DISEASE", 46, 56], ["obesity", "DISEASE", 61, 68], ["obesity", "DISEASE", 631, 638], ["patient", "ORGANISM", 280, 287], ["patient", "SPECIES", 280, 287], ["overweight", "PROBLEM", 46, 56], ["obesity", "PROBLEM", 61, 68], ["weight", "TEST", 99, 105], ["OBESITY", "PROBLEM", 186, 193], ["review study", "TEST", 211, 223], ["public or patient involvement", "PROBLEM", 270, 299], ["COVID", "TEST", 594, 599], ["obesity", "PROBLEM", 631, 638], ["OBESITY", "OBSERVATION", 186, 193], ["obesity", "OBSERVATION", 631, 638]]], ["We briefly reviewed the abstracts and results and located 75 publications available by 15 July 2020 that presented data on the BMIs or BMI categories of diagnosed COVID-19 patients.", [["COVID", "DISEASE", 163, 168], ["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180]]], ["All of our authors performed the literature searches and reviews.| Study characteristicsWe found 1733 studies, 75 of which provided data we could use in this review ( Figure 2 ).", [["Study characteristics", "TEST", 67, 88]]], ["All were conducted between January and June 2020, including five case-control studies, 33 retrospective or prospective cohort studies and 37 observational cross-sectional studies.| Study characteristicsSample sizes varied from 24 to 109 367 diagnosed patients in more than 10 countries in Asia, Europe and North and South America.", [["patients", "ORGANISM", 251, 259], ["patients", "SPECIES", 251, 259], ["prospective cohort studies", "TEST", 107, 133], ["Study characteristics", "TEST", 181, 202], ["Sample sizes", "TEST", 202, 214], ["sizes", "OBSERVATION_MODIFIER", 209, 214], ["varied", "OBSERVATION_MODIFIER", 215, 221]]], ["In total, we included 399 461 diagnosed patients in this study, about 55% of whom were male.", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["this study", "TEST", 52, 62]]], ["Table S2 presents detailed demographic data from the studies we used, including a few studies that had inadequate data for use in the meta-analysis.", [["the studies", "TEST", 49, 60], ["a few studies", "TEST", 80, 93], ["the meta-analysis", "TEST", 130, 147]]], ["We used STATA (version 16, College Station, TX) to perform all random-effects meta-analysis and used residual maximum likelihood to fit all models.", [["TX", "TREATMENT", 44, 46]]], ["24| Being an individual with obesity and the risk of COVID-19We identified 20 studies that assessed the association between individuals with obesity and COVID-19, all but two of which showed that individuals with obesity significantly increase the risk of COVID-19 (Table S3) .", [["obesity", "DISEASE", 29, 36], ["obesity", "DISEASE", 141, 148], ["obesity", "DISEASE", 213, 220], ["obesity", "PROBLEM", 29, 36], ["COVID", "TEST", 53, 58], ["obesity", "PROBLEM", 141, 148], ["COVID", "TEST", 153, 158], ["obesity", "PROBLEM", 213, 220], ["COVID", "TEST", 256, 261], ["obesity", "OBSERVATION", 29, 36], ["obesity", "OBSERVATION", 141, 148], ["obesity", "OBSERVATION", 213, 220]]], ["[25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] One study in Denmark showed that the prevalence of overweight and individuals with obesity was lower in SARS-CoV-2 positive cases than SARS-CoV-2 test-negative individuals (8.6%| Being an individual with obesity and the risk of COVID-19vs.", [["[25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41", "CHEMICAL", 0, 83], ["overweight", "DISEASE", 146, 156], ["obesity", "DISEASE", 178, 185], ["SARS", "DISEASE", 199, 203], ["SARS", "DISEASE", 230, 234], ["obesity", "DISEASE", 299, 306], ["[25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43]", "SIMPLE_CHEMICAL", 0, 94], ["SARS-CoV-2", "ORGANISM", 199, 209], ["SARS-CoV-2", "ORGANISM", 230, 240], ["individuals", "ORGANISM", 255, 266], ["SARS-CoV", "SPECIES", 199, 207], ["SARS-CoV", "SPECIES", 230, 238], ["One study", "TEST", 95, 104], ["overweight and individuals", "PROBLEM", 146, 172], ["obesity", "PROBLEM", 178, 185], ["CoV", "TEST", 204, 207], ["SARS", "TEST", 230, 234], ["CoV", "TEST", 235, 238], ["individuals", "TEST", 255, 266], ["obesity", "PROBLEM", 299, 306], ["COVID", "TEST", 323, 328], ["obesity", "OBSERVATION", 178, 185], ["obesity", "OBSERVATION", 299, 306]]], ["44 The results may be biased because body weight status was determined at hospital discharge.", [["body", "ANATOMY", 37, 41], ["body", "ORGANISM_SUBDIVISION", 37, 41], ["body weight status", "PROBLEM", 37, 55]]], ["A study used U.K. Biobank data CI, 1.46-2.65; p < 0.0001), adjusted for age, sex, ethnicity and socioeconomic deprivation as measured by unemployment, assets and household density.", [["A study", "TEST", 0, 7], ["CI", "TEST", 31, 33], ["socioeconomic deprivation", "PROBLEM", 96, 121]]], ["32 The authors tested only a small portion of individuals (0.5%) for COVID-19, a key limitation of this study.", [["COVID", "TEST", 69, 74], ["this study", "TEST", 99, 109], ["small", "OBSERVATION_MODIFIER", 29, 34]]], ["A better way to calculate OR for this study is to compare the odds between subjects who tested positive and those who tested negative.", [["this study", "TEST", 33, 43]]], ["Our pooled data analysis showed that the odds of individuals with obesity being COVID-19 positive were 46.0% (OR = 1.46; 95% CI, 1.30-1.65; p < 0.0001) higher than those of individuals who were not obese ( Figure 3 ).| Being an individual with obesity and COVID-19 illness severityBeing an individual with obesity increases the odds of COVID-19 patients being hospitalized.", [["obesity", "DISEASE", 66, 73], ["obesity", "DISEASE", 244, 251], ["illness", "DISEASE", 265, 272], ["obesity", "DISEASE", 306, 313], ["COVID-19", "GENE_OR_GENE_PRODUCT", 80, 88], ["patients", "ORGANISM", 345, 353], ["patients", "SPECIES", 345, 353], ["Our pooled data analysis", "TEST", 0, 24], ["obesity", "PROBLEM", 66, 73], ["COVID", "TEST", 80, 85], ["CI", "TEST", 125, 127], ["p", "TEST", 140, 141], ["obese", "PROBLEM", 198, 203], ["obesity", "PROBLEM", 244, 251], ["COVID", "TEST", 256, 261], ["illness severity", "PROBLEM", 265, 281], ["obesity", "PROBLEM", 306, 313], ["obesity", "OBSERVATION", 66, 73], ["obesity", "OBSERVATION", 244, 251], ["obesity", "OBSERVATION", 306, 313]]], ["Among diagnosed COVID-19 patients, the prevalence of individuals with obesity in hospitalized patients was much higher than that in nonhospitalized patients.", [["obesity", "DISEASE", 70, 77], ["patients", "ORGANISM", 25, 33], ["individuals", "ORGANISM", 53, 64], ["patients", "ORGANISM", 94, 102], ["patients", "ORGANISM", 148, 156], ["patients", "SPECIES", 25, 33], ["patients", "SPECIES", 94, 102], ["patients", "SPECIES", 148, 156], ["obesity", "PROBLEM", 70, 77], ["obesity", "OBSERVATION", 70, 77]]], ["For example, a report that included 5700 patients with obesity in New York City 45 showed that 41.7% of COVID-19 hospitalized patients were individuals with obesity, whereas the average prevalence of individuals with obesity in New York City was 22.0%.", [["obesity", "DISEASE", 55, 62], ["obesity", "DISEASE", 157, 164], ["obesity", "DISEASE", 217, 224], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 126, 134], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 126, 134], ["obesity", "PROBLEM", 55, 62], ["COVID", "TEST", 104, 109], ["obesity", "PROBLEM", 157, 164], ["obesity", "PROBLEM", 217, 224], ["obesity", "OBSERVATION", 55, 62], ["obesity", "OBSERVATION", 157, 164], ["obesity", "OBSERVATION", 217, 224]]], ["46 Many studies reported COVID-19 hospitalizations, but only a few reported the relationship between individuals with obesity and hospitalization.", [["obesity", "DISEASE", 118, 125], ["Many studies", "TEST", 3, 15], ["COVID", "TEST", 25, 30], ["obesity", "PROBLEM", 118, 125], ["obesity", "OBSERVATION", 118, 125]]], ["We identified 19 studies that examined the relationship and included them in this analysis.", [["19 studies", "TEST", 14, 24], ["this analysis", "TEST", 77, 90]]], ["1, 28, 38, 40, 44, [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] Table S4 presents the results 1, 45, 47, 48, 59, 60 ; all showed a significantly higher prevalence of individuals with obesity among hospitalized patients than among patients not hospitalized or the general population.| Being an individual with obesity and COVID-19 illness severityThe pooled OR was 2.13 (95% CI, 1.74-2.60; p < 0.0001) ( Figure 4 ).| Being an individual with obesity and COVID-19 illness severityAmong patients with symptoms, those with severe or critical conditions had much higher BMIs and individuals with obesity prevalence than the normal population or patients who were COVID-19 negative.", [["obesity", "DISEASE", 198, 205], ["obesity", "DISEASE", 324, 331], ["illness", "DISEASE", 345, 352], ["obesity", "DISEASE", 456, 463], ["illness", "DISEASE", 477, 484], ["obesity", "DISEASE", 606, 613], ["[47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57", "SIMPLE_CHEMICAL", 19, 72], ["patients", "ORGANISM", 225, 233], ["patients", "ORGANISM", 245, 253], ["patients", "ORGANISM", 499, 507], ["patients", "ORGANISM", 655, 663], ["patients", "SPECIES", 225, 233], ["patients", "SPECIES", 245, 253], ["patients", "SPECIES", 499, 507], ["patients", "SPECIES", 655, 663], ["obesity", "PROBLEM", 198, 205], ["obesity", "PROBLEM", 324, 331], ["COVID", "TEST", 336, 341], ["illness severity", "PROBLEM", 345, 361], ["CI", "TEST", 389, 391], ["p", "TEST", 404, 405], ["obesity", "PROBLEM", 456, 463], ["COVID", "TEST", 468, 473], ["illness severity", "PROBLEM", 477, 493], ["symptoms", "PROBLEM", 513, 521], ["severe or critical conditions", "PROBLEM", 534, 563], ["obesity prevalence", "PROBLEM", 606, 624], ["COVID", "TEST", 673, 678], ["obesity", "OBSERVATION", 198, 205], ["obesity", "OBSERVATION", 324, 331], ["obesity", "OBSERVATION", 456, 463]]], ["32, [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] Two studies showed that the odds of having COVID-19 increased by 30% (OR = 1.30; 95% CI, 1.09-1.54; p = 0.0030) 61 and by 38% (OR = 1.38; p < 0.0001), 32 respectively, among the individuals with obesity ( Table 1 ).| Being an individual with obesity and COVID-19 illness severityAll studies reported that among those diagnosed, patients with obesity were more likely to be admitted to ICUs. * However, the effect sizes in the studies with smaller sample sizes were not statistically significant.", [["obesity", "DISEASE", 249, 256], ["obesity", "DISEASE", 296, 303], ["illness", "DISEASE", 317, 324], ["obesity", "DISEASE", 396, 403], ["COVID-19", "CHEMICAL", 97, 105], ["[61] [62] [63] [64] [65] [66] [67] [68] [69] [70", "SIMPLE_CHEMICAL", 4, 52], ["patients", "ORGANISM", 382, 390], ["patients", "SPECIES", 382, 390], ["Two studies", "TEST", 54, 65], ["COVID", "TEST", 97, 102], ["CI", "TEST", 139, 141], ["p", "TEST", 154, 155], ["p", "TEST", 192, 193], ["obesity", "PROBLEM", 249, 256], ["obesity", "PROBLEM", 296, 303], ["COVID", "TEST", 308, 313], ["illness severity", "PROBLEM", 317, 333], ["All studies", "TEST", 333, 344], ["obesity", "PROBLEM", 396, 403], ["the studies", "TEST", 476, 487], ["smaller sample sizes", "PROBLEM", 493, 513], ["obesity", "OBSERVATION", 249, 256], ["obesity", "OBSERVATION", 296, 303], ["effect", "OBSERVATION_MODIFIER", 460, 466], ["sizes", "OBSERVATION_MODIFIER", 467, 472], ["smaller", "OBSERVATION_MODIFIER", 493, 500], ["sizes", "OBSERVATION_MODIFIER", 508, 513], ["not statistically", "UNCERTAINTY", 519, 536], ["significant", "OBSERVATION_MODIFIER", 537, 548]]], ["48, 72, 73 In the studies that found that being an individual with obesity did not significantly increase the odds of being admitted to the ICU, individuals with morbid obesity (defined as BMI \u2265 35) did significantly increase the odds of ICU admittance.", [["obesity", "DISEASE", 67, 74], ["obesity", "DISEASE", 169, 176], ["the studies", "TEST", 14, 25], ["obesity", "PROBLEM", 67, 74], ["morbid obesity", "PROBLEM", 162, 176], ["obesity", "OBSERVATION", 67, 74]]], ["Our pooled data (from 22 studies) showed that individuals with obesity increased the odds of being admitted to the ICU by 74% (OR = 1.68; 95% CI, 1.46-2.08; p < 0.0001) ( Figure 5 and Table S5 ).| Being an individual with obesity and COVID-19 illness severityReports that had smaller sample sizes from the United Kingdom and some other countries showed that patients with obesity had higher but insignificant odds of invasive mechanical ventilation (IMV) than patients without obesity.", [["obesity", "DISEASE", 63, 70], ["obesity", "DISEASE", 222, 229], ["illness", "DISEASE", 243, 250], ["obesity", "DISEASE", 372, 379], ["obesity", "DISEASE", 477, 484], ["patients", "ORGANISM", 358, 366], ["patients", "ORGANISM", 460, 468], ["patients", "SPECIES", 358, 366], ["patients", "SPECIES", 460, 468], ["Our pooled data", "TEST", 0, 15], ["22 studies", "TEST", 22, 32], ["obesity", "PROBLEM", 63, 70], ["CI", "TEST", 142, 144], ["p", "TEST", 157, 158], ["Figure", "TEST", 171, 177], ["obesity", "PROBLEM", 222, 229], ["COVID", "TEST", 234, 239], ["illness severity", "PROBLEM", 243, 259], ["smaller sample sizes", "PROBLEM", 276, 296], ["obesity", "PROBLEM", 372, 379], ["invasive mechanical ventilation", "TREATMENT", 417, 448], ["obesity", "PROBLEM", 477, 484], ["obesity", "OBSERVATION", 63, 70], ["obesity", "OBSERVATION", 222, 229], ["smaller", "OBSERVATION_MODIFIER", 276, 283], ["sample", "OBSERVATION_MODIFIER", 284, 290], ["sizes", "OBSERVATION_MODIFIER", 291, 296], ["obesity", "OBSERVATION", 372, 379], ["invasive", "OBSERVATION_MODIFIER", 417, 425], ["mechanical ventilation", "OBSERVATION", 426, 448], ["without", "UNCERTAINTY", 469, 476], ["obesity", "OBSERVATION", 477, 484]]], ["48, 72, 86 Reports from Mexico and some U.S. cities showed significantly higher odds of IMV in patients with obesity than in patients without obesity. \u2020 The pooled data (from 14 studies) showed a 66% increase in IMV in patients with obesity (OR = 1.66; 95% CI, 1.38-1.99; p < 0.0001) ( Figure 6 and Table S6 ).| Being an individual with obesity and COVID-19 prognosisThe association between obesity and COVID-19 prognosis is complex, because patients discharged from ICUs may be still hospitalized or deceased later.", [["obesity", "DISEASE", 109, 116], ["obesity", "DISEASE", 142, 149], ["obesity", "DISEASE", 233, 240], ["obesity", "DISEASE", 337, 344], ["obesity", "DISEASE", 391, 398], ["patients", "ORGANISM", 95, 103], ["patients", "ORGANISM", 125, 133], ["patients", "ORGANISM", 219, 227], ["patients", "ORGANISM", 442, 450], ["patients", "SPECIES", 95, 103], ["patients", "SPECIES", 125, 133], ["patients", "SPECIES", 219, 227], ["patients", "SPECIES", 442, 450], ["IMV", "TREATMENT", 88, 91], ["obesity", "PROBLEM", 109, 116], ["obesity", "PROBLEM", 142, 149], ["The pooled data", "TEST", 153, 168], ["14 studies", "TEST", 175, 185], ["a 66% increase in IMV", "PROBLEM", 194, 215], ["obesity", "PROBLEM", 233, 240], ["CI", "TEST", 257, 259], ["p", "TEST", 272, 273], ["Figure", "TEST", 286, 292], ["obesity", "PROBLEM", 337, 344], ["COVID", "TEST", 349, 354], ["obesity", "PROBLEM", 391, 398], ["COVID", "TEST", 403, 408], ["obesity", "OBSERVATION", 109, 116], ["without", "UNCERTAINTY", 134, 141], ["obesity", "OBSERVATION", 142, 149], ["increase", "OBSERVATION_MODIFIER", 200, 208], ["IMV", "ANATOMY", 212, 215], ["obesity", "OBSERVATION", 233, 240], ["obesity", "OBSERVATION", 337, 344]]], ["For example, 4.5% died after they were discharged from ICU; 11.5% remained in the hospital after leaving the ICU in one study.", [["one study", "TEST", 116, 125]]], ["31 A few studies showed that individuals with F I G U R E 4 Meta-analysis of the association between individuals with obesity and the risk of hospitalization with COVID-19 Figure 7 and Table S7 ). \u2021 We excluded two studies that had very large OR and very wide 95% CI, one study in China (OR = 32.08; 95% CI, 6.73-153) 65| WHY ARE INDIVIDUALS WITH OBESITY AT SERIOUS RISK FOR COVID-19?Being an individual with obesity is associated with numerous underlying risk factors for COVID-19, including hypertension, dyslipidaemia, type 2 diabetes (T2D) and chronic kidney or liver disease.", [["kidney", "ANATOMY", 556, 562], ["liver", "ANATOMY", 566, 571], ["obesity", "DISEASE", 118, 125], ["obesity", "DISEASE", 409, 416], ["hypertension", "DISEASE", 493, 505], ["dyslipidaemia", "DISEASE", 507, 520], ["type 2 diabetes", "DISEASE", 522, 537], ["T2D", "DISEASE", 539, 542], ["chronic kidney or liver disease", "DISEASE", 548, 579], ["kidney", "ORGAN", 556, 562], ["liver", "ORGAN", 566, 571], ["A few studies", "TEST", 3, 16], ["obesity", "PROBLEM", 118, 125], ["COVID", "TEST", 163, 168], ["two studies", "TEST", 211, 222], ["one study", "TEST", 268, 277], ["CI", "TEST", 304, 306], ["OBESITY", "PROBLEM", 347, 354], ["COVID", "TEST", 375, 380], ["obesity", "PROBLEM", 409, 416], ["COVID", "TEST", 473, 478], ["hypertension", "PROBLEM", 493, 505], ["dyslipidaemia", "PROBLEM", 507, 520], ["type 2 diabetes (T2D)", "PROBLEM", 522, 543], ["chronic kidney", "PROBLEM", 548, 562], ["liver disease", "PROBLEM", 566, 579], ["obesity", "OBSERVATION", 118, 125], ["large", "OBSERVATION_MODIFIER", 237, 242], ["OBESITY", "OBSERVATION", 347, 354], ["obesity", "OBSERVATION", 409, 416], ["hypertension", "OBSERVATION", 493, 505], ["dyslipidaemia", "OBSERVATION", 507, 520], ["diabetes", "OBSERVATION", 529, 537], ["chronic", "OBSERVATION_MODIFIER", 548, 555], ["kidney", "ANATOMY", 556, 562], ["liver", "ANATOMY", 566, 571], ["disease", "OBSERVATION", 572, 579]]], ["Coronaviruses are typically not associated with severe disease and were mostly thought to cause only mild respiratory infections until the emergence of the 2002 severe acute respiratory syndrome coronavirus (SARS-CoV) in Guangdong, China.", [["respiratory", "ANATOMY", 106, 117], ["respiratory infections", "DISEASE", 106, 128], ["acute respiratory syndrome coronavirus", "DISEASE", 168, 206], ["SARS-CoV)", "DISEASE", 208, 217], ["SARS-CoV", "ORGANISM", 208, 216], ["2002 severe acute respiratory syndrome coronavirus", "SPECIES", 156, 206], ["SARS-CoV", "SPECIES", 208, 216], ["Coronaviruses", "PROBLEM", 0, 13], ["severe disease", "PROBLEM", 48, 62], ["mild respiratory infections", "PROBLEM", 101, 128], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 161, 206], ["not associated with", "UNCERTAINTY", 28, 47], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["disease", "OBSERVATION", 55, 62], ["mild", "OBSERVATION_MODIFIER", 101, 105], ["respiratory", "ANATOMY", 106, 117], ["infections", "OBSERVATION", 118, 128], ["severe", "OBSERVATION_MODIFIER", 161, 167], ["acute", "OBSERVATION_MODIFIER", 168, 173], ["respiratory syndrome coronavirus", "OBSERVATION", 174, 206]]], ["The SARS-CoV outbreak was ultimately contained thanks to its low viral load within the beginning stages of symptom onset, allowing time for identification and isolation of infected individuals.", [["SARS", "DISEASE", 4, 8], ["SARS-CoV", "ORGANISM", 4, 12], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS-CoV outbreak", "PROBLEM", 0, 21], ["its low viral load", "PROBLEM", 57, 75], ["symptom onset", "PROBLEM", 107, 120], ["identification", "TEST", 140, 154], ["infected individuals", "PROBLEM", 172, 192], ["CoV", "OBSERVATION_MODIFIER", 9, 12], ["infected", "OBSERVATION", 172, 180]]], ["107 The 2009 influenza pandemic, caused by an outbreak of the upper respiratory influenza A H1N1 virus, identified individuals with obesity as an independent risk factor for severe influenza morbidity and mortality.", [["influenza pandemic", "DISEASE", 13, 31], ["obesity", "DISEASE", 132, 139], ["influenza", "DISEASE", 181, 190], ["upper respiratory influenza A H1N1", "ORGANISM", 62, 96], ["influenza A H1N1 virus", "SPECIES", 80, 102], ["upper respiratory influenza A H1N1 virus", "SPECIES", 62, 102], ["influenza", "PROBLEM", 13, 22], ["the upper respiratory influenza A H1N1 virus", "PROBLEM", 58, 102], ["obesity", "PROBLEM", 132, 139], ["severe influenza morbidity", "PROBLEM", 174, 200], ["upper", "ANATOMY_MODIFIER", 62, 67], ["respiratory influenza", "ANATOMY", 68, 89], ["obesity", "OBSERVATION", 132, 139], ["severe", "OBSERVATION_MODIFIER", 174, 180], ["influenza", "OBSERVATION", 181, 190]]], ["10 Subsequently, emergence of the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012 exhibited high prevalence among individuals with obesity.", [["respiratory syndrome coronavirus", "DISEASE", 46, 78], ["obesity", "DISEASE", 147, 154], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 34, 78], ["MERS-CoV", "ORGANISM", 80, 88], ["Middle East respiratory syndrome coronavirus", "SPECIES", 34, 78], ["MERS-CoV", "SPECIES", 80, 88], ["the Middle East respiratory syndrome coronavirus", "PROBLEM", 30, 78], ["obesity", "PROBLEM", 147, 154], ["Middle", "ANATOMY_MODIFIER", 34, 40], ["respiratory syndrome", "ANATOMY", 46, 66], ["obesity", "OBSERVATION", 147, 154]]], ["108 The growing evidence detailed above demonstrates that obesity increases the risks of hospitalization, severity and in some cases death with viral respiratory infections, increasing the likelihood that obesity may also independently increase the risk for COVID-19, another respiratory viral disease.", [["respiratory", "ANATOMY", 150, 161], ["obesity", "DISEASE", 58, 65], ["death", "DISEASE", 133, 138], ["viral respiratory infections", "DISEASE", 144, 172], ["obesity", "DISEASE", 205, 212], ["respiratory viral disease", "DISEASE", 276, 301], ["obesity", "PROBLEM", 58, 65], ["severity", "PROBLEM", 106, 114], ["some cases death", "PROBLEM", 122, 138], ["viral respiratory infections", "PROBLEM", 144, 172], ["obesity", "PROBLEM", 205, 212], ["COVID", "TEST", 258, 263], ["another respiratory viral disease", "PROBLEM", 268, 301], ["obesity", "OBSERVATION", 58, 65], ["viral", "OBSERVATION_MODIFIER", 144, 149], ["respiratory infections", "OBSERVATION", 150, 172], ["obesity", "OBSERVATION", 205, 212], ["respiratory", "ANATOMY", 276, 287], ["viral disease", "OBSERVATION", 288, 301]]], ["Several reports summarize the current understanding of the pathogenicity and immune response to SARS-CoV-2 based on available data from animal and human studies.", [["SARS", "DISEASE", 96, 100], ["SARS-CoV-2", "ORGANISM", 96, 106], ["human", "ORGANISM", 147, 152], ["human", "SPECIES", 147, 152], ["SARS-CoV", "SPECIES", 96, 104], ["human", "SPECIES", 147, 152], ["the pathogenicity", "PROBLEM", 55, 72], ["SARS", "TEST", 96, 100], ["CoV", "TEST", 101, 104], ["animal and human studies", "TEST", 136, 160]]], ["109| Individuals with obesity's metabolic and physiological impairments linked to COVID-19Being an individual with obesity is a major risk factor for severe cases of certain infectious diseases, like influenza, hepatitis and nosocomial infections.", [["obesity", "DISEASE", 22, 29], ["metabolic and physiological impairments", "DISEASE", 32, 71], ["obesity", "DISEASE", 115, 122], ["infectious diseases", "DISEASE", 174, 193], ["influenza", "DISEASE", 200, 209], ["hepatitis", "DISEASE", 211, 220], ["nosocomial infections", "DISEASE", 225, 246], ["obesity", "PROBLEM", 22, 29], ["physiological impairments", "PROBLEM", 46, 71], ["COVID", "TEST", 82, 87], ["obesity", "PROBLEM", 115, 122], ["certain infectious diseases", "PROBLEM", 166, 193], ["influenza", "PROBLEM", 200, 209], ["hepatitis", "PROBLEM", 211, 220], ["nosocomial infections", "PROBLEM", 225, 246], ["obesity", "OBSERVATION", 115, 122], ["infectious", "OBSERVATION", 174, 184], ["influenza", "OBSERVATION", 200, 209], ["hepatitis", "OBSERVATION", 211, 220], ["nosocomial", "OBSERVATION_MODIFIER", 225, 235], ["infections", "OBSERVATION", 236, 246]]], ["111 Hyperglycaemia, a key hallmark of T2D, is highly associated with individuals with obesity.", [["Hyperglycaemia", "DISEASE", 4, 18], ["T2D", "DISEASE", 38, 41], ["obesity", "DISEASE", 86, 93], ["Hyperglycaemia", "PROBLEM", 4, 18], ["a key hallmark of T2D", "PROBLEM", 20, 41], ["obesity", "PROBLEM", 86, 93], ["Hyperglycaemia", "OBSERVATION", 4, 18], ["T2D", "OBSERVATION", 38, 41], ["obesity", "OBSERVATION", 86, 93]]], ["Importantly, uncontrolled serum glucose has been shown to significantly increase COVID-19 mortality.", [["serum", "ANATOMY", 26, 31], ["glucose", "CHEMICAL", 32, 39], ["glucose", "CHEMICAL", 32, 39], ["serum", "ORGANISM_SUBSTANCE", 26, 31], ["glucose", "SIMPLE_CHEMICAL", 32, 39], ["uncontrolled serum glucose", "TEST", 13, 39], ["COVID", "TEST", 81, 86]]], ["116| Being an individual with obesity impairs the immune response to SARS-CoV-2Being an individual with obesity has modulatory effects on key immune cell populations critical in the response to SARS-CoV-2. liver, heart and kidneys.", [["immune cell", "ANATOMY", 142, 153], ["liver", "ANATOMY", 206, 211], ["heart", "ANATOMY", 213, 218], ["kidneys", "ANATOMY", 223, 230], ["obesity", "DISEASE", 30, 37], ["SARS", "DISEASE", 69, 73], ["obesity", "DISEASE", 104, 111], ["SARS", "DISEASE", 194, 198], ["SARS-CoV-2Being", "ORGANISM", 69, 84], ["immune cell populations", "CELL", 142, 165], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 194, 204], ["liver", "ORGAN", 206, 211], ["heart", "ORGAN", 213, 218], ["kidneys", "ORGAN", 223, 230], ["immune cell populations", "CELL_TYPE", 142, 165], ["SARS-CoV-2Being", "SPECIES", 69, 84], ["SARS-CoV", "SPECIES", 194, 202], ["obesity", "PROBLEM", 30, 37], ["SARS", "TEST", 69, 73], ["CoV", "TEST", 74, 77], ["obesity", "PROBLEM", 104, 111], ["modulatory effects", "PROBLEM", 116, 134], ["key immune cell populations", "TREATMENT", 138, 165], ["CoV", "TEST", 199, 202], ["obesity", "OBSERVATION", 30, 37], ["obesity", "OBSERVATION", 104, 111], ["immune cell", "OBSERVATION", 142, 153], ["heart", "ANATOMY", 213, 218], ["kidneys", "ANATOMY", 223, 230]]], ["109, 142 This mechanism is thought to drive increased incidence of ischemic and coagulopathy conditions in COVID-19 patients.| Inflammatory considerations of COVID-19 in individuals with obesityARDS and acute lung injury (ALI) are two of the primary causes of morbidity and mortality among adults infected with SARS-CoV-2.", [["lung", "ANATOMY", 209, 213], ["coagulopathy", "DISEASE", 80, 92], ["COVID-19", "CHEMICAL", 158, 166], ["obesityARDS", "DISEASE", 187, 198], ["acute lung injury", "DISEASE", 203, 220], ["ALI", "DISEASE", 222, 225], ["SARS", "DISEASE", 311, 315], ["COVID-19", "CHEMICAL", 158, 166], ["patients", "ORGANISM", 116, 124], ["COVID-19", "GENE_OR_GENE_PRODUCT", 158, 166], ["individuals", "ORGANISM", 170, 181], ["lung", "ORGAN", 209, 213], ["SARS-CoV-2", "ORGANISM", 311, 321], ["patients", "SPECIES", 116, 124], ["SARS-CoV", "SPECIES", 311, 319], ["ischemic and coagulopathy conditions", "PROBLEM", 67, 103], ["COVID", "TEST", 158, 163], ["obesityARDS", "PROBLEM", 187, 198], ["acute lung injury", "PROBLEM", 203, 220], ["morbidity", "PROBLEM", 260, 269], ["thought to drive", "UNCERTAINTY", 27, 43], ["ischemic", "OBSERVATION_MODIFIER", 67, 75], ["coagulopathy", "OBSERVATION", 80, 92], ["acute", "OBSERVATION_MODIFIER", 203, 208], ["lung", "ANATOMY", 209, 213], ["injury", "OBSERVATION", 214, 220], ["morbidity", "OBSERVATION", 260, 269]]], ["143 Presentation of ARDS and ALI is characterized by respiratory failure due to excessive pro-inflammatory cytokine production.", [["respiratory", "ANATOMY", 53, 64], ["ARDS", "DISEASE", 20, 24], ["ALI", "DISEASE", 29, 32], ["respiratory failure", "DISEASE", 53, 72], ["pro-inflammatory cytokine", "PROTEIN", 90, 115], ["ARDS", "PROBLEM", 20, 24], ["ALI", "PROBLEM", 29, 32], ["respiratory failure", "PROBLEM", 53, 72], ["excessive pro-inflammatory cytokine production", "PROBLEM", 80, 126], ["ARDS", "OBSERVATION", 20, 24], ["ALI", "OBSERVATION", 29, 32], ["respiratory failure", "OBSERVATION", 53, 72], ["excessive", "OBSERVATION_MODIFIER", 80, 89], ["pro-inflammatory cytokine production", "OBSERVATION", 90, 126]]], ["This inflammatory state leads to extensive lung damage, hypoxemic respiratory failure regardless of oxygen administration and pulmonary oedema not caused by congestive heart failure.", [["lung", "ANATOMY", 43, 47], ["respiratory", "ANATOMY", 66, 77], ["pulmonary", "ANATOMY", 126, 135], ["heart", "ANATOMY", 168, 173], ["lung damage", "DISEASE", 43, 54], ["hypoxemic respiratory failure", "DISEASE", 56, 85], ["oxygen", "CHEMICAL", 100, 106], ["pulmonary oedema", "DISEASE", 126, 142], ["congestive heart failure", "DISEASE", 157, 181], ["oxygen", "CHEMICAL", 100, 106], ["lung", "ORGAN", 43, 47], ["oxygen", "SIMPLE_CHEMICAL", 100, 106], ["pulmonary", "ORGAN", 126, 135], ["heart", "ORGAN", 168, 173], ["This inflammatory state", "PROBLEM", 0, 23], ["extensive lung damage", "PROBLEM", 33, 54], ["hypoxemic respiratory failure", "PROBLEM", 56, 85], ["oxygen administration", "TREATMENT", 100, 121], ["pulmonary oedema", "PROBLEM", 126, 142], ["congestive heart failure", "PROBLEM", 157, 181], ["inflammatory", "OBSERVATION", 5, 17], ["extensive", "OBSERVATION_MODIFIER", 33, 42], ["lung", "ANATOMY", 43, 47], ["damage", "OBSERVATION", 48, 54], ["hypoxemic", "OBSERVATION_MODIFIER", 56, 65], ["respiratory failure", "OBSERVATION", 66, 85], ["oxygen administration", "OBSERVATION", 100, 121], ["pulmonary", "ANATOMY", 126, 135], ["oedema", "OBSERVATION", 136, 142], ["congestive", "OBSERVATION_MODIFIER", 157, 167], ["heart", "ANATOMY", 168, 173], ["failure", "OBSERVATION", 174, 181]]], ["144 Men also experience a higher burden of COVID-19 than women.", [["women", "ORGANISM", 57, 62], ["women", "SPECIES", 57, 62], ["a higher burden of COVID", "PROBLEM", 24, 48]]], ["59 Being a man with obesity increases aromatase activity, which can convert testosterone to estradiol.", [["obesity", "DISEASE", 20, 27], ["testosterone", "CHEMICAL", 76, 88], ["estradiol", "CHEMICAL", 92, 101], ["testosterone", "CHEMICAL", 76, 88], ["estradiol", "CHEMICAL", 92, 101], ["man", "ORGANISM", 11, 14], ["aromatase", "GENE_OR_GENE_PRODUCT", 38, 47], ["testosterone", "SIMPLE_CHEMICAL", 76, 88], ["estradiol", "SIMPLE_CHEMICAL", 92, 101], ["man", "SPECIES", 11, 14], ["obesity increases aromatase activity", "PROBLEM", 20, 56], ["testosterone", "TREATMENT", 76, 88], ["estradiol", "TREATMENT", 92, 101], ["obesity", "OBSERVATION", 20, 27]]], ["152 Oestrogen receptor signalling can subsequently down-regulate IL-6 expression through inhibition of NF-\u03baB, 153 which has been shown to confer protective effects against influenza A virus in women through stimulation of neutrophil and virus-specific CD8 T cell responses.", [["neutrophil", "ANATOMY", 222, 232], ["CD8 T cell", "ANATOMY", 252, 262], ["influenza A virus", "DISEASE", 172, 189], ["Oestrogen", "CHEMICAL", 4, 13], ["Oestrogen receptor", "GENE_OR_GENE_PRODUCT", 4, 22], ["IL-6", "GENE_OR_GENE_PRODUCT", 65, 69], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 103, 108], ["influenza A virus", "ORGANISM", 172, 189], ["women", "ORGANISM", 193, 198], ["neutrophil", "CELL", 222, 232], ["CD8 T cell", "CELL", 252, 262], ["Oestrogen receptor", "PROTEIN", 4, 22], ["IL-6", "PROTEIN", 65, 69], ["NF-\u03baB", "PROTEIN", 103, 108], ["CD8", "PROTEIN", 252, 255], ["influenza A virus", "SPECIES", 172, 189], ["women", "SPECIES", 193, 198], ["influenza A virus", "SPECIES", 172, 189], ["Oestrogen receptor signalling", "TEST", 4, 33], ["IL", "TEST", 65, 67], ["NF", "TEST", 103, 105], ["influenza A virus", "PROBLEM", 172, 189], ["neutrophil", "TEST", 222, 232], ["virus", "TEST", 237, 242]]], ["154 Interestingly, however, men with obesity have impaired oestrogen receptor signalling, which leads to increased androgenic hormones and elevated oestrogen production from adipose tissue.", [["adipose tissue", "ANATOMY", 174, 188], ["obesity", "DISEASE", 37, 44], ["oestrogen", "CHEMICAL", 148, 157], ["oestrogen", "CHEMICAL", 59, 68], ["oestrogen", "CHEMICAL", 148, 157], ["men", "ORGANISM", 28, 31], ["oestrogen receptor", "GENE_OR_GENE_PRODUCT", 59, 77], ["oestrogen", "SIMPLE_CHEMICAL", 148, 157], ["adipose tissue", "TISSUE", 174, 188], ["oestrogen receptor", "PROTEIN", 59, 77], ["men", "SPECIES", 28, 31], ["obesity", "PROBLEM", 37, 44], ["impaired oestrogen receptor signalling", "PROBLEM", 50, 88], ["increased androgenic hormones", "PROBLEM", 105, 134], ["elevated oestrogen production", "PROBLEM", 139, 168], ["adipose tissue", "PROBLEM", 174, 188], ["obesity", "OBSERVATION", 37, 44], ["impaired", "OBSERVATION_MODIFIER", 50, 58], ["oestrogen", "OBSERVATION", 59, 68], ["increased", "OBSERVATION_MODIFIER", 105, 114], ["androgenic hormones", "OBSERVATION", 115, 134], ["elevated", "OBSERVATION_MODIFIER", 139, 147], ["oestrogen production", "OBSERVATION", 148, 168], ["adipose tissue", "OBSERVATION", 174, 188]]], ["155 Recently, androgen depletion therapy has been shown to protect against COVID-19 in male prostate cancer patients.", [["prostate cancer", "ANATOMY", 92, 107], ["COVID-19", "CHEMICAL", 75, 83], ["prostate cancer", "DISEASE", 92, 107], ["androgen", "CHEMICAL", 14, 22], ["androgen", "SIMPLE_CHEMICAL", 14, 22], ["COVID-19", "GENE_OR_GENE_PRODUCT", 75, 83], ["prostate cancer", "CANCER", 92, 107], ["patients", "ORGANISM", 108, 116], ["patients", "SPECIES", 108, 116], ["androgen depletion therapy", "TREATMENT", 14, 40], ["prostate", "ANATOMY", 92, 100], ["cancer", "OBSERVATION", 101, 107]]], ["156 However, more information is needed to understand the mechanism of action of androgens and androgen depletion therapy.", [["androgens", "CHEMICAL", 81, 90], ["androgens", "CHEMICAL", 81, 90], ["androgen", "CHEMICAL", 95, 103], ["androgens", "SIMPLE_CHEMICAL", 81, 90], ["androgen", "SIMPLE_CHEMICAL", 95, 103], ["androgens", "TREATMENT", 81, 90], ["androgen depletion therapy", "TREATMENT", 95, 121]]], ["Nonetheless, adequate control of proand anti-inflammatory responses during SARS-CoV-2 infections is critical to limit nonspecific tissue damage and subsequent development of ARDS, which has a higher burden among COVID-19 cases with obesity.| Implications for treatment and vaccination strategies for being an individual with obesityObesity may also impair therapeutic treatments during COVID-19| Implications for treatment and vaccination strategies for being an individual with obesityinfections.", [["tissue", "ANATOMY", 130, 136], ["SARS", "DISEASE", 75, 79], ["infections", "DISEASE", 86, 96], ["ARDS", "DISEASE", 174, 178], ["obesity", "DISEASE", 232, 239], ["obesityObesity", "DISEASE", 325, 339], ["obesityinfections", "DISEASE", 479, 496], ["SARS-CoV-2", "ORGANISM", 75, 85], ["tissue", "TISSUE", 130, 136], ["SARS-CoV", "SPECIES", 75, 83], ["proand anti-inflammatory responses", "TREATMENT", 33, 67], ["SARS", "PROBLEM", 75, 79], ["CoV-2 infections", "PROBLEM", 80, 96], ["nonspecific tissue damage", "PROBLEM", 118, 143], ["ARDS", "PROBLEM", 174, 178], ["obesity", "PROBLEM", 232, 239], ["treatment", "TREATMENT", 259, 268], ["vaccination strategies", "TREATMENT", 273, 295], ["obesityObesity", "TREATMENT", 325, 339], ["therapeutic treatments", "TREATMENT", 356, 378], ["treatment", "TREATMENT", 413, 422], ["vaccination strategies", "TREATMENT", 427, 449], ["obesityinfections", "PROBLEM", 479, 496], ["nonspecific tissue", "OBSERVATION_MODIFIER", 118, 136], ["damage", "OBSERVATION", 137, 143], ["ARDS", "OBSERVATION", 174, 178], ["higher", "OBSERVATION_MODIFIER", 192, 198], ["burden", "OBSERVATION_MODIFIER", 199, 205], ["obesity", "OBSERVATION", 232, 239]]], ["ACE inhibitors, which are commonly used to treat hypertension, may increase COVID-19 severity in T2D patients, especially those with poorly controlled blood glucose.", [["blood", "ANATOMY", 151, 156], ["ACE inhibitors", "CHEMICAL", 0, 14], ["hypertension", "DISEASE", 49, 61], ["T2D", "DISEASE", 97, 100], ["glucose", "CHEMICAL", 157, 164], ["glucose", "CHEMICAL", 157, 164], ["ACE", "GENE_OR_GENE_PRODUCT", 0, 3], ["COVID-19", "GENE_OR_GENE_PRODUCT", 76, 84], ["patients", "ORGANISM", 101, 109], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["glucose", "SIMPLE_CHEMICAL", 157, 164], ["patients", "SPECIES", 101, 109], ["ACE inhibitors", "TREATMENT", 0, 14], ["hypertension", "PROBLEM", 49, 61], ["COVID", "TEST", 76, 81], ["blood glucose", "TEST", 151, 164], ["hypertension", "OBSERVATION", 49, 61]]], ["157 While discontinuing use of ACE inhibitors is not advisable at this time due to offsetting cardiovascular benefits, 158 binding.", [["cardiovascular", "ANATOMY", 94, 108], ["ACE inhibitors", "CHEMICAL", 31, 45], ["ACE", "GENE_OR_GENE_PRODUCT", 31, 34], ["cardiovascular", "ANATOMICAL_SYSTEM", 94, 108], ["ACE inhibitors", "TREATMENT", 31, 45]]], ["How these treatments in patients with obesity contribute to COVID-19 severity, however, will be a key question in their overall effectiveness.", [["obesity", "DISEASE", 38, 45], ["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["obesity", "PROBLEM", 38, 45], ["COVID", "TEST", 60, 65]]], ["The IL-6 receptor (IL-6R) antagonist tocilizumab may reduce IL-6 signalling in severe COVID-19 cases where cytokine release syndrome is a major factor of mortality.", [["tocilizumab", "CHEMICAL", 37, 48], ["COVID", "DISEASE", 86, 91], ["IL-6 receptor", "GENE_OR_GENE_PRODUCT", 4, 17], ["IL-6R", "GENE_OR_GENE_PRODUCT", 19, 24], ["tocilizumab", "SIMPLE_CHEMICAL", 37, 48], ["IL-6", "GENE_OR_GENE_PRODUCT", 60, 64], ["IL-6 receptor", "PROTEIN", 4, 17], ["IL-6", "PROTEIN", 60, 64], ["cytokine", "PROTEIN", 107, 115], ["The IL-6 receptor (IL-6R) antagonist tocilizumab", "TREATMENT", 0, 48], ["IL", "TEST", 60, 62], ["severe COVID", "PROBLEM", 79, 91], ["cytokine release syndrome", "PROBLEM", 107, 132]]], ["159 As noted above, chronic inflammation is a hallmark of individuals with obesity, which includes elevated levels of IL-6.", [["inflammation", "DISEASE", 28, 40], ["obesity", "DISEASE", 75, 82], ["IL-6", "GENE_OR_GENE_PRODUCT", 118, 122], ["IL-6", "PROTEIN", 118, 122], ["chronic inflammation", "PROBLEM", 20, 40], ["obesity", "PROBLEM", 75, 82], ["elevated levels of IL", "PROBLEM", 99, 120], ["chronic", "OBSERVATION_MODIFIER", 20, 27], ["inflammation", "OBSERVATION", 28, 40], ["hallmark", "OBSERVATION_MODIFIER", 46, 54], ["obesity", "OBSERVATION", 75, 82], ["elevated", "OBSERVATION_MODIFIER", 99, 107], ["levels", "OBSERVATION_MODIFIER", 108, 114]]], ["Preliminary data suggest tocilizumab treatment can reduce fever and oxygen requirement.", [["tocilizumab", "CHEMICAL", 25, 36], ["fever", "DISEASE", 58, 63], ["oxygen", "CHEMICAL", 68, 74], ["oxygen", "CHEMICAL", 68, 74], ["tocilizumab", "SIMPLE_CHEMICAL", 25, 36], ["oxygen", "SIMPLE_CHEMICAL", 68, 74], ["Preliminary data", "TEST", 0, 16], ["tocilizumab treatment", "TREATMENT", 25, 46], ["fever", "PROBLEM", 58, 63], ["oxygen requirement", "PROBLEM", 68, 86], ["tocilizumab", "OBSERVATION", 25, 36], ["oxygen requirement", "OBSERVATION", 68, 86]]], ["160 middle-income countries.", [["middle", "OBSERVATION_MODIFIER", 4, 10]]], ["174 The impact on not only malnutrition but increased food insecurity for the large proportion of lower income families is expected to be significant.", [["malnutrition", "DISEASE", 27, 39], ["malnutrition", "PROBLEM", 27, 39], ["significant", "OBSERVATION_MODIFIER", 138, 149]]], ["174 One might suspect we would see a decline in obesity if the food insecurity impacts the individuals with overweight and obesity in many low-and middle-income countries.", [["obesity", "DISEASE", 48, 55], ["overweight", "DISEASE", 108, 118], ["obesity", "DISEASE", 123, 130], ["obesity", "PROBLEM", 48, 55], ["obesity", "PROBLEM", 123, 130], ["obesity", "OBSERVATION", 48, 55]]], ["If the diets shifts to increased consumption of refined carbohydrates, fried food and other unhealthy aspects of the traditional diet or to increased highly or ultraprocessed food we may experience increases in the prevalence of individuals with obesity.", [["obesity", "DISEASE", 246, 253], ["carbohydrates", "CHEMICAL", 56, 69], ["obesity", "PROBLEM", 246, 253], ["obesity", "OBSERVATION", 246, 253]]], ["Similarly studies in higher income countries suggest weight gains or no shift in weight.", [["weight gains", "PROBLEM", 53, 65], ["shift in weight", "PROBLEM", 72, 87]]], ["175 At the same time, some studies from higher income countries suggest potential increases in obesity.", [["obesity", "DISEASE", 95, 102], ["some studies", "TEST", 22, 34], ["obesity", "PROBLEM", 95, 102], ["increases", "OBSERVATION_MODIFIER", 82, 91], ["obesity", "OBSERVATION", 95, 102]]], ["175, 176 While we do not have data on sales of ultraprocessed foods and beverages, many reports both from organizations monitoring food purchases and global company reports suggest that in higher and middle-income countries access to fresh foods, especially fruits and vegetables is impacted due to breakdowns in local supply chains, and the demand for packaged processed food has increased, especially in the ready-to-eat and -drink categories.", [["fruits", "ANATOMY", 258, 264], ["vegetables", "ANATOMY", 269, 279], ["fruits", "ORGANISM_SUBDIVISION", 258, 264], ["vegetables", "ORGANISM_SUBDIVISION", 269, 279], ["breakdowns in local supply chains", "PROBLEM", 299, 332], ["increased", "OBSERVATION_MODIFIER", 381, 390]]], ["8, 177 These foods tend to be ultraprocessed and high in energy density, saturated fat, sodium and sugar.", [["sodium", "CHEMICAL", 88, 94], ["sodium", "CHEMICAL", 88, 94], ["sugar", "CHEMICAL", 99, 104], ["fat", "TISSUE", 83, 86], ["sodium", "SIMPLE_CHEMICAL", 88, 94], ["sugar", "SIMPLE_CHEMICAL", 99, 104], ["sodium", "TEST", 88, 94], ["sugar", "TEST", 99, 104], ["high", "OBSERVATION_MODIFIER", 49, 53]]], ["In addition, they are relatively inexpensive due to the large economies of scale in their production.", [["large", "OBSERVATION_MODIFIER", 56, 61], ["economies", "OBSERVATION", 62, 71]]], ["Particularly where costs loom greatly in food-purchasing decisions, as among the lower income segments of the population, these cheaper products may be consumed in much greater quantities.", [["these cheaper products", "TREATMENT", 122, 144]]], ["However, ultraprocessed foods are a major contributor to obesity and other non-communicable diseases (NCDs).", [["obesity", "DISEASE", 57, 64], ["non-communicable diseases", "DISEASE", 75, 100], ["NCDs", "DISEASE", 102, 106], ["obesity", "PROBLEM", 57, 64], ["other non-communicable diseases", "PROBLEM", 69, 100], ["obesity", "OBSERVATION", 57, 64], ["non-communicable diseases", "OBSERVATION", 75, 100]]], ["The literature linking ultraprocessed foods with adverse health outcomes is large and consistent.", [["adverse health outcomes", "PROBLEM", 49, 72], ["large", "OBSERVATION_MODIFIER", 76, 81]]], ["[178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195] Additionally| Policy implicationsVaccination remains the best protection against infectious diseases like COVID-19.", [["infectious diseases", "DISEASE", 189, 208], ["[178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] [195]", "SIMPLE_CHEMICAL", 0, 107], ["Vaccination", "TREATMENT", 141, 152], ["infectious diseases", "PROBLEM", 189, 208], ["COVID", "TEST", 214, 219]]], ["Therapeutics targeted at limiting viral replication or remediating complications of infection may help limit severe cases and moderately reduce mortality.", [["infection", "DISEASE", 84, 93], ["Therapeutics", "TREATMENT", 0, 12], ["viral replication", "TREATMENT", 34, 51], ["infection", "PROBLEM", 84, 93], ["severe cases", "PROBLEM", 109, 121], ["moderately reduce mortality", "PROBLEM", 126, 153], ["infection", "OBSERVATION", 84, 93]]], ["Public health experts agree that viral spread will continue to cause tremendous health and economic problems until we reach vaccination and/or community-acquired herd immunity.", [["herd", "ORGANISM_SUBDIVISION", 162, 166], ["viral spread", "PROBLEM", 33, 45], ["economic problems", "PROBLEM", 91, 108]]], ["Current models project that intermittent times of social distancing and lockdown measures will be required until a viable vaccine can be widely produced, 197 and these measures are likely to extend into the foreseeable future.", [["social distancing and lockdown measures", "TREATMENT", 50, 89], ["a viable vaccine", "TREATMENT", 113, 129]]], ["This paper highlights another concernthat is, vaccines may not be as effective in individuals with overweight/obesity.", [["overweight/obesity", "DISEASE", 99, 117], ["vaccines", "TREATMENT", 46, 54], ["overweight/obesity", "PROBLEM", 99, 117], ["obesity", "OBSERVATION", 110, 117]]], ["Given the large prevalence of the world population that is composed of individuals with overweight/obesity, it is imperative that governments ensure that testing and research focus not only on the general efficacy of vaccines and therapeutics but also on how they will impact individuals with obesity.| Policy implicationsFurthermore, we must carefully monitor and regulate the consumption of ultraprocessed foods and beverages through fiscal policies such as taxation and regulating marketing and promotion of such foods.", [["overweight/obesity", "DISEASE", 88, 106], ["obesity", "DISEASE", 293, 300], ["overweight/obesity", "PROBLEM", 88, 106], ["testing", "TEST", 154, 161], ["vaccines", "TREATMENT", 217, 225], ["therapeutics", "TREATMENT", 230, 242], ["obesity", "PROBLEM", 293, 300], ["fiscal policies", "TREATMENT", 436, 451], ["taxation", "TREATMENT", 460, 468], ["large", "OBSERVATION_MODIFIER", 10, 15], ["obesity", "OBSERVATION", 99, 106], ["obesity", "OBSERVATION", 293, 300]]], ["If as expected this behaviour is increasing, it will exacerbate other health concerns, including risks of increased adiposity and major| Policy implicationsNCDs.", [["increased adiposity", "PROBLEM", 106, 125], ["increasing", "OBSERVATION_MODIFIER", 33, 43]]], ["When compounded with reduced physical activity and increased sedentary behaviour, the risk of increased adiposity is clearly an important concern.", [["reduced physical activity", "PROBLEM", 21, 46], ["increased sedentary behaviour", "PROBLEM", 51, 80], ["increased adiposity", "PROBLEM", 94, 113], ["increased", "OBSERVATION_MODIFIER", 51, 60], ["sedentary", "OBSERVATION", 61, 70], ["increased adiposity", "OBSERVATION", 94, 113]]], ["Finally, the poor around much of the globe also face increased hunger and with it the potential for elevated stunting and its consequences, including the long-term risks of central visceral adiposity and many NCDs.", [["visceral", "ANATOMY", 181, 189], ["stunting", "DISEASE", 109, 117], ["visceral adiposity", "DISEASE", 181, 199], ["NCDs", "DISEASE", 209, 213], ["globe", "ORGAN", 37, 42], ["visceral", "ORGANISM_SUBDIVISION", 181, 189], ["face increased hunger", "PROBLEM", 48, 69], ["elevated stunting", "PROBLEM", 100, 117], ["central visceral adiposity", "PROBLEM", 173, 199], ["poor", "OBSERVATION_MODIFIER", 13, 17], ["globe", "ANATOMY", 37, 42], ["face", "OBSERVATION_MODIFIER", 48, 52], ["increased", "OBSERVATION_MODIFIER", 53, 62], ["hunger", "OBSERVATION", 63, 69], ["elevated", "OBSERVATION_MODIFIER", 100, 108], ["stunting", "OBSERVATION", 109, 117], ["long-term", "OBSERVATION_MODIFIER", 154, 163], ["central", "ANATOMY_MODIFIER", 173, 180], ["visceral", "ANATOMY", 181, 189], ["adiposity", "OBSERVATION", 190, 199], ["many", "OBSERVATION_MODIFIER", 204, 208], ["NCDs", "OBSERVATION", 209, 213]]], ["Increasing hunger and stunting can have long-term adverse impacts on health and well-being in multiple ways, and major policies to mitigate this effect are critical when resources are available.| Policy implicationsIn addition to COVID-19's critical economic constraints, its impacts on diets may pose lifelong risks to populations around the globe.", [["stunting", "DISEASE", 22, 30], ["Increasing hunger", "PROBLEM", 0, 17], ["stunting", "PROBLEM", 22, 30], ["COVID", "TEST", 230, 235], ["critical economic constraints", "PROBLEM", 241, 270], ["hunger", "OBSERVATION", 11, 17], ["stunting", "OBSERVATION", 22, 30], ["long-term", "OBSERVATION_MODIFIER", 40, 49], ["economic constraints", "OBSERVATION", 250, 270], ["globe", "ANATOMY", 343, 348]]], ["NCD and individuals with obesity risks are far more predominant in the former, whereas the latter face high levels of the double burden of malnutrition, in which slow declines in stunting are likely to shift to increased stunting and wasting accompanied by rapid increases in individuals with obesity.| Policy implicationsCreative policies to reduce consumption of ultraprocessed foods and increase consumption of healthier foods, such as legumes, selected whole grains, vegetables and fresh fruits, are important for all countries.", [["grains", "ANATOMY", 463, 469], ["vegetables", "ANATOMY", 471, 481], ["fruits", "ANATOMY", 492, 498], ["NCD", "DISEASE", 0, 3], ["obesity", "DISEASE", 25, 32], ["malnutrition", "DISEASE", 139, 151], ["stunting", "DISEASE", 179, 187], ["stunting", "DISEASE", 221, 229], ["wasting", "DISEASE", 234, 241], ["obesity", "DISEASE", 293, 300], ["grains", "ORGANISM_SUBDIVISION", 463, 469], ["vegetables", "ORGANISM_SUBDIVISION", 471, 481], ["fruits", "ORGANISM_SUBDIVISION", 492, 498], ["obesity risks", "PROBLEM", 25, 38], ["the double burden of malnutrition", "PROBLEM", 118, 151], ["slow declines in stunting", "PROBLEM", 162, 187], ["increased stunting and wasting", "PROBLEM", 211, 241], ["obesity", "PROBLEM", 293, 300], ["Creative policies", "TREATMENT", 322, 339], ["ultraprocessed foods", "TREATMENT", 365, 385], ["obesity", "OBSERVATION", 25, 32], ["more predominant", "OBSERVATION_MODIFIER", 47, 63], ["malnutrition", "OBSERVATION", 139, 151], ["slow", "OBSERVATION_MODIFIER", 162, 166], ["declines", "OBSERVATION_MODIFIER", 167, 175], ["increased", "OBSERVATION_MODIFIER", 211, 220], ["stunting", "OBSERVATION", 221, 229], ["rapid", "OBSERVATION_MODIFIER", 257, 262], ["increases", "OBSERVATION_MODIFIER", 263, 272], ["obesity", "OBSERVATION", 293, 300]]], ["12, 198, 199 It is quite that likely Chile's policies could significantly reduce the current growth in consumption of ultraprocessed foods.", [["Chile's policies", "TREATMENT", 37, 53], ["growth", "OBSERVATION_MODIFIER", 93, 99]]], ["Moreover, a tax accompanying purchases of those foods would potentially increase fiscal space in countries suffering from the economic impacts of COVID-19, albeit few countries have successfully allocated these resources for health or nutrition programmes.", [["tax", "PROTEIN", 12, 15], ["COVID", "TEST", 146, 151], ["nutrition programmes", "TREATMENT", 235, 255], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["fiscal space", "OBSERVATION", 81, 93]]], ["Some countries are finding ways to provide boxes of fresh vegetables and fruits to the elderly such as one programme in several Chilean cities 200 ; however, most low-and middleincome countries do not have the resources for such efforts though combined with taxation and marketing controls, such efforts would be more feasible.", [["vegetables", "ANATOMY", 58, 68], ["fruits", "ANATOMY", 73, 79], ["vegetables", "ORGANISM_SUBDIVISION", 58, 68], ["fruits", "ORGANISM_SUBDIVISION", 73, 79], ["taxation", "TREATMENT", 258, 266]]], ["201 The COVID-19 pandemic challenges all countries enormously.| Policy implicationsOur systems, institutions, health and welfare will feel the impacts for many years.", [["The COVID", "TREATMENT", 4, 13]]], ["The high prevalence of individuals with obesity exacerbates the threat to everyone's health, and the economic, social distancing and stay-at-home components compound the impacts.", [["obesity", "DISEASE", 40, 47], ["obesity", "PROBLEM", 40, 47], ["high prevalence", "OBSERVATION_MODIFIER", 4, 19], ["obesity", "OBSERVATION", 40, 47]]], ["We will need creative solutions quickly to prevent undesirable dietary patterns and promote healthy eating, which is so critical to our future health and for building resilience against future threats.", [["creative solutions", "TREATMENT", 13, 31]]]], "PMC7460690": [["COVID-19: Epidemiological and clinical context ::: IntroductionThe pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-coronavirus disease 2019 (COVID-19)-started at the end of 2019, affecting all the countries in the world.", [["acute respiratory syndrome coronavirus", "DISEASE", 97, 135], ["infection-coronavirus disease", "DISEASE", 151, 180], ["COVID-19", "CHEMICAL", 187, 195], ["SARS-CoV-2", "ORGANISM", 139, 149], ["coronavirus", "ORGANISM", 161, 172], ["severe acute respiratory syndrome coronavirus", "SPECIES", 90, 135], ["SARS-CoV-2", "SPECIES", 139, 149], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 86, 135], ["SARS", "TEST", 139, 143], ["CoV", "TEST", 144, 147], ["infection", "PROBLEM", 151, 160], ["coronavirus disease", "PROBLEM", 161, 180], ["COVID", "TEST", 187, 192], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["acute", "OBSERVATION_MODIFIER", 97, 102], ["respiratory syndrome", "OBSERVATION", 103, 123], ["coronavirus disease", "OBSERVATION", 161, 180]]], ["Till date (08.06.2020), more than seven million persons are infected worldwide, with close to 500.000 casualties (1).", [["persons", "ORGANISM", 48, 55], ["persons", "SPECIES", 48, 55], ["infected", "OBSERVATION", 60, 68]]], ["The clinical picture is dominated by flu-like respiratory and general symptoms (such as fever, fatigue, loss of smell, cough, myalgia, diarrhea, and dyspnea).", [["respiratory", "ANATOMY", 46, 57], ["flu-like respiratory and general symptoms", "DISEASE", 37, 78], ["fever", "DISEASE", 88, 93], ["fatigue", "DISEASE", 95, 102], ["loss of smell", "DISEASE", 104, 117], ["cough", "DISEASE", 119, 124], ["myalgia", "DISEASE", 126, 133], ["diarrhea", "DISEASE", 135, 143], ["dyspnea", "DISEASE", 149, 156], ["flu-like respiratory and general symptoms", "PROBLEM", 37, 78], ["fever", "PROBLEM", 88, 93], ["fatigue", "PROBLEM", 95, 102], ["loss of smell", "PROBLEM", 104, 117], ["cough", "PROBLEM", 119, 124], ["myalgia", "PROBLEM", 126, 133], ["diarrhea", "PROBLEM", 135, 143], ["dyspnea", "PROBLEM", 149, 156], ["flu", "OBSERVATION", 37, 40], ["respiratory", "ANATOMY", 46, 57]]], ["The disease is mild in the majority of cases.", [["The disease", "PROBLEM", 0, 11], ["disease", "OBSERVATION", 4, 11], ["mild", "OBSERVATION_MODIFIER", 15, 19]]], ["However, interstitial pneumonia and respiratory failure can occur in 15%\u201320% of patients.", [["interstitial", "ANATOMY", 9, 21], ["respiratory", "ANATOMY", 36, 47], ["interstitial pneumonia", "DISEASE", 9, 31], ["respiratory failure", "DISEASE", 36, 55], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["interstitial pneumonia", "PROBLEM", 9, 31], ["respiratory failure", "PROBLEM", 36, 55], ["interstitial", "ANATOMY_MODIFIER", 9, 21], ["pneumonia", "OBSERVATION", 22, 31], ["respiratory failure", "OBSERVATION", 36, 55]]], ["In the case of respiratory failure, dyspnea associated with hypoxemia is characteristic, and progression to more severe forms requiring mechanical ventilation could be rapid.", [["respiratory", "ANATOMY", 15, 26], ["respiratory failure", "DISEASE", 15, 34], ["dyspnea", "DISEASE", 36, 43], ["hypoxemia", "DISEASE", 60, 69], ["respiratory failure", "PROBLEM", 15, 34], ["dyspnea", "PROBLEM", 36, 43], ["hypoxemia", "PROBLEM", 60, 69], ["mechanical ventilation", "TREATMENT", 136, 158], ["respiratory", "ANATOMY", 15, 26], ["failure", "OBSERVATION", 27, 34], ["dyspnea", "OBSERVATION", 36, 43], ["hypoxemia", "OBSERVATION", 60, 69], ["more severe", "OBSERVATION_MODIFIER", 108, 119], ["mechanical ventilation", "OBSERVATION", 136, 158]]], ["The involvement of other organs, systems, and homeostatic mechanisms\u2013liver, kidney, heart and circulatory system, nervous system, and coagulation system (hypercoagulability)\u2013also occur frequently.", [["organs", "ANATOMY", 25, 31], ["mechanisms\u2013liver", "ANATOMY", 58, 74], ["kidney", "ANATOMY", 76, 82], ["heart", "ANATOMY", 84, 89], ["circulatory system", "ANATOMY", 94, 112], ["nervous system", "ANATOMY", 114, 128], ["hypercoagulability", "DISEASE", 154, 172], ["organs", "ORGAN", 25, 31], ["kidney", "ORGAN", 76, 82], ["heart", "ORGAN", 84, 89], ["circulatory system", "ANATOMICAL_SYSTEM", 94, 112], ["nervous system", "ANATOMICAL_SYSTEM", 114, 128], ["homeostatic mechanisms\u2013liver, kidney, heart and circulatory system, nervous system", "PROBLEM", 46, 128], ["coagulation system", "TEST", 134, 152], ["organs", "ANATOMY", 25, 31], ["kidney", "ANATOMY", 76, 82], ["heart", "ANATOMY", 84, 89], ["circulatory system", "ANATOMY", 94, 112], ["nervous system", "ANATOMY", 114, 128]]], ["The definitive diagnosis of active infection is provided by the detection of the virus in the patient\u2019s nasopharyngeal secretions, using real-time reverse transcription polymerase chain reaction (rRT-PCR) assay.", [["nasopharyngeal secretions", "ANATOMY", 104, 129], ["infection", "DISEASE", 35, 44], ["patient", "ORGANISM", 94, 101], ["nasopharyngeal secretions", "ORGAN", 104, 129], ["patient", "SPECIES", 94, 101], ["active infection", "PROBLEM", 28, 44], ["the virus", "PROBLEM", 77, 86], ["nasopharyngeal secretions", "PROBLEM", 104, 129], ["real-time reverse transcription polymerase chain reaction", "TREATMENT", 137, 194], ["active", "OBSERVATION_MODIFIER", 28, 34], ["infection", "OBSERVATION", 35, 44], ["nasopharyngeal", "ANATOMY", 104, 118], ["secretions", "OBSERVATION", 119, 129]]], ["The clinical management of COVID-19 is still evolving and includes antiviral (mostly empirical and still investigational), and immunomodulatory therapies, as well as intensive care measures (such as mechanical ventilation) for those in critical conditions (2, 3).Pathophysiological background of pulmonary involvement and respiratory failure in SARS-CoV-2 infection ::: IntroductionLung involvement is the main pathological feature of COVID-19, and is responsible for respiratory failure, the leading cause of death.", [["pulmonary", "ANATOMY", 296, 305], ["respiratory", "ANATOMY", 322, 333], ["respiratory", "ANATOMY", 468, 479], ["respiratory failure", "DISEASE", 322, 341], ["SARS-CoV-2 infection", "DISEASE", 345, 365], ["respiratory failure", "DISEASE", 468, 487], ["death", "DISEASE", 510, 515], ["pulmonary", "ORGAN", 296, 305], ["SARS-CoV-2", "ORGANISM", 345, 355], ["COVID-19", "CELL", 435, 443], ["SARS-CoV", "SPECIES", 345, 353], ["COVID", "TEST", 27, 32], ["antiviral", "TREATMENT", 67, 76], ["immunomodulatory therapies", "TREATMENT", 127, 153], ["intensive care measures", "TREATMENT", 166, 189], ["mechanical ventilation", "TREATMENT", 199, 221], ["pulmonary involvement", "PROBLEM", 296, 317], ["respiratory failure", "PROBLEM", 322, 341], ["SARS", "PROBLEM", 345, 349], ["COVID", "TEST", 435, 440], ["respiratory failure", "PROBLEM", 468, 487], ["death", "PROBLEM", 510, 515], ["pulmonary", "ANATOMY", 296, 305], ["respiratory failure", "OBSERVATION", 322, 341], ["infection", "OBSERVATION", 356, 365], ["main", "OBSERVATION_MODIFIER", 406, 410], ["responsible for", "UNCERTAINTY", 452, 467], ["respiratory failure", "OBSERVATION", 468, 487]]], ["The lung injury produced by SARS-CoV-2 starts with viral attachment to angiotensin converting enzyme 2 (ACE2) receptors, present on the apical surface of respiratory epithelial cells in the conductive airways.", [["lung", "ANATOMY", 4, 8], ["apical surface", "ANATOMY", 136, 150], ["respiratory epithelial cells", "ANATOMY", 154, 182], ["conductive airways", "ANATOMY", 190, 208], ["lung injury", "DISEASE", 4, 15], ["SARS", "DISEASE", 28, 32], ["angiotensin", "CHEMICAL", 71, 82], ["lung", "ORGAN", 4, 8], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 71, 102], ["ACE2", "GENE_OR_GENE_PRODUCT", 104, 108], ["apical surface", "CELLULAR_COMPONENT", 136, 150], ["respiratory epithelial cells", "CELL", 154, 182], ["airways", "MULTI-TISSUE_STRUCTURE", 201, 208], ["angiotensin converting enzyme 2 (ACE2) receptors", "PROTEIN", 71, 119], ["respiratory epithelial cells", "CELL_TYPE", 154, 182], ["SARS-CoV", "SPECIES", 28, 36], ["The lung injury", "PROBLEM", 0, 15], ["SARS", "PROBLEM", 28, 32], ["viral attachment", "PROBLEM", 51, 67], ["angiotensin converting enzyme", "TEST", 71, 100], ["respiratory epithelial cells", "PROBLEM", 154, 182], ["lung", "ANATOMY", 4, 8], ["injury", "OBSERVATION", 9, 15], ["apical", "ANATOMY_MODIFIER", 136, 142], ["surface", "ANATOMY_MODIFIER", 143, 150], ["respiratory epithelial cells", "OBSERVATION", 154, 182], ["conductive", "ANATOMY_MODIFIER", 190, 200], ["airways", "ANATOMY", 201, 208]]], ["The infected respiratory epithelial cells are the source of the local and systemic (to distant organs) viral spread, a process which is facilitated by inflammation and alveolar-capillary damage (4).", [["respiratory epithelial cells", "ANATOMY", 13, 41], ["organs", "ANATOMY", 95, 101], ["alveolar", "ANATOMY", 168, 176], ["capillary", "ANATOMY", 177, 186], ["inflammation", "DISEASE", 151, 163], ["respiratory epithelial cells", "CELL", 13, 41], ["organs", "ORGAN", 95, 101], ["alveolar-", "TISSUE", 168, 177], ["capillary", "TISSUE", 177, 186], ["infected respiratory epithelial cells", "CELL_TYPE", 4, 41], ["The infected respiratory epithelial cells", "PROBLEM", 0, 41], ["viral spread", "PROBLEM", 103, 115], ["inflammation", "PROBLEM", 151, 163], ["alveolar-capillary damage", "PROBLEM", 168, 193], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["respiratory epithelial cells", "OBSERVATION", 13, 41], ["local", "OBSERVATION_MODIFIER", 64, 69], ["systemic", "OBSERVATION_MODIFIER", 74, 82], ["viral spread", "OBSERVATION", 103, 115], ["inflammation", "OBSERVATION", 151, 163], ["alveolar", "ANATOMY_MODIFIER", 168, 176], ["capillary damage", "OBSERVATION", 177, 193]]], ["ACE2 is a membrane-associated aminopeptidase expressed in the pulmonary epithelium, vascular endothelia, renal and cardiovascular tissue, and the epithelia of small intestines and testes (5).", [["membrane", "ANATOMY", 10, 18], ["pulmonary epithelium", "ANATOMY", 62, 82], ["vascular endothelia", "ANATOMY", 84, 103], ["renal", "ANATOMY", 105, 110], ["cardiovascular tissue", "ANATOMY", 115, 136], ["epithelia", "ANATOMY", 146, 155], ["small intestines", "ANATOMY", 159, 175], ["testes", "ANATOMY", 180, 186], ["ACE2", "GENE_OR_GENE_PRODUCT", 0, 4], ["membrane", "CELLULAR_COMPONENT", 10, 18], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 30, 44], ["pulmonary epithelium", "TISSUE", 62, 82], ["vascular endothelia", "TISSUE", 84, 103], ["renal", "TISSUE", 105, 110], ["cardiovascular tissue", "TISSUE", 115, 136], ["epithelia", "TISSUE", 146, 155], ["small intestines", "ORGAN", 159, 175], ["testes", "ORGAN", 180, 186], ["ACE2", "PROTEIN", 0, 4], ["membrane-associated aminopeptidase", "PROTEIN", 10, 44], ["renal and cardiovascular tissue", "PROBLEM", 105, 136], ["aminopeptidase expressed", "OBSERVATION", 30, 54], ["pulmonary", "ANATOMY", 62, 71], ["epithelium", "ANATOMY_MODIFIER", 72, 82], ["vascular endothelia", "ANATOMY", 84, 103], ["renal", "ANATOMY", 105, 110], ["cardiovascular tissue", "ANATOMY", 115, 136], ["epithelia", "ANATOMY_MODIFIER", 146, 155], ["small intestines", "ANATOMY", 159, 175], ["testes", "ANATOMY", 180, 186]]], ["Beyond replication in the epithelial cells, SARS-CoV-2 down-regulates the expression of ACE2 receptors, which results in increased angiotensin II levels and induction of further lung injury via angiotensin II receptor type 1 stimulation.", [["epithelial cells", "ANATOMY", 26, 42], ["lung", "ANATOMY", 178, 182], ["angiotensin II", "CHEMICAL", 131, 145], ["lung injury", "DISEASE", 178, 189], ["angiotensin II", "CHEMICAL", 194, 208], ["epithelial cells", "CELL", 26, 42], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 44, 54], ["ACE2", "GENE_OR_GENE_PRODUCT", 88, 92], ["angiotensin II", "GENE_OR_GENE_PRODUCT", 131, 145], ["lung", "ORGAN", 178, 182], ["angiotensin II receptor type 1", "GENE_OR_GENE_PRODUCT", 194, 224], ["epithelial cells", "CELL_TYPE", 26, 42], ["ACE2 receptors", "PROTEIN", 88, 102], ["angiotensin II", "PROTEIN", 131, 145], ["the epithelial cells", "TEST", 22, 42], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52], ["ACE2 receptors", "TEST", 88, 102], ["increased angiotensin II levels", "PROBLEM", 121, 152], ["further lung injury", "PROBLEM", 170, 189], ["angiotensin II receptor type 1 stimulation", "TREATMENT", 194, 236], ["epithelial cells", "ANATOMY", 26, 42], ["increased", "OBSERVATION_MODIFIER", 121, 130], ["angiotensin II", "OBSERVATION", 131, 145], ["lung", "ANATOMY", 178, 182], ["injury", "OBSERVATION", 183, 189]]], ["Lung damage is also promoted by the so-called cytokine storm (hyperinflammatory response), a part of the patient\u2019s immune reaction (4, 6).Pathophysiological background of pulmonary involvement and respiratory failure in SARS-CoV-2 infection ::: IntroductionOn microscopy, lung injury in COVID-19 is characterized by alveolar hyaline membrane formation, fibrin exudates, epithelial damage, vascular congestion, and diffuse-type II pneumocyte hyperplasia.", [["Lung", "ANATOMY", 0, 4], ["pulmonary", "ANATOMY", 171, 180], ["respiratory", "ANATOMY", 197, 208], ["lung", "ANATOMY", 272, 276], ["alveolar hyaline membrane", "ANATOMY", 316, 341], ["fibrin exudates", "ANATOMY", 353, 368], ["epithelial", "ANATOMY", 370, 380], ["vascular", "ANATOMY", 389, 397], ["Lung damage", "DISEASE", 0, 11], ["respiratory failure", "DISEASE", 197, 216], ["SARS-CoV-2 infection", "DISEASE", 220, 240], ["lung injury", "DISEASE", 272, 283], ["epithelial damage", "DISEASE", 370, 387], ["vascular congestion", "DISEASE", 389, 408], ["hyperplasia", "DISEASE", 441, 452], ["Lung", "ORGAN", 0, 4], ["patient", "ORGANISM", 105, 112], ["pulmonary", "ORGAN", 171, 180], ["SARS-CoV-2", "ORGANISM", 220, 230], ["lung", "ORGAN", 272, 276], ["alveolar hyaline membrane", "TISSUE", 316, 341], ["fibrin", "GENE_OR_GENE_PRODUCT", 353, 359], ["epithelial", "TISSUE", 370, 380], ["vascular", "MULTI-TISSUE_STRUCTURE", 389, 397], ["cytokine", "PROTEIN", 46, 54], ["patient", "SPECIES", 105, 112], ["SARS-CoV", "SPECIES", 220, 228], ["Lung damage", "PROBLEM", 0, 11], ["immune reaction", "PROBLEM", 115, 130], ["pulmonary involvement", "PROBLEM", 171, 192], ["respiratory failure", "PROBLEM", 197, 216], ["SARS", "PROBLEM", 220, 224], ["IntroductionOn microscopy", "TEST", 245, 270], ["lung injury", "PROBLEM", 272, 283], ["COVID", "TEST", 287, 292], ["alveolar hyaline membrane formation", "PROBLEM", 316, 351], ["fibrin exudates", "PROBLEM", 353, 368], ["epithelial damage", "PROBLEM", 370, 387], ["vascular congestion", "PROBLEM", 389, 408], ["diffuse-type II pneumocyte hyperplasia", "PROBLEM", 414, 452], ["damage", "OBSERVATION", 5, 11], ["cytokine storm", "OBSERVATION", 46, 60], ["pulmonary", "ANATOMY", 171, 180], ["respiratory failure", "OBSERVATION", 197, 216], ["infection", "OBSERVATION", 231, 240], ["lung", "ANATOMY", 272, 276], ["injury", "OBSERVATION", 277, 283], ["alveolar", "ANATOMY_MODIFIER", 316, 324], ["hyaline membrane formation", "OBSERVATION", 325, 351], ["fibrin exudates", "OBSERVATION", 353, 368], ["epithelial damage", "OBSERVATION", 370, 387], ["vascular", "ANATOMY", 389, 397], ["congestion", "OBSERVATION", 398, 408], ["diffuse", "OBSERVATION_MODIFIER", 414, 421], ["type II", "OBSERVATION_MODIFIER", 422, 429], ["pneumocyte hyperplasia", "OBSERVATION", 430, 452]]], ["The pulmonary interstitium is infiltrated by monocytes, macrophages, and lymphocytes.", [["pulmonary interstitium", "ANATOMY", 4, 26], ["monocytes", "ANATOMY", 45, 54], ["macrophages", "ANATOMY", 56, 67], ["lymphocytes", "ANATOMY", 73, 84], ["pulmonary interstitium", "MULTI-TISSUE_STRUCTURE", 4, 26], ["monocytes", "CELL", 45, 54], ["macrophages", "CELL", 56, 67], ["lymphocytes", "CELL", 73, 84], ["monocytes", "CELL_TYPE", 45, 54], ["macrophages", "CELL_TYPE", 56, 67], ["lymphocytes", "CELL_TYPE", 73, 84], ["monocytes", "TEST", 45, 54], ["macrophages", "TEST", 56, 67], ["lymphocytes", "TEST", 73, 84], ["pulmonary", "ANATOMY", 4, 13], ["interstitium", "ANATOMY_MODIFIER", 14, 26], ["infiltrated", "OBSERVATION", 30, 41], ["monocytes", "OBSERVATION", 45, 54], ["macrophages", "OBSERVATION_MODIFIER", 56, 67], ["lymphocytes", "ANATOMY", 73, 84]]], ["In more advanced phases of the disease, thickening of the alveolar walls and interstitium can be observed, with intraalveolar organization caused by fibroblastic proliferation and extracellular matrix formation (7).", [["alveolar walls", "ANATOMY", 58, 72], ["interstitium", "ANATOMY", 77, 89], ["intraalveolar", "ANATOMY", 112, 125], ["fibroblastic", "ANATOMY", 149, 161], ["extracellular matrix", "ANATOMY", 180, 200], ["alveolar walls", "MULTI-TISSUE_STRUCTURE", 58, 72], ["interstitium", "MULTI-TISSUE_STRUCTURE", 77, 89], ["fibroblastic", "CELL", 149, 161], ["extracellular matrix", "CELLULAR_COMPONENT", 180, 200], ["the disease", "PROBLEM", 27, 38], ["thickening of the alveolar walls and interstitium", "PROBLEM", 40, 89], ["intraalveolar organization", "PROBLEM", 112, 138], ["fibroblastic proliferation and extracellular matrix formation", "PROBLEM", 149, 210], ["advanced phases", "OBSERVATION_MODIFIER", 8, 23], ["disease", "OBSERVATION", 31, 38], ["thickening", "OBSERVATION", 40, 50], ["alveolar", "ANATOMY_MODIFIER", 58, 66], ["walls", "ANATOMY_MODIFIER", 67, 72], ["interstitium", "ANATOMY_MODIFIER", 77, 89], ["intraalveolar", "ANATOMY_MODIFIER", 112, 125], ["fibroblastic proliferation", "OBSERVATION", 149, 175], ["extracellular matrix formation", "OBSERVATION", 180, 210]]], ["An important and specific pathological finding in COVID-19 patients is the extensive microangiopathy of pulmonary vessels, associated with microthrombosis and neoangiogenesis (8).Pathophysiological background of pulmonary involvement and respiratory failure in SARS-CoV-2 infection ::: IntroductionThe morphological lesions developed in the lungs have characteristic (although not specific) correspondents on chest computed tomography images: ground-glass opacities reflecting edema of the alveolar septa, hyperplasia of the interstitium, partial filling of airspaces, or their combination; crazy-paving patterns corresponding to hyperplasia of inter- and intra-lobular interstitial tissue; and consolidations, which correspond to advanced alveolar damage, and can appear in the center of ground-glass opacities or be patchy.", [["pulmonary vessels", "ANATOMY", 104, 121], ["pulmonary", "ANATOMY", 212, 221], ["respiratory", "ANATOMY", 238, 249], ["lesions", "ANATOMY", 316, 323], ["lungs", "ANATOMY", 341, 346], ["alveolar septa", "ANATOMY", 490, 504], ["interstitium", "ANATOMY", 525, 537], ["airspaces", "ANATOMY", 558, 567], ["intra-lobular interstitial tissue", "ANATOMY", 656, 689], ["alveolar", "ANATOMY", 740, 748], ["microangiopathy of pulmonary vessels", "DISEASE", 85, 121], ["microthrombosis", "DISEASE", 139, 154], ["neoangiogenesis", "DISEASE", 159, 174], ["respiratory failure", "DISEASE", 238, 257], ["SARS-CoV-2 infection", "DISEASE", 261, 281], ["edema", "DISEASE", 477, 482], ["hyperplasia", "DISEASE", 630, 641], ["alveolar damage", "DISEASE", 740, 755], ["patients", "ORGANISM", 59, 67], ["pulmonary vessels", "MULTI-TISSUE_STRUCTURE", 104, 121], ["pulmonary", "ORGAN", 212, 221], ["SARS-CoV-2", "ORGANISM", 261, 271], ["lesions", "PATHOLOGICAL_FORMATION", 316, 323], ["lungs", "ORGAN", 341, 346], ["edema", "PATHOLOGICAL_FORMATION", 477, 482], ["alveolar septa", "MULTI-TISSUE_STRUCTURE", 490, 504], ["interstitium", "TISSUE", 525, 537], ["airspaces", "MULTI-TISSUE_STRUCTURE", 558, 567], ["intra-lobular interstitial tissue", "TISSUE", 656, 689], ["alveolar", "TISSUE", 740, 748], ["patients", "SPECIES", 59, 67], ["SARS-CoV", "SPECIES", 261, 269], ["the extensive microangiopathy of pulmonary vessels", "PROBLEM", 71, 121], ["microthrombosis", "PROBLEM", 139, 154], ["neoangiogenesis", "PROBLEM", 159, 174], ["pulmonary involvement", "PROBLEM", 212, 233], ["respiratory failure", "PROBLEM", 238, 257], ["SARS", "PROBLEM", 261, 265], ["The morphological lesions", "PROBLEM", 298, 323], ["chest computed tomography images", "TEST", 409, 441], ["ground-glass opacities", "PROBLEM", 443, 465], ["edema of the alveolar septa", "PROBLEM", 477, 504], ["hyperplasia of the interstitium", "PROBLEM", 506, 537], ["partial filling of airspaces", "PROBLEM", 539, 567], ["hyperplasia of inter- and intra-lobular interstitial tissue", "PROBLEM", 630, 689], ["consolidations", "PROBLEM", 695, 709], ["advanced alveolar damage", "PROBLEM", 731, 755], ["ground-glass opacities", "PROBLEM", 789, 811], ["patchy", "PROBLEM", 818, 824], ["extensive", "OBSERVATION_MODIFIER", 75, 84], ["microangiopathy", "OBSERVATION", 85, 100], ["pulmonary vessels", "ANATOMY", 104, 121], ["microthrombosis", "OBSERVATION", 139, 154], ["neoangiogenesis", "OBSERVATION", 159, 174], ["pulmonary", "ANATOMY", 212, 221], ["respiratory failure", "OBSERVATION", 238, 257], ["infection", "OBSERVATION", 272, 281], ["morphological", "OBSERVATION_MODIFIER", 302, 315], ["lesions", "OBSERVATION", 316, 323], ["lungs", "ANATOMY", 341, 346], ["chest", "ANATOMY", 409, 414], ["ground", "OBSERVATION", 443, 449], ["glass opacities", "OBSERVATION", 450, 465], ["edema", "OBSERVATION", 477, 482], ["alveolar", "ANATOMY_MODIFIER", 490, 498], ["septa", "ANATOMY_MODIFIER", 499, 504], ["hyperplasia", "OBSERVATION", 506, 517], ["interstitium", "ANATOMY_MODIFIER", 525, 537], ["partial", "OBSERVATION_MODIFIER", 539, 546], ["filling", "OBSERVATION_MODIFIER", 547, 554], ["airspaces", "OBSERVATION", 558, 567], ["crazy", "OBSERVATION_MODIFIER", 591, 596], ["hyperplasia", "OBSERVATION", 630, 641], ["inter", "OBSERVATION_MODIFIER", 645, 650], ["intra-lobular", "ANATOMY_MODIFIER", 656, 669], ["interstitial tissue", "ANATOMY", 670, 689], ["consolidations", "OBSERVATION", 695, 709], ["advanced", "OBSERVATION_MODIFIER", 731, 739], ["alveolar", "ANATOMY_MODIFIER", 740, 748], ["damage", "OBSERVATION", 749, 755], ["ground-glass opacities", "OBSERVATION", 789, 811], ["patchy", "OBSERVATION_MODIFIER", 818, 824]]], ["The lesions are frequently localized in the lower lobes of both lungs, subpleurally.", [["lesions", "ANATOMY", 4, 11], ["lower lobes", "ANATOMY", 44, 55], ["lungs", "ANATOMY", 64, 69], ["subpleurally", "ANATOMY", 71, 83], ["lesions", "CANCER", 4, 11], ["lower lobes", "ORGAN", 44, 55], ["lungs", "ORGAN", 64, 69], ["The lesions", "PROBLEM", 0, 11], ["lesions", "OBSERVATION", 4, 11], ["lower lobes", "ANATOMY_MODIFIER", 44, 55], ["both", "ANATOMY_MODIFIER", 59, 63], ["lungs", "ANATOMY", 64, 69]]], ["The global aspect in the early stages of lung injury corresponds to the diagnosis of viral pneumonia.", [["lung", "ANATOMY", 41, 45], ["lung injury", "DISEASE", 41, 52], ["viral pneumonia", "DISEASE", 85, 100], ["lung", "ORGAN", 41, 45], ["lung injury", "PROBLEM", 41, 52], ["viral pneumonia", "PROBLEM", 85, 100], ["global", "OBSERVATION_MODIFIER", 4, 10], ["early", "OBSERVATION_MODIFIER", 25, 30], ["stages", "OBSERVATION_MODIFIER", 31, 37], ["lung", "ANATOMY", 41, 45], ["injury", "OBSERVATION", 46, 52], ["viral", "OBSERVATION_MODIFIER", 85, 90], ["pneumonia", "OBSERVATION", 91, 100]]], ["In the case of progression, later stages of the disease can be accompanied by typical morphological and imaging pictures of acute respiratory distress syndrome (ARDS) (9).Pathophysiological background of pulmonary involvement and respiratory failure in SARS-CoV-2 infection ::: IntroductionRecent data support that vascular damage and dysfunction play an essential role in the development of respiratory failure and ARDS in COVID-19 patients.", [["respiratory", "ANATOMY", 130, 141], ["pulmonary", "ANATOMY", 204, 213], ["respiratory", "ANATOMY", 230, 241], ["vascular", "ANATOMY", 315, 323], ["respiratory", "ANATOMY", 392, 403], ["acute respiratory distress syndrome", "DISEASE", 124, 159], ["ARDS", "DISEASE", 161, 165], ["respiratory failure", "DISEASE", 230, 249], ["SARS-CoV-2 infection", "DISEASE", 253, 273], ["vascular damage", "DISEASE", 315, 330], ["respiratory failure", "DISEASE", 392, 411], ["ARDS", "DISEASE", 416, 420], ["pulmonary", "ORGAN", 204, 213], ["SARS-CoV-2", "ORGANISM", 253, 263], ["vascular", "MULTI-TISSUE_STRUCTURE", 315, 323], ["patients", "ORGANISM", 433, 441], ["patients", "SPECIES", 433, 441], ["SARS-CoV", "SPECIES", 253, 261], ["the disease", "PROBLEM", 44, 55], ["imaging pictures", "TEST", 104, 120], ["acute respiratory distress syndrome", "PROBLEM", 124, 159], ["ARDS", "PROBLEM", 161, 165], ["pulmonary involvement", "PROBLEM", 204, 225], ["respiratory failure", "PROBLEM", 230, 249], ["SARS", "PROBLEM", 253, 257], ["vascular damage", "PROBLEM", 315, 330], ["dysfunction", "PROBLEM", 335, 346], ["respiratory failure", "PROBLEM", 392, 411], ["ARDS", "PROBLEM", 416, 420], ["progression", "OBSERVATION_MODIFIER", 15, 26], ["disease", "OBSERVATION", 48, 55], ["acute", "OBSERVATION_MODIFIER", 124, 129], ["respiratory distress syndrome", "OBSERVATION", 130, 159], ["pulmonary", "ANATOMY", 204, 213], ["respiratory failure", "OBSERVATION", 230, 249], ["infection", "OBSERVATION", 264, 273], ["vascular", "ANATOMY", 315, 323], ["damage", "OBSERVATION", 324, 330], ["respiratory failure", "OBSERVATION", 392, 411], ["ARDS", "OBSERVATION", 416, 420]]], ["Insufficient hypoxic vasoconstriction response in poorly ventilated pulmonary areas causes hypoxemia by ventilation/perfusion mismatch.", [["pulmonary areas", "ANATOMY", 68, 83], ["hypoxemia", "DISEASE", 91, 100], ["pulmonary", "ORGAN", 68, 77], ["Insufficient hypoxic vasoconstriction response", "PROBLEM", 0, 46], ["poorly ventilated pulmonary areas", "PROBLEM", 50, 83], ["hypoxemia", "PROBLEM", 91, 100], ["ventilation/perfusion mismatch", "TREATMENT", 104, 134], ["hypoxic", "OBSERVATION_MODIFIER", 13, 20], ["vasoconstriction", "OBSERVATION", 21, 37], ["poorly", "OBSERVATION_MODIFIER", 50, 56], ["ventilated", "OBSERVATION", 57, 67], ["pulmonary", "ANATOMY", 68, 77], ["hypoxemia", "OBSERVATION", 91, 100], ["perfusion mismatch", "OBSERVATION", 116, 134]]], ["In the early phase of respiratory failure, the lung has low elastance, the ventilation-to-perfusion (VA/Q) ratio is low, and there is a low lung recruitability (type L phenotype).", [["respiratory", "ANATOMY", 22, 33], ["lung", "ANATOMY", 47, 51], ["lung", "ANATOMY", 140, 144], ["respiratory failure", "DISEASE", 22, 41], ["lung", "ORGAN", 47, 51], ["lung", "ORGAN", 140, 144], ["respiratory failure", "PROBLEM", 22, 41], ["low elastance", "PROBLEM", 56, 69], ["the ventilation", "TEST", 71, 86], ["VA/Q) ratio", "TEST", 101, 112], ["a low lung recruitability", "PROBLEM", 134, 159], ["type L phenotype)", "PROBLEM", 161, 178], ["early", "OBSERVATION_MODIFIER", 7, 12], ["phase", "OBSERVATION_MODIFIER", 13, 18], ["respiratory failure", "OBSERVATION", 22, 41], ["lung", "ANATOMY", 47, 51], ["low elastance", "OBSERVATION", 56, 69], ["low", "OBSERVATION_MODIFIER", 116, 119], ["low", "OBSERVATION_MODIFIER", 136, 139], ["lung", "ANATOMY", 140, 144], ["recruitability", "OBSERVATION", 145, 159]]], ["Progression of pulmonary lesions causes, in the later phase, the morpho-functional picture of a classical ARDS, with high pulmonary elastance, high right-to-left shunt and high lung recruitability (type H phenotype).", [["pulmonary lesions", "ANATOMY", 15, 32], ["pulmonary", "ANATOMY", 122, 131], ["lung", "ANATOMY", 177, 181], ["pulmonary lesions", "DISEASE", 15, 32], ["ARDS", "DISEASE", 106, 110], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 15, 32], ["pulmonary", "ORGAN", 122, 131], ["lung", "ORGAN", 177, 181], ["pulmonary lesions", "PROBLEM", 15, 32], ["a classical ARDS", "PROBLEM", 94, 110], ["high pulmonary elastance", "PROBLEM", 117, 141], ["high right-to-left shunt", "PROBLEM", 143, 167], ["high lung recruitability", "PROBLEM", 172, 196], ["type H phenotype)", "PROBLEM", 198, 215], ["pulmonary", "ANATOMY", 15, 24], ["lesions", "OBSERVATION", 25, 32], ["ARDS", "OBSERVATION", 106, 110], ["high", "OBSERVATION_MODIFIER", 117, 121], ["pulmonary", "ANATOMY", 122, 131], ["elastance", "OBSERVATION", 132, 141], ["high", "OBSERVATION_MODIFIER", 143, 147], ["right", "ANATOMY_MODIFIER", 148, 153], ["left", "ANATOMY_MODIFIER", 157, 161], ["shunt", "OBSERVATION", 162, 167], ["high", "OBSERVATION_MODIFIER", 172, 176], ["lung", "ANATOMY", 177, 181], ["recruitability", "OBSERVATION", 182, 196]]], ["These types of ARDS have to be considered when setting a mechanical ventilation strategy and parameters (tidal volume, positive end-expiratory pressure level, etc.) (10, 11).Pathophysiological background of pulmonary involvement and respiratory failure in SARS-CoV-2 infection ::: IntroductionPulmonary involvement could be accompanied and aggravated by cardiac, liver, renal, and nervous system dysfunctions, as well as the prothrombotic state prone to cause thromboembolic complications.Pathophysiological background of pulmonary involvement and respiratory failure in SARS-CoV-2 infection ::: IntroductionSubsequently, we present the principal technical, practical and clinical data regarding the use of lung ultrasound (LUS)-an emerging bedside imaging tool-in evaluating pulmonary involvement in COVID-19 patients.General principles of lung ultrasound examination ::: IntroductionDespite the initial caveats due to the presence of air in the lungs, LUS has proven over time to be useful in the imaging of pulmonary structures (pleura, subpleural space, and parenchyma), gaining an important diagnostic and prognostic role in pulmonary medicine and cardiology.", [["pulmonary", "ANATOMY", 207, 216], ["respiratory", "ANATOMY", 233, 244], ["IntroductionPulmonary", "ANATOMY", 281, 302], ["cardiac", "ANATOMY", 354, 361], ["liver", "ANATOMY", 363, 368], ["renal", "ANATOMY", 370, 375], ["nervous system", "ANATOMY", 381, 395], ["pulmonary", "ANATOMY", 522, 531], ["respiratory", "ANATOMY", 548, 559], ["lung", "ANATOMY", 707, 711], ["pulmonary", "ANATOMY", 776, 785], ["lung", "ANATOMY", 841, 845], ["lungs", "ANATOMY", 947, 952], ["pulmonary structures", "ANATOMY", 1010, 1030], ["pleura", "ANATOMY", 1032, 1038], ["subpleural space", "ANATOMY", 1040, 1056], ["parenchyma", "ANATOMY", 1062, 1072], ["pulmonary", "ANATOMY", 1130, 1139], ["ARDS", "DISEASE", 15, 19], ["respiratory failure", "DISEASE", 233, 252], ["SARS-CoV-2 infection", "DISEASE", 256, 276], ["cardiac, liver, renal, and nervous system dysfunctions", "DISEASE", 354, 408], ["thromboembolic", "DISEASE", 460, 474], ["respiratory failure", "DISEASE", 548, 567], ["SARS-CoV-2 infection", "DISEASE", 571, 591], ["pulmonary", "ORGAN", 207, 216], ["SARS-CoV-2", "ORGANISM", 256, 266], ["cardiac", "ORGAN", 354, 361], ["liver", "ORGAN", 363, 368], ["renal", "ORGAN", 370, 375], ["nervous system", "ANATOMICAL_SYSTEM", 381, 395], ["pulmonary", "ORGAN", 522, 531], ["SARS-CoV-2", "ORGANISM", 571, 581], ["lung", "ORGAN", 707, 711], ["pulmonary", "ORGAN", 776, 785], ["patients", "ORGANISM", 810, 818], ["lung", "ORGAN", 841, 845], ["lungs", "ORGAN", 947, 952], ["LUS", "MULTI-TISSUE_STRUCTURE", 954, 957], ["pulmonary structures", "MULTI-TISSUE_STRUCTURE", 1010, 1030], ["pleura", "MULTI-TISSUE_STRUCTURE", 1032, 1038], ["subpleural space", "MULTI-TISSUE_STRUCTURE", 1040, 1056], ["parenchyma", "MULTI-TISSUE_STRUCTURE", 1062, 1072], ["pulmonary", "ORGAN", 1130, 1139], ["patients", "SPECIES", 810, 818], ["SARS-CoV", "SPECIES", 256, 264], ["SARS-CoV", "SPECIES", 571, 579], ["ARDS", "PROBLEM", 15, 19], ["a mechanical ventilation strategy", "TREATMENT", 55, 88], ["tidal volume", "TEST", 105, 117], ["expiratory pressure level", "TEST", 132, 157], ["pulmonary involvement", "PROBLEM", 207, 228], ["respiratory failure", "PROBLEM", 233, 252], ["SARS", "PROBLEM", 256, 260], ["IntroductionPulmonary involvement", "PROBLEM", 281, 314], ["cardiac, liver, renal, and nervous system dysfunctions", "PROBLEM", 354, 408], ["the prothrombotic state", "PROBLEM", 421, 444], ["thromboembolic complications", "PROBLEM", 460, 488], ["pulmonary involvement", "PROBLEM", 522, 543], ["respiratory failure", "PROBLEM", 548, 567], ["SARS", "PROBLEM", 571, 575], ["lung ultrasound", "TEST", 707, 722], ["LUS", "TEST", 724, 727], ["an emerging bedside imaging tool", "TEST", 729, 761], ["lung ultrasound examination", "TEST", 841, 868], ["air in the lungs", "PROBLEM", 936, 952], ["LUS", "TEST", 954, 957], ["the imaging", "TEST", 995, 1006], ["pleura, subpleural space", "PROBLEM", 1032, 1056], ["ARDS", "OBSERVATION", 15, 19], ["pulmonary", "ANATOMY", 207, 216], ["respiratory failure", "OBSERVATION", 233, 252], ["infection", "OBSERVATION", 267, 276], ["cardiac", "ANATOMY", 354, 361], ["liver", "ANATOMY", 363, 368], ["renal", "ANATOMY", 370, 375], ["nervous system", "ANATOMY", 381, 395], ["pulmonary", "ANATOMY", 522, 531], ["respiratory failure", "OBSERVATION", 548, 567], ["infection", "OBSERVATION", 582, 591], ["lung", "ANATOMY", 707, 711], ["pulmonary", "ANATOMY", 776, 785], ["lung", "ANATOMY", 841, 845], ["air", "OBSERVATION", 936, 939], ["lungs", "ANATOMY", 947, 952], ["pulmonary structures", "ANATOMY", 1010, 1030], ["pleura", "ANATOMY", 1032, 1038], ["subpleural", "ANATOMY_MODIFIER", 1040, 1050], ["parenchyma", "ANATOMY_MODIFIER", 1062, 1072], ["pulmonary", "ANATOMY", 1130, 1139]]], ["LUS came in handy in the recent COVID-19 era (12).General principles of lung ultrasound examination ::: IntroductionLUS is performed in most cases by using a convex ultrasound probe (with a variable frequency between 2 and 5 MHz).", [["lung", "ANATOMY", 72, 76], ["lung", "ORGAN", 72, 76], ["LUS", "TEST", 0, 3], ["lung ultrasound examination", "TEST", 72, 99], ["a convex ultrasound probe", "TEST", 156, 181], ["lung", "ANATOMY", 72, 76]]], ["On the other hand, a linear probe (with a variable frequency between 4 and 12 MHz) allows a better definition of the pleural line and the proximal subpleural space.", [["pleural line", "ANATOMY", 117, 129], ["subpleural space", "ANATOMY", 147, 163], ["pleural line", "CELL", 117, 129], ["subpleural space", "MULTI-TISSUE_STRUCTURE", 147, 163], ["a linear probe", "TREATMENT", 19, 33], ["linear", "OBSERVATION_MODIFIER", 21, 27], ["pleural", "ANATOMY", 117, 124], ["line", "OBSERVATION", 125, 129], ["proximal", "ANATOMY_MODIFIER", 138, 146], ["subpleural", "ANATOMY_MODIFIER", 147, 157]]], ["It is ideal when the machine has a lung preset, otherwise, an abdominal preset with a depth of 8\u201310 cm is used.", [["lung", "ANATOMY", 35, 39], ["abdominal", "ANATOMY", 62, 71], ["lung", "ORGAN", 35, 39], ["abdominal", "ORGANISM_SUBDIVISION", 62, 71], ["lung", "ANATOMY", 35, 39], ["abdominal", "ANATOMY", 62, 71], ["8\u201310 cm", "OBSERVATION_MODIFIER", 95, 102]]], ["This may differ depending on the patient\u2019s body constitution.", [["body", "ANATOMY", 43, 47], ["patient", "ORGANISM", 33, 40], ["body", "ORGANISM_SUBDIVISION", 43, 47], ["patient", "SPECIES", 33, 40]]], ["The gain and focus should be adjusted, and positioned to optimize the visualization of the pleural line and lung sliding.", [["pleural line", "ANATOMY", 91, 103], ["lung", "ANATOMY", 108, 112], ["pleural line", "CELL", 91, 103], ["lung", "ORGAN", 108, 112], ["the pleural line", "TREATMENT", 87, 103], ["lung sliding", "TREATMENT", 108, 120], ["pleural", "ANATOMY", 91, 98], ["line", "OBSERVATION", 99, 103], ["lung", "ANATOMY", 108, 112], ["sliding", "OBSERVATION", 113, 120]]], ["The mechanical index should be kept low, and the frame rate maximized (13, 14).General principles of lung ultrasound examination ::: IntroductionWhen scanning the lungs, a distinction should be made between healthy and pathological parenchyma.", [["lung", "ANATOMY", 101, 105], ["lungs", "ANATOMY", 163, 168], ["parenchyma", "ANATOMY", 232, 242], ["lung", "ORGAN", 101, 105], ["lungs", "ORGAN", 163, 168], ["parenchyma", "TISSUE", 232, 242], ["The mechanical index", "TEST", 0, 20], ["the frame rate", "TEST", 45, 59], ["lung ultrasound examination", "TEST", 101, 128], ["mechanical index", "OBSERVATION", 4, 20], ["lung", "ANATOMY", 101, 105], ["lungs", "ANATOMY", 163, 168], ["parenchyma", "ANATOMY_MODIFIER", 232, 242]]], ["A-lines are horizontal artifacts, which can be seen in parallel with the thin, hyperechogenic pleural line that moves synchronously with respiratory movements.", [["pleural line", "ANATOMY", 94, 106], ["respiratory", "ANATOMY", 137, 148], ["respiratory movements", "DISEASE", 137, 158], ["pleural line", "CELL", 94, 106], ["A-lines", "TREATMENT", 0, 7], ["horizontal artifacts", "PROBLEM", 12, 32], ["the thin, hyperechogenic pleural line", "PROBLEM", 69, 106], ["horizontal", "OBSERVATION_MODIFIER", 12, 22], ["artifacts", "OBSERVATION", 23, 32], ["thin", "OBSERVATION_MODIFIER", 73, 77], ["hyperechogenic", "OBSERVATION_MODIFIER", 79, 93], ["pleural", "ANATOMY", 94, 101], ["line", "OBSERVATION", 102, 106], ["respiratory movements", "OBSERVATION", 137, 158]]], ["These artifacts are caused by the normally aerated lung.", [["lung", "ANATOMY", 51, 55], ["lung", "ORGAN", 51, 55], ["the normally aerated lung", "PROBLEM", 30, 55], ["artifacts", "OBSERVATION", 6, 15], ["normally", "OBSERVATION_MODIFIER", 34, 42], ["aerated", "OBSERVATION", 43, 50], ["lung", "ANATOMY", 51, 55]]], ["In the case of lungs with reduced air content (such as pulmonary congestion, acute interstitial lung injury, fibrosis), A-lines disappear, and B-lines appear.", [["lungs", "ANATOMY", 15, 20], ["pulmonary", "ANATOMY", 55, 64], ["interstitial lung", "ANATOMY", 83, 100], ["B-lines", "ANATOMY", 143, 150], ["pulmonary congestion", "DISEASE", 55, 75], ["interstitial lung injury", "DISEASE", 83, 107], ["fibrosis", "DISEASE", 109, 117], ["lungs", "ORGAN", 15, 20], ["pulmonary", "ORGAN", 55, 64], ["lung", "ORGAN", 96, 100], ["A-lines", "CELL", 120, 127], ["B-lines", "CELL", 143, 150], ["A-lines", "CELL_LINE", 120, 127], ["B-lines", "CELL_LINE", 143, 150], ["reduced air content", "PROBLEM", 26, 45], ["pulmonary congestion", "PROBLEM", 55, 75], ["acute interstitial lung injury", "PROBLEM", 77, 107], ["fibrosis", "PROBLEM", 109, 117], ["A-lines", "TREATMENT", 120, 127], ["B-lines", "TREATMENT", 143, 150], ["lungs", "ANATOMY", 15, 20], ["reduced", "OBSERVATION_MODIFIER", 26, 33], ["air content", "OBSERVATION", 34, 45], ["pulmonary", "ANATOMY", 55, 64], ["congestion", "OBSERVATION", 65, 75], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["interstitial", "ANATOMY_MODIFIER", 83, 95], ["lung", "ANATOMY", 96, 100], ["injury", "OBSERVATION", 101, 107], ["fibrosis", "OBSERVATION", 109, 117], ["lines disappear", "OBSERVATION", 122, 137]]], ["These are comet-tail-shaped, laser-beam like, reverberation artifacts, which begin at the pleural line and penetrate downwards to the bottom of the scanning sector, their motion being synchronous with breathing movements.", [["pleural line", "ANATOMY", 90, 102], ["laser-beam", "TREATMENT", 29, 39], ["reverberation artifacts", "PROBLEM", 46, 69], ["comet", "OBSERVATION", 10, 15], ["tail", "OBSERVATION_MODIFIER", 16, 20], ["shaped", "OBSERVATION_MODIFIER", 21, 27], ["laser", "OBSERVATION_MODIFIER", 29, 34], ["beam like", "OBSERVATION_MODIFIER", 35, 44], ["reverberation artifacts", "OBSERVATION", 46, 69], ["pleural", "ANATOMY", 90, 97], ["line", "OBSERVATION", 98, 102], ["bottom", "ANATOMY_MODIFIER", 134, 140], ["breathing movements", "OBSERVATION", 201, 220]]], ["B-lines are oriented vertically (when using a linear probe) or radially (when using a convex probe) and are hyperechoic.", [["B-lines", "ANATOMY", 0, 7], ["B-lines", "CELL", 0, 7], ["B-lines", "CELL_LINE", 0, 7], ["B-lines", "TREATMENT", 0, 7], ["a linear probe", "TREATMENT", 44, 58], ["a convex probe", "TREATMENT", 84, 98], ["hyperechoic", "PROBLEM", 108, 119], ["lines", "OBSERVATION", 2, 7], ["oriented", "OBSERVATION_MODIFIER", 12, 20], ["vertically", "OBSERVATION_MODIFIER", 21, 31], ["hyperechoic", "OBSERVATION", 108, 119]]], ["In the case of worsening congestion due to left heart failure, the number of B-lines increase, and pleural effusion can occur.", [["left heart", "ANATOMY", 43, 53], ["B-lines", "ANATOMY", 77, 84], ["pleural effusion", "ANATOMY", 99, 115], ["congestion", "DISEASE", 25, 35], ["left heart failure", "DISEASE", 43, 61], ["pleural effusion", "DISEASE", 99, 115], ["heart", "ORGAN", 48, 53], ["B-lines", "CELL", 77, 84], ["pleural", "ORGAN", 99, 106], ["worsening congestion", "PROBLEM", 15, 35], ["left heart failure", "PROBLEM", 43, 61], ["B-lines", "TREATMENT", 77, 84], ["pleural effusion", "PROBLEM", 99, 115], ["worsening", "OBSERVATION_MODIFIER", 15, 24], ["congestion", "OBSERVATION", 25, 35], ["left", "ANATOMY_MODIFIER", 43, 47], ["heart", "ANATOMY", 48, 53], ["failure", "OBSERVATION", 54, 61], ["number", "OBSERVATION_MODIFIER", 67, 73], ["B", "OBSERVATION_MODIFIER", 77, 78], ["-lines", "OBSERVATION", 78, 84], ["increase", "OBSERVATION_MODIFIER", 85, 93], ["pleural", "ANATOMY", 99, 106], ["effusion", "OBSERVATION", 107, 115]]], ["If there is an inflammatory process in the lung interstitium, the number of B-lines increases, but because of the changes which can take place in the pleura and the adjacent pulmonary parenchyma, this could be accompanied by pleural line irregularity and disruption, and the appearance of a subpleural consolidation pattern.", [["lung interstitium", "ANATOMY", 43, 60], ["B-lines", "ANATOMY", 76, 83], ["pleura", "ANATOMY", 150, 156], ["pulmonary parenchyma", "ANATOMY", 174, 194], ["pleural line", "ANATOMY", 225, 237], ["subpleural", "ANATOMY", 291, 301], ["lung interstitium", "MULTI-TISSUE_STRUCTURE", 43, 60], ["B-lines", "CELL", 76, 83], ["pleura", "ORGAN", 150, 156], ["pulmonary parenchyma", "MULTI-TISSUE_STRUCTURE", 174, 194], ["pleural line", "CELL", 225, 237], ["B-lines", "CELL_LINE", 76, 83], ["an inflammatory process in the lung interstitium", "PROBLEM", 12, 60], ["B-lines", "TREATMENT", 76, 83], ["pleural line irregularity", "PROBLEM", 225, 250], ["disruption", "PROBLEM", 255, 265], ["a subpleural consolidation pattern", "PROBLEM", 289, 323], ["inflammatory", "OBSERVATION_MODIFIER", 15, 27], ["process", "OBSERVATION", 28, 35], ["lung", "ANATOMY", 43, 47], ["interstitium", "ANATOMY_MODIFIER", 48, 60], ["number", "OBSERVATION_MODIFIER", 66, 72], ["B", "OBSERVATION_MODIFIER", 76, 77], ["-lines", "OBSERVATION_MODIFIER", 77, 83], ["increases", "OBSERVATION_MODIFIER", 84, 93], ["pleura", "ANATOMY", 150, 156], ["adjacent", "ANATOMY_MODIFIER", 165, 173], ["pulmonary", "ANATOMY", 174, 183], ["parenchyma", "ANATOMY_MODIFIER", 184, 194], ["pleural", "ANATOMY", 225, 232], ["line", "OBSERVATION", 233, 237], ["irregularity", "OBSERVATION_MODIFIER", 238, 250], ["disruption", "OBSERVATION_MODIFIER", 255, 265], ["subpleural", "ANATOMY_MODIFIER", 291, 301], ["consolidation", "OBSERVATION", 302, 315]]], ["The latter appears on LUS as a \u201ctissue-like\u201d echogenic mass in the lung, arising from the pleural line in the absence of pleural effusion, and having a nearly identical echodensity with the liver (13-17).The methodology of examination: Our practice ::: IntroductionTo avoid the nosocomial spread of the virus and minimize the risk of infection of healthcare workers, portable (hand-held) ultrasound devices are recommended for LUS examination in COVID-19 patients.", [["tissue", "ANATOMY", 32, 38], ["echogenic mass", "ANATOMY", 45, 59], ["lung", "ANATOMY", 67, 71], ["pleural line", "ANATOMY", 90, 102], ["pleural effusion", "ANATOMY", 121, 137], ["liver", "ANATOMY", 190, 195], ["hand", "ANATOMY", 377, 381], ["pleural effusion", "DISEASE", 121, 137], ["infection", "DISEASE", 334, 343], ["LUS", "CANCER", 22, 25], ["tissue", "TISSUE", 32, 38], ["lung", "ORGAN", 67, 71], ["pleural line", "CELL", 90, 102], ["pleural effusion", "PATHOLOGICAL_FORMATION", 121, 137], ["liver", "ORGAN", 190, 195], ["hand", "ORGANISM_SUBDIVISION", 377, 381], ["patients", "ORGANISM", 455, 463], ["patients", "SPECIES", 455, 463], ["LUS", "TEST", 22, 25], ["a \u201ctissue-like\u201d echogenic mass in the lung", "PROBLEM", 29, 71], ["pleural effusion", "PROBLEM", 121, 137], ["IntroductionTo", "TREATMENT", 253, 267], ["the nosocomial spread", "PROBLEM", 274, 295], ["the virus", "PROBLEM", 299, 308], ["ultrasound devices", "TREATMENT", 388, 406], ["LUS examination", "TEST", 427, 442], ["echogenic", "OBSERVATION_MODIFIER", 45, 54], ["mass", "OBSERVATION", 55, 59], ["lung", "ANATOMY", 67, 71], ["pleural", "ANATOMY", 90, 97], ["line", "OBSERVATION", 98, 102], ["pleural", "ANATOMY", 121, 128], ["effusion", "OBSERVATION", 129, 137], ["nearly", "OBSERVATION_MODIFIER", 152, 158], ["identical", "OBSERVATION_MODIFIER", 159, 168], ["echodensity", "OBSERVATION", 169, 180], ["liver", "ANATOMY", 190, 195]]], ["They are easier to carry for bedside examinations, and can easily be disinfected and protected (by using a plastic foil for example) (18, 19).The methodology of examination: Our practice ::: IntroductionFor the LUS in our patients, General Electric V-Scan 2 (linear probe of 3.4\u20138.0 MHz) and Philips Lumify (convex probe of 2\u20135 MHz and linear probe of 4\u201312 MHz) hand-held ultrasound devices were used.", [["hand", "ANATOMY", 362, 366], ["patients", "ORGANISM", 222, 230], ["General Electric V-Scan 2", "DNA", 232, 257], ["Philips Lumify", "DNA", 292, 306], ["patients", "SPECIES", 222, 230], ["bedside examinations", "TEST", 29, 49], ["a plastic foil", "TREATMENT", 105, 119], ["the LUS", "TEST", 207, 214], ["General Electric V-Scan", "TEST", 232, 255], ["linear probe", "TEST", 259, 271], ["Philips Lumify (convex probe", "TREATMENT", 292, 320], ["linear probe of 4\u201312 MHz)", "TREATMENT", 336, 361], ["hand-held ultrasound devices", "TREATMENT", 362, 390]]], ["The examination requisites, including the ultrasound device(s), disinfectant, ultrasound gel, disposable paper towel, a pack of gloves, and plastic foil were prepared on a pushable 4-wheel mobile table (Fig. 1).", [["The examination", "TEST", 0, 15], ["the ultrasound device", "TEST", 38, 59], ["ultrasound gel", "TREATMENT", 78, 92], ["disposable paper towel", "TREATMENT", 94, 116], ["a pack of gloves", "TREATMENT", 118, 134]]], ["This preparation enabled the examination to be performed by one operator, at bedside.", [["the examination", "TEST", 25, 40]]], ["During the examination, the ultrasound recordings were saved for off-line analysis and further validation by two properly trained ultrasonographers.The methodology of examination: Our practice ::: IntroductionThe LUS was performed with the patient in a sitting position, except for mechanically ventilated patients, who were examined in the supine position.", [["LUS", "MULTI-TISSUE_STRUCTURE", 213, 216], ["patient", "ORGANISM", 240, 247], ["patients", "ORGANISM", 306, 314], ["patient", "SPECIES", 240, 247], ["patients", "SPECIES", 306, 314], ["the examination", "TEST", 7, 22], ["the ultrasound recordings", "TEST", 24, 49], ["line analysis", "TEST", 69, 82], ["further validation", "TEST", 87, 105], ["The LUS", "TEST", 209, 216]]], ["The best examination protocol in COVID-19 patients is still subject to debate, however, we used a previously developed, standardized scanning protocol.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["The best examination protocol", "TEST", 0, 29], ["standardized scanning protocol", "TEST", 120, 150]]], ["Sixteen areas were scanned per patient, with a recording duration of 5\u20136 seconds per area, containing at least one complete respiratory cycle.", [["respiratory", "ANATOMY", 124, 135], ["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["respiratory cycle", "OBSERVATION", 124, 141]]], ["The average time of LUS per patient was 7 minutes (13, 14, 20).The methodology of examination: Our practice ::: IntroductionBetween the two possible positions of the ultrasound probe in relation to the ribs, longitudinal (perpendicular) and transversal (parallel), the latter was our preferred approach.", [["ribs", "ANATOMY", 202, 206], ["patient", "ORGANISM", 28, 35], ["ribs", "ORGAN", 202, 206], ["ultrasound probe", "DNA", 166, 182], ["patient", "SPECIES", 28, 35], ["LUS", "TEST", 20, 23], ["the ultrasound probe", "TEST", 162, 182], ["longitudinal (perpendicular) and transversal (parallel)", "TREATMENT", 208, 263], ["ribs", "ANATOMY", 202, 206]]], ["The chest wall was divided into 4 regions on both sides by 5 anatomical lines (parasternal, anterior and posterior axillary, scapular and paravertebral).", [["chest wall", "ANATOMY", 4, 14], ["parasternal", "ANATOMY", 79, 90], ["anterior", "ANATOMY", 92, 100], ["posterior axillary", "ANATOMY", 105, 123], ["scapular", "ANATOMY", 125, 133], ["paravertebral", "ANATOMY", 138, 151], ["chest wall", "MULTI-TISSUE_STRUCTURE", 4, 14], ["parasternal", "MULTI-TISSUE_STRUCTURE", 79, 90], ["anterior", "MULTI-TISSUE_STRUCTURE", 92, 100], ["posterior axillary", "MULTI-TISSUE_STRUCTURE", 105, 123], ["scapular", "ORGANISM_SUBDIVISION", 125, 133], ["paravertebral", "ORGAN", 138, 151], ["chest", "ANATOMY", 4, 9], ["wall", "ANATOMY_MODIFIER", 10, 14], ["divided", "OBSERVATION", 19, 26], ["4 regions", "ANATOMY_MODIFIER", 32, 41], ["anatomical lines", "OBSERVATION", 61, 77], ["parasternal", "ANATOMY", 79, 90], ["anterior", "ANATOMY_MODIFIER", 92, 100], ["posterior", "ANATOMY_MODIFIER", 105, 114], ["axillary", "ANATOMY", 115, 123], ["scapular", "ANATOMY", 125, 133], ["paravertebral", "ANATOMY", 138, 151]]], ["Every region was further divided into an upper and a lower area (Fig. 2).", [["upper", "ORGANISM_SUBDIVISION", 41, 46], ["upper", "ANATOMY_MODIFIER", 41, 46], ["lower", "ANATOMY_MODIFIER", 53, 58]]], ["Although the posterior chest wall (areas 7 and 8 on both sides) was not always accessible for examination as in the case of mechanically ventilated patients, we always tried to visualize this region (by tilting the patient on the side), because of the frequent occurrence of pulmonary lesions in this site, especially in the early phase of the disease.", [["posterior chest wall", "ANATOMY", 13, 33], ["pulmonary lesions", "ANATOMY", 275, 292], ["site", "ANATOMY", 301, 305], ["pulmonary lesions", "DISEASE", 275, 292], ["posterior chest wall", "MULTI-TISSUE_STRUCTURE", 13, 33], ["patients", "ORGANISM", 148, 156], ["patient", "ORGANISM", 215, 222], ["pulmonary lesions", "PATHOLOGICAL_FORMATION", 275, 292], ["patients", "SPECIES", 148, 156], ["patient", "SPECIES", 215, 222], ["examination", "TEST", 94, 105], ["pulmonary lesions in this site", "PROBLEM", 275, 305], ["the disease", "PROBLEM", 340, 351], ["posterior", "ANATOMY_MODIFIER", 13, 22], ["chest", "ANATOMY", 23, 28], ["wall", "ANATOMY_MODIFIER", 29, 33], ["pulmonary", "ANATOMY", 275, 284], ["lesions", "OBSERVATION", 285, 292], ["early", "OBSERVATION_MODIFIER", 325, 330], ["phase", "OBSERVATION_MODIFIER", 331, 336], ["disease", "OBSERVATION", 344, 351]]], ["The sequence of examination was left to right, anterior to posterior and top-down (14, 17-19).", [["right", "ANATOMY", 40, 45], ["The sequence of examination", "TEST", 0, 27], ["left", "ANATOMY_MODIFIER", 32, 36], ["right", "ANATOMY_MODIFIER", 40, 45], ["anterior", "ANATOMY_MODIFIER", 47, 55], ["posterior", "ANATOMY_MODIFIER", 59, 68], ["top", "OBSERVATION_MODIFIER", 73, 76]]], ["The worksheet (score table) used in our department with the scanning areas is presented in Table 1.Lung ultrasound patterns in COVID-19 patients ::: IntroductionIn the articles published so far, SARS-Cov-2 infection does not seem to produce characteristic or unique image patterns on LUS.", [["Lung", "ANATOMY", 99, 103], ["SARS", "DISEASE", 195, 199], ["infection", "DISEASE", 206, 215], ["Lung", "ORGAN", 99, 103], ["patients", "ORGANISM", 136, 144], ["LUS", "MULTI-TISSUE_STRUCTURE", 284, 287], ["patients", "SPECIES", 136, 144], ["Lung ultrasound patterns", "TEST", 99, 123], ["COVID", "TEST", 127, 132], ["SARS", "PROBLEM", 195, 199], ["Cov-2 infection", "PROBLEM", 200, 215], ["LUS", "TEST", 284, 287], ["infection", "OBSERVATION", 206, 215]]], ["The findings vary depending on the severity and nature of the inflammatory process in the lung.", [["lung", "ANATOMY", 90, 94], ["lung", "ORGAN", 90, 94], ["the inflammatory process in the lung", "PROBLEM", 58, 94], ["inflammatory", "OBSERVATION", 62, 74], ["lung", "ANATOMY", 90, 94]]], ["Thus, the spectrum of ultrasound changes ranges from normal-looking lung parenchyma and the image of simple interstitial involvement to consolidation (pneumonia) patterns.", [["lung parenchyma", "ANATOMY", 68, 83], ["interstitial", "ANATOMY", 108, 120], ["pneumonia", "DISEASE", 151, 160], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 68, 83], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 108, 120], ["ultrasound changes", "TEST", 22, 40], ["simple interstitial involvement", "PROBLEM", 101, 132], ["consolidation (pneumonia) patterns", "PROBLEM", 136, 170], ["normal", "OBSERVATION", 53, 59], ["lung", "ANATOMY", 68, 72], ["parenchyma", "ANATOMY_MODIFIER", 73, 83], ["simple", "OBSERVATION_MODIFIER", 101, 107], ["interstitial", "OBSERVATION_MODIFIER", 108, 120], ["involvement", "OBSERVATION", 121, 132], ["consolidation", "OBSERVATION", 136, 149], ["pneumonia", "OBSERVATION", 151, 160]]], ["The type and characteristics of ultrasound findings correlate well with the pathological changes taking place in the lungs (19, 20).Lung ultrasound patterns in COVID-19 patients ::: IntroductionThe following patterns can be observed on LUS in COVID-19 patients (14, 19-21):Lung ultrasound patterns in COVID-19 patients ::: Introduction", [["lungs", "ANATOMY", 117, 122], ["Lung", "ANATOMY", 132, 136], ["Lung", "ANATOMY", 273, 277], ["lungs", "ORGAN", 117, 122], ["Lung", "ORGAN", 132, 136], ["patients", "ORGANISM", 169, 177], ["patients", "ORGANISM", 252, 260], ["Lung", "ORGAN", 273, 277], ["patients", "ORGANISM", 310, 318], ["patients", "SPECIES", 169, 177], ["patients", "SPECIES", 252, 260], ["patients", "SPECIES", 310, 318], ["ultrasound findings", "TEST", 32, 51], ["the pathological changes", "PROBLEM", 72, 96], ["Lung ultrasound patterns", "TEST", 132, 156], ["COVID", "TEST", 160, 165], ["LUS", "TEST", 236, 239], ["COVID", "TEST", 243, 248], ["Lung ultrasound patterns", "TEST", 273, 297], ["lungs", "ANATOMY", 117, 122], ["Lung", "ANATOMY", 273, 277]]]], "49daf278f5a58c4d7381c543420a623c7870333a": [["2 (B and C) HEK-293T cells were co-transfected with different fragments of the GST-IFITM3 fusion (cloned in pEBG vector) and VAPA-FLAG (cloned in pCDH vector).", [["HEK-293T cells", "ANATOMY", 12, 26], ["fragments", "ANATOMY", 62, 71], ["B", "CELL", 3, 4], ["HEK-293T cells", "CELL", 12, 26], ["GST", "GENE_OR_GENE_PRODUCT", 79, 82], ["IFITM3", "GENE_OR_GENE_PRODUCT", 83, 89], ["pEBG", "GENE_OR_GENE_PRODUCT", 108, 112], ["VAPA-FLAG", "GENE_OR_GENE_PRODUCT", 125, 134], ["pCDH", "GENE_OR_GENE_PRODUCT", 146, 150], ["B and C) HEK-293T cells", "CELL_LINE", 3, 26], ["GST", "PROTEIN", 79, 82], ["IFITM3 fusion", "DNA", 83, 96], ["pEBG vector", "DNA", 108, 119], ["VAPA", "DNA", 125, 129], ["FLAG", "DNA", 130, 134], ["pCDH vector", "DNA", 146, 157], ["B and C) HEK", "TEST", 3, 15], ["different fragments", "PROBLEM", 52, 71], ["the GST", "TREATMENT", 75, 82], ["IFITM3 fusion", "TREATMENT", 83, 96], ["pEBG vector", "TREATMENT", 108, 119], ["VAPA", "TREATMENT", 125, 129], ["IFITM3 fusion", "OBSERVATION", 83, 96]]], ["At 2 days posttransfection, cells were subjected to IP with anti-FLAG antibody or GST pull-down, and then IB with the indicated antibodies.", [["cells", "ANATOMY", 28, 33], ["cells", "CELL", 28, 33], ["GST", "GENE_OR_GENE_PRODUCT", 82, 85], ["anti-FLAG antibody", "PROTEIN", 60, 78], ["GST", "PROTEIN", 82, 85], ["antibodies", "PROTEIN", 128, 138], ["anti-FLAG antibody", "TEST", 60, 78], ["GST pull", "TEST", 82, 90]]]], "4bfec743cd9b5985470763fdbb807a2b00ff63ba": [["INTRODUCTIONMultiple sclerosis (MS) is an inflammatory disorder of the central nervous system (CNS) pathologically characterized by focal demyelination, neuronal damage, and astrocyte and microglia activation (Sospedra and Martin, 2005) .", [["central nervous system", "ANATOMY", 71, 93], ["CNS", "ANATOMY", 95, 98], ["neuronal", "ANATOMY", 153, 161], ["astrocyte", "ANATOMY", 174, 183], ["microglia", "ANATOMY", 188, 197], ["INTRODUCTIONMultiple sclerosis", "DISEASE", 0, 30], ["MS", "DISEASE", 32, 34], ["disorder of the central nervous system", "DISEASE", 55, 93], ["demyelination", "DISEASE", 138, 151], ["neuronal damage", "DISEASE", 153, 168], ["central nervous system", "ANATOMICAL_SYSTEM", 71, 93], ["CNS", "ANATOMICAL_SYSTEM", 95, 98], ["neuronal", "CELL", 153, 161], ["astrocyte", "CELL", 174, 183], ["microglia", "CELL", 188, 197], ["INTRODUCTIONMultiple sclerosis (MS)", "PROBLEM", 0, 35], ["an inflammatory disorder of the central nervous system", "PROBLEM", 39, 93], ["focal demyelination", "PROBLEM", 132, 151], ["neuronal damage", "PROBLEM", 153, 168], ["astrocyte and microglia activation", "PROBLEM", 174, 208], ["sclerosis", "OBSERVATION", 21, 30], ["inflammatory", "OBSERVATION", 42, 54], ["central", "ANATOMY_MODIFIER", 71, 78], ["nervous system", "ANATOMY", 79, 93], ["CNS", "ANATOMY", 95, 98], ["focal", "OBSERVATION_MODIFIER", 132, 137], ["demyelination", "OBSERVATION", 138, 151], ["neuronal damage", "OBSERVATION", 153, 168], ["astrocyte", "ANATOMY", 174, 183], ["microglia activation", "OBSERVATION", 188, 208]]], ["Although CD4 T lymphocytes have been established as important players in MS pathogenesis, CD8 T lymphocytes are increasingly recognized as potential contributors to tissue damage (Friese and Fugger, 2009; Mars et al., 2010) .", [["CD4 T lymphocytes", "ANATOMY", 9, 26], ["CD8 T lymphocytes", "ANATOMY", 90, 107], ["tissue", "ANATOMY", 165, 171], ["MS", "DISEASE", 73, 75], ["CD4 T", "GENE_OR_GENE_PRODUCT", 9, 14], ["CD8 T lymphocytes", "CELL", 90, 107], ["tissue", "TISSUE", 165, 171], ["CD4 T lymphocytes", "CELL_TYPE", 9, 26], ["CD8 T lymphocytes", "CELL_TYPE", 90, 107], ["CD4 T lymphocytes", "PROBLEM", 9, 26], ["MS pathogenesis", "PROBLEM", 73, 88], ["CD8 T lymphocytes", "PROBLEM", 90, 107], ["tissue damage", "PROBLEM", 165, 178]]], ["CD8 T lymphocytes are detected in MS lesions, preferentially in the parenchyma and in greater amount than their CD4 counterparts (Lassmann, 2004; Neumann et al., 2002) .", [["CD8 T lymphocytes", "ANATOMY", 0, 17], ["MS lesions", "ANATOMY", 34, 44], ["parenchyma", "ANATOMY", 68, 78], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["MS lesions", "CANCER", 34, 44], ["parenchyma", "TISSUE", 68, 78], ["CD4", "GENE_OR_GENE_PRODUCT", 112, 115], ["CD8 T lymphocytes", "CELL_TYPE", 0, 17], ["CD4 counterparts", "CELL_TYPE", 112, 128], ["CD8 T lymphocytes", "TEST", 0, 17], ["MS lesions", "PROBLEM", 34, 44], ["lymphocytes", "ANATOMY", 6, 17], ["MS", "OBSERVATION_MODIFIER", 34, 36], ["lesions", "OBSERVATION", 37, 44], ["parenchyma", "ANATOMY_MODIFIER", 68, 78], ["greater", "OBSERVATION_MODIFIER", 86, 93], ["amount", "OBSERVATION_MODIFIER", 94, 100]]], ["Detection of oligoclonal expansion of CD8 T lymphocytes in the CNS of MS patients (Babbe et al., 2000; Jacobsen et al., 2002; Junker et al., 2007; Skulina et al., 2004) suggests their local activation.", [["CD8 T lymphocytes", "ANATOMY", 38, 55], ["CNS", "ANATOMY", 63, 66], ["MS", "DISEASE", 70, 72], ["CD8 T", "GENE_OR_GENE_PRODUCT", 38, 43], ["CNS", "ANATOMICAL_SYSTEM", 63, 66], ["patients", "ORGANISM", 73, 81], ["CD8 T lymphocytes", "CELL_TYPE", 38, 55], ["patients", "SPECIES", 73, 81], ["oligoclonal expansion", "PROBLEM", 13, 34], ["oligoclonal expansion", "OBSERVATION", 13, 34], ["CD8 T lymphocytes", "OBSERVATION", 38, 55], ["CNS", "ANATOMY", 63, 66], ["local activation", "OBSERVATION", 184, 200]]], ["CD8 T lymphocytes with polarized cytolytic granules are observed in close apposition to oligodendrocytes and demyelinated axons (Neumann et al., 2002) .", [["CD8 T lymphocytes", "ANATOMY", 0, 17], ["cytolytic granules", "ANATOMY", 33, 51], ["oligodendrocytes", "ANATOMY", 88, 104], ["demyelinated axons", "ANATOMY", 109, 127], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["granules", "ORGANISM_SUBSTANCE", 43, 51], ["oligodendrocytes", "CELL", 88, 104], ["demyelinated axons", "CELLULAR_COMPONENT", 109, 127], ["CD8 T lymphocytes", "CELL_TYPE", 0, 17], ["oligodendrocytes", "CELL_TYPE", 88, 104], ["CD8 T lymphocytes", "TEST", 0, 17], ["polarized cytolytic granules", "PROBLEM", 23, 51], ["lymphocytes", "ANATOMY", 6, 17], ["polarized", "OBSERVATION_MODIFIER", 23, 32], ["cytolytic granules", "OBSERVATION", 33, 51], ["demyelinated", "OBSERVATION_MODIFIER", 109, 121], ["axons", "OBSERVATION_MODIFIER", 122, 127]]], ["Finally, up-regulated expression of major histocompatibility complex Class I (MHC-I) on microglia/ macrophages, astrocytes, oligodendrocytes, and neurons in MS lesions supports the concept that CNS cells could be recognized and targeted by CD8 T cells (Hoftberger et al., 2004) .INTRODUCTIONT cell responses are triggered by the T-cell receptor (TCR) recognition of MHC-peptide complexes and modulated by an array of co-activating or co-inhibiting molecules.", [["microglia", "ANATOMY", 88, 97], ["macrophages", "ANATOMY", 99, 110], ["astrocytes", "ANATOMY", 112, 122], ["oligodendrocytes", "ANATOMY", 124, 140], ["neurons", "ANATOMY", 146, 153], ["MS lesions", "ANATOMY", 157, 167], ["CNS cells", "ANATOMY", 194, 203], ["CD8 T cells", "ANATOMY", 240, 251], ["cell", "ANATOMY", 293, 297], ["T-cell", "ANATOMY", 329, 335], ["major histocompatibility complex Class I", "GENE_OR_GENE_PRODUCT", 36, 76], ["MHC-I", "GENE_OR_GENE_PRODUCT", 78, 83], ["microglia", "CELL", 88, 97], ["macrophages", "CELL", 99, 110], ["astrocytes", "CELL", 112, 122], ["oligodendrocytes", "CELL", 124, 140], ["neurons", "CELL", 146, 153], ["MS lesions", "CANCER", 157, 167], ["CNS cells", "CELL", 194, 203], ["CD8 T cells", "CELL", 240, 251], ["cell", "CELL", 293, 297], ["T-cell receptor", "GENE_OR_GENE_PRODUCT", 329, 344], ["TCR", "GENE_OR_GENE_PRODUCT", 346, 349], ["major histocompatibility complex Class I (MHC-I", "PROTEIN", 36, 83], ["microglia", "CELL_TYPE", 88, 97], ["macrophages", "CELL_TYPE", 99, 110], ["astrocytes", "CELL_TYPE", 112, 122], ["oligodendrocytes", "CELL_TYPE", 124, 140], ["CNS cells", "CELL_TYPE", 194, 203], ["CD8 T cells", "CELL_TYPE", 240, 251], ["T-cell receptor", "PROTEIN", 329, 344], ["TCR", "PROTEIN", 346, 349], ["MHC", "PROTEIN", 366, 369], ["co-activating or co-inhibiting molecules", "PROTEIN", 417, 457], ["microglia/ macrophages", "TEST", 88, 110], ["astrocytes", "PROBLEM", 112, 122], ["oligodendrocytes", "PROBLEM", 124, 140], ["neurons in MS lesions", "PROBLEM", 146, 167], ["CNS cells", "PROBLEM", 194, 203], ["peptide complexes", "PROBLEM", 370, 387], ["co-activating", "PROBLEM", 417, 430], ["co-inhibiting molecules", "PROBLEM", 434, 457], ["macrophages", "ANATOMY", 99, 110], ["astrocytes", "ANATOMY", 112, 122], ["neurons", "ANATOMY", 146, 153], ["lesions", "OBSERVATION", 160, 167]]], ["The B7-CD28 family members play key roles in T-cell responses by contributing both co-stimulatory and co-inhibitory signals.", [["T-cell", "ANATOMY", 45, 51], ["B7", "GENE_OR_GENE_PRODUCT", 4, 6], ["CD28", "GENE_OR_GENE_PRODUCT", 7, 11], ["T-cell", "CELL", 45, 51], ["B7", "PROTEIN", 4, 6], ["CD28 family members", "PROTEIN", 7, 26]]], ["Programmed death-1 (PD-1), also called CD279, belongs to this family and is a crucial co-inhibitory receptor expressed by activated immune cells (Keir et al., 2008) .", [["immune cells", "ANATOMY", 132, 144], ["Programmed death-1", "GENE_OR_GENE_PRODUCT", 0, 18], ["PD-1", "GENE_OR_GENE_PRODUCT", 20, 24], ["CD279", "GENE_OR_GENE_PRODUCT", 39, 44], ["immune cells", "CELL", 132, 144], ["CD279", "DNA", 39, 44], ["co-inhibitory receptor", "PROTEIN", 86, 108], ["activated immune cells", "CELL_TYPE", 122, 144], ["Programmed death", "PROBLEM", 0, 16]]], ["Whilst only small numbers of na\u20ac \u0131ve or resting human T lymphocytes express detectable PD-1, a proportion of these cells up-regulate this receptor upon activation (Kinter et al., 2008) ; however, the mechanisms dictating PD-1 acquisition by a fraction of activated T lymphocytes are still poorly understood.", [["na\u20ac \u0131ve", "ANATOMY", 29, 36], ["T lymphocytes", "ANATOMY", 54, 67], ["cells", "ANATOMY", 115, 120], ["T lymphocytes", "ANATOMY", 265, 278], ["na\u20ac \u0131ve", "CELL", 29, 36], ["human", "ORGANISM", 48, 53], ["T lymphocytes", "CELL", 54, 67], ["PD-1", "GENE_OR_GENE_PRODUCT", 87, 91], ["cells", "CELL", 115, 120], ["PD-1", "GENE_OR_GENE_PRODUCT", 221, 225], ["T lymphocytes", "CELL", 265, 278], ["na\u20ac \u0131ve", "CELL_LINE", 29, 36], ["resting human T lymphocytes", "CELL_TYPE", 40, 67], ["activated T lymphocytes", "CELL_TYPE", 255, 278], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["na\u20ac", "TEST", 29, 32], ["resting human T lymphocytes", "TEST", 40, 67], ["PD", "TEST", 87, 89], ["these cells", "TEST", 109, 120], ["activated T lymphocytes", "TREATMENT", 255, 278], ["small", "OBSERVATION_MODIFIER", 12, 17], ["numbers", "OBSERVATION_MODIFIER", 18, 25]]], ["PD-1 participates in immune dysfunction and anergy of human CD8 T lymphocytes during chronic viral infections (Day et al., 2006; Trautmann et al., 2006; Urbani et al., 2006) .", [["CD8 T lymphocytes", "ANATOMY", 60, 77], ["chronic viral infections", "DISEASE", 85, 109], ["PD-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 54, 59], ["CD8 T lymphocytes", "CELL", 60, 77], ["human CD8 T lymphocytes", "CELL_TYPE", 54, 77], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["PD", "TEST", 0, 2], ["immune dysfunction", "PROBLEM", 21, 39], ["anergy of human CD8 T lymphocytes", "PROBLEM", 44, 77], ["chronic viral infections", "PROBLEM", 85, 109], ["immune dysfunction", "OBSERVATION", 21, 39], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["viral infections", "OBSERVATION", 93, 109]]], ["The interaction between PD-1 and its ligands PD-L1 or PD-L2 inhibits the TCR-mediated antigen receptor signaling including T-cell proliferation, cytokine production, and cytotoxicity (Carter et al., 2002; Freeman et al., 2000; Rodig et al., 2003) .", [["T-cell", "ANATOMY", 123, 129], ["PD-1", "GENE_OR_GENE_PRODUCT", 24, 28], ["PD-L1", "GENE_OR_GENE_PRODUCT", 45, 50], ["PD-L2", "GENE_OR_GENE_PRODUCT", 54, 59], ["TCR", "GENE_OR_GENE_PRODUCT", 73, 76], ["antigen receptor", "GENE_OR_GENE_PRODUCT", 86, 102], ["T-cell", "CELL", 123, 129], ["TCR", "PROTEIN", 73, 76], ["cytokine", "PROTEIN", 145, 153], ["PD", "TEST", 24, 26], ["its ligands PD", "TEST", 33, 47], ["PD", "TEST", 54, 56], ["the TCR", "TEST", 69, 76], ["T-cell proliferation", "PROBLEM", 123, 143], ["cytokine production", "PROBLEM", 145, 164], ["L1", "ANATOMY", 48, 50], ["L2", "ANATOMY", 57, 59], ["cell proliferation", "OBSERVATION", 125, 143]]], ["Moreover, this interaction provides essential inhibitory signals to the fine balance between appropriate versus detrimental T-cell activation as illustrated by the various autoimmune diseases spontaneously developed by PD-1-deficient mice (Nishimura et al. 1999 (Nishimura et al. , 2001 .", [["T-cell", "ANATOMY", 124, 130], ["autoimmune diseases", "DISEASE", 172, 191], ["T-cell", "CELL", 124, 130], ["PD-1", "GENE_OR_GENE_PRODUCT", 219, 223], ["mice", "ORGANISM", 234, 238], ["mice", "SPECIES", 234, 238], ["mice", "SPECIES", 234, 238], ["the various autoimmune diseases", "PROBLEM", 160, 191], ["PD", "TEST", 219, 221]]], ["PD-L1 (also known as B7-H1 or CD274) is widely expressed on activated T and B lymphocytes, macrophages, dendritic cells, and non-immune cells.", [["T", "ANATOMY", 70, 71], ["B lymphocytes", "ANATOMY", 76, 89], ["macrophages", "ANATOMY", 91, 102], ["dendritic cells", "ANATOMY", 104, 119], ["cells", "ANATOMY", 136, 141], ["PD-L1", "GENE_OR_GENE_PRODUCT", 0, 5], ["B7-H1", "GENE_OR_GENE_PRODUCT", 21, 26], ["CD274", "GENE_OR_GENE_PRODUCT", 30, 35], ["T", "CELL", 70, 71], ["B lymphocytes", "CELL", 76, 89], ["macrophages", "CELL", 91, 102], ["dendritic cells", "CELL", 104, 119], ["non-immune cells", "CELL", 125, 141], ["PD-L1", "DNA", 0, 5], ["B7", "PROTEIN", 21, 23], ["H1", "PROTEIN", 24, 26], ["CD274", "PROTEIN", 30, 35], ["activated T and B lymphocytes", "CELL_TYPE", 60, 89], ["macrophages", "CELL_TYPE", 91, 102], ["dendritic cells", "CELL_TYPE", 104, 119], ["non-immune cells", "CELL_TYPE", 125, 141], ["PD", "TEST", 0, 2], ["H1", "PROBLEM", 24, 26], ["macrophages", "PROBLEM", 91, 102], ["dendritic cells", "PROBLEM", 104, 119], ["non-immune cells", "PROBLEM", 125, 141], ["L1", "ANATOMY", 3, 5], ["lymphocytes", "ANATOMY", 78, 89], ["macrophages", "ANATOMY", 91, 102], ["dendritic cells", "OBSERVATION", 104, 119], ["non-immune cells", "OBSERVATION", 125, 141]]], ["In contrast, PD-L2 (also called B7-DC or CD273) expression is restricted to macrophages, dendritic cells, and mast cells (Keir et al., 2008) .INTRODUCTIONThe role and expression of PD-1 and its ligands in CNS diseases has been studied in numerous animal models including MS models.", [["B7-DC", "ANATOMY", 32, 37], ["macrophages", "ANATOMY", 76, 87], ["dendritic cells", "ANATOMY", 89, 104], ["mast cells", "ANATOMY", 110, 120], ["CNS", "ANATOMY", 205, 208], ["CNS diseases", "DISEASE", 205, 217], ["PD-L2", "GENE_OR_GENE_PRODUCT", 13, 18], ["B7-DC", "GENE_OR_GENE_PRODUCT", 32, 37], ["CD273", "GENE_OR_GENE_PRODUCT", 41, 46], ["macrophages", "CELL", 76, 87], ["dendritic cells", "CELL", 89, 104], ["mast cells", "CELL", 110, 120], ["PD-1", "GENE_OR_GENE_PRODUCT", 181, 185], ["CNS", "ANATOMICAL_SYSTEM", 205, 208], ["B7", "PROTEIN", 32, 34], ["CD273", "PROTEIN", 41, 46], ["macrophages", "CELL_TYPE", 76, 87], ["dendritic cells", "CELL_TYPE", 89, 104], ["mast cells", "CELL_TYPE", 110, 120], ["PD-1", "PROTEIN", 181, 185], ["dendritic cells", "PROBLEM", 89, 104], ["mast cells", "PROBLEM", 110, 120], ["PD", "PROBLEM", 181, 183], ["CNS diseases", "PROBLEM", 205, 217], ["L2", "ANATOMY", 16, 18], ["macrophages", "OBSERVATION", 76, 87], ["dendritic cells", "OBSERVATION", 89, 104], ["mast cells", "OBSERVATION", 110, 120], ["CNS", "ANATOMY", 205, 208], ["diseases", "OBSERVATION", 209, 217]]], ["Blockade of the PD-1-PD-L1/2 pathway increased the susceptibility to or disease severity of experimental autoimmune encephalomyelitis (EAE), an MS model, in a strain-specific manner .", [["autoimmune encephalomyelitis", "DISEASE", 105, 133], ["EAE", "DISEASE", 135, 138], ["PD-1", "GENE_OR_GENE_PRODUCT", 16, 20], ["PD-L1", "GENE_OR_GENE_PRODUCT", 21, 26], ["2", "GENE_OR_GENE_PRODUCT", 27, 28], ["the PD", "TEST", 12, 18], ["PD", "TEST", 21, 23], ["the susceptibility", "PROBLEM", 47, 65], ["experimental autoimmune encephalomyelitis", "PROBLEM", 92, 133], ["an MS model", "TEST", 141, 152], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["experimental", "OBSERVATION_MODIFIER", 92, 104], ["autoimmune encephalomyelitis", "OBSERVATION", 105, 133]]], ["Conversely, blocking PD-1 led to a more rapid and severe disease characterized by a boosted number of CNS immune infiltrating cells, especially CD8 T cells (Kroner et al., 2009a,b; Salama et al., 2003; Wang et al., 2010) .", [["CNS immune infiltrating cells", "ANATOMY", 102, 131], ["CD8 T cells", "ANATOMY", 144, 155], ["PD-1", "GENE_OR_GENE_PRODUCT", 21, 25], ["CNS immune infiltrating cells", "CELL", 102, 131], ["CD8 T cells", "CELL", 144, 155], ["PD-1", "DNA", 21, 25], ["CNS immune infiltrating cells", "CELL_TYPE", 102, 131], ["CD8 T cells", "CELL_TYPE", 144, 155], ["a more rapid and severe disease", "PROBLEM", 33, 64], ["CNS immune infiltrating cells", "PROBLEM", 102, 131], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["disease", "OBSERVATION", 57, 64], ["CNS", "ANATOMY", 102, 105], ["immune", "OBSERVATION", 106, 112], ["infiltrating cells", "OBSERVATION", 113, 131]]], ["In EAE mice, up-regulated PD-1 expression has been observed on infiltrating cells, while PD-L1 was detected on microglia (Magnus et al., 2005; Salama et al., 2003) and astrocytes (Salama et al., 2003) .", [["infiltrating cells", "ANATOMY", 63, 81], ["microglia", "ANATOMY", 111, 120], ["astrocytes", "ANATOMY", 168, 178], ["EAE", "DISEASE", 3, 6], ["mice", "ORGANISM", 7, 11], ["PD-1", "GENE_OR_GENE_PRODUCT", 26, 30], ["cells", "CELL", 76, 81], ["PD-L1", "GENE_OR_GENE_PRODUCT", 89, 94], ["microglia", "CELL", 111, 120], ["astrocytes", "CELL", 168, 178], ["infiltrating cells", "CELL_TYPE", 63, 81], ["PD-L1", "PROTEIN", 89, 94], ["microglia", "CELL_TYPE", 111, 120], ["astrocytes", "CELL_TYPE", 168, 178], ["mice", "SPECIES", 7, 11], ["mice", "SPECIES", 7, 11], ["infiltrating cells", "PROBLEM", 63, 81], ["PD", "TEST", 89, 91], ["infiltrating cells", "OBSERVATION", 63, 81], ["L1", "ANATOMY", 92, 94], ["astrocytes", "ANATOMY", 168, 178]]], ["Other murine CNS inflammatory models have illustrated the capacity of CNS cells to express PD-L1 in response to a variety of insults (Lafon et al., 2008; Lipp et al., 2007; Phares et al., 2009) .INTRODUCTIONEnhanced PD-L1 immunodetection in MS brain sections compared with controls and detection on microglia/ macrophage-like cells have been reported (Ortler et al., 2008) .", [["CNS", "ANATOMY", 13, 16], ["CNS cells", "ANATOMY", 70, 79], ["MS brain sections", "ANATOMY", 241, 258], ["microglia", "ANATOMY", 299, 308], ["macrophage-like cells", "ANATOMY", 310, 331], ["murine", "ORGANISM", 6, 12], ["CNS", "ANATOMICAL_SYSTEM", 13, 16], ["CNS cells", "CELL", 70, 79], ["PD-L1", "GENE_OR_GENE_PRODUCT", 91, 96], ["PD-L1", "GENE_OR_GENE_PRODUCT", 216, 221], ["brain sections", "MULTI-TISSUE_STRUCTURE", 244, 258], ["microglia", "CELL", 299, 308], ["macrophage", "CELL", 310, 320], ["-like cells", "CELL", 320, 331], ["CNS cells", "CELL_TYPE", 70, 79], ["PD-L1", "PROTEIN", 91, 96], ["microglia", "CELL_TYPE", 299, 308], ["macrophage-like cells", "CELL_TYPE", 310, 331], ["murine", "SPECIES", 6, 12], ["Other murine CNS inflammatory models", "PROBLEM", 0, 36], ["CNS cells", "PROBLEM", 70, 79], ["PD-L1 immunodetection", "TREATMENT", 216, 237], ["MS brain sections", "TEST", 241, 258], ["microglia/ macrophage", "TEST", 299, 320], ["like cells", "PROBLEM", 321, 331], ["CNS", "ANATOMY", 13, 16], ["inflammatory", "OBSERVATION", 17, 29], ["CNS", "ANATOMY", 70, 73], ["L1", "ANATOMY", 94, 96], ["L1", "ANATOMY", 219, 221]]], ["However, which CNS cell types express this molecule has not been completely resolved and whether these levels are sufficient to modulate human T-cell responses has not been addressed.INTRODUCTIONIn this study, we investigated the expression of PD-L1 and PD-L2 by human CNS cells.", [["CNS cell", "ANATOMY", 15, 23], ["T-cell", "ANATOMY", 143, 149], ["CNS cells", "ANATOMY", 269, 278], ["CNS cell", "CELL", 15, 23], ["human", "ORGANISM", 137, 142], ["T-cell", "CELL", 143, 149], ["PD-L1", "GENE_OR_GENE_PRODUCT", 244, 249], ["PD-L2", "GENE_OR_GENE_PRODUCT", 254, 259], ["human", "ORGANISM", 263, 268], ["CNS cells", "CELL", 269, 278], ["PD-L2", "DNA", 254, 259], ["human CNS cells", "CELL_TYPE", 263, 278], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 263, 268], ["human", "SPECIES", 137, 142], ["human", "SPECIES", 263, 268], ["these levels", "TEST", 97, 109], ["this study", "TEST", 198, 208], ["CNS cell types", "OBSERVATION", 15, 29], ["L1", "ANATOMY", 247, 249], ["L2", "ANATOMY_MODIFIER", 257, 259], ["CNS cells", "OBSERVATION", 269, 278]]], ["We assessed the impact of such expression specifically on human CD8 T-cell functions since all CNS cell types in MS lesions could potentially interact with infiltrating CD8 T cells given their MHC-I expression (Hoftberger et al., 2004) .", [["CD8 T-cell", "ANATOMY", 64, 74], ["CNS cell", "ANATOMY", 95, 103], ["MS lesions", "ANATOMY", 113, 123], ["CD8 T cells", "ANATOMY", 169, 180], ["human", "ORGANISM", 58, 63], ["CD8 T-cell", "CELL", 64, 74], ["CNS cell", "CELL", 95, 103], ["MS lesions", "PATHOLOGICAL_FORMATION", 113, 123], ["CD8 T cells", "CELL", 169, 180], ["MHC-I", "GENE_OR_GENE_PRODUCT", 193, 198], ["infiltrating CD8 T cells", "CELL_TYPE", 156, 180], ["MHC", "PROTEIN", 193, 196], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["MS lesions", "PROBLEM", 113, 123], ["infiltrating CD8 T cells", "PROBLEM", 156, 180], ["CNS", "ANATOMY", 95, 98], ["cell", "OBSERVATION", 99, 103], ["lesions", "OBSERVATION", 116, 123]]], ["We demonstrate that human CNS cells express low PD-L1 and PD-L2 levels under basal conditions, but inflammatory stimuli up-regulate PD-L1 on these cells.", [["CNS cells", "ANATOMY", 26, 35], ["cells", "ANATOMY", 147, 152], ["human", "ORGANISM", 20, 25], ["CNS cells", "CELL", 26, 35], ["PD-L1", "GENE_OR_GENE_PRODUCT", 48, 53], ["PD-L2", "GENE_OR_GENE_PRODUCT", 58, 63], ["PD-L1", "GENE_OR_GENE_PRODUCT", 132, 137], ["cells", "CELL", 147, 152], ["human CNS cells", "CELL_TYPE", 20, 35], ["PD-L1", "PROTEIN", 132, 137], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["human CNS cells", "TEST", 20, 35], ["basal conditions", "TEST", 77, 93], ["inflammatory stimuli", "TEST", 99, 119], ["L2", "ANATOMY", 61, 63], ["inflammatory", "OBSERVATION_MODIFIER", 99, 111], ["L1", "ANATOMY", 135, 137]]], ["We establish that glial cells can locally modulate CD8 T cell responses via PD-L1 expression.", [["glial cells", "ANATOMY", 18, 29], ["CD8 T cell", "ANATOMY", 51, 61], ["glial cells", "CELL", 18, 29], ["CD8 T cell", "CELL", 51, 61], ["PD-L1", "GENE_OR_GENE_PRODUCT", 76, 81], ["glial cells", "CELL_TYPE", 18, 29], ["CD8", "PROTEIN", 51, 54], ["glial cells", "PROBLEM", 18, 29], ["PD", "TEST", 76, 78], ["glial cells", "OBSERVATION", 18, 29], ["L1", "ANATOMY", 79, 81]]], ["Finally, we show that PD-L1 is highly expressed in MS lesions but that only small numbers of infiltrating CD8 T lymphocytes express PD-1.", [["MS lesions", "ANATOMY", 51, 61], ["CD8 T lymphocytes", "ANATOMY", 106, 123], ["PD-L1", "GENE_OR_GENE_PRODUCT", 22, 27], ["MS lesions", "CANCER", 51, 61], ["CD8 T lymphocytes", "GENE_OR_GENE_PRODUCT", 106, 123], ["PD-1", "GENE_OR_GENE_PRODUCT", 132, 136], ["PD-L1", "DNA", 22, 27], ["infiltrating CD8 T lymphocytes", "CELL_TYPE", 93, 123], ["PD-L1", "PROBLEM", 22, 27], ["MS lesions", "PROBLEM", 51, 61], ["PD", "TEST", 132, 134], ["L1", "ANATOMY", 25, 27], ["lesions", "OBSERVATION", 54, 61], ["small", "OBSERVATION_MODIFIER", 76, 81], ["numbers", "OBSERVATION_MODIFIER", 82, 89], ["infiltrating", "OBSERVATION_MODIFIER", 93, 105], ["CD8 T lymphocytes", "OBSERVATION", 106, 123]]], ["Our data suggest that during MS pathogenesis the inflamed CNS attempts to protect itself against active T lymphocytes via the expression of PD-L1, but fails because most infiltrating CD8 T lymphocytes lack PD-1.MATERIALS AND METHODS Isolation of Human Foetal Astrocytes and NeuronsHuman foetal CNS tissue from 14-to 20-week-old embryos was provided by the Albert Einstein College of Medicine (Bronx, NY).", [["CNS", "ANATOMY", 58, 61], ["T lymphocytes", "ANATOMY", 104, 117], ["CD8 T lymphocytes", "ANATOMY", 183, 200], ["Foetal Astrocytes", "ANATOMY", 252, 269], ["foetal CNS tissue", "ANATOMY", 287, 304], ["embryos", "ANATOMY", 328, 335], ["CNS", "ANATOMICAL_SYSTEM", 58, 61], ["T lymphocytes", "CELL", 104, 117], ["PD-L1", "GENE_OR_GENE_PRODUCT", 140, 145], ["CD8", "GENE_OR_GENE_PRODUCT", 183, 186], ["PD-1", "GENE_OR_GENE_PRODUCT", 206, 210], ["Human", "ORGANISM", 246, 251], ["Foetal Astrocytes", "CELL", 252, 269], ["NeuronsHuman foetal CNS tissue", "TISSUE", 274, 304], ["embryos", "ORGANISM", 328, 335], ["T lymphocytes", "CELL_TYPE", 104, 117], ["L1", "PROTEIN", 143, 145], ["infiltrating CD8 T lymphocytes", "CELL_TYPE", 170, 200], ["Human Foetal Astrocytes", "CELL_TYPE", 246, 269], ["Human", "SPECIES", 246, 251], ["Human", "SPECIES", 246, 251], ["Our data", "TEST", 0, 8], ["the inflamed CNS attempts", "TREATMENT", 45, 70], ["active T lymphocytes", "PROBLEM", 97, 117], ["PD-L1", "TREATMENT", 140, 145], ["PD", "TEST", 206, 208], ["Human Foetal Astrocytes", "TEST", 246, 269], ["NeuronsHuman foetal CNS tissue", "PROBLEM", 274, 304], ["inflamed", "OBSERVATION", 49, 57], ["L1", "ANATOMY", 143, 145]]], ["Their and McGill University\u00d5 ethical review boards approved the studies.", [["the studies", "TEST", 60, 71]]], ["Astrocytes and neurons were isolated as previously described (Saikali et al., 2007) .", [["Astrocytes", "ANATOMY", 0, 10], ["neurons", "ANATOMY", 15, 22], ["Astrocytes", "CELL", 0, 10], ["neurons", "CELL", 15, 22], ["Astrocytes", "CELL_TYPE", 0, 10], ["neurons", "CELL_TYPE", 15, 22], ["neurons", "ANATOMY", 15, 22]]], ["Cells were treated for 24 (qPCR) or 48 hours (FACS/immunocytochemistry) with interferon-g (IFN-g, 200 U/ml; Thermo Scientific, Rockford, IL), tumour necrosis factor (TNF, 200 U/ml; Invitrogen, Camarillo, CA), interleukin-1b (IL-1b, 10 ng/ml, Invitrogen), or combinations of these cytokines.Isolation of Adult Human Oligodendrocytes and MicrogliaAdult oligodendrocytes and microglia were obtained from surgical resections performed for the treatment of nontumour-related intractable epilepsy as previously described (Saikali et al., 2007) and in accordance with guidelines of the ethical board of McGill University.", [["Cells", "ANATOMY", 0, 5], ["Oligodendrocytes", "ANATOMY", 315, 331], ["MicrogliaAdult oligodendrocytes", "ANATOMY", 336, 367], ["microglia", "ANATOMY", 372, 381], ["nontumour", "ANATOMY", 452, 461], ["necrosis", "DISEASE", 149, 157], ["epilepsy", "DISEASE", 482, 490], ["Cells", "CELL", 0, 5], ["interferon-g", "GENE_OR_GENE_PRODUCT", 77, 89], ["IL", "GENE_OR_GENE_PRODUCT", 137, 139], ["tumour necrosis factor", "GENE_OR_GENE_PRODUCT", 142, 164], ["TNF", "GENE_OR_GENE_PRODUCT", 166, 169], ["Camarillo, CA", "GENE_OR_GENE_PRODUCT", 193, 206], ["interleukin-1b", "GENE_OR_GENE_PRODUCT", 209, 223], ["IL-1b", "GENE_OR_GENE_PRODUCT", 225, 230], ["Invitrogen", "SIMPLE_CHEMICAL", 242, 252], ["Human", "ORGANISM", 309, 314], ["Oligodendrocytes", "CELL", 315, 331], ["MicrogliaAdult oligodendrocytes", "CELL", 336, 367], ["microglia", "CELL", 372, 381], ["interferon", "PROTEIN", 77, 87], ["IFN", "PROTEIN", 91, 94], ["tumour necrosis factor", "PROTEIN", 142, 164], ["TNF", "PROTEIN", 166, 169], ["Camarillo", "PROTEIN", 193, 202], ["interleukin", "PROTEIN", 209, 220], ["IL", "PROTEIN", 225, 227], ["cytokines", "PROTEIN", 280, 289], ["Adult Human Oligodendrocytes", "CELL_TYPE", 303, 331], ["MicrogliaAdult oligodendrocytes", "CELL_TYPE", 336, 367], ["microglia", "CELL_TYPE", 372, 381], ["Human", "SPECIES", 309, 314], ["Cells", "TEST", 0, 5], ["FACS", "TEST", 46, 50], ["immunocytochemistry", "TEST", 51, 70], ["interferon", "TREATMENT", 77, 87], ["tumour necrosis factor", "PROBLEM", 142, 164], ["TNF", "TEST", 166, 169], ["Invitrogen", "TEST", 181, 191], ["Camarillo", "TEST", 193, 202], ["CA", "TEST", 204, 206], ["interleukin", "TEST", 209, 220], ["IL-1b", "TREATMENT", 225, 230], ["Invitrogen", "TREATMENT", 242, 252], ["these cytokines", "TREATMENT", 274, 289], ["Adult Human Oligodendrocytes", "PROBLEM", 303, 331], ["MicrogliaAdult oligodendrocytes", "PROBLEM", 336, 367], ["microglia", "PROBLEM", 372, 381], ["surgical resections", "TREATMENT", 401, 420], ["nontumour-related intractable epilepsy", "PROBLEM", 452, 490], ["tumour necrosis", "OBSERVATION", 142, 157], ["cytokines", "OBSERVATION", 280, 289], ["Adult Human Oligodendrocytes", "OBSERVATION", 303, 331], ["MicrogliaAdult oligodendrocytes", "OBSERVATION", 336, 367], ["microglia", "ANATOMY", 372, 381], ["intractable", "OBSERVATION_MODIFIER", 470, 481], ["epilepsy", "OBSERVATION", 482, 490]]], ["Cells were treated with cytokines as described above.Isolation of Human CD8 T LymphocytesThese studies were approved by the ethical board of the Centre Hospitalier de l'Universit e de Montr eal (CHUM) and informed consent was obtained from healthy donors.", [["Cells", "ANATOMY", 0, 5], ["CD8 T Lymphocytes", "ANATOMY", 72, 89], ["Cells", "CELL", 0, 5], ["Human", "ORGANISM", 66, 71], ["CD8 T Lymphocytes", "CELL", 72, 89], ["donors", "ORGANISM", 248, 254], ["cytokines", "PROTEIN", 24, 33], ["Human CD8 T Lymphocytes", "CELL_TYPE", 66, 89], ["Human", "SPECIES", 66, 71], ["cytokines", "TREATMENT", 24, 33], ["These studies", "TEST", 89, 102], ["Human CD8", "OBSERVATION", 66, 75]]], ["Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll density gradient.", [["Peripheral blood mononuclear cells", "ANATOMY", 0, 34], ["PBMCs", "ANATOMY", 36, 41], ["Peripheral blood mononuclear cells", "CELL", 0, 34], ["PBMCs", "CELL", 36, 41], ["Peripheral blood mononuclear cells", "CELL_TYPE", 0, 34], ["PBMCs", "CELL_TYPE", 36, 41], ["Peripheral blood mononuclear cells", "TEST", 0, 34], ["PBMCs", "TEST", 36, 41], ["Ficoll density gradient", "TEST", 60, 83], ["blood", "ANATOMY", 11, 16], ["mononuclear cells", "OBSERVATION", 17, 34], ["Ficoll density", "OBSERVATION", 60, 74]]], ["CD8 T lymphocytes were isolated using CD8 beads (MACS, Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions; purity assessed by FACS was >95%.RNA Isolation, Reverse Transcription, and qPCRTotal RNA was isolated using TRIzol (Invitrogen) and subsequently the Qiagen RNeasy Mini Kit (Qiagen, Mississauga, ON, Canada) according to the manufacturer's instructions and as previously described (Saikali et al., 2007) .", [["CD8 T lymphocytes", "ANATOMY", 0, 17], ["CD8", "GENE_OR_GENE_PRODUCT", 0, 3], ["CD8", "GENE_OR_GENE_PRODUCT", 38, 41], ["CD8 T lymphocytes", "CELL_TYPE", 0, 17], ["MACS", "CELL_TYPE", 49, 53], ["Miltenyi Biotec", "PROTEIN", 55, 70], ["qPCRTotal RNA", "RNA", 205, 218], ["CD8 T lymphocytes", "TEST", 0, 17], ["CD8 beads", "TREATMENT", 38, 47], ["MACS", "TEST", 49, 53], ["Miltenyi Biotec", "TREATMENT", 55, 70], ["RNA Isolation", "TREATMENT", 163, 176], ["Reverse Transcription", "TREATMENT", 178, 199], ["qPCRTotal RNA", "TREATMENT", 205, 218], ["TRIzol (Invitrogen", "TREATMENT", 238, 256], ["the Qiagen RNeasy Mini Kit (Qiagen, Mississauga", "TREATMENT", 275, 322], ["lymphocytes", "ANATOMY", 6, 17]]], ["RNA samples were transcribed into cDNA using Quantitect Reverse Transcription kit according to the manufacturer's instruction (Qiagen).", [["samples", "ANATOMY", 4, 11], ["cDNA", "DNA", 34, 38], ["RNA samples", "TEST", 0, 11]]], ["PD-L1 and PD-L2 gene expression was determined by quantitative realtime PCR (qPCR) using primers and Taqman probes obtained from Applied Biosystems (Foster City, CA).", [["PD-L1", "GENE_OR_GENE_PRODUCT", 0, 5], ["PD-L2", "GENE_OR_GENE_PRODUCT", 10, 15], ["PD-L1 and PD-L2 gene", "DNA", 0, 20], ["Taqman probes", "DNA", 101, 114], ["PD-L1 and PD-L2 gene expression", "TREATMENT", 0, 31], ["quantitative realtime PCR", "TEST", 50, 75], ["Taqman probes", "TEST", 101, 114], ["L1", "ANATOMY", 3, 5], ["L2", "ANATOMY", 13, 15]]], ["Amplification of 18S was used as an endogenous control; results are presented as fold increase compared with untreated cells.Fluorescence Activated Cell Sorting (FACS)Brain cells were detached using PBS-EDTA and then labelled for surface (PD-L1 or PD-L2, HLA-A, B, C, CD11c, Nogo-A) and intracellular (glial fibrillary acidic protein, GFAP) human molecules as previously described (Saikali et al., 2007) (see list of reagents Table 1 ).", [["cells", "ANATOMY", 119, 124], ["Cell", "ANATOMY", 148, 152], ["Brain cells", "ANATOMY", 167, 178], ["surface", "ANATOMY", 230, 237], ["intracellular", "ANATOMY", 287, 300], ["EDTA", "CHEMICAL", 203, 207], ["18S", "GENE_OR_GENE_PRODUCT", 17, 20], ["cells", "CELL", 119, 124], ["Cell", "CELL", 148, 152], ["Brain cells", "CELL", 167, 178], ["PBS-EDTA", "SIMPLE_CHEMICAL", 199, 207], ["surface", "CELLULAR_COMPONENT", 230, 237], ["PD-L1", "GENE_OR_GENE_PRODUCT", 239, 244], ["PD-L2", "GENE_OR_GENE_PRODUCT", 248, 253], ["HLA-A", "GENE_OR_GENE_PRODUCT", 255, 260], ["B", "GENE_OR_GENE_PRODUCT", 262, 263], ["C", "GENE_OR_GENE_PRODUCT", 265, 266], ["CD11c", "GENE_OR_GENE_PRODUCT", 268, 273], ["Nogo-A", "GENE_OR_GENE_PRODUCT", 275, 281], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 287, 300], ["glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 302, 333], ["GFAP", "GENE_OR_GENE_PRODUCT", 335, 339], ["human", "ORGANISM", 341, 346], ["18S", "DNA", 17, 20], ["untreated cells", "CELL_TYPE", 109, 124], ["Activated Cell Sorting (FACS)Brain cells", "CELL_LINE", 138, 178], ["L1", "PROTEIN", 242, 244], ["PD", "PROTEIN", 248, 250], ["L2", "PROTEIN", 251, 253], ["HLA", "PROTEIN", 255, 258], ["B", "PROTEIN", 262, 263], ["CD11c", "PROTEIN", 268, 273], ["Nogo", "PROTEIN", 275, 279], ["intracellular (glial fibrillary acidic protein", "PROTEIN", 287, 333], ["GFAP", "PROTEIN", 335, 339], ["human molecules", "PROTEIN", 341, 356], ["human", "SPECIES", 341, 346], ["human", "SPECIES", 341, 346], ["Amplification of 18S", "TREATMENT", 0, 20], ["an endogenous control", "TREATMENT", 33, 54], ["Fluorescence Activated Cell Sorting (FACS)Brain cells", "TREATMENT", 125, 178], ["PBS", "TEST", 199, 202], ["EDTA", "TEST", 203, 207], ["surface", "TEST", 230, 237], ["PD", "TEST", 239, 241], ["PD", "TEST", 248, 250], ["HLA", "TEST", 255, 258], ["A", "TEST", 259, 260], ["B", "TEST", 262, 263], ["C", "TEST", 265, 266], ["CD11c", "TEST", 268, 273], ["Nogo", "TEST", 275, 279], ["intracellular (glial fibrillary acidic protein", "TEST", 287, 333], ["Brain", "ANATOMY", 167, 172], ["L2", "ANATOMY", 251, 253]]], ["Appropriate isotype controls were used for all stainings.", [["Appropriate isotype controls", "TREATMENT", 0, 28]]], ["DMedian fluorescence intensity (MFI) was calculated by subtracting the fluorescence of the isotype from that of the stain.ImmunocytochemistryCNS cells were fixed with either cold acetone or paraformaldehyde and blocked in HBSS containing goat and horse sera, FBS, HEPES buffer, and sodium azide.", [["ImmunocytochemistryCNS cells", "ANATOMY", 122, 150], ["sera", "ANATOMY", 253, 257], ["FBS", "ANATOMY", 259, 262], ["paraformaldehyde", "CHEMICAL", 190, 206], ["sodium azide", "CHEMICAL", 282, 294], ["acetone", "CHEMICAL", 179, 186], ["paraformaldehyde", "CHEMICAL", 190, 206], ["HEPES", "CHEMICAL", 264, 269], ["sodium azide", "CHEMICAL", 282, 294], ["ImmunocytochemistryCNS cells", "CELL", 122, 150], ["acetone", "SIMPLE_CHEMICAL", 179, 186], ["paraformaldehyde", "SIMPLE_CHEMICAL", 190, 206], ["HBSS", "SIMPLE_CHEMICAL", 222, 226], ["goat", "ORGANISM", 238, 242], ["horse", "ORGANISM", 247, 252], ["sera", "ORGANISM_SUBSTANCE", 253, 257], ["FBS", "ORGANISM_SUBSTANCE", 259, 262], ["sodium azide", "SIMPLE_CHEMICAL", 282, 294], ["ImmunocytochemistryCNS cells", "CELL_LINE", 122, 150], ["goat", "SPECIES", 238, 242], ["horse", "SPECIES", 247, 252], ["goat", "SPECIES", 238, 242], ["horse", "SPECIES", 247, 252], ["the stain", "TEST", 112, 121], ["ImmunocytochemistryCNS cells", "PROBLEM", 122, 150], ["cold acetone", "TREATMENT", 174, 186], ["paraformaldehyde", "TREATMENT", 190, 206], ["HBSS", "TEST", 222, 226], ["horse sera", "TEST", 247, 257], ["FBS", "TEST", 259, 262], ["HEPES buffer", "TREATMENT", 264, 276], ["sodium azide", "TREATMENT", 282, 294]]], ["Cells were incubated overnight with antibodies specific for either PD-L1 or PD-L2 (see list of reagents in Table 1 ) and then for 2 hours with secondary reagents (Table 1; biotinylated goat-a-mouse and Cy TM 3-conjugated streptavidin) in combination with antibodies targeting cellspecific markers.", [["Cells", "ANATOMY", 0, 5], ["Cy", "CHEMICAL", 202, 204], ["Cells", "CELL", 0, 5], ["PD-L1", "GENE_OR_GENE_PRODUCT", 67, 72], ["Cy TM 3-conjugated streptavidin", "SIMPLE_CHEMICAL", 202, 233], ["antibodies", "PROTEIN", 36, 46], ["biotinylated goat", "PROTEIN", 172, 189], ["conjugated streptavidin", "PROTEIN", 210, 233], ["antibodies", "PROTEIN", 255, 265], ["cellspecific markers", "PROTEIN", 276, 296], ["goat", "SPECIES", 185, 189], ["antibodies", "TEST", 36, 46], ["PD", "TEST", 67, 69], ["PD", "TEST", 76, 78], ["secondary reagents", "TREATMENT", 143, 161], ["biotinylated goat", "TEST", 172, 189], ["a-mouse", "TREATMENT", 190, 197], ["Cy TM 3-conjugated streptavidin", "TREATMENT", 202, 233], ["antibodies", "TREATMENT", 255, 265], ["L1", "ANATOMY", 70, 72], ["L2", "ANATOMY", 79, 81]]], ["To identify CNS cell types, astrocytes were costained for GFAP, oligodendrocytes for Nogo-A, and microglia for CD68.", [["CNS cell", "ANATOMY", 12, 20], ["astrocytes", "ANATOMY", 28, 38], ["oligodendrocytes", "ANATOMY", 64, 80], ["microglia", "ANATOMY", 97, 106], ["CNS cell", "CELL", 12, 20], ["astrocytes", "CELL", 28, 38], ["GFAP", "GENE_OR_GENE_PRODUCT", 58, 62], ["oligodendrocytes", "CELL", 64, 80], ["Nogo-A", "GENE_OR_GENE_PRODUCT", 85, 91], ["microglia", "CELL", 97, 106], ["CD68", "GENE_OR_GENE_PRODUCT", 111, 115], ["astrocytes", "CELL_TYPE", 28, 38], ["GFAP", "PROTEIN", 58, 62], ["oligodendrocytes", "CELL_TYPE", 64, 80], ["Nogo-A", "PROTEIN", 85, 91], ["microglia", "CELL_TYPE", 97, 106], ["CD68", "PROTEIN", 111, 115], ["CNS cell types", "TEST", 12, 26], ["astrocytes", "TEST", 28, 38], ["GFAP", "TEST", 58, 62], ["oligodendrocytes", "TEST", 64, 80], ["Nogo", "TEST", 85, 89], ["CD68", "TEST", 111, 115], ["CNS cell types", "OBSERVATION", 12, 26], ["astrocytes", "ANATOMY", 28, 38]]], ["Cells were finally incubated with Hoechst 33258 nuclear stain (Invitrogen), and mounted in Gelvatol.", [["Cells", "ANATOMY", 0, 5], ["nuclear", "ANATOMY", 48, 55], ["Hoechst 33258", "CHEMICAL", 34, 47], ["Gelvatol", "CHEMICAL", 91, 99], ["Hoechst 33258", "CHEMICAL", 34, 47], ["Gelvatol", "CHEMICAL", 91, 99], ["Cells", "CELL", 0, 5], ["Hoechst 33258", "SIMPLE_CHEMICAL", 34, 47], ["Gelvatol", "SIMPLE_CHEMICAL", 91, 99], ["nuclear stain", "TEST", 48, 61], ["Invitrogen", "TEST", 63, 73], ["Gelvatol", "TREATMENT", 91, 99]]], ["Slides were observed using a Leica fluorescent microscope.ImmunocytochemistrysiRNA Astrocytes were plated (2 3 10 5 cells/well) in a 24well plate for 48 hours and then were washed with Opti-MEM (Invitrogen).", [["Astrocytes", "ANATOMY", 83, 93], ["cells", "ANATOMY", 116, 121], ["Astrocytes", "CELL", 83, 93], ["cells", "CELL", 116, 121], ["a Leica fluorescent microscope", "TREATMENT", 27, 57], ["ImmunocytochemistrysiRNA Astrocytes", "TEST", 58, 93], ["a 24well plate", "TREATMENT", 131, 145], ["Opti-MEM (Invitrogen", "TREATMENT", 185, 205]]], ["PD-L1 specific (catalog number 4392420 from Applied Biosystems) or control siRNA (catalog number 4390844) were introduced into cells at an optimal concentration (7.5 pmol) with the Lipofectamine TM 2000 (Invitrogen) diluted in Opti-MEM.", [["cells", "ANATOMY", 127, 132], ["PD-L1", "GENE_OR_GENE_PRODUCT", 0, 5], ["cells", "CELL", 127, 132], ["Opti-MEM", "ORGANISM_SUBSTANCE", 227, 235], ["PD-L1", "DNA", 0, 5], ["PD", "TEST", 0, 2], ["the Lipofectamine TM", "TREATMENT", 177, 197], ["L1", "ANATOMY", 3, 5]]], ["Cells were kept 24 hours with the siRNA, and then washed.ImmunocytochemistryProinflammatory cytokine IFN-g (200 U/ml) was then added to the culture for 24 hours.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["IFN-g", "GENE_OR_GENE_PRODUCT", 101, 106], ["IFN", "PROTEIN", 101, 104], ["Cells", "TEST", 0, 5], ["the siRNA", "TREATMENT", 30, 39], ["Immunocytochemistry", "TEST", 57, 76], ["Proinflammatory cytokine", "TREATMENT", 76, 100], ["IFN", "TEST", 101, 104], ["the culture", "TEST", 136, 147]]], ["Freshly isolated alloreactive CFSE-labeled CD8 T cells (2 3 10 5 cells/well) were added to washed astrocytes in the presence of anti-CD3 (0.18 lg/ml, clone OKT3) and anti-CD28 (1 lg/ml, BD Biosciences) antibodies.", [["CD8 T cells", "ANATOMY", 43, 54], ["cells", "ANATOMY", 65, 70], ["astrocytes", "ANATOMY", 98, 108], ["CFSE", "CHEMICAL", 30, 34], ["CFSE", "CHEMICAL", 30, 34], ["CFSE", "SIMPLE_CHEMICAL", 30, 34], ["CD8 T cells", "CELL", 43, 54], ["cells", "CELL", 65, 70], ["astrocytes", "CELL", 98, 108], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 128, 136], ["OKT3", "GENE_OR_GENE_PRODUCT", 156, 160], ["anti-CD28", "SIMPLE_CHEMICAL", 166, 175], ["CD8 T cells", "CELL_TYPE", 43, 54], ["washed astrocytes", "CELL_TYPE", 91, 108], ["anti-CD3", "PROTEIN", 128, 136], ["clone OKT3", "PROTEIN", 150, 160], ["anti-CD28", "PROTEIN", 166, 175], ["BD Biosciences) antibodies", "PROTEIN", 186, 212], ["Freshly isolated alloreactive CFSE", "TEST", 0, 34], ["CD8 T cells", "TEST", 43, 54], ["anti-CD3", "TEST", 128, 136], ["clone OKT3", "TREATMENT", 150, 160], ["anti-CD28", "TREATMENT", 166, 175], ["BD Biosciences", "TEST", 186, 200], ["alloreactive CFSE", "OBSERVATION", 17, 34]]], ["Inhibition of PD-L1 expression was confirmed by FACS on astrocytes the same day that CD8 T cells were added.", [["astrocytes", "ANATOMY", 56, 66], ["CD8 T cells", "ANATOMY", 85, 96], ["PD-L1", "GENE_OR_GENE_PRODUCT", 14, 19], ["astrocytes", "CELL", 56, 66], ["CD8 T cells", "CELL", 85, 96], ["PD", "DNA", 14, 16], ["L1", "DNA", 17, 19], ["astrocytes", "CELL_TYPE", 56, 66], ["CD8 T cells", "CELL_TYPE", 85, 96], ["PD-L1 expression", "TREATMENT", 14, 30], ["CD8 T cells", "TREATMENT", 85, 96], ["PD", "OBSERVATION", 14, 16], ["L1", "ANATOMY", 17, 19]]], ["After a 6-day co-culture, cell supernatants were harvested and frozen for future CXCL10 ELISA assessment (OptEIA set; BD Bioscience) and CD8 T cells were collected and stained for CD8 in the presence of Live/dead fixable Aqua Dead Cell Stain kit (Invitrogen) to exclude dead cells and intracellularly stained for IFN-g, TNF, and granzyme B (see reagents in Table 1 ).ImmunohistochemistryPostmortem brain sections from tissue donors without CNS disease and patients diagnosed clinically and confirmed by neuropathological examination as having MS were obtained from the NeuroResource tissue bank, UCL Institute of Neurology, London, UK.", [["cell supernatants", "ANATOMY", 26, 43], ["CD8 T cells", "ANATOMY", 137, 148], ["Cell", "ANATOMY", 231, 235], ["cells", "ANATOMY", 275, 280], ["ImmunohistochemistryPostmortem brain sections", "ANATOMY", 367, 412], ["tissue", "ANATOMY", 418, 424], ["CNS", "ANATOMY", 440, 443], ["tissue", "ANATOMY", 583, 589], ["CNS disease", "DISEASE", 440, 451], ["cell supernatants", "CELL", 26, 43], ["CXCL10", "GENE_OR_GENE_PRODUCT", 81, 87], ["CD8", "GENE_OR_GENE_PRODUCT", 180, 183], ["cells", "CELL", 275, 280], ["IFN-g", "GENE_OR_GENE_PRODUCT", 313, 318], ["TNF", "GENE_OR_GENE_PRODUCT", 320, 323], ["granzyme B", "GENE_OR_GENE_PRODUCT", 329, 339], ["brain sections", "MULTI-TISSUE_STRUCTURE", 398, 412], ["tissue donors", "MULTI-TISSUE_STRUCTURE", 418, 431], ["CNS disease", "CANCER", 440, 451], ["patients", "ORGANISM", 456, 464], ["tissue", "TISSUE", 583, 589], ["CXCL10", "PROTEIN", 81, 87], ["CD8 T cells", "CELL_TYPE", 137, 148], ["CD8", "PROTEIN", 180, 183], ["dead cells", "CELL_TYPE", 270, 280], ["IFN", "PROTEIN", 313, 316], ["TNF", "PROTEIN", 320, 323], ["granzyme B", "PROTEIN", 329, 339], ["patients", "SPECIES", 456, 464], ["cell supernatants", "TREATMENT", 26, 43], ["future CXCL10 ELISA assessment", "TEST", 74, 104], ["BD Bioscience", "TEST", 118, 131], ["CD8 T cells", "TEST", 137, 148], ["CD8", "PROBLEM", 180, 183], ["Invitrogen", "TEST", 247, 257], ["dead cells", "PROBLEM", 270, 280], ["IFN", "TEST", 313, 316], ["TNF", "TEST", 320, 323], ["CNS disease", "PROBLEM", 440, 451], ["neuropathological examination", "TEST", 503, 532], ["MS", "PROBLEM", 543, 545], ["dead cells", "OBSERVATION", 270, 280], ["without", "UNCERTAINTY", 432, 439], ["CNS", "ANATOMY", 440, 443], ["disease", "OBSERVATION", 444, 451]]], ["Tissues were donated to the tissue bank with informed consent following ethical review by the London Research Ethics Committee, UK.", [["Tissues", "ANATOMY", 0, 7], ["tissue", "ANATOMY", 28, 34], ["Tissues", "CANCER", 0, 7], ["tissue", "TISSUE", 28, 34]]], ["This study was approved by the CHUM Ethical Committee.", [["This study", "TEST", 0, 10]]], ["Snap-frozen coded sections were cut from blocks of normal control and MS brain tissues.", [["sections", "ANATOMY", 18, 26], ["MS brain tissues", "ANATOMY", 70, 86], ["sections", "MULTI-TISSUE_STRUCTURE", 18, 26], ["brain tissues", "TISSUE", 73, 86], ["Snap", "TEST", 0, 4], ["normal", "OBSERVATION", 51, 57], ["brain tissues", "ANATOMY", 73, 86]]], ["Sections cut before and immediately after the ones used for the immunofluorescence studies were stained with oil red O and hematoxylin, and scored as previously described (Li et al., 1996) (Table 2 ).", [["O", "CHEMICAL", 117, 118], ["hematoxylin", "CHEMICAL", 123, 134], ["oil red O", "SIMPLE_CHEMICAL", 109, 118], ["hematoxylin", "SIMPLE_CHEMICAL", 123, 134], ["the immunofluorescence studies", "TEST", 60, 90], ["hematoxylin", "TREATMENT", 123, 134]]], ["Sections were airdried, fixed in cold acetone, and blocked in HBSS containing horse serum, FBS, HEPES buffer and sodium azide and then blocked using the Blocking Kit (Vector Laboratories).", [["serum", "ANATOMY", 84, 89], ["FBS", "ANATOMY", 91, 94], ["sodium azide", "CHEMICAL", 113, 125], ["acetone", "CHEMICAL", 38, 45], ["HEPES", "CHEMICAL", 96, 101], ["sodium azide", "CHEMICAL", 113, 125], ["acetone", "SIMPLE_CHEMICAL", 38, 45], ["horse", "ORGANISM", 78, 83], ["serum", "ORGANISM_SUBSTANCE", 84, 89], ["FBS", "ORGANISM_SUBSTANCE", 91, 94], ["sodium azide", "SIMPLE_CHEMICAL", 113, 125], ["horse", "SPECIES", 78, 83], ["horse", "SPECIES", 78, 83], ["cold acetone", "TREATMENT", 33, 45], ["HBSS", "TEST", 62, 66], ["horse serum", "TEST", 78, 89], ["FBS", "TEST", 91, 94], ["HEPES buffer", "TREATMENT", 96, 108], ["sodium azide", "TREATMENT", 113, 125]]], ["Primary antibodies targeting PD-L1 (see Table 1 for all staining reagents) or PD-1 were incubated overnight.", [["PD-L1", "GENE_OR_GENE_PRODUCT", 29, 34], ["PD-1", "GENE_OR_GENE_PRODUCT", 78, 82], ["PD-L1", "DNA", 29, 34], ["Primary antibodies", "TEST", 0, 18], ["all staining reagents", "TEST", 52, 73], ["PD", "TEST", 78, 80], ["L1", "ANATOMY", 32, 34]]], ["Sections were then washed with PBS and incubated for 2 hours with biotinylated goat-antimouse and subsequently with Cy3-conjugated streptavidin concomitantly with antibodies targeting cell specific marker for either astrocytes (GFAP), microglia (Iba-1), oligodendrocytes (Nogo-A), CD8, or CD4 T cells followed by a 2-hour incubation with appropriate secondary reagent.", [["cell", "ANATOMY", 184, 188], ["astrocytes", "ANATOMY", 216, 226], ["microglia", "ANATOMY", 235, 244], ["Iba-1", "ANATOMY", 246, 251], ["oligodendrocytes", "ANATOMY", 254, 270], ["CD8", "ANATOMY", 281, 284], ["CD4 T cells", "ANATOMY", 289, 300], ["goat", "ORGANISM", 79, 83], ["Cy3-conjugated streptavidin", "SIMPLE_CHEMICAL", 116, 143], ["cell", "CELL", 184, 188], ["astrocytes", "CELL", 216, 226], ["GFAP", "GENE_OR_GENE_PRODUCT", 228, 232], ["microglia", "CELL", 235, 244], ["Iba-1", "GENE_OR_GENE_PRODUCT", 246, 251], ["oligodendrocytes", "CELL", 254, 270], ["Nogo-A", "GENE_OR_GENE_PRODUCT", 272, 278], ["CD8", "GENE_OR_GENE_PRODUCT", 281, 284], ["biotinylated goat-antimouse", "PROTEIN", 66, 93], ["antibodies", "PROTEIN", 163, 173], ["astrocytes", "CELL_TYPE", 216, 226], ["GFAP", "PROTEIN", 228, 232], ["microglia", "CELL_TYPE", 235, 244], ["Iba", "PROTEIN", 246, 249], ["oligodendrocytes", "CELL_TYPE", 254, 270], ["Nogo", "PROTEIN", 272, 276], ["CD8", "PROTEIN", 281, 284], ["CD4 T cells", "CELL_TYPE", 289, 300], ["goat", "SPECIES", 79, 83], ["goat", "SPECIES", 79, 83], ["PBS", "TREATMENT", 31, 34], ["biotinylated goat-antimouse", "TREATMENT", 66, 93], ["Cy3-conjugated streptavidin", "TREATMENT", 116, 143], ["antibodies", "TREATMENT", 163, 173], ["GFAP", "TEST", 228, 232], ["microglia", "TEST", 235, 244], ["Iba", "TEST", 246, 249], ["oligodendrocytes", "TEST", 254, 270], ["Nogo", "TEST", 272, 276], ["CD8", "TEST", 281, 284], ["CD4 T cells", "PROBLEM", 289, 300], ["a 2-hour incubation", "TREATMENT", 313, 332], ["appropriate secondary reagent", "TREATMENT", 338, 367]]], ["Finally, sections were treated with RNase and then incubated with a nuclear stain TO-PRO\u00d2-3 iodide (Invitrogen).", [["sections", "ANATOMY", 9, 17], ["nuclear", "ANATOMY", 68, 75], ["PRO\u00d2-3 iodide", "CHEMICAL", 85, 98], ["TO-PRO\u00d2-3 iodide", "CHEMICAL", 82, 98], ["RNase", "GENE_OR_GENE_PRODUCT", 36, 41], ["PRO\u00d2-3 iodide", "SIMPLE_CHEMICAL", 85, 98], ["Invitrogen", "SIMPLE_CHEMICAL", 100, 110], ["RNase", "PROTEIN", 36, 41], ["RNase", "TREATMENT", 36, 41], ["a nuclear stain", "TEST", 66, 81]]], ["Sections were treated with 1% Sudan black in 70% ethanol to quench tissue autofluorescence.", [["tissue", "ANATOMY", 67, 73], ["ethanol", "CHEMICAL", 49, 56], ["ethanol", "CHEMICAL", 49, 56], ["ethanol", "SIMPLE_CHEMICAL", 49, 56], ["tissue", "TISSUE", 67, 73]]], ["Controls were concurrently carried out on adjacent sections using appropriate primary isotype controls at the same concentrations.", [["sections", "ANATOMY", 51, 59], ["sections", "MULTI-TISSUE_STRUCTURE", 51, 59], ["adjacent sections", "TREATMENT", 42, 59], ["appropriate primary isotype controls", "TREATMENT", 66, 102]]], ["Slides were observed using a SP5 Leica confocal microscope and confocal images acquired simultaneously in different channels throughout 4 to 8 lm z-stack every 0.2 to 0.5 lm.StatisticsData were analyzed using GraphPad Prism software.", [["confocal images", "TEST", 63, 78], ["StatisticsData", "TEST", 174, 188]]], ["Results are shown as mean 6 SEM and statistical MilliporeStatisticsBD Biosciences Mouse a-PD-1 Abcam Biotinylated goat a-mouse Dako Cy TM 3-conjugated Streptavidin Jackson Immuno Alexa Fluor\u00d2 488-conjugated goat a-rabbit Invitrogen analyses included paired and unpaired Student's t-test.", [["Alexa Fluor\u00d2 488", "SIMPLE_CHEMICAL", 179, 195], ["Mouse a-PD-1 Abcam Biotinylated goat a-mouse Dako Cy TM 3-conjugated Streptavidin Jackson Immuno Alexa Fluor\u00d2 488", "PROTEIN", 82, 195], ["Mouse", "SPECIES", 82, 87], ["goat", "SPECIES", 114, 118], ["goat", "SPECIES", 207, 211], ["goat", "SPECIES", 114, 118], ["goat", "SPECIES", 207, 211], ["mean", "TEST", 21, 25], ["statistical MilliporeStatisticsBD Biosciences", "TEST", 36, 81], ["PD", "TEST", 90, 92], ["Abcam", "TEST", 95, 100], ["Biotinylated", "TEST", 101, 113], ["a-mouse", "TEST", 119, 126], ["Cy", "TEST", 132, 134], ["TM", "TEST", 135, 137], ["Alexa Fluor\u00d2", "TEST", 179, 191]]], ["P values less than 0.05 were considered significant.Proinflammatory Cytokines Increase PD-L1 Expression on Human AstrocytesWe elected to evaluate whether different human CNS cell types express PD-L1 or PD-L2 under basal levels or upon inflammatory conditions.", [["CNS cell", "ANATOMY", 170, 178], ["PD-L1", "GENE_OR_GENE_PRODUCT", 87, 92], ["Human", "ORGANISM", 107, 112], ["human", "ORGANISM", 164, 169], ["CNS cell", "CELL", 170, 178], ["PD-L1", "GENE_OR_GENE_PRODUCT", 193, 198], ["PD-L2", "GENE_OR_GENE_PRODUCT", 202, 207], ["Proinflammatory Cytokines", "PROTEIN", 52, 77], ["Human AstrocytesWe", "CELL_TYPE", 107, 125], ["human CNS cell types", "CELL_TYPE", 164, 184], ["Human", "SPECIES", 107, 112], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 164, 169], ["P values", "TEST", 0, 8], ["Proinflammatory Cytokines", "PROBLEM", 52, 77], ["PD", "TEST", 193, 195], ["PD-L2 under basal levels", "TEST", 202, 226], ["inflammatory conditions", "PROBLEM", 235, 258], ["L1", "ANATOMY", 90, 92], ["L1", "ANATOMY", 196, 198], ["L2", "ANATOMY", 205, 207], ["basal", "ANATOMY_MODIFIER", 214, 219], ["inflammatory", "OBSERVATION", 235, 247]]], ["Primary cultures of human astrocytes were either untreated (NIL) or activated with different proinflammatory cytokines: IFN-g, TNF, IL-1b, IFN-g 1 TNF, TNF 1 IL-1b, or IFN-g 1 IL-1b to mimic the proinflammatory environment found in the CNS of MS patients.", [["Primary cultures", "ANATOMY", 0, 16], ["astrocytes", "ANATOMY", 26, 36], ["NIL", "ANATOMY", 60, 63], ["CNS", "ANATOMY", 236, 239], ["MS", "DISEASE", 243, 245], ["human", "ORGANISM", 20, 25], ["astrocytes", "CELL", 26, 36], ["IFN-g", "GENE_OR_GENE_PRODUCT", 120, 125], ["TNF", "GENE_OR_GENE_PRODUCT", 127, 130], ["IL-1b", "GENE_OR_GENE_PRODUCT", 132, 137], ["IFN-g 1 TNF", "GENE_OR_GENE_PRODUCT", 139, 150], ["TNF 1", "GENE_OR_GENE_PRODUCT", 152, 157], ["IL-1b", "GENE_OR_GENE_PRODUCT", 158, 163], ["IL-1b", "GENE_OR_GENE_PRODUCT", 176, 181], ["CNS", "ANATOMICAL_SYSTEM", 236, 239], ["patients", "ORGANISM", 246, 254], ["human astrocytes", "CELL_TYPE", 20, 36], ["proinflammatory cytokines", "PROTEIN", 93, 118], ["IFN", "PROTEIN", 120, 123], ["TNF", "PROTEIN", 127, 130], ["IFN", "PROTEIN", 139, 142], ["TNF", "PROTEIN", 147, 150], ["TNF 1 IL-1b", "PROTEIN", 152, 163], ["IFN-g 1 IL-1b", "PROTEIN", 168, 181], ["human", "SPECIES", 20, 25], ["patients", "SPECIES", 246, 254], ["human", "SPECIES", 20, 25], ["Primary cultures of human astrocytes", "TEST", 0, 36], ["different proinflammatory cytokines", "TEST", 83, 118], ["IFN", "TEST", 120, 123], ["g", "TEST", 124, 125], ["TNF", "TEST", 127, 130], ["IL", "TEST", 132, 134], ["IFN", "TEST", 139, 142], ["g", "TEST", 143, 144], ["TNF", "TEST", 147, 150], ["TNF", "TEST", 152, 155], ["IL", "TEST", 158, 160], ["IFN", "TEST", 168, 171], ["IL", "TEST", 176, 178], ["the proinflammatory environment", "PROBLEM", 191, 222], ["human astrocytes", "ANATOMY", 20, 36]]], ["We first conducted qPCR analysis to assess PD-L1 and PD-L2 mRNA levels and found that astrocytes expressed only low levels of both PD-L1 and PD-L2 under basal conditions (Fig. 1A ,B).", [["astrocytes", "ANATOMY", 86, 96], ["PD-L1", "GENE_OR_GENE_PRODUCT", 43, 48], ["PD-L2", "GENE_OR_GENE_PRODUCT", 53, 58], ["astrocytes", "CELL", 86, 96], ["PD-L1", "GENE_OR_GENE_PRODUCT", 131, 136], ["PD-L2", "GENE_OR_GENE_PRODUCT", 141, 146], ["B", "GENE_OR_GENE_PRODUCT", 180, 181], ["PD-L1 and PD-L2 mRNA", "RNA", 43, 63], ["astrocytes", "CELL_TYPE", 86, 96], ["qPCR analysis", "TEST", 19, 32], ["PD", "TEST", 43, 45], ["L1 and PD-L2 mRNA levels", "TEST", 46, 70], ["astrocytes", "TEST", 86, 96], ["L1", "ANATOMY", 134, 136], ["L2", "ANATOMY", 144, 146], ["basal", "ANATOMY_MODIFIER", 153, 158]]], ["However, following single cytokine treatment we detected a significant increase in PD-L1 levels compared with untreated cells (IFN-g or TNF: P < 0.05 vs. NIL).", [["cells", "ANATOMY", 120, 125], ["PD-L1", "GENE_OR_GENE_PRODUCT", 83, 88], ["cells", "CELL", 120, 125], ["IFN-g", "GENE_OR_GENE_PRODUCT", 127, 132], ["TNF", "GENE_OR_GENE_PRODUCT", 136, 139], ["cytokine", "PROTEIN", 26, 34], ["untreated cells", "CELL_TYPE", 110, 125], ["IFN", "PROTEIN", 127, 130], ["TNF", "PROTEIN", 136, 139], ["single cytokine treatment", "TREATMENT", 19, 44], ["a significant increase in PD-L1 levels", "PROBLEM", 57, 95], ["untreated cells", "PROBLEM", 110, 125], ["IFN", "TEST", 127, 130], ["TNF", "TEST", 136, 139], ["significant", "OBSERVATION_MODIFIER", 59, 70], ["increase", "OBSERVATION_MODIFIER", 71, 79], ["L1", "ANATOMY", 86, 88]]], ["In contrast, cytokines or cytokine combinations had only a small impact on PD-L2 mRNA levels.Proinflammatory Cytokines Increase PD-L1 Expression on Human AstrocytesWe next investigated whether astrocytes expressed detectable protein levels of these two ligands using FACS.", [["astrocytes", "ANATOMY", 193, 203], ["PD-L2", "GENE_OR_GENE_PRODUCT", 75, 80], ["PD-L1", "GENE_OR_GENE_PRODUCT", 128, 133], ["Human", "ORGANISM", 148, 153], ["astrocytes", "CELL", 193, 203], ["cytokines", "PROTEIN", 13, 22], ["cytokine", "PROTEIN", 26, 34], ["PD-L2 mRNA", "RNA", 75, 85], ["Proinflammatory Cytokines", "PROTEIN", 93, 118], ["PD", "PROTEIN", 128, 130], ["astrocytes", "CELL_TYPE", 193, 203], ["Human", "SPECIES", 148, 153], ["cytokine combinations", "TREATMENT", 26, 47], ["a small impact on PD", "PROBLEM", 57, 77], ["Proinflammatory Cytokines", "TEST", 93, 118], ["PD", "TEST", 128, 130], ["Human AstrocytesWe", "TEST", 148, 166], ["protein levels", "TEST", 225, 239], ["small", "OBSERVATION_MODIFIER", 59, 64], ["L2", "ANATOMY", 78, 80], ["L1 Expression", "OBSERVATION_MODIFIER", 131, 144]]], ["In agreement with our qPCR results, low protein levels of PD-L1 and PD-L2 were detected on astrocytes under basal conditions ( Fig. 1C -F).", [["astrocytes", "ANATOMY", 91, 101], ["PD-L1", "GENE_OR_GENE_PRODUCT", 58, 63], ["PD-L2", "GENE_OR_GENE_PRODUCT", 68, 73], ["astrocytes", "CELL", 91, 101], ["astrocytes", "CELL_TYPE", 91, 101], ["our qPCR", "TEST", 18, 26], ["low protein levels", "PROBLEM", 36, 54], ["PD", "TEST", 58, 60], ["L2", "ANATOMY", 71, 73]]], ["Adding one proinflammatory cytokine elevated PD-L1 expression and IFN-g 1 TNF or IFN-g 1 IL-1b combinations caused even a greater increase of PD-L1 on all astrocytes (Fig. 1C ).", [["astrocytes", "ANATOMY", 155, 165], ["PD-L1", "GENE_OR_GENE_PRODUCT", 45, 50], ["IFN-g 1 TNF", "GENE_OR_GENE_PRODUCT", 66, 77], ["IFN-g 1", "GENE_OR_GENE_PRODUCT", 81, 88], ["IL-1b", "GENE_OR_GENE_PRODUCT", 89, 94], ["PD-L1", "GENE_OR_GENE_PRODUCT", 142, 147], ["astrocytes", "CELL", 155, 165], ["proinflammatory cytokine", "PROTEIN", 11, 35], ["IFN", "PROTEIN", 66, 69], ["astrocytes", "CELL_TYPE", 155, 165], ["one proinflammatory cytokine elevated PD", "PROBLEM", 7, 47], ["L1 expression", "TEST", 48, 61], ["IFN", "TEST", 66, 69], ["TNF", "TEST", 74, 77], ["IFN", "TEST", 81, 84], ["a greater increase of PD", "PROBLEM", 120, 144], ["L1", "ANATOMY", 48, 50]]], ["These enhanced protein levels compared with untreated samples were observed on all samples tested reaching almost significance (n: 0.05 > P 0.1; TNF, IL-1b, IFNg 1 TNF, IFN-g 1 IL-1b, or TNF 1 IL-1b vs. NIL).", [["samples", "ANATOMY", 54, 61], ["samples", "ANATOMY", 83, 90], ["NIL", "ANATOMY", 203, 206], ["TNF", "GENE_OR_GENE_PRODUCT", 145, 148], ["IL-1b", "GENE_OR_GENE_PRODUCT", 150, 155], ["IFNg 1 TNF", "GENE_OR_GENE_PRODUCT", 157, 167], ["IFN-g 1", "GENE_OR_GENE_PRODUCT", 169, 176], ["IL-1b", "GENE_OR_GENE_PRODUCT", 177, 182], ["TNF 1", "GENE_OR_GENE_PRODUCT", 187, 192], ["IL-1b", "GENE_OR_GENE_PRODUCT", 193, 198], ["NIL", "MULTI-TISSUE_STRUCTURE", 203, 206], ["TNF", "PROTEIN", 145, 148], ["IL", "PROTEIN", 150, 152], ["TNF", "PROTEIN", 164, 167], ["IFN", "PROTEIN", 169, 172], ["TNF 1", "PROTEIN", 187, 192], ["These enhanced protein levels", "TEST", 0, 29], ["untreated samples", "PROBLEM", 44, 61], ["all samples", "TEST", 79, 90], ["P", "TEST", 138, 139], ["TNF", "TEST", 145, 148], ["IL", "TEST", 150, 152], ["IFNg", "TEST", 157, 161], ["TNF", "TEST", 164, 167], ["IFN", "TEST", 169, 172], ["g", "TEST", 173, 174], ["IL", "TEST", 177, 179], ["TNF", "TEST", 187, 190], ["IL", "TEST", 193, 195]]], ["These treatments had only a small impact on PD-L2 expression (Fig. 1D ,F).", [["PD-L2", "GENE_OR_GENE_PRODUCT", 44, 49], ["L2", "DNA", 47, 49], ["These treatments", "TREATMENT", 0, 16], ["PD-L2 expression", "TREATMENT", 44, 60], ["small", "OBSERVATION_MODIFIER", 28, 33], ["L2", "ANATOMY", 47, 49]]], ["To document the activation status of astrocytes, we assessed their MHC-I expression and secretion of CXCL10, both known to be robustly enhanced following their activation .", [["astrocytes", "ANATOMY", 37, 47], ["astrocytes", "CELL", 37, 47], ["MHC-I", "GENE_OR_GENE_PRODUCT", 67, 72], ["CXCL10", "GENE_OR_GENE_PRODUCT", 101, 107], ["astrocytes", "CELL_TYPE", 37, 47], ["MHC", "PROTEIN", 67, 70], ["CXCL10", "PROTEIN", 101, 107], ["secretion of CXCL10", "PROBLEM", 88, 107]]], ["MHC-I levels were increased in response to each treatment tested (Fig. 1G ) similarly to what we observed for PD-L1 expression.", [["MHC-I", "GENE_OR_GENE_PRODUCT", 0, 5], ["PD-L1", "GENE_OR_GENE_PRODUCT", 110, 115], ["MHC", "PROTEIN", 0, 3], ["MHC-I levels", "TEST", 0, 12], ["each treatment", "TREATMENT", 43, 57], ["PD", "PROBLEM", 110, 112], ["L1", "ANATOMY", 113, 115]]], ["Moreover, CXCL10 secretion augmented in response to proinflammatory treatments, especially with IFN-g 1 TNF or IFN-g 1 IL-1b combinations (Fig. 1H ).", [["1H", "CHEMICAL", 144, 146], ["CXCL10", "GENE_OR_GENE_PRODUCT", 10, 16], ["IFN-g 1 TNF", "GENE_OR_GENE_PRODUCT", 96, 107], ["IL-1b", "GENE_OR_GENE_PRODUCT", 119, 124], ["CXCL10", "PROTEIN", 10, 16], ["IFN", "PROTEIN", 96, 99], ["TNF", "PROTEIN", 104, 107], ["IFN", "PROTEIN", 111, 114], ["CXCL10 secretion", "PROBLEM", 10, 26], ["proinflammatory treatments", "TREATMENT", 52, 78], ["IFN", "TREATMENT", 96, 99], ["TNF", "TREATMENT", 104, 107], ["IFN", "TREATMENT", 111, 114]]], ["Addition of IL-17 or IL-22, two cytokines produced by Th17 cells, did not alter PD-L1, (blue) with the corresponding isotype.", [["Th17 cells", "ANATOMY", 54, 64], ["IL-17", "GENE_OR_GENE_PRODUCT", 12, 17], ["IL-22", "GENE_OR_GENE_PRODUCT", 21, 26], ["Th17 cells", "CELL", 54, 64], ["PD-L1", "GENE_OR_GENE_PRODUCT", 80, 85], ["IL", "PROTEIN", 12, 14], ["IL-22", "PROTEIN", 21, 26], ["cytokines", "PROTEIN", 32, 41], ["Th17 cells", "CELL_TYPE", 54, 64], ["IL", "TEST", 12, 14], ["IL", "TEST", 21, 23], ["L1", "ANATOMY", 83, 85], ["isotype", "OBSERVATION", 117, 124]]], ["Paired Student's t-test comparing nil versus indicated cytokine treatment *P < 0.05; **P < 0.01; n: 0.05 > P < 0.1.", [["cytokine", "PROTEIN", 55, 63], ["cytokine treatment", "TREATMENT", 55, 73]]], ["PD-L2, or MHC-I expression on astrocytes (data not shown).Proinflammatory Cytokines Increase PD-L1 Expression on Human AstrocytesPD-L1 was undetectable or barely detectable by immunocytochemistry on untreated astrocytes, but we observed an increased PD-L1 expression after IFN-g 1 TNF treatment (Fig. 1I ).", [["astrocytes", "ANATOMY", 30, 40], ["astrocytes", "ANATOMY", 209, 219], ["PD-L2", "GENE_OR_GENE_PRODUCT", 0, 5], ["MHC-I", "GENE_OR_GENE_PRODUCT", 10, 15], ["astrocytes", "CELL", 30, 40], ["PD-L1", "GENE_OR_GENE_PRODUCT", 93, 98], ["Human", "ORGANISM", 113, 118], ["AstrocytesPD-L1", "GENE_OR_GENE_PRODUCT", 119, 134], ["astrocytes", "CELL", 209, 219], ["PD-L1", "GENE_OR_GENE_PRODUCT", 250, 255], ["IFN-g 1 TNF", "GENE_OR_GENE_PRODUCT", 273, 284], ["MHC", "PROTEIN", 10, 13], ["astrocytes", "CELL_TYPE", 30, 40], ["Proinflammatory Cytokines", "PROTEIN", 58, 83], ["AstrocytesPD", "PROTEIN", 119, 131], ["L1", "DNA", 132, 134], ["astrocytes", "CELL_TYPE", 209, 219], ["IFN", "PROTEIN", 273, 276], ["TNF", "PROTEIN", 281, 284], ["Human", "SPECIES", 113, 118], ["PD", "TEST", 0, 2], ["Proinflammatory Cytokines", "TEST", 58, 83], ["PD", "TEST", 93, 95], ["Human AstrocytesPD-L1", "TEST", 113, 134], ["immunocytochemistry on untreated astrocytes", "PROBLEM", 176, 219], ["an increased PD", "PROBLEM", 237, 252], ["IFN-g 1 TNF treatment", "TREATMENT", 273, 294], ["L2", "ANATOMY", 3, 5], ["L1 Expression", "OBSERVATION_MODIFIER", 96, 109], ["L1", "ANATOMY", 132, 134], ["increased", "OBSERVATION_MODIFIER", 240, 249], ["PD", "OBSERVATION", 250, 252], ["L1", "ANATOMY", 253, 255]]], ["IFN-g and TNF alone also induced an increase of PD-L1 expression, but to a lesser extent than IFN-g 1 TNF (data not shown).", [["IFN", "CHEMICAL", 0, 3], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["TNF", "GENE_OR_GENE_PRODUCT", 10, 13], ["PD-L1", "GENE_OR_GENE_PRODUCT", 48, 53], ["IFN-g 1 TNF", "GENE_OR_GENE_PRODUCT", 94, 105], ["IFN", "PROTEIN", 0, 3], ["TNF", "PROTEIN", 10, 13], ["IFN", "PROTEIN", 94, 97], ["TNF", "PROTEIN", 102, 105], ["IFN", "TEST", 0, 3], ["TNF", "PROBLEM", 10, 13], ["PD", "PROBLEM", 48, 50], ["IFN", "TEST", 94, 97], ["increase", "OBSERVATION_MODIFIER", 36, 44], ["L1 expression", "OBSERVATION_MODIFIER", 51, 64], ["lesser extent", "OBSERVATION_MODIFIER", 75, 88]]], ["The small PD-L2 increased expression observed by qPCR and FACS following proinflammatory treatment was below detection levels by immunocytochemistry (data not shown).Human Oligodendrocytes and Microglia Express PD-L1 in Response to Proinflammatory CytokinesWe evaluated whether other CNS cell types express PD-L1 or PD-L2 in response to proinflammatory cytokines.", [["Oligodendrocytes", "ANATOMY", 172, 188], ["Microglia", "ANATOMY", 193, 202], ["CNS cell", "ANATOMY", 284, 292], ["PD-L2", "GENE_OR_GENE_PRODUCT", 10, 15], ["Human", "ORGANISM", 166, 171], ["Oligodendrocytes", "CELL", 172, 188], ["Microglia", "CELL", 193, 202], ["PD-L1", "GENE_OR_GENE_PRODUCT", 211, 216], ["CNS cell", "CELL", 284, 292], ["PD-L1", "GENE_OR_GENE_PRODUCT", 307, 312], ["PD-L2", "GENE_OR_GENE_PRODUCT", 316, 321], ["Human Oligodendrocytes", "CELL_TYPE", 166, 188], ["Microglia", "CELL_TYPE", 193, 202], ["PD-L1", "PROTEIN", 211, 216], ["Proinflammatory CytokinesWe", "PROTEIN", 232, 259], ["proinflammatory cytokines", "PROTEIN", 337, 362], ["Human", "SPECIES", 166, 171], ["Human", "SPECIES", 166, 171], ["The small PD-L2 increased expression", "PROBLEM", 0, 36], ["qPCR", "TEST", 49, 53], ["proinflammatory treatment", "TREATMENT", 73, 98], ["detection levels", "TEST", 109, 125], ["immunocytochemistry (data", "TEST", 129, 154], ["Human Oligodendrocytes", "TEST", 166, 188], ["Proinflammatory CytokinesWe", "TEST", 232, 259], ["PD", "TEST", 307, 309], ["proinflammatory cytokines", "PROBLEM", 337, 362], ["small", "OBSERVATION_MODIFIER", 4, 9], ["PD", "OBSERVATION", 10, 12], ["L2", "ANATOMY", 13, 15], ["increased expression", "OBSERVATION", 16, 36], ["L1", "ANATOMY", 214, 216], ["CNS cell", "OBSERVATION", 284, 292], ["L1", "ANATOMY", 310, 312], ["L2", "ANATOMY", 319, 321], ["proinflammatory cytokines", "OBSERVATION", 337, 362]]], ["As experiments performed on astrocytes showed similar results between mRNA levels and protein levels, PD-L1 and PD-L2 expression were assessed at the protein level by immunocytochemistry and FACS.", [["astrocytes", "ANATOMY", 28, 38], ["astrocytes", "CELL", 28, 38], ["PD-L1", "GENE_OR_GENE_PRODUCT", 102, 107], ["PD-L2", "GENE_OR_GENE_PRODUCT", 112, 117], ["astrocytes", "CELL_TYPE", 28, 38], ["astrocytes", "TEST", 28, 38], ["mRNA levels", "TEST", 70, 81], ["protein levels", "TEST", 86, 100], ["PD", "TEST", 102, 104], ["PD", "TEST", 112, 114], ["immunocytochemistry", "TEST", 167, 186], ["L1", "ANATOMY", 105, 107], ["L2", "ANATOMY", 115, 117]]], ["Adult CNS cells enriched for oligodendrocytes or microglia were either untreated or cytokine stimulated before PD-L1 and PD-L2 detection concomitantly with either CD68 or CD11c (for microglia) or Nogo-A (for oligodendrocytes) labeling.", [["CNS cells", "ANATOMY", 6, 15], ["oligodendrocytes", "ANATOMY", 29, 45], ["microglia", "ANATOMY", 49, 58], ["microglia", "ANATOMY", 182, 191], ["oligodendrocytes", "ANATOMY", 208, 224], ["CNS cells", "CELL", 6, 15], ["oligodendrocytes", "CELL", 29, 45], ["microglia", "CELL", 49, 58], ["PD-L1", "GENE_OR_GENE_PRODUCT", 111, 116], ["PD-L2", "GENE_OR_GENE_PRODUCT", 121, 126], ["CD68", "GENE_OR_GENE_PRODUCT", 163, 167], ["CD11c", "GENE_OR_GENE_PRODUCT", 171, 176], ["microglia", "CELL", 182, 191], ["Nogo-A", "GENE_OR_GENE_PRODUCT", 196, 202], ["oligodendrocytes", "CELL", 208, 224], ["CNS cells", "CELL_TYPE", 6, 15], ["oligodendrocytes", "CELL_TYPE", 29, 45], ["microglia", "CELL_TYPE", 49, 58], ["cytokine", "PROTEIN", 84, 92], ["CD68", "PROTEIN", 163, 167], ["CD11c", "PROTEIN", 171, 176], ["microglia", "CELL_TYPE", 182, 191], ["Nogo-A", "PROTEIN", 196, 202], ["Adult CNS cells", "PROBLEM", 0, 15], ["oligodendrocytes", "PROBLEM", 29, 45], ["microglia", "PROBLEM", 49, 58], ["PD", "TEST", 111, 113], ["PD-L2 detection", "TEST", 121, 136], ["CD68", "TEST", 163, 167], ["microglia", "TEST", 182, 191], ["Nogo", "TEST", 196, 200], ["CNS cells", "OBSERVATION", 6, 15], ["L2", "ANATOMY", 124, 126]]], ["One representative example out of four tested donors is illustrated in Fig. 2 .", [["donors", "ORGANISM", 46, 52]]], ["Untreated microglia and oligodendrocytes had very low or undetectable levels of PD-L1 ( Fig. 2A-C ,H-J,O-P) and PD-L2 (data not shown).", [["microglia", "ANATOMY", 10, 19], ["oligodendrocytes", "ANATOMY", 24, 40], ["2A-C", "CHEMICAL", 93, 97], ["O-P", "CHEMICAL", 103, 106], ["microglia", "CELL", 10, 19], ["oligodendrocytes", "CELL", 24, 40], ["PD-L1", "GENE_OR_GENE_PRODUCT", 80, 85], ["2A-C", "SIMPLE_CHEMICAL", 93, 97], ["H-J", "SIMPLE_CHEMICAL", 99, 102], ["O-P", "SIMPLE_CHEMICAL", 103, 106], ["microglia", "CELL_TYPE", 10, 19], ["oligodendrocytes", "CELL_TYPE", 24, 40], ["Untreated microglia and oligodendrocytes", "PROBLEM", 0, 40], ["very low", "PROBLEM", 45, 53], ["PD", "TEST", 80, 82], ["2A-C ,H-J,O-P) and PD-L2 (data", "TEST", 93, 123], ["microglia", "OBSERVATION", 10, 19], ["very", "OBSERVATION_MODIFIER", 45, 49], ["low", "OBSERVATION_MODIFIER", 50, 53], ["L1", "ANATOMY", 83, 85], ["L2", "ANATOMY", 115, 117]]], ["However, PD-L1 expression was increased on microglia ( Fig. 2D-F,O) and oligodendrocytes ( Fig. 2K -M,P) following IFN-g 1 TNF treatment; the DMFI for PD-L1 levels reached on average 1,213 for microglia and 403 for oligodendrocytes.", [["microglia", "ANATOMY", 43, 52], ["oligodendrocytes", "ANATOMY", 72, 88], ["microglia", "ANATOMY", 193, 202], ["oligodendrocytes", "ANATOMY", 215, 231], ["PD-L1", "GENE_OR_GENE_PRODUCT", 9, 14], ["microglia", "CELL", 43, 52], ["Fig. 2D-F,O", "CELL", 55, 66], ["oligodendrocytes", "CELL", 72, 88], ["IFN-g 1 TNF", "GENE_OR_GENE_PRODUCT", 115, 126], ["PD-L1", "GENE_OR_GENE_PRODUCT", 151, 156], ["microglia", "CELL", 193, 202], ["oligodendrocytes", "CELL", 215, 231], ["L1", "DNA", 12, 14], ["microglia", "CELL_TYPE", 43, 52], ["oligodendrocytes", "CELL_TYPE", 72, 88], ["IFN", "PROTEIN", 115, 118], ["TNF", "PROTEIN", 123, 126], ["microglia", "CELL_TYPE", 193, 202], ["oligodendrocytes", "CELL_TYPE", 215, 231], ["PD", "TEST", 9, 11], ["microglia", "TEST", 43, 52], ["oligodendrocytes", "TEST", 72, 88], ["IFN", "TREATMENT", 115, 118], ["1 TNF treatment", "TREATMENT", 121, 136], ["the DMFI", "TEST", 138, 146], ["PD-L1 levels", "TEST", 151, 163], ["microglia", "TEST", 193, 202], ["oligodendrocytes", "PROBLEM", 215, 231], ["L1", "ANATOMY", 12, 14], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["L1", "ANATOMY", 154, 156]]], ["IFN-g alone had also the capacity to induce a detectable increase of PD-L1 on microglia and oligodendrocytes ( Fig. 2P and data not shown).", [["microglia", "ANATOMY", 78, 87], ["oligodendrocytes", "ANATOMY", 92, 108], ["IFN", "CHEMICAL", 0, 3], ["IFN-g", "GENE_OR_GENE_PRODUCT", 0, 5], ["PD-L1", "GENE_OR_GENE_PRODUCT", 69, 74], ["microglia", "CELL", 78, 87], ["oligodendrocytes", "CELL", 92, 108], ["IFN", "PROTEIN", 0, 3], ["PD-L1", "PROTEIN", 69, 74], ["microglia", "CELL_TYPE", 78, 87], ["oligodendrocytes", "CELL_TYPE", 92, 108], ["the capacity", "PROBLEM", 21, 33], ["a detectable increase of PD", "PROBLEM", 44, 71], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["L1", "ANATOMY", 72, 74]]], ["These cytokine treatments did not induce detectable expression of PD-L2 (data not shown).", [["PD-L2", "GENE_OR_GENE_PRODUCT", 66, 71], ["cytokine", "PROTEIN", 6, 14], ["These cytokine treatments", "TREATMENT", 0, 25]]], ["These results illustrate that oligodendrocytes and microglia have the capacity to express enhanced levels of PD-L1 in an inflammatory milieu.Neurons Slightly Increase PD-L1 Expression Upon ProinflammationWe also assessed the expression of PD-L1 and PD-L2 on primary cultures of human neurons using FACS and excluded GFAP1 cells (astrocytes) from our analysis.", [["oligodendrocytes", "ANATOMY", 30, 46], ["microglia", "ANATOMY", 51, 60], ["Neurons", "ANATOMY", 141, 148], ["primary cultures", "ANATOMY", 258, 274], ["neurons", "ANATOMY", 284, 291], ["GFAP1 cells", "ANATOMY", 316, 327], ["astrocytes", "ANATOMY", 329, 339], ["oligodendrocytes", "CELL", 30, 46], ["microglia", "CELL", 51, 60], ["PD-L1", "GENE_OR_GENE_PRODUCT", 109, 114], ["PD-L1", "GENE_OR_GENE_PRODUCT", 167, 172], ["PD-L1", "GENE_OR_GENE_PRODUCT", 239, 244], ["PD-L2", "GENE_OR_GENE_PRODUCT", 249, 254], ["human", "ORGANISM", 278, 283], ["neurons", "CELL", 284, 291], ["FACS", "CELL", 298, 302], ["GFAP1 cells", "CELL", 316, 327], ["astrocytes", "CELL", 329, 339], ["oligodendrocytes", "CELL_TYPE", 30, 46], ["microglia", "CELL_TYPE", 51, 60], ["PD-L1", "PROTEIN", 109, 114], ["PD-L2", "DNA", 249, 254], ["human neurons", "CELL_TYPE", 278, 291], ["FACS", "CELL_TYPE", 298, 302], ["GFAP1 cells", "CELL_LINE", 316, 327], ["astrocytes", "CELL_TYPE", 329, 339], ["human", "SPECIES", 278, 283], ["human", "SPECIES", 278, 283], ["the capacity", "PROBLEM", 66, 78], ["Increase PD", "PROBLEM", 158, 169], ["PD", "TEST", 239, 241], ["primary cultures", "TEST", 258, 274], ["FACS", "TEST", 298, 302], ["GFAP1 cells", "PROBLEM", 316, 327], ["our analysis", "TEST", 346, 358], ["L1", "ANATOMY", 112, 114], ["inflammatory", "OBSERVATION", 121, 133], ["L1", "ANATOMY", 170, 172], ["L1", "ANATOMY", 242, 244], ["L2", "ANATOMY", 252, 254]]], ["PD-L1 and PD-L2 levels did not differ from the isotype control under basal conditions (Fig. 3A,B) .", [["PD-L1", "GENE_OR_GENE_PRODUCT", 0, 5], ["PD-L2", "GENE_OR_GENE_PRODUCT", 10, 15], ["PD-L1 and PD-L2 levels", "TEST", 0, 22], ["L1", "ANATOMY", 3, 5], ["L2", "ANATOMY", 13, 15]]], ["However, stimulation with IFN-g or IFN-g 1 TNF induced a significant increase of PD-L1 on the surface of neurons (n 5 5); (IFN-g or IFN-g 1 TNF vs. NIL: *P < 0.01), while TNF had no effect on PD-L1 levels (Fig. 3C) .", [["surface", "ANATOMY", 94, 101], ["neurons", "ANATOMY", 105, 112], ["IFN-g", "GENE_OR_GENE_PRODUCT", 26, 31], ["IFN-g 1 TNF", "GENE_OR_GENE_PRODUCT", 35, 46], ["PD-L1", "GENE_OR_GENE_PRODUCT", 81, 86], ["surface", "CELLULAR_COMPONENT", 94, 101], ["neurons", "CELL", 105, 112], ["IFN-g", "GENE_OR_GENE_PRODUCT", 123, 128], ["TNF", "GENE_OR_GENE_PRODUCT", 140, 143], ["TNF", "GENE_OR_GENE_PRODUCT", 171, 174], ["PD-L1", "GENE_OR_GENE_PRODUCT", 192, 197], ["IFN", "PROTEIN", 26, 29], ["IFN", "PROTEIN", 35, 38], ["TNF", "PROTEIN", 43, 46], ["PD-L1", "PROTEIN", 81, 86], ["IFN", "PROTEIN", 123, 126], ["IFN", "PROTEIN", 132, 135], ["TNF", "PROTEIN", 140, 143], ["TNF", "PROTEIN", 171, 174], ["stimulation", "TEST", 9, 20], ["IFN", "TEST", 26, 29], ["IFN", "TEST", 35, 38], ["TNF", "PROBLEM", 43, 46], ["a significant increase of PD", "PROBLEM", 55, 83], ["IFN", "TEST", 123, 126], ["IFN", "TEST", 132, 135], ["TNF", "TEST", 140, 143], ["P", "TEST", 154, 155], ["TNF", "TEST", 171, 174], ["PD", "TEST", 192, 194], ["significant", "OBSERVATION_MODIFIER", 57, 68], ["increase", "OBSERVATION_MODIFIER", 69, 77], ["L1", "ANATOMY", 84, 86], ["neurons", "ANATOMY", 105, 112], ["L1", "ANATOMY", 195, 197]]], ["The increase (DMFI) observed on neurons (Fig. 3C , NIL: 0 vs. IFN-g 1 TNF: 83 6 20 or IFN-g: 113 6 18) remained; however, much lower than what we detected on astrocytes similarly treated (Fig. 1E, NIL: 581 6 163 vs. IFN-g 1 TNF: 7098 6 2148).", [["neurons", "ANATOMY", 32, 39], ["astrocytes", "ANATOMY", 158, 168], ["7098 6 2148", "CHEMICAL", 229, 240], ["neurons", "CELL", 32, 39], ["IFN-g 1 TNF", "GENE_OR_GENE_PRODUCT", 62, 73], ["astrocytes", "CELL", 158, 168], ["IFN", "PROTEIN", 62, 65], ["IFN", "PROTEIN", 86, 89], ["astrocytes", "CELL_TYPE", 158, 168], ["IFN", "PROTEIN", 216, 219], ["The increase (DMFI)", "PROBLEM", 0, 19], ["IFN", "TEST", 62, 65], ["TNF", "TEST", 70, 73], ["IFN", "TEST", 86, 89], ["increase", "OBSERVATION_MODIFIER", 4, 12]]], ["PD-L2 was not detectable on neurons upon any treatment (Fig. 3B) .Human Astrocytes Modulate CD8 T Cell Responses via PD-L1Although previous studies have shown the capacity of PD-L1 expressing murine microglia (Magnus et al., 2005) or oligodendrocytes (Phares et al., 2009) to inhibit T-cell responses, whether PD-L1 levels expressed by human CNS cells, and especially astrocytes, have a consequential impact on immune cell responses has not been previously tested.", [["neurons", "ANATOMY", 28, 35], ["Astrocytes", "ANATOMY", 72, 82], ["CD8 T Cell", "ANATOMY", 92, 102], ["microglia", "ANATOMY", 199, 208], ["oligodendrocytes", "ANATOMY", 234, 250], ["T-cell", "ANATOMY", 284, 290], ["CNS cells", "ANATOMY", 342, 351], ["astrocytes", "ANATOMY", 368, 378], ["immune cell", "ANATOMY", 411, 422], ["PD-L2", "GENE_OR_GENE_PRODUCT", 0, 5], ["neurons", "CELL", 28, 35], ["Human", "ORGANISM", 66, 71], ["Astrocytes", "CELL", 72, 82], ["CD8", "GENE_OR_GENE_PRODUCT", 92, 95], ["PD-L1", "GENE_OR_GENE_PRODUCT", 175, 180], ["murine", "ORGANISM", 192, 198], ["microglia", "CELL", 199, 208], ["oligodendrocytes", "CELL", 234, 250], ["T-cell", "CELL", 284, 290], ["PD-L1", "GENE_OR_GENE_PRODUCT", 310, 315], ["human", "ORGANISM", 336, 341], ["CNS cells", "CELL", 342, 351], ["astrocytes", "CELL", 368, 378], ["immune cell", "CELL", 411, 422], ["Human Astrocytes", "CELL_TYPE", 66, 82], ["murine microglia", "CELL_TYPE", 192, 208], ["oligodendrocytes", "CELL_TYPE", 234, 250], ["human CNS cells", "CELL_TYPE", 336, 351], ["astrocytes", "CELL_TYPE", 368, 378], ["Human", "SPECIES", 66, 71], ["murine", "SPECIES", 192, 198], ["human", "SPECIES", 336, 341], ["Human", "SPECIES", 66, 71], ["human", "SPECIES", 336, 341], ["any treatment", "TREATMENT", 41, 54], ["Human Astrocytes", "TEST", 66, 82], ["PD", "TEST", 117, 119], ["previous studies", "TEST", 131, 147], ["PD", "TEST", 175, 177], ["oligodendrocytes", "PROBLEM", 234, 250], ["T-cell responses", "TEST", 284, 300], ["PD-L1 levels", "TEST", 310, 322], ["human CNS cells", "PROBLEM", 336, 351], ["immune cell responses", "TREATMENT", 411, 432], ["L2", "ANATOMY", 3, 5], ["L1", "ANATOMY", 178, 180], ["L1", "ANATOMY", 313, 315], ["CNS cells", "ANATOMY", 342, 351]]], ["As a proof of concept we investigated whether PD-L1 provided by human astrocytes influences CD8 T-cell functions.", [["astrocytes", "ANATOMY", 70, 80], ["CD8 T-cell", "ANATOMY", 92, 102], ["PD-L1", "GENE_OR_GENE_PRODUCT", 46, 51], ["human", "ORGANISM", 64, 69], ["astrocytes", "CELL", 70, 80], ["CD8", "GENE_OR_GENE_PRODUCT", 92, 95], ["PD-L1", "PROTEIN", 46, 51], ["human astrocytes", "CELL_TYPE", 64, 80], ["human", "SPECIES", 64, 69], ["human", "SPECIES", 64, 69], ["PD", "TEST", 46, 48]]], ["We elected to use this CNS-immune cell interaction paradigm since PD-1 engagement by PD-L1 inhibits TCR signaling and that CD8 T lymphocytes recognize, via their TCR, MHC Class I-peptide complexes, which are enhanced on CNS cells during MS pathogenesis (Hoftberger et al., 2004) .", [["cell", "ANATOMY", 34, 38], ["CD8 T lymphocytes", "ANATOMY", 123, 140], ["CNS cells", "ANATOMY", 220, 229], ["MS", "DISEASE", 237, 239], ["CNS-immune cell", "CELL", 23, 38], ["PD-1", "GENE_OR_GENE_PRODUCT", 66, 70], ["PD-L1", "GENE_OR_GENE_PRODUCT", 85, 90], ["TCR", "GENE_OR_GENE_PRODUCT", 100, 103], ["CD8 T", "GENE_OR_GENE_PRODUCT", 123, 128], ["TCR", "GENE_OR_GENE_PRODUCT", 162, 165], ["CNS cells", "CELL", 220, 229], ["TCR", "PROTEIN", 100, 103], ["CD8 T lymphocytes", "CELL_TYPE", 123, 140], ["TCR", "PROTEIN", 162, 165], ["MHC Class I-peptide complexes", "PROTEIN", 167, 196], ["CNS cells", "CELL_TYPE", 220, 229], ["PD", "TEST", 66, 68], ["PD", "TEST", 85, 87], ["MS pathogenesis", "PROBLEM", 237, 252], ["L1", "ANATOMY", 88, 90]]], ["We specifically knocked down PD-L1 expression by astrocytes using a siRNA approach.", [["astrocytes", "ANATOMY", 49, 59], ["PD-L1", "GENE_OR_GENE_PRODUCT", 29, 34], ["astrocytes", "CELL", 49, 59], ["PD", "DNA", 29, 31], ["L1", "DNA", 32, 34], ["astrocytes", "CELL_TYPE", 49, 59], ["a siRNA approach", "TREATMENT", 66, 82], ["L1", "ANATOMY", 32, 34]]], ["Astrocytes treated with PD-L1 specific siRNA (siPDL1) typically reduced by 60% to 70% their PD-L1 mRNA levels ( Fig. 4A ; left panel: qPCR results) and by 70% to 77% their PD-L1 protein levels compared with control siRNA (siCTL) (Fig. 4A ; right panel: FACS data; representative of four astrocyte donors).", [["Astrocytes", "ANATOMY", 0, 10], ["astrocyte", "ANATOMY", 287, 296], ["Astrocytes", "CELL", 0, 10], ["PD-L1", "GENE_OR_GENE_PRODUCT", 24, 29], ["siPDL1", "GENE_OR_GENE_PRODUCT", 46, 52], ["PD-L1", "GENE_OR_GENE_PRODUCT", 92, 97], ["PD-L1", "GENE_OR_GENE_PRODUCT", 172, 177], ["astrocyte", "CELL", 287, 296], ["Astrocytes", "CELL_TYPE", 0, 10], ["siPDL1", "DNA", 46, 52], ["PD-L1 mRNA", "RNA", 92, 102], ["Astrocytes", "PROBLEM", 0, 10], ["PD-L1 specific siRNA", "TREATMENT", 24, 44], ["L1 mRNA levels", "TEST", 95, 109], ["left panel", "TEST", 122, 132], ["qPCR", "TEST", 134, 138], ["their PD", "TEST", 166, 174], ["L1 protein levels", "TEST", 175, 192], ["control siRNA", "TEST", 207, 220], ["right panel", "TEST", 240, 251], ["FACS data", "TEST", 253, 262], ["four astrocyte donors", "TREATMENT", 282, 303], ["left", "ANATOMY_MODIFIER", 122, 126], ["right", "ANATOMY_MODIFIER", 240, 245]]], ["However, MHC-I expression ( Fig. 4A ; right panel) by these astrocytes was not affected by such treatment.Human Astrocytes Modulate CD8 T Cell Responses via PD-L1CFSE-labeled alloreactive human CD8 T cells were cocultured with astrocytes treated with either siCTL or siPDL1 and proliferation and production of IFN-g, TNF, and granzyme B were assessed.", [["astrocytes", "ANATOMY", 60, 70], ["Astrocytes", "ANATOMY", 112, 122], ["CD8 T Cell", "ANATOMY", 132, 142], ["CD8 T cells", "ANATOMY", 194, 205], ["astrocytes", "ANATOMY", 227, 237], ["MHC-I", "GENE_OR_GENE_PRODUCT", 9, 14], ["astrocytes", "CELL", 60, 70], ["Human", "ORGANISM", 106, 111], ["Astrocytes", "CELL", 112, 122], ["CD8", "GENE_OR_GENE_PRODUCT", 132, 135], ["PD-L1CFSE", "GENE_OR_GENE_PRODUCT", 157, 166], ["human", "ORGANISM", 188, 193], ["CD8 T cells", "CELL", 194, 205], ["astrocytes", "CELL", 227, 237], ["siCTL", "GENE_OR_GENE_PRODUCT", 258, 263], ["siPDL1", "GENE_OR_GENE_PRODUCT", 267, 273], ["IFN-g", "GENE_OR_GENE_PRODUCT", 310, 315], ["TNF", "GENE_OR_GENE_PRODUCT", 317, 320], ["granzyme B", "GENE_OR_GENE_PRODUCT", 326, 336], ["MHC", "PROTEIN", 9, 12], ["astrocytes", "CELL_TYPE", 60, 70], ["Human Astrocytes", "CELL_TYPE", 106, 122], ["PD-L1CFSE-labeled alloreactive human CD8 T cells", "CELL_LINE", 157, 205], ["astrocytes", "CELL_TYPE", 227, 237], ["siCTL", "PROTEIN", 258, 263], ["IFN", "PROTEIN", 310, 313], ["TNF", "PROTEIN", 317, 320], ["granzyme B", "PROTEIN", 326, 336], ["Human", "SPECIES", 106, 111], ["human", "SPECIES", 188, 193], ["Human", "SPECIES", 106, 111], ["human", "SPECIES", 188, 193], ["right panel", "TEST", 38, 49], ["Human Astrocytes", "TEST", 106, 122], ["Responses", "TEST", 143, 152], ["PD", "TEST", 157, 159], ["L1CFSE", "TEST", 160, 166], ["alloreactive human CD8 T cells", "TREATMENT", 175, 205], ["astrocytes", "PROBLEM", 227, 237], ["siPDL1", "TREATMENT", 267, 273], ["IFN", "TREATMENT", 310, 313], ["TNF", "TREATMENT", 317, 320], ["right", "ANATOMY_MODIFIER", 38, 43]]], ["For comparison, PD-1 expression acquired by CD8 T cells cultured in the presence of anti-CD31anti-CD28 is illustrated ( Fig. 4B ; upper panel one representative donor, lower panel three donors).", [["CD8 T cells", "ANATOMY", 44, 55], ["PD-1", "GENE_OR_GENE_PRODUCT", 16, 20], ["CD8 T cells", "CELL", 44, 55], ["anti-CD31anti-CD28", "GENE_OR_GENE_PRODUCT", 84, 102], ["donors", "ORGANISM", 186, 192], ["CD8 T cells", "CELL_TYPE", 44, 55], ["anti-CD31anti", "PROTEIN", 84, 97], ["CD28", "PROTEIN", 98, 102], ["PD", "TEST", 16, 18], ["CD8 T cells", "TEST", 44, 55], ["anti-CD31anti-CD28", "TREATMENT", 84, 102], ["upper panel", "TEST", 130, 141]]], ["Typical FACS profiles of CD8 T cells following co-culture with astrocytes are illustrated (Fig. 4C) ; 40% (23.6% 1 16.4%) of CD8 T cells co-cultured with siPDL1transfected astrocytes proliferated compared with only 29.1% (17.1% 1 12.0%) for those co-cultured with siCTL-transfected astrocytes.", [["CD8 T cells", "ANATOMY", 25, 36], ["astrocytes", "ANATOMY", 63, 73], ["CD8 T cells", "ANATOMY", 125, 136], ["astrocytes", "ANATOMY", 172, 182], ["astrocytes", "ANATOMY", 282, 292], ["CD8 T cells", "CELL", 25, 36], ["astrocytes", "CELL", 63, 73], ["CD8 T cells", "CELL", 125, 136], ["astrocytes", "CELL", 172, 182], ["siCTL", "GENE_OR_GENE_PRODUCT", 264, 269], ["astrocytes", "CELL", 282, 292], ["CD8 T cells", "CELL_TYPE", 25, 36], ["astrocytes", "CELL_TYPE", 63, 73], ["CD8 T cells", "CELL_TYPE", 125, 136], ["siPDL1transfected astrocytes", "CELL_TYPE", 154, 182], ["siCTL", "PROTEIN", 264, 269], ["astrocytes", "CELL_TYPE", 282, 292], ["CD8 T cells", "PROBLEM", 25, 36], ["co-culture", "TEST", 47, 57], ["astrocytes", "TEST", 63, 73], ["CD8 T cells", "TEST", 125, 136], ["siPDL1transfected astrocytes", "PROBLEM", 154, 182], ["siCTL", "TEST", 264, 269], ["transfected astrocytes", "OBSERVATION", 270, 292]]], ["Moreover, 23.6% of CD8 T cells proliferated and produced IFN-g when co-cultured on siPDL1-transfected astrocytes whereas only 17.3% did for those co-cultured with siCTL-transfected astrocytes.", [["CD8 T cells", "ANATOMY", 19, 30], ["astrocytes", "ANATOMY", 102, 112], ["astrocytes", "ANATOMY", 181, 191], ["CD8 T cells", "CELL", 19, 30], ["IFN-g", "GENE_OR_GENE_PRODUCT", 57, 62], ["siPDL1", "SIMPLE_CHEMICAL", 83, 89], ["astrocytes", "CELL", 102, 112], ["siCTL", "GENE_OR_GENE_PRODUCT", 163, 168], ["astrocytes", "CELL", 181, 191], ["CD8 T cells", "CELL_TYPE", 19, 30], ["IFN", "PROTEIN", 57, 60], ["siPDL1", "CELL_LINE", 83, 89], ["astrocytes", "CELL_TYPE", 102, 112], ["siCTL", "PROTEIN", 163, 168], ["astrocytes", "CELL_TYPE", 181, 191], ["Moreover", "TEST", 0, 8], ["CD8 T cells", "TEST", 19, 30], ["IFN", "TEST", 57, 60], ["siPDL1", "TEST", 83, 89], ["transfected astrocytes", "TEST", 90, 112], ["siCTL-transfected astrocytes", "PROBLEM", 163, 191], ["transfected astrocytes", "OBSERVATION", 169, 191]]], ["We observed a similar pattern for granzyme B production as the proportion of CD8 T cells that proliferated and produced granzyme B reached 10.0% when cocultured on siPDL1-astrocytes but only 6.9% when cocultured with siCTL-astrocytes.", [["CD8 T cells", "ANATOMY", 77, 88], ["siPDL1-astrocytes", "ANATOMY", 164, 181], ["siCTL-astrocytes", "ANATOMY", 217, 233], ["granzyme B", "GENE_OR_GENE_PRODUCT", 34, 44], ["CD8 T cells", "CELL", 77, 88], ["granzyme B", "GENE_OR_GENE_PRODUCT", 120, 130], ["siPDL1-astrocytes", "CELL", 164, 181], ["siCTL-astrocytes", "CELL", 217, 233], ["granzyme B", "PROTEIN", 34, 44], ["CD8 T cells", "CELL_TYPE", 77, 88], ["granzyme B", "PROTEIN", 120, 130], ["astrocytes", "CELL_TYPE", 171, 181], ["siCTL", "CELL_TYPE", 217, 222], ["astrocytes", "CELL_TYPE", 223, 233], ["granzyme B production", "PROBLEM", 34, 55], ["CD8 T cells", "PROBLEM", 77, 88], ["granzyme B", "TEST", 120, 130], ["siPDL1", "TEST", 164, 170], ["astrocytes", "TEST", 171, 181], ["astrocytes", "ANATOMY", 223, 233]]], ["We observed a significant (**P < 0.01) increase in the proliferation and production of IFN-g, granzyme B, and TNF by CD8 T cells co-cultured on siPDL1-astrocytes compared to siCTLastrocytes; results obtained from five CD8 T cell donors tested on three astrocyte donors are shown in Fig. 4D .", [["CD8 T cells", "ANATOMY", 117, 128], ["siPDL1-astrocytes", "ANATOMY", 144, 161], ["siCTLastrocytes", "ANATOMY", 174, 189], ["CD8 T cell", "ANATOMY", 218, 228], ["astrocyte", "ANATOMY", 252, 261], ["IFN-g", "GENE_OR_GENE_PRODUCT", 87, 92], ["granzyme B", "GENE_OR_GENE_PRODUCT", 94, 104], ["TNF", "GENE_OR_GENE_PRODUCT", 110, 113], ["CD8", "GENE_OR_GENE_PRODUCT", 117, 120], ["siPDL1-astrocytes", "CELL", 144, 161], ["siCTLastrocytes", "CELL", 174, 189], ["CD8", "GENE_OR_GENE_PRODUCT", 218, 221], ["astrocyte donors", "CELL", 252, 268], ["IFN", "PROTEIN", 87, 90], ["granzyme B", "PROTEIN", 94, 104], ["TNF", "PROTEIN", 110, 113], ["CD8 T cells", "CELL_TYPE", 117, 128], ["siPDL1", "PROTEIN", 144, 150], ["astrocytes", "CELL_TYPE", 151, 161], ["siCTLastrocytes", "CELL_TYPE", 174, 189], ["the proliferation", "PROBLEM", 51, 68], ["IFN", "TEST", 87, 90], ["granzyme B", "TEST", 94, 104], ["TNF", "TEST", 110, 113], ["CD8 T cells", "TEST", 117, 128], ["siPDL1", "TEST", 144, 150], ["siCTLastrocytes", "TEST", 174, 189], ["CD8 T cell donors", "TEST", 218, 235], ["three astrocyte donors", "TREATMENT", 246, 268], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["proliferation", "OBSERVATION_MODIFIER", 55, 68]]], ["Our results demonstrate that PD-L1 expressed by astrocytes was sufficient to significantly diminish the proliferation and effector functions (cytokines and lytic enzyme) of human CD8 T cells.PD-L1 is Highly Expressed in MS Brain Lesions but not in Control TissuesTo assess whether human CNS cells can provide PD-L1 in vivo, we performed immunohistochemistry on postmortem brain tissues obtained from normal controls and MS patients, see description in Table 2 .", [["astrocytes", "ANATOMY", 48, 58], ["CD8 T cells", "ANATOMY", 179, 190], ["Brain Lesions", "ANATOMY", 223, 236], ["Tissues", "ANATOMY", 256, 263], ["CNS cells", "ANATOMY", 287, 296], ["postmortem brain tissues", "ANATOMY", 361, 385], ["PD-L1", "GENE_OR_GENE_PRODUCT", 29, 34], ["astrocytes", "CELL", 48, 58], ["human", "ORGANISM", 173, 178], ["CD8 T cells", "CELL", 179, 190], ["PD-L1", "GENE_OR_GENE_PRODUCT", 191, 196], ["MS Brain Lesions", "CANCER", 220, 236], ["human", "ORGANISM", 281, 286], ["CNS cells", "CELL", 287, 296], ["PD-L1", "GENE_OR_GENE_PRODUCT", 309, 314], ["brain tissues", "TISSUE", 372, 385], ["patients", "ORGANISM", 423, 431], ["PD-L1", "PROTEIN", 29, 34], ["astrocytes", "CELL_TYPE", 48, 58], ["cytokines", "PROTEIN", 142, 151], ["lytic enzyme", "PROTEIN", 156, 168], ["human CD8 T cells", "CELL_TYPE", 173, 190], ["L1", "DNA", 194, 196], ["human CNS cells", "CELL_TYPE", 281, 296], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 281, 286], ["patients", "SPECIES", 423, 431], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 281, 286], ["PD", "TEST", 29, 31], ["astrocytes", "PROBLEM", 48, 58], ["the proliferation", "PROBLEM", 100, 117], ["cytokines", "TEST", 142, 151], ["lytic enzyme", "TEST", 156, 168], ["MS Brain Lesions", "PROBLEM", 220, 236], ["human CNS cells", "PROBLEM", 281, 296], ["immunohistochemistry", "TEST", 337, 357], ["postmortem brain tissues", "TEST", 361, 385], ["L1", "ANATOMY", 32, 34], ["proliferation", "OBSERVATION_MODIFIER", 104, 117], ["L1", "ANATOMY", 194, 196], ["Brain", "ANATOMY", 223, 228], ["Lesions", "OBSERVATION", 229, 236]]], ["MS lesions were characterized using the ORO and hematoxylin scoring as being acute (AQ), containing numerous phagocytic macrophages that have recently engulfed lipid debris, or subacute (SAQ), containing demyelinated areas but demonstrating less recent myelin destruction.", [["MS lesions", "ANATOMY", 0, 10], ["phagocytic macrophages", "ANATOMY", 109, 131], ["lipid debris", "ANATOMY", 160, 172], ["demyelinated areas", "ANATOMY", 204, 222], ["myelin", "ANATOMY", 253, 259], ["myelin destruction", "DISEASE", 253, 271], ["hematoxylin", "CHEMICAL", 48, 59], ["MS lesions", "CANCER", 0, 10], ["hematoxylin", "SIMPLE_CHEMICAL", 48, 59], ["phagocytic macrophages", "CELL", 109, 131], ["lipid debris", "CELLULAR_COMPONENT", 160, 172], ["myelin", "GENE_OR_GENE_PRODUCT", 253, 259], ["phagocytic macrophages", "CELL_TYPE", 109, 131], ["MS lesions", "PROBLEM", 0, 10], ["the ORO", "TEST", 36, 43], ["hematoxylin scoring", "TEST", 48, 67], ["acute (AQ)", "PROBLEM", 77, 87], ["numerous phagocytic macrophages", "PROBLEM", 100, 131], ["recently engulfed lipid debris", "PROBLEM", 142, 172], ["subacute (SAQ)", "PROBLEM", 177, 191], ["demyelinated areas", "PROBLEM", 204, 222], ["less recent myelin destruction", "PROBLEM", 241, 271], ["lesions", "OBSERVATION", 3, 10], ["acute", "OBSERVATION_MODIFIER", 77, 82], ["numerous", "OBSERVATION_MODIFIER", 100, 108], ["phagocytic macrophages", "OBSERVATION", 109, 131], ["engulfed", "OBSERVATION_MODIFIER", 151, 159], ["lipid debris", "OBSERVATION", 160, 172], ["subacute", "OBSERVATION_MODIFIER", 177, 185], ["demyelinated", "OBSERVATION_MODIFIER", 204, 216], ["less", "OBSERVATION_MODIFIER", 241, 245], ["myelin destruction", "OBSERVATION", 253, 271]]], ["Brain sections were stained for PD-L1 and GFAP or appropriate isotype controls.", [["Brain sections", "ANATOMY", 0, 14], ["Brain sections", "CANCER", 0, 14], ["PD-L1", "GENE_OR_GENE_PRODUCT", 32, 37], ["GFAP", "GENE_OR_GENE_PRODUCT", 42, 46], ["GFAP", "PROTEIN", 42, 46], ["Brain sections", "TEST", 0, 14], ["PD", "TEST", 32, 34], ["GFAP", "TEST", 42, 46], ["appropriate isotype controls", "TREATMENT", 50, 78], ["isotype controls", "OBSERVATION", 62, 78]]], ["Six to 10 fields (at 6303, each field covering 0.0625 mm 2 ) per section (three sections from controls and seven sections from MS patients) containing GFAP-positive cells were thoroughly analyzed to determine the percentage of cells positive for PD-L1 and representative fields are illustrated (Fig. 5A -O).", [["sections", "ANATOMY", 80, 88], ["sections", "ANATOMY", 113, 121], ["cells", "ANATOMY", 165, 170], ["cells", "ANATOMY", 227, 232], ["5A -O", "CHEMICAL", 300, 305], ["5A -O", "CHEMICAL", 300, 305], ["patients", "ORGANISM", 130, 138], ["GFAP", "GENE_OR_GENE_PRODUCT", 151, 155], ["cells", "CELL", 227, 232], ["PD-L1", "GENE_OR_GENE_PRODUCT", 246, 251], ["5A -O", "SIMPLE_CHEMICAL", 300, 305], ["GFAP", "PROTEIN", 151, 155], ["patients", "SPECIES", 130, 138], ["GFAP", "TEST", 151, 155], ["positive cells", "PROBLEM", 156, 170], ["PD", "TEST", 246, 248], ["L1", "ANATOMY", 249, 251]]], ["Although we observed PD-L1-positive cells in all sections analyzed, the proportion of PD-L1-expressing cells as well as the PD-L1 signal intensity were greatly enhanced in MS lesions compared with control sections (Fig. 5A,F,K) .", [["PD-L1-positive cells", "ANATOMY", 21, 41], ["sections", "ANATOMY", 49, 57], ["PD-L1-expressing cells", "ANATOMY", 86, 108], ["MS lesions", "ANATOMY", 172, 182], ["sections", "ANATOMY", 205, 213], ["PD-L1", "GENE_OR_GENE_PRODUCT", 21, 26], ["PD-L1", "GENE_OR_GENE_PRODUCT", 86, 91], ["cells", "CELL", 103, 108], ["PD-L1", "GENE_OR_GENE_PRODUCT", 124, 129], ["MS lesions", "CANCER", 172, 182], ["PD-L1-positive cells", "CELL_LINE", 21, 41], ["PD-L1-expressing cells", "CELL_LINE", 86, 108], ["PD", "TEST", 21, 23], ["all sections", "TEST", 45, 57], ["PD", "TEST", 86, 88], ["the PD-L1 signal intensity", "TEST", 120, 146], ["greatly enhanced in MS lesions", "PROBLEM", 152, 182], ["L1", "ANATOMY", 24, 26], ["positive cells", "OBSERVATION", 27, 41], ["L1", "ANATOMY", 89, 91], ["expressing cells", "OBSERVATION", 92, 108], ["L1", "ANATOMY", 127, 129], ["intensity", "OBSERVATION_MODIFIER", 137, 146], ["greatly", "OBSERVATION_MODIFIER", 152, 159], ["enhanced", "OBSERVATION_MODIFIER", 160, 168], ["MS", "OBSERVATION_MODIFIER", 172, 174], ["lesions", "OBSERVATION", 175, 182]]], ["The proportion of GFAP1 cells per surface area varied throughout sections.", [["GFAP1 cells", "ANATOMY", 18, 29], ["surface area", "ANATOMY", 34, 46], ["sections", "ANATOMY", 65, 73], ["GFAP1 cells", "CELL", 18, 29], ["GFAP1 cells", "CELL_LINE", 18, 29], ["GFAP1 cells", "PROBLEM", 18, 29], ["GFAP1 cells", "OBSERVATION", 18, 29], ["surface", "OBSERVATION_MODIFIER", 34, 41]]], ["However, the majority of astrocytes expressed PD-L1 in MS lesions (Fig. 5H ,M,P) while few were positive in control tissues (Fig. 5C ,P).", [["astrocytes", "ANATOMY", 25, 35], ["MS lesions", "ANATOMY", 55, 65], ["tissues", "ANATOMY", 116, 123], ["astrocytes", "CELL", 25, 35], ["PD-L1", "GENE_OR_GENE_PRODUCT", 46, 51], ["MS lesions", "CANCER", 55, 65], ["tissues", "TISSUE", 116, 123], ["astrocytes", "CELL_TYPE", 25, 35], ["PD-L1", "DNA", 46, 51], ["MS lesions", "PROBLEM", 55, 65], ["astrocytes", "ANATOMY", 25, 35], ["L1", "ANATOMY", 49, 51], ["lesions", "OBSERVATION", 58, 65], ["positive", "OBSERVATION", 96, 104]]], ["We also used the Sudan black staining to identify demyelinated versus non-demyelinated area and observed that most PD-L11 cells were localized in demyelinated or juxtaposed to demyelinated areas.", [["non-demyelinated area", "ANATOMY", 70, 91], ["PD-L11 cells", "ANATOMY", 115, 127], ["demyelinated areas", "ANATOMY", 176, 194], ["Sudan black", "CHEMICAL", 17, 28], ["PD-L11 cells", "CELL", 115, 127], ["PD-L11 cells", "CELL_LINE", 115, 127], ["the Sudan black staining", "TREATMENT", 13, 37], ["demyelinated versus non-demyelinated area", "PROBLEM", 50, 91], ["most PD-L11 cells", "PROBLEM", 110, 127], ["demyelinated", "PROBLEM", 146, 158], ["L11 cells", "OBSERVATION", 118, 127], ["demyelinated", "OBSERVATION", 176, 188]]], ["Finally, our quantitative analysis revealed that AQ and SAQ MS sections bore significantly more PD-L1-expressing astrocytes per mm 2 than control sections (Fig. 5N ) (SAQ or AQ vs. NC: *P < 0.05).PD-L1 is Highly Expressed in MS Brain Lesions but not in Control TissuesWe observed PD-L1 positive cells that were negative for GFAP in MS sections (Fig. 5H, pink arrows) .", [["astrocytes", "ANATOMY", 113, 123], ["sections", "ANATOMY", 146, 154], ["Brain Lesions", "ANATOMY", 228, 241], ["PD-L1 positive cells", "ANATOMY", 280, 300], ["sections", "ANATOMY", 335, 343], ["AQ", "CHEMICAL", 49, 51], ["AQ", "SIMPLE_CHEMICAL", 49, 51], ["PD-L1", "GENE_OR_GENE_PRODUCT", 96, 101], ["astrocytes", "CELL", 113, 123], ["PD-L1", "GENE_OR_GENE_PRODUCT", 196, 201], ["MS Brain Lesions", "CANCER", 225, 241], ["PD-L1", "GENE_OR_GENE_PRODUCT", 280, 285], ["cells", "CELL", 295, 300], ["GFAP", "GENE_OR_GENE_PRODUCT", 324, 328], ["astrocytes", "CELL_TYPE", 113, 123], ["PD", "DNA", 196, 198], ["L1", "DNA", 199, 201], ["PD-L1 positive cells", "CELL_LINE", 280, 300], ["GFAP", "PROTEIN", 324, 328], ["our quantitative analysis", "TEST", 9, 34], ["AQ", "TEST", 49, 51], ["SAQ MS sections", "TEST", 56, 71], ["PD", "TEST", 96, 98], ["MS Brain Lesions", "PROBLEM", 225, 241], ["L1 positive cells", "PROBLEM", 283, 300], ["GFAP in MS sections", "TEST", 324, 343], ["L1", "ANATOMY", 199, 201], ["Brain", "ANATOMY", 228, 233], ["Lesions", "OBSERVATION", 234, 241], ["L1", "ANATOMY", 283, 285]]], ["To identify these cells, we stained adjacent sections for Iba-1 (see Fig. 6 ), a marker for macrophage/microglia, or for Nogo-A (see Fig. 7 ), a marker for oligodendrocytes.", [["cells", "ANATOMY", 18, 23], ["sections", "ANATOMY", 45, 53], ["macrophage", "ANATOMY", 92, 102], ["microglia", "ANATOMY", 103, 112], ["oligodendrocytes", "ANATOMY", 156, 172], ["cells", "CELL", 18, 23], ["Iba-1", "GENE_OR_GENE_PRODUCT", 58, 63], ["see Fig. 6", "GENE_OR_GENE_PRODUCT", 65, 75], ["macrophage", "CELL", 92, 102], ["microglia", "CELL", 103, 112], ["Nogo-A", "GENE_OR_GENE_PRODUCT", 121, 127], ["see Fig. 7", "GENE_OR_GENE_PRODUCT", 129, 139], ["oligodendrocytes", "CELL", 156, 172], ["Iba-1", "PROTEIN", 58, 63], ["macrophage", "CELL_TYPE", 92, 102], ["microglia", "CELL_TYPE", 103, 112], ["Nogo-A", "PROTEIN", 121, 127], ["oligodendrocytes", "CELL_TYPE", 156, 172], ["Iba", "TEST", 58, 61], ["macrophage/microglia", "PROBLEM", 92, 112], ["Nogo", "TEST", 121, 125], ["oligodendrocytes", "PROBLEM", 156, 172], ["microglia", "ANATOMY", 103, 112]]], ["In control sections, only few microglia expressed PD-L1 (0%-5%) (Fig. 6C,P) .", [["sections", "ANATOMY", 11, 19], ["microglia", "ANATOMY", 30, 39], ["microglia", "CELL", 30, 39], ["PD-L1", "GENE_OR_GENE_PRODUCT", 50, 55], ["microglia", "CELL_TYPE", 30, 39], ["PD", "TEST", 50, 52], ["few", "OBSERVATION_MODIFIER", 26, 29], ["microglia", "OBSERVATION", 30, 39], ["L1", "ANATOMY", 53, 55]]], ["However, the percentage of macrophages/microglia expressing PD-L1 was statistically increased in MS lesions compared with controls ( Fig. 6H ,M,P) as we measured an increase of up to 60% in MS lesions (Fig. 6P) .", [["macrophages", "ANATOMY", 27, 38], ["microglia", "ANATOMY", 39, 48], ["MS lesions", "ANATOMY", 97, 107], ["MS lesions", "ANATOMY", 190, 200], ["macrophages", "CELL", 27, 38], ["microglia", "CELL", 39, 48], ["PD-L1", "GENE_OR_GENE_PRODUCT", 60, 65], ["MS lesions", "CANCER", 97, 107], ["MS lesions", "CANCER", 190, 200], ["macrophages", "CELL_TYPE", 27, 38], ["microglia", "CELL_TYPE", 39, 48], ["MS lesions", "PROBLEM", 97, 107], ["MS lesions", "PROBLEM", 190, 200], ["percentage", "OBSERVATION_MODIFIER", 13, 23], ["macrophages", "OBSERVATION", 27, 38], ["microglia", "ANATOMY", 39, 48], ["L1", "ANATOMY", 63, 65], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["MS", "OBSERVATION_MODIFIER", 97, 99], ["lesions", "OBSERVATION", 100, 107], ["increase", "OBSERVATION_MODIFIER", 165, 173], ["lesions", "OBSERVATION", 193, 200]]], ["The number of PD-L1 positive microglia/macrophages per surface area was also significantly elevated in AQ and SAQ MS lesions compared with controls ( Fig. 6Q ; NC vs. SAQ **P < 0.01; and NC vs. AQ *P < 0.05).", [["PD-L1 positive microglia", "ANATOMY", 14, 38], ["macrophages", "ANATOMY", 39, 50], ["surface area", "ANATOMY", 55, 67], ["SAQ MS lesions", "ANATOMY", 110, 124], ["PD-L1", "GENE_OR_GENE_PRODUCT", 14, 19], ["macrophages", "CELL", 39, 50], ["AQ", "SIMPLE_CHEMICAL", 103, 105], ["lesions", "PATHOLOGICAL_FORMATION", 117, 124], ["PD-L1 positive microglia", "CELL_LINE", 14, 38], ["macrophages", "CELL_TYPE", 39, 50], ["PD", "TEST", 14, 16], ["significantly elevated", "PROBLEM", 77, 99], ["SAQ MS lesions", "PROBLEM", 110, 124], ["NC", "TEST", 160, 162], ["SAQ", "TEST", 167, 170], ["P", "TEST", 173, 174], ["NC", "TEST", 187, 189], ["macrophages", "OBSERVATION", 39, 50], ["elevated", "OBSERVATION_MODIFIER", 91, 99], ["lesions", "OBSERVATION", 117, 124]]], ["Thus, both astrocytes and microglia/ macrophages displayed significantly boosted PD-L1 expression in MS lesions compared with controls.The Majority of CNS-Infiltrating CD8 T Cells do not Express PD-1Our in vitro functional assays demonstrated that CNS cells, in particular inflamed astrocytes, express sufficient levels of PD-L1 to modulate CD8 T cell responses.", [["astrocytes", "ANATOMY", 11, 21], ["microglia", "ANATOMY", 26, 35], ["macrophages", "ANATOMY", 37, 48], ["MS lesions", "ANATOMY", 101, 111], ["CNS", "ANATOMY", 151, 154], ["Infiltrating CD8 T Cells", "ANATOMY", 155, 179], ["CNS cells", "ANATOMY", 248, 257], ["astrocytes", "ANATOMY", 282, 292], ["CD8 T cell", "ANATOMY", 341, 351], ["astrocytes", "CELL", 11, 21], ["microglia", "CELL", 26, 35], ["macrophages", "CELL", 37, 48], ["PD-L1", "GENE_OR_GENE_PRODUCT", 81, 86], ["MS lesions", "CANCER", 101, 111], ["CNS-Infiltrating CD8 T Cells", "CELL", 151, 179], ["PD-1Our", "GENE_OR_GENE_PRODUCT", 195, 202], ["CNS cells", "CELL", 248, 257], ["astrocytes", "CELL", 282, 292], ["PD-L1", "GENE_OR_GENE_PRODUCT", 323, 328], ["CD8 T cell", "CELL", 341, 351], ["astrocytes", "CELL_TYPE", 11, 21], ["microglia", "CELL_TYPE", 26, 35], ["macrophages", "CELL_TYPE", 37, 48], ["Infiltrating CD8 T Cells", "CELL_TYPE", 155, 179], ["CNS cells", "CELL_TYPE", 248, 257], ["inflamed astrocytes", "CELL_TYPE", 273, 292], ["CD8", "PROTEIN", 341, 344], ["microglia/ macrophages", "TEST", 26, 48], ["significantly boosted PD", "PROBLEM", 59, 83], ["MS lesions", "PROBLEM", 101, 111], ["Infiltrating CD8 T Cells", "PROBLEM", 155, 179], ["PD", "TEST", 195, 197], ["vitro functional assays", "TEST", 206, 229], ["CNS cells", "PROBLEM", 248, 257], ["inflamed astrocytes", "PROBLEM", 273, 292], ["PD", "TEST", 323, 325], ["astrocytes", "ANATOMY", 11, 21], ["microglia", "ANATOMY", 26, 35], ["macrophages", "ANATOMY", 37, 48], ["L1", "ANATOMY", 84, 86], ["lesions", "OBSERVATION", 104, 111], ["CNS", "ANATOMY", 151, 154], ["Infiltrating CD8", "OBSERVATION", 155, 171], ["CNS cells", "OBSERVATION", 248, 257], ["L1", "ANATOMY", 326, 328], ["CD8 T cell", "OBSERVATION", 341, 351]]], ["We next evaluated whether human infiltrating CD8 T cells found in MS lesions express detectable levels of PD-1, which would dictate their susceptibility to immunomodulation by PD-L1 and PD-L2 on CNS cells.", [["infiltrating CD8 T cells", "ANATOMY", 32, 56], ["MS lesions", "ANATOMY", 66, 76], ["CNS cells", "ANATOMY", 195, 204], ["human", "ORGANISM", 26, 31], ["CD8 T cells", "CELL", 45, 56], ["MS lesions", "CANCER", 66, 76], ["PD-1", "GENE_OR_GENE_PRODUCT", 106, 110], ["PD-L1", "GENE_OR_GENE_PRODUCT", 176, 181], ["PD-L2", "GENE_OR_GENE_PRODUCT", 186, 191], ["CNS cells", "CELL", 195, 204], ["human infiltrating CD8 T cells", "CELL_TYPE", 26, 56], ["CNS cells", "CELL_TYPE", 195, 204], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 26, 31], ["human infiltrating CD8 T cells", "PROBLEM", 26, 56], ["MS lesions", "PROBLEM", 66, 76], ["PD", "TEST", 106, 108], ["PD", "TEST", 176, 178], ["PD", "TEST", 186, 188], ["L1", "ANATOMY", 179, 181], ["L2", "ANATOMY", 189, 191], ["CNS cells", "ANATOMY", 195, 204]]], ["We stained for CD8 and PD-1 (see Fig. 8 ) on the same postmortem brain tissues previously used (see Table 2 ) for PD-L1 detection and performed a similar analysis.", [["postmortem brain tissues", "ANATOMY", 54, 78], ["CD8", "GENE_OR_GENE_PRODUCT", 15, 18], ["PD-1", "GENE_OR_GENE_PRODUCT", 23, 27], ["brain tissues", "TISSUE", 65, 78], ["CD8", "PROTEIN", 15, 18], ["PD-1", "PROTEIN", 23, 27], ["CD8", "TEST", 15, 18], ["PD", "TEST", 23, 25], ["PD-L1 detection", "TEST", 114, 129], ["a similar analysis", "TEST", 144, 162], ["brain tissues", "ANATOMY", 65, 78], ["L1", "ANATOMY", 117, 119]]], ["We employed the same monoclonal clone (NAT) than others have successfully used to detect PD-1 in human tissues (Roncador et al., 2007; Wu et al., 2009) .", [["tissues", "ANATOMY", 103, 110], ["PD-1", "GENE_OR_GENE_PRODUCT", 89, 93], ["human", "ORGANISM", 97, 102], ["tissues", "TISSUE", 103, 110], ["monoclonal clone", "CELL_LINE", 21, 37], ["NAT", "PROTEIN", 39, 42], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102], ["PD", "TEST", 89, 91], ["human tissues", "ANATOMY", 97, 110]]], ["As expected, only rare and isolated CD8 T cells were found in the parenchyma of control patients, and few were located perivascularly (Fig. 8B) .", [["CD8 T cells", "ANATOMY", 36, 47], ["parenchyma", "ANATOMY", 66, 76], ["CD8 T cells", "CELL", 36, 47], ["parenchyma", "TISSUE", 66, 76], ["patients", "ORGANISM", 88, 96], ["CD8 T cells", "CELL_TYPE", 36, 47], ["patients", "SPECIES", 88, 96], ["rare and isolated CD8 T cells", "PROBLEM", 18, 47], ["CD8 T cells", "OBSERVATION", 36, 47], ["parenchyma", "ANATOMY_MODIFIER", 66, 76]]], ["In contrast, we detected substantially more CD8 T cells per surface area in both AQ and SAQ MS lesions (Fig. 8G ,L,Q) (SAQ vs. NC P 5 0.14; AQ vs. NC **P < 0.01).", [["CD8 T cells", "ANATOMY", 44, 55], ["surface area", "ANATOMY", 60, 72], ["SAQ MS lesions", "ANATOMY", 88, 102], ["CD8 T cells", "CELL", 44, 55], ["AQ", "SIMPLE_CHEMICAL", 81, 83], ["lesions", "PATHOLOGICAL_FORMATION", 95, 102], ["CD8 T cells", "CELL_TYPE", 44, 55], ["SAQ MS lesions", "PROBLEM", 88, 102], ["Fig.", "TEST", 104, 108], ["SAQ", "TEST", 119, 122], ["NC P", "TEST", 127, 131], ["AQ vs", "TEST", 140, 145], ["CD8 T cells", "OBSERVATION", 44, 55], ["both", "ANATOMY_MODIFIER", 76, 80], ["lesions", "OBSERVATION", 95, 102]]], ["The vast majority of CD8 T cells observed in controls was positive for PD-1, regardless of localization ( Fig. 8A-D) .", [["CD8 T cells", "ANATOMY", 21, 32], ["CD8 T", "GENE_OR_GENE_PRODUCT", 21, 26], ["PD-1", "GENE_OR_GENE_PRODUCT", 71, 75], ["CD8 T cells", "CELL_TYPE", 21, 32], ["CD8 T cells", "PROBLEM", 21, 32], ["PD", "TEST", 71, 73], ["localization", "TEST", 91, 103]]], ["However, in MS lesions only a few CD8 T cells expressed PD-1 (Fig. 8F-I,K-N) .", [["MS lesions", "ANATOMY", 12, 22], ["CD8 T cells", "ANATOMY", 34, 45], ["MS lesions", "CANCER", 12, 22], ["CD8 T", "GENE_OR_GENE_PRODUCT", 34, 39], ["PD-1", "GENE_OR_GENE_PRODUCT", 56, 60], ["K-N", "GENE_OR_GENE_PRODUCT", 72, 75], ["CD8 T cells", "CELL_TYPE", 34, 45], ["MS lesions", "PROBLEM", 12, 22], ["PD", "TEST", 56, 58], ["lesions", "OBSERVATION", 15, 22], ["few", "OBSERVATION_MODIFIER", 30, 33]]], ["We quantified more specifically CD8 T cells located in the parenchyma, where these cells could more likely interact with PD-L1 expressing astrocytes and microglia/macrophages, and determine their proportion expressing PD-1.", [["CD8 T cells", "ANATOMY", 32, 43], ["parenchyma", "ANATOMY", 59, 69], ["cells", "ANATOMY", 83, 88], ["astrocytes", "ANATOMY", 138, 148], ["microglia", "ANATOMY", 153, 162], ["macrophages", "ANATOMY", 163, 174], ["CD8 T cells", "CELL", 32, 43], ["parenchyma", "TISSUE", 59, 69], ["cells", "CELL", 83, 88], ["PD-L1", "GENE_OR_GENE_PRODUCT", 121, 126], ["astrocytes", "CELL", 138, 148], ["microglia", "CELL", 153, 162], ["macrophages", "CELL", 163, 174], ["PD-1", "GENE_OR_GENE_PRODUCT", 218, 222], ["CD8 T cells", "CELL_TYPE", 32, 43], ["astrocytes", "CELL_TYPE", 138, 148], ["microglia", "CELL_TYPE", 153, 162], ["macrophages", "CELL_TYPE", 163, 174], ["CD8 T cells", "PROBLEM", 32, 43], ["these cells", "PROBLEM", 77, 88], ["PD", "TEST", 121, 123], ["parenchyma", "ANATOMY", 59, 69], ["L1", "ANATOMY", 124, 126]]], ["Most of the very few CD8 T cells present in the parenchyma of controls were positive for PD-1 (between 50% and 100%).", [["CD8 T cells", "ANATOMY", 21, 32], ["parenchyma", "ANATOMY", 48, 58], ["CD8", "GENE_OR_GENE_PRODUCT", 21, 24], ["parenchyma", "TISSUE", 48, 58], ["controls", "ORGANISM", 62, 70], ["PD-1", "GENE_OR_GENE_PRODUCT", 89, 93], ["CD8 T cells", "CELL_TYPE", 21, 32], ["PD", "TEST", 89, 91], ["very", "OBSERVATION_MODIFIER", 12, 16], ["few", "OBSERVATION_MODIFIER", 17, 20], ["CD8 T cells", "OBSERVATION", 21, 32], ["parenchyma", "ANATOMY_MODIFIER", 48, 58]]], ["In lesions the percentage of CD8 T cells expressing this inhibitory receptor went down to 0%-65%, (NC vs. SAQ *P < 0.05 and NC vs. AQ vs. n Lower panel: pooled data of PD-1 percentage on CD8 T cells ex vivo or stimulated with anti-CD3 and anti-CD28 for 3 and 6 days (n 5 3 donors).", [["lesions", "ANATOMY", 3, 10], ["CD8 T cells", "ANATOMY", 29, 40], ["CD8 T cells", "ANATOMY", 187, 198], ["AQ", "CHEMICAL", 131, 133], ["lesions", "PATHOLOGICAL_FORMATION", 3, 10], ["CD8 T", "GENE_OR_GENE_PRODUCT", 29, 34], ["AQ", "SIMPLE_CHEMICAL", 131, 133], ["PD-1", "GENE_OR_GENE_PRODUCT", 168, 172], ["CD8 T cells", "CELL", 187, 198], ["anti-CD3", "GENE_OR_GENE_PRODUCT", 226, 234], ["anti-CD28", "SIMPLE_CHEMICAL", 239, 248], ["donors", "ORGANISM", 273, 279], ["CD8 T cells", "CELL_TYPE", 29, 40], ["inhibitory receptor", "PROTEIN", 57, 76], ["CD8 T cells", "CELL_TYPE", 187, 198], ["anti-CD3", "PROTEIN", 226, 234], ["anti-CD28", "PROTEIN", 239, 248], ["CD8 T cells", "PROBLEM", 29, 40], ["P", "TEST", 111, 112], ["NC vs", "TEST", 124, 129], ["Lower panel", "TEST", 140, 151], ["PD", "TEST", 168, 170], ["CD8 T cells", "TREATMENT", 187, 198], ["anti-CD3", "TREATMENT", 226, 234], ["anti-CD28", "TREATMENT", 239, 248], ["lesions", "OBSERVATION", 3, 10], ["percentage", "OBSERVATION_MODIFIER", 15, 25], ["CD8 T cells", "OBSERVATION", 29, 40]]], ["(C) Representative dot plots of immune responses observed for CD8 T cells (gated on living CD8 T cells) co-cultured with astrocytes treated with either siCTRL or siPDL1.", [["CD8 T cells", "ANATOMY", 62, 73], ["CD8 T cells", "ANATOMY", 91, 102], ["astrocytes", "ANATOMY", 121, 131], ["CD8 T cells", "CELL", 62, 73], ["CD8 T cells", "CELL", 91, 102], ["astrocytes", "CELL", 121, 131], ["siCTRL", "GENE_OR_GENE_PRODUCT", 152, 158], ["siPDL1", "GENE_OR_GENE_PRODUCT", 162, 168], ["CD8 T cells", "CELL_TYPE", 62, 73], ["CD8 T cells", "CELL_TYPE", 91, 102], ["astrocytes", "CELL_TYPE", 121, 131], ["siCTRL", "PROTEIN", 152, 158], ["siPDL1", "PROTEIN", 162, 168], ["immune responses", "TEST", 32, 48], ["CD8 T cells", "PROBLEM", 62, 73], ["living CD8 T cells", "TEST", 84, 102], ["astrocytes", "PROBLEM", 121, 131]]], ["Proliferation assessed by CFSE dilution (x-axis) versus IFN-g (top panel) or granzyme B (bottom panel) production (y-axis).", [["CFSE", "CHEMICAL", 26, 30], ["CFSE", "CHEMICAL", 26, 30], ["CFSE", "SIMPLE_CHEMICAL", 26, 30], ["IFN-g", "GENE_OR_GENE_PRODUCT", 56, 61], ["granzyme B", "GENE_OR_GENE_PRODUCT", 77, 87], ["IFN", "PROTEIN", 56, 59], ["granzyme B", "PROTEIN", 77, 87], ["Proliferation", "TEST", 0, 13], ["CFSE dilution", "TEST", 26, 39], ["IFN", "TEST", 56, 59], ["g (top panel", "TEST", 60, 72], ["granzyme B (bottom panel", "TEST", 77, 101]]], ["(D) Data obtained from five donors of CD8 T cells co-cultured with astrocytes treated with either siCTRL or siPDL assessing proliferation (top left), IFN-g (top right), granzyme B (bottom left), and TNF production (bottom right).", [["CD8 T cells", "ANATOMY", 38, 49], ["astrocytes", "ANATOMY", 67, 77], ["donors", "ORGANISM", 28, 34], ["CD8 T cells", "CELL", 38, 49], ["astrocytes", "CELL", 67, 77], ["siPDL", "SIMPLE_CHEMICAL", 108, 113], ["IFN-g", "GENE_OR_GENE_PRODUCT", 150, 155], ["granzyme B", "GENE_OR_GENE_PRODUCT", 169, 179], ["TNF", "GENE_OR_GENE_PRODUCT", 199, 202], ["CD8 T cells", "CELL_TYPE", 38, 49], ["astrocytes", "CELL_TYPE", 67, 77], ["siCTRL", "PROTEIN", 98, 104], ["siPDL", "PROTEIN", 108, 113], ["IFN", "PROTEIN", 150, 153], ["granzyme B", "PROTEIN", 169, 179], ["TNF", "PROTEIN", 199, 202], ["CD8 T cells", "TREATMENT", 38, 49], ["astrocytes", "PROBLEM", 67, 77], ["IFN", "TEST", 150, 153], ["TNF production", "PROBLEM", 199, 213], ["left", "ANATOMY_MODIFIER", 143, 147], ["right", "ANATOMY_MODIFIER", 161, 166], ["bottom", "ANATOMY_MODIFIER", 181, 187], ["left", "ANATOMY_MODIFIER", 188, 192], ["bottom", "ANATOMY_MODIFIER", 215, 221], ["right", "ANATOMY_MODIFIER", 222, 227]]], ["Cells displaying a leukocyte morphology and devoid of CD8 expressed detectable PD-1 in the CNS parenchyma and around blood vessels of MS lesions (Fig. 8H,M; pink arrows) ; an average of 86 PD-11 cells/mm 2 in MS lesions were not CD8 T lymphocytes.", [["Cells", "ANATOMY", 0, 5], ["leukocyte", "ANATOMY", 19, 28], ["CD8", "ANATOMY", 54, 57], ["CNS parenchyma", "ANATOMY", 91, 105], ["blood vessels", "ANATOMY", 117, 130], ["MS lesions", "ANATOMY", 134, 144], ["cells", "ANATOMY", 195, 200], ["MS lesions", "ANATOMY", 209, 219], ["CD8 T lymphocytes", "ANATOMY", 229, 246], ["Cells", "CELL", 0, 5], ["leukocyte", "CELL", 19, 28], ["CD8", "GENE_OR_GENE_PRODUCT", 54, 57], ["PD-1", "GENE_OR_GENE_PRODUCT", 79, 83], ["CNS parenchyma", "MULTI-TISSUE_STRUCTURE", 91, 105], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 117, 130], ["lesions", "PATHOLOGICAL_FORMATION", 137, 144], ["cells", "CELL", 195, 200], ["MS lesions", "CANCER", 209, 219], ["CD8 T lymphocytes", "CELL", 229, 246], ["CD8", "PROTEIN", 54, 57], ["CD8 T lymphocytes", "CELL_TYPE", 229, 246], ["a leukocyte morphology", "TEST", 17, 39], ["CD8", "TEST", 54, 57], ["PD", "TEST", 79, 81], ["MS lesions", "PROBLEM", 134, 144], ["PD", "TEST", 189, 191], ["cells", "TEST", 195, 200], ["MS lesions", "PROBLEM", 209, 219], ["leukocyte morphology", "OBSERVATION", 19, 39], ["CNS", "ANATOMY", 91, 94], ["parenchyma", "ANATOMY_MODIFIER", 95, 105], ["blood vessels", "ANATOMY", 117, 130], ["MS", "OBSERVATION_MODIFIER", 134, 136], ["lesions", "OBSERVATION", 137, 144], ["lesions", "OBSERVATION", 212, 219], ["not", "UNCERTAINTY", 225, 228], ["CD8 T lymphocytes", "OBSERVATION", 229, 246]]], ["To identify these cells we performed co-staining for PD-1 and CD4 and observed that most infiltrating CD4 T cells in MS lesions expressed PD-1 (Fig. 8R-V) .DISCUSSIONOur study demonstrates that exposure to proinflammatory stimuli increases the expression of PD-L1, an inhibitory ligand, on most human CNS cells.", [["cells", "ANATOMY", 18, 23], ["infiltrating CD4 T cells", "ANATOMY", 89, 113], ["MS lesions", "ANATOMY", 117, 127], ["CNS cells", "ANATOMY", 301, 310], ["cells", "CELL", 18, 23], ["PD-1", "GENE_OR_GENE_PRODUCT", 53, 57], ["CD4", "GENE_OR_GENE_PRODUCT", 62, 65], ["CD4 T cells", "CELL", 102, 113], ["MS lesions", "CANCER", 117, 127], ["PD-1", "GENE_OR_GENE_PRODUCT", 138, 142], ["PD-L1", "GENE_OR_GENE_PRODUCT", 258, 263], ["human", "ORGANISM", 295, 300], ["CNS cells", "CELL", 301, 310], ["PD-1", "PROTEIN", 53, 57], ["CD4", "PROTEIN", 62, 65], ["infiltrating CD4 T cells", "CELL_TYPE", 89, 113], ["PD-L1", "PROTEIN", 258, 263], ["human CNS cells", "CELL_TYPE", 295, 310], ["human", "SPECIES", 295, 300], ["human", "SPECIES", 295, 300], ["PD", "TEST", 53, 55], ["CD4", "TEST", 62, 65], ["MS lesions", "PROBLEM", 117, 127], ["PD", "TEST", 138, 140], ["DISCUSSIONOur study", "TEST", 156, 175], ["proinflammatory stimuli", "TEST", 206, 229], ["an inhibitory ligand", "PROBLEM", 265, 285], ["proinflammatory stimuli", "OBSERVATION", 206, 229], ["L1", "ANATOMY", 261, 263]]], ["Inflamed astrocytes express sufficient levels of PD-L1 to modulate CD8 T-cell immune responses.", [["astrocytes", "ANATOMY", 9, 19], ["CD8 T-cell", "ANATOMY", 67, 77], ["astrocytes", "CELL", 9, 19], ["PD-L1", "GENE_OR_GENE_PRODUCT", 49, 54], ["CD8", "GENE_OR_GENE_PRODUCT", 67, 70], ["astrocytes", "CELL_TYPE", 9, 19], ["PD-L1", "PROTEIN", 49, 54], ["Inflamed astrocytes", "PROBLEM", 0, 19], ["PD", "TEST", 49, 51], ["L1", "ANATOMY", 52, 54]]], ["In addition, we showed that PD-L1 is significantly more expressed in MS brain lesions than in control tissues and that astrocytes and microglia/macrophages are significant and abundant sources of this ligand in MS lesions.", [["MS brain lesions", "ANATOMY", 69, 85], ["tissues", "ANATOMY", 102, 109], ["astrocytes", "ANATOMY", 119, 129], ["microglia", "ANATOMY", 134, 143], ["macrophages", "ANATOMY", 144, 155], ["MS lesions", "ANATOMY", 211, 221], ["MS", "DISEASE", 211, 213], ["PD-L1", "GENE_OR_GENE_PRODUCT", 28, 33], ["MS brain lesions", "CANCER", 69, 85], ["tissues", "TISSUE", 102, 109], ["astrocytes", "CELL", 119, 129], ["microglia", "CELL", 134, 143], ["macrophages", "CELL", 144, 155], ["MS lesions", "CANCER", 211, 221], ["L1", "PROTEIN", 31, 33], ["astrocytes", "CELL_TYPE", 119, 129], ["microglia", "CELL_TYPE", 134, 143], ["macrophages", "CELL_TYPE", 144, 155], ["PD-L1", "PROBLEM", 28, 33], ["MS brain lesions", "PROBLEM", 69, 85], ["astrocytes and microglia/macrophages", "PROBLEM", 119, 155], ["this ligand in MS lesions", "PROBLEM", 196, 221], ["L1", "ANATOMY", 31, 33], ["significantly", "OBSERVATION_MODIFIER", 37, 50], ["more expressed", "OBSERVATION_MODIFIER", 51, 65], ["brain", "ANATOMY", 72, 77], ["lesions", "OBSERVATION", 78, 85], ["astrocytes", "ANATOMY", 119, 129], ["lesions", "OBSERVATION", 214, 221]]], ["In contrast, most infiltrating CD8 T lymphocytes found in MS lesions especially in the parenchyma are devoid of PD-1.", [["infiltrating CD8 T lymphocytes", "ANATOMY", 18, 48], ["MS lesions", "ANATOMY", 58, 68], ["parenchyma", "ANATOMY", 87, 97], ["CD8 T lymphocytes", "CELL", 31, 48], ["MS lesions", "CANCER", 58, 68], ["parenchyma", "TISSUE", 87, 97], ["PD-1", "GENE_OR_GENE_PRODUCT", 112, 116], ["infiltrating CD8 T lymphocytes", "CELL_TYPE", 18, 48], ["most infiltrating CD8 T lymphocytes", "PROBLEM", 13, 48], ["MS lesions", "PROBLEM", 58, 68], ["PD", "TEST", 112, 114], ["infiltrating", "OBSERVATION_MODIFIER", 18, 30], ["CD8 T lymphocytes", "OBSERVATION", 31, 48], ["MS", "OBSERVATION_MODIFIER", 58, 60], ["lesions", "OBSERVATION", 61, 68], ["parenchyma", "ANATOMY", 87, 97]]], ["Our observations suggest that although PD-L1 is abundantly expressed in MS lesions by astrocytes and microglia/ macrophages, infiltrating CD8 T cells would not be susceptible to this local PD-L1-mediated inhibition.DISCUSSIONWe performed an extensive study of primary human CNS cells and treated astrocytes, microglia, oligodendrocytes, and neurons with cytokines known to be abundantly present in MS lesions (Sospedra and Martin, 2005) .", [["MS lesions", "ANATOMY", 72, 82], ["astrocytes", "ANATOMY", 86, 96], ["microglia", "ANATOMY", 101, 110], ["macrophages", "ANATOMY", 112, 123], ["CD8 T cells", "ANATOMY", 138, 149], ["CNS cells", "ANATOMY", 274, 283], ["astrocytes", "ANATOMY", 296, 306], ["microglia", "ANATOMY", 308, 317], ["oligodendrocytes", "ANATOMY", 319, 335], ["neurons", "ANATOMY", 341, 348], ["MS lesions", "ANATOMY", 398, 408], ["PD-L1", "GENE_OR_GENE_PRODUCT", 39, 44], ["MS lesions", "PATHOLOGICAL_FORMATION", 72, 82], ["astrocytes", "CELL", 86, 96], ["microglia", "CELL", 101, 110], ["macrophages", "CELL", 112, 123], ["CD8 T cells", "CELL", 138, 149], ["PD-L1", "GENE_OR_GENE_PRODUCT", 189, 194], ["human", "ORGANISM", 268, 273], ["CNS cells", "CELL", 274, 283], ["astrocytes", "CELL", 296, 306], ["microglia", "CELL", 308, 317], ["oligodendrocytes", "CELL", 319, 335], ["neurons", "CELL", 341, 348], ["MS lesions", "CANCER", 398, 408], ["L1", "DNA", 42, 44], ["astrocytes", "CELL_TYPE", 86, 96], ["microglia", "CELL_TYPE", 101, 110], ["macrophages", "CELL_TYPE", 112, 123], ["infiltrating CD8 T cells", "CELL_TYPE", 125, 149], ["primary human CNS cells", "CELL_TYPE", 260, 283], ["astrocytes", "CELL_TYPE", 296, 306], ["microglia", "CELL_TYPE", 308, 317], ["oligodendrocytes", "CELL_TYPE", 319, 335], ["cytokines", "PROTEIN", 354, 363], ["human", "SPECIES", 268, 273], ["human", "SPECIES", 268, 273], ["Our observations", "TEST", 0, 16], ["PD-L1", "PROBLEM", 39, 44], ["MS lesions", "PROBLEM", 72, 82], ["astrocytes", "TEST", 86, 96], ["microglia/ macrophages", "PROBLEM", 101, 123], ["infiltrating CD8 T cells", "PROBLEM", 125, 149], ["this local PD", "TEST", 178, 191], ["an extensive study", "TEST", 238, 256], ["primary human CNS cells", "PROBLEM", 260, 283], ["treated astrocytes", "PROBLEM", 288, 306], ["cytokines", "TREATMENT", 354, 363], ["MS lesions", "PROBLEM", 398, 408], ["L1", "ANATOMY", 42, 44], ["lesions", "OBSERVATION", 75, 82], ["astrocytes", "ANATOMY", 86, 96], ["microglia", "ANATOMY", 101, 110], ["macrophages", "ANATOMY", 112, 123], ["lesions", "OBSERVATION", 401, 408]]], ["We observed low basal levels of PD-L1 and PD- L2, but IFN-g treatment up-regulated PD-L1 and the combination of IFN-g and TNF led to even greater levels in astrocytes but not neurons.", [["astrocytes", "ANATOMY", 156, 166], ["neurons", "ANATOMY", 175, 182], ["PD-L1", "GENE_OR_GENE_PRODUCT", 32, 37], ["PD- L2", "GENE_OR_GENE_PRODUCT", 42, 48], ["IFN-g", "GENE_OR_GENE_PRODUCT", 54, 59], ["PD-L1", "GENE_OR_GENE_PRODUCT", 83, 88], ["IFN-g", "GENE_OR_GENE_PRODUCT", 112, 117], ["TNF", "GENE_OR_GENE_PRODUCT", 122, 125], ["astrocytes", "CELL", 156, 166], ["neurons", "CELL", 175, 182], ["IFN", "PROTEIN", 54, 57], ["PD-L1", "PROTEIN", 83, 88], ["IFN", "PROTEIN", 112, 115], ["TNF", "PROTEIN", 122, 125], ["astrocytes", "CELL_TYPE", 156, 166], ["neurons", "CELL_TYPE", 175, 182], ["low basal levels of PD", "PROBLEM", 12, 34], ["IFN-g treatment", "TREATMENT", 54, 69], ["IFN-g", "TREATMENT", 112, 117], ["TNF", "PROBLEM", 122, 125], ["low", "OBSERVATION_MODIFIER", 12, 15], ["basal", "ANATOMY_MODIFIER", 16, 21], ["L1", "ANATOMY", 35, 37], ["L2", "ANATOMY", 46, 48], ["L1", "ANATOMY", 86, 88], ["astrocytes", "ANATOMY", 156, 166]]], ["This was unexpected as TNF receptors are constitutively expressed by neurons (Tobinick, 2009) and TNF triggers neuronal responses (Kraft et al., 2009; Rainey-Smith et al., 2010) .", [["neurons", "ANATOMY", 69, 76], ["neuronal", "ANATOMY", 111, 119], ["TNF receptors", "GENE_OR_GENE_PRODUCT", 23, 36], ["neurons", "CELL", 69, 76], ["TNF", "GENE_OR_GENE_PRODUCT", 98, 101], ["neuronal", "CELL", 111, 119], ["TNF receptors", "PROTEIN", 23, 36], ["TNF", "PROTEIN", 98, 101]]], ["However, PD-L1 levels on IFN-g2treated neurons never reached those observed on other CNS cells, especially astrocytes.", [["neurons", "ANATOMY", 39, 46], ["CNS cells", "ANATOMY", 85, 94], ["astrocytes", "ANATOMY", 107, 117], ["PD-L1", "GENE_OR_GENE_PRODUCT", 9, 14], ["neurons", "CELL", 39, 46], ["CNS cells", "CELL", 85, 94], ["astrocytes", "CELL", 107, 117], ["IFN-g2treated neurons", "CELL_LINE", 25, 46], ["CNS cells", "CELL_TYPE", 85, 94], ["astrocytes", "CELL_TYPE", 107, 117], ["PD-L1 levels", "TEST", 9, 21], ["IFN", "TEST", 25, 28], ["g2treated neurons", "PROBLEM", 29, 46], ["L1", "ANATOMY", 12, 14], ["CNS cells", "ANATOMY", 85, 94]]], ["In contrast, cytokines had no or only a small impact on PD-L2 levels (Figs.", [["PD-L2", "GENE_OR_GENE_PRODUCT", 56, 61], ["cytokines", "PROTEIN", 13, 22], ["a small impact on PD", "PROBLEM", 38, 58], ["small", "OBSERVATION_MODIFIER", 40, 45], ["impact", "OBSERVATION", 46, 52], ["L2", "ANATOMY", 59, 61]]], ["Our results substantiate that PD-L2 is more restricted than PD-L1 in the CNS similarly to other organs (Keir et al., 2008) .DISCUSSIONMurine in vivo CNS models have shown that strategies systemically inhibiting the PD-L1/2-PD-1 interac-tion either through peripheral blocking antibody injection or use of globally knockout mice enhanced disease severity, T cell and macrophage infiltration, and T-cell responses (Kroner et al., 2009a; Ortler et al., 2008; Phares et al., 2009; Salama et al., 2003) .", [["CNS", "ANATOMY", 73, 76], ["organs", "ANATOMY", 96, 102], ["CNS", "ANATOMY", 149, 152], ["T cell", "ANATOMY", 355, 361], ["macrophage", "ANATOMY", 366, 376], ["T-cell", "ANATOMY", 395, 401], ["PD-L2", "GENE_OR_GENE_PRODUCT", 30, 35], ["PD-L1", "GENE_OR_GENE_PRODUCT", 60, 65], ["CNS", "ANATOMICAL_SYSTEM", 73, 76], ["organs", "ORGAN", 96, 102], ["CNS", "ANATOMICAL_SYSTEM", 149, 152], ["PD-L1", "GENE_OR_GENE_PRODUCT", 215, 220], ["2", "GENE_OR_GENE_PRODUCT", 221, 222], ["PD-1", "GENE_OR_GENE_PRODUCT", 223, 227], ["mice", "ORGANISM", 323, 327], ["T cell", "CELL", 355, 361], ["macrophage", "CELL", 366, 376], ["T-cell", "CELL", 395, 401], ["PD-L1", "DNA", 60, 65], ["mice", "SPECIES", 323, 327], ["mice", "SPECIES", 323, 327], ["PD-L2", "PROBLEM", 30, 35], ["the PD", "TEST", 211, 217], ["PD", "TEST", 223, 225], ["peripheral blocking antibody injection", "TREATMENT", 256, 294], ["globally knockout mice enhanced disease severity", "PROBLEM", 305, 353], ["T cell and macrophage infiltration", "PROBLEM", 355, 389], ["L2", "ANATOMY", 33, 35], ["CNS", "ANATOMY", 73, 76], ["macrophage infiltration", "OBSERVATION", 366, 389]]], ["However, these reports did not assess the impact of local CNS PD-L1 or PD-L2 expression on T-cell functions.", [["CNS", "ANATOMY", 58, 61], ["T-cell", "ANATOMY", 91, 97], ["PD-L1", "GENE_OR_GENE_PRODUCT", 62, 67], ["PD-L2", "GENE_OR_GENE_PRODUCT", 71, 76], ["T-cell", "CELL", 91, 97], ["local CNS PD", "PROBLEM", 52, 64], ["PD", "PROBLEM", 71, 73], ["L1", "ANATOMY", 65, 67], ["L2", "ANATOMY", 74, 76]]], ["Since T lymphocytes can also express PD-L1, especially following their activation (Kinter et al., 2008) , it was essential to specifically block the expression of this ligand in CNS cells.", [["T lymphocytes", "ANATOMY", 6, 19], ["CNS cells", "ANATOMY", 178, 187], ["T lymphocytes", "CELL", 6, 19], ["PD-L1", "GENE_OR_GENE_PRODUCT", 37, 42], ["CNS cells", "CELL", 178, 187], ["T lymphocytes", "CELL_TYPE", 6, 19], ["PD-L1", "PROTEIN", 37, 42], ["CNS cells", "CELL_TYPE", 178, 187], ["lymphocytes", "ANATOMY", 8, 19], ["L1", "ANATOMY", 40, 42], ["CNS cells", "ANATOMY", 178, 187]]], ["Our siRNA approach allowed us to specifically abolish PD-L1 expression on astrocytes which would not have been possible with antibody.", [["astrocytes", "ANATOMY", 74, 84], ["PD-L1", "GENE_OR_GENE_PRODUCT", 54, 59], ["astrocytes", "CELL", 74, 84], ["L1", "DNA", 57, 59], ["astrocytes", "CELL_TYPE", 74, 84], ["Our siRNA approach", "TREATMENT", 0, 18], ["PD-L1 expression on astrocytes", "PROBLEM", 54, 84], ["antibody", "PROBLEM", 125, 133], ["L1", "ANATOMY", 57, 59]]], ["Our results demonstrate that CNS cells, especially astrocytes, express functional and sufficient levels of PD-L1 to locally dampen CD8 T cell responses (proliferation, IFN-g, TNF, granzyme B).", [["CNS cells", "ANATOMY", 29, 38], ["astrocytes", "ANATOMY", 51, 61], ["CD8 T cell", "ANATOMY", 131, 141], ["CNS cells", "CELL", 29, 38], ["astrocytes", "CELL", 51, 61], ["PD-L1", "GENE_OR_GENE_PRODUCT", 107, 112], ["CD8 T cell", "CELL", 131, 141], ["IFN-g", "GENE_OR_GENE_PRODUCT", 168, 173], ["TNF", "GENE_OR_GENE_PRODUCT", 175, 178], ["granzyme B", "GENE_OR_GENE_PRODUCT", 180, 190], ["CNS cells", "CELL_TYPE", 29, 38], ["astrocytes", "CELL_TYPE", 51, 61], ["CD8", "PROTEIN", 131, 134], ["IFN", "PROTEIN", 168, 171], ["TNF", "PROTEIN", 175, 178], ["granzyme B", "PROTEIN", 180, 190], ["CNS cells", "PROBLEM", 29, 38], ["astrocytes", "PROBLEM", 51, 61], ["PD", "TEST", 107, 109], ["proliferation", "TEST", 153, 166], ["IFN", "TEST", 168, 171], ["TNF", "TREATMENT", 175, 178], ["CNS cells", "OBSERVATION", 29, 38], ["L1", "ANATOMY", 110, 112]]], ["The boosted immune responses of CD8 T cells we observed upon co-culture on PD-L1 knockdown astrocytes were partial as only a proportion of ex vivo or activated human CD8 T cells bear PD-1, the necessary receptor for PD-L1-mediated inhibition (Bengsch et al., 2010; Day et al., 2006; Kinter et al., 2008) .", [["CD8 T cells", "ANATOMY", 32, 43], ["astrocytes", "ANATOMY", 91, 101], ["CD8 T cells", "ANATOMY", 166, 177], ["CD8 T cells", "CELL", 32, 43], ["PD-L1", "GENE_OR_GENE_PRODUCT", 75, 80], ["astrocytes", "CELL", 91, 101], ["human", "ORGANISM", 160, 165], ["CD8 T cells", "CELL", 166, 177], ["PD-1", "GENE_OR_GENE_PRODUCT", 183, 187], ["PD-L1", "GENE_OR_GENE_PRODUCT", 216, 221], ["CD8 T cells", "CELL_TYPE", 32, 43], ["PD-L1 knockdown astrocytes", "CELL_LINE", 75, 101], ["activated human CD8 T cells", "CELL_TYPE", 150, 177], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["CD8 T cells", "PROBLEM", 32, 43], ["co-culture", "TEST", 61, 71], ["PD", "TEST", 75, 77], ["L1 knockdown astrocytes", "PROBLEM", 78, 101], ["PD", "TEST", 183, 185], ["PD", "TEST", 216, 218]]], ["Moreover, inflamed astrocytes express a plethora of activating mediators (boosted MHC expression, secreted cytokine, etc) thus, their final impact on T-cell functions will be dictated by the addition of these numerous factors and PD-L1 is one of them.DISCUSSIONMurine CNS PD-L1 expression has been shown to be up-regulated upon various stimuli including inflammation and viral infections.", [["astrocytes", "ANATOMY", 19, 29], ["T-cell", "ANATOMY", 150, 156], ["inflammation", "DISEASE", 354, 366], ["viral infections", "DISEASE", 371, 387], ["astrocytes", "CELL", 19, 29], ["MHC", "GENE_OR_GENE_PRODUCT", 82, 85], ["etc", "GENE_OR_GENE_PRODUCT", 117, 120], ["T-cell", "CELL", 150, 156], ["PD-L1", "GENE_OR_GENE_PRODUCT", 230, 235], ["PD-L1", "GENE_OR_GENE_PRODUCT", 272, 277], ["inflamed astrocytes", "CELL_TYPE", 10, 29], ["activating mediators", "PROTEIN", 52, 72], ["MHC", "PROTEIN", 82, 85], ["secreted cytokine", "PROTEIN", 98, 115], ["L1", "PROTEIN", 233, 235], ["L1", "DNA", 275, 277], ["inflamed astrocytes", "PROBLEM", 10, 29], ["activating mediators", "PROBLEM", 52, 72], ["PD-L1", "TREATMENT", 230, 235], ["inflammation", "PROBLEM", 354, 366], ["viral infections", "PROBLEM", 371, 387], ["inflamed astrocytes", "OBSERVATION", 10, 29], ["L1", "ANATOMY", 275, 277], ["inflammation", "OBSERVATION", 354, 366], ["viral", "OBSERVATION_MODIFIER", 371, 376], ["infections", "OBSERVATION", 377, 387]]], ["In EAE, PD-L1 was detected on microglia (Magnus et al., 2005) and astrocytes (Salama et al., 2003) ; but PD-L2 was absent (Salama et al., 2003) .", [["microglia", "ANATOMY", 30, 39], ["astrocytes", "ANATOMY", 66, 76], ["EAE", "DISEASE", 3, 6], ["PD-L1", "GENE_OR_GENE_PRODUCT", 8, 13], ["microglia", "CELL", 30, 39], ["astrocytes", "CELL", 66, 76], ["PD-L2", "GENE_OR_GENE_PRODUCT", 105, 110], ["microglia", "CELL_TYPE", 30, 39], ["astrocytes", "CELL_TYPE", 66, 76], ["PD", "TEST", 8, 10], ["microglia", "TEST", 30, 39], ["Magnus et al.", "TEST", 41, 54], ["astrocytes", "TEST", 66, 76], ["PD", "TEST", 105, 107], ["L1", "ANATOMY", 11, 13], ["astrocytes", "ANATOMY", 66, 76], ["L2", "ANATOMY", 108, 110]]], ["PD-L1 expression was increased on astrocytes, but not on active microglia or neurons in mice suffering from entorhinal cortex lesions (Lipp et al., 2007) .", [["astrocytes", "ANATOMY", 34, 44], ["microglia", "ANATOMY", 64, 73], ["neurons", "ANATOMY", 77, 84], ["entorhinal cortex lesions", "ANATOMY", 108, 133], ["entorhinal cortex lesions", "DISEASE", 108, 133], ["PD-L1", "GENE_OR_GENE_PRODUCT", 0, 5], ["astrocytes", "CELL", 34, 44], ["microglia", "CELL", 64, 73], ["neurons", "CELL", 77, 84], ["mice", "ORGANISM", 88, 92], ["entorhinal cortex lesions", "CANCER", 108, 133], ["L1", "DNA", 3, 5], ["astrocytes", "CELL_TYPE", 34, 44], ["microglia", "CELL_TYPE", 64, 73], ["mice", "SPECIES", 88, 92], ["mice", "SPECIES", 88, 92], ["astrocytes", "PROBLEM", 34, 44], ["entorhinal cortex lesions", "PROBLEM", 108, 133], ["L1", "ANATOMY", 3, 5], ["increased", "OBSERVATION_MODIFIER", 21, 30], ["entorhinal cortex", "ANATOMY", 108, 125], ["lesions", "OBSERVATION", 126, 133]]], ["PD-L1 was detected at high and sustained levels on oligodendrocytes but more transiently on microglia in mice infected with a neurotropic coronavirus, JHM strain of mouse hepatitis virus (Phares et al., 2009) .", [["oligodendrocytes", "ANATOMY", 51, 67], ["microglia", "ANATOMY", 92, 101], ["neurotropic coronavirus", "DISEASE", 126, 149], ["mouse hepatitis virus", "DISEASE", 165, 186], ["PD-L1", "GENE_OR_GENE_PRODUCT", 0, 5], ["oligodendrocytes", "CELL", 51, 67], ["microglia", "CELL", 92, 101], ["mice", "ORGANISM", 105, 109], ["neurotropic coronavirus", "ORGANISM", 126, 149], ["JHM strain", "ORGANISM", 151, 161], ["mouse hepatitis virus", "ORGANISM", 165, 186], ["PD-L1", "DNA", 0, 5], ["oligodendrocytes", "CELL_TYPE", 51, 67], ["microglia", "CELL_TYPE", 92, 101], ["mice", "SPECIES", 105, 109], ["mouse", "SPECIES", 165, 170], ["hepatitis virus", "SPECIES", 171, 186], ["mice", "SPECIES", 105, 109], ["neurotropic coronavirus", "SPECIES", 126, 149], ["mouse hepatitis virus", "SPECIES", 165, 186], ["PD", "TEST", 0, 2], ["sustained levels on oligodendrocytes", "PROBLEM", 31, 67], ["a neurotropic coronavirus", "PROBLEM", 124, 149], ["mouse hepatitis virus", "PROBLEM", 165, 186], ["L1", "ANATOMY", 3, 5], ["neurotropic coronavirus", "ANATOMY", 126, 149]]], ["In contrast, rabies virus infection up-regulated PD-L1 in infected murine neurons and immortalized human neurons (Lafon et al., 2008) .", [["neurons", "ANATOMY", 74, 81], ["neurons", "ANATOMY", 105, 112], ["rabies virus infection", "DISEASE", 13, 35], ["rabies virus", "ORGANISM", 13, 25], ["PD-L1", "GENE_OR_GENE_PRODUCT", 49, 54], ["murine", "ORGANISM", 67, 73], ["neurons", "CELL", 74, 81], ["human", "ORGANISM", 99, 104], ["neurons", "CELL", 105, 112], ["PD-L1", "DNA", 49, 54], ["infected murine neurons", "CELL_TYPE", 58, 81], ["immortalized human neurons", "CELL_TYPE", 86, 112], ["rabies virus", "SPECIES", 13, 25], ["murine", "SPECIES", 67, 73], ["human", "SPECIES", 99, 104], ["rabies virus", "SPECIES", 13, 25], ["human", "SPECIES", 99, 104], ["rabies virus infection", "PROBLEM", 13, 35], ["L1", "ANATOMY", 52, 54]]], ["Therefore, different insults could trigger PD-L1 expression by distinct CNS cell subsets.DISCUSSIONFew studies have addressed the PD-L1 expression in the human CNS.", [["CNS cell", "ANATOMY", 72, 80], ["CNS", "ANATOMY", 160, 163], ["PD-L1", "GENE_OR_GENE_PRODUCT", 43, 48], ["CNS cell subsets", "CELL", 72, 88], ["PD-L1", "GENE_OR_GENE_PRODUCT", 130, 135], ["human", "ORGANISM", 154, 159], ["CNS", "ANATOMICAL_SYSTEM", 160, 163], ["L1", "DNA", 46, 48], ["CNS cell subsets", "CELL_TYPE", 72, 88], ["L1", "DNA", 133, 135], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["different insults", "PROBLEM", 11, 28], ["PD", "PROBLEM", 43, 45], ["DISCUSSIONFew studies", "TEST", 89, 110], ["the PD", "PROBLEM", 126, 132], ["L1 expression", "OBSERVATION_MODIFIER", 46, 59], ["distinct", "OBSERVATION_MODIFIER", 63, 71], ["CNS cell subsets", "OBSERVATION", 72, 88]]], ["One group did not detect PD-L1 in brain tissue sections from normal controls (Wintterle et al., 2003) ; in contrast, others observed few scattered cells bearing a microglial like morphology expressing PD-L1 in nonpathological CNS sections (Ortler et al., 2008) .", [["brain tissue sections", "ANATOMY", 34, 55], ["cells", "ANATOMY", 147, 152], ["microglial", "ANATOMY", 163, 173], ["CNS sections", "ANATOMY", 226, 238], ["PD-L1", "GENE_OR_GENE_PRODUCT", 25, 30], ["brain tissue sections", "TISSUE", 34, 55], ["cells", "CELL", 147, 152], ["microglial", "CELL", 163, 173], ["PD-L1", "GENE_OR_GENE_PRODUCT", 201, 206], ["CNS sections", "MULTI-TISSUE_STRUCTURE", 226, 238], ["PD-L1", "DNA", 201, 206], ["PD", "TEST", 25, 27], ["few scattered cells", "PROBLEM", 133, 152], ["L1", "ANATOMY", 28, 30], ["brain tissue", "ANATOMY", 34, 46], ["few", "OBSERVATION_MODIFIER", 133, 136], ["scattered cells", "OBSERVATION", 137, 152], ["microglial", "OBSERVATION_MODIFIER", 163, 173], ["L1", "ANATOMY", 204, 206], ["CNS", "ANATOMY", 226, 229]]], ["Similarly, we also observed that up to 5% of microglia in control CNS samples display PD-L1 staining.", [["microglia", "ANATOMY", 45, 54], ["CNS samples", "ANATOMY", 66, 77], ["microglia", "CELL", 45, 54], ["CNS samples", "CANCER", 66, 77], ["PD-L1", "GENE_OR_GENE_PRODUCT", 86, 91], ["microglia", "CELL_TYPE", 45, 54], ["CNS samples", "TEST", 66, 77], ["PD-L1 staining", "PROBLEM", 86, 100], ["L1", "ANATOMY", 89, 91], ["staining", "OBSERVATION", 92, 100]]], ["Thus, a small subset of microglia bear PD-L1 in non-CNS disease patients suggesting that these donors had small and localized CNS insults.", [["microglia", "ANATOMY", 24, 33], ["CNS", "ANATOMY", 126, 129], ["non-CNS disease", "DISEASE", 48, 63], ["microglia", "CELL", 24, 33], ["PD-L1", "GENE_OR_GENE_PRODUCT", 39, 44], ["non-CNS", "CANCER", 48, 55], ["patients", "ORGANISM", 64, 72], ["donors", "ORGANISM", 95, 101], ["CNS", "ANATOMICAL_SYSTEM", 126, 129], ["microglia", "CELL_TYPE", 24, 33], ["patients", "SPECIES", 64, 72], ["a small subset of microglia bear PD", "PROBLEM", 6, 41], ["non-CNS disease", "PROBLEM", 48, 63], ["small and localized CNS insults", "PROBLEM", 106, 137], ["small", "OBSERVATION_MODIFIER", 8, 13], ["subset", "OBSERVATION_MODIFIER", 14, 20], ["microglia bear PD", "OBSERVATION", 24, 41], ["L1", "ANATOMY", 42, 44], ["non-CNS", "ANATOMY", 48, 55], ["disease", "OBSERVATION", 56, 63], ["small", "OBSERVATION_MODIFIER", 106, 111], ["localized", "OBSERVATION_MODIFIER", 116, 125], ["CNS insults", "OBSERVATION", 126, 137]]], ["We also observed in controls few astrocytes co-stained for PD-L1, except for one section obtained from a donor who died from cardiac arrest (see Table 2 , block 6) which had the highest number of astrocytes positive for PD-L1 of the control samples (see Fig. 5 ).", [["astrocytes", "ANATOMY", 33, 43], ["cardiac", "ANATOMY", 125, 132], ["astrocytes", "ANATOMY", 196, 206], ["samples", "ANATOMY", 241, 248], ["cardiac arrest", "DISEASE", 125, 139], ["astrocytes", "CELL", 33, 43], ["PD-L1", "GENE_OR_GENE_PRODUCT", 59, 64], ["cardiac", "ORGAN", 125, 132], ["astrocytes", "CELL", 196, 206], ["PD-L1", "GENE_OR_GENE_PRODUCT", 220, 225], ["astrocytes", "CELL_TYPE", 33, 43], ["astrocytes", "CELL_TYPE", 196, 206], ["cardiac arrest", "PROBLEM", 125, 139], ["PD", "PROBLEM", 220, 222], ["L1", "ANATOMY", 62, 64], ["cardiac", "ANATOMY", 125, 132], ["arrest", "OBSERVATION", 133, 139]]], ["We could speculate that a CNS insult triggered such expression in this particular donor.", [["CNS", "ANATOMY", 26, 29], ["CNS", "ANATOMICAL_SYSTEM", 26, 29], ["a CNS insult", "PROBLEM", 24, 36], ["CNS", "ANATOMY", 26, 29]]], ["PD-L1 has been detected in MS patient brain especially in AQ lesions on cells bearing a microglia/macrophage like morphology (Ortler et al., 2008) but quantification or co-staining was not performed in this study.", [["brain", "ANATOMY", 38, 43], ["AQ lesions", "ANATOMY", 58, 68], ["cells", "ANATOMY", 72, 77], ["microglia", "ANATOMY", 88, 97], ["macrophage", "ANATOMY", 98, 108], ["PD-L1", "GENE_OR_GENE_PRODUCT", 0, 5], ["patient", "ORGANISM", 30, 37], ["brain", "ORGAN", 38, 43], ["AQ lesions", "PATHOLOGICAL_FORMATION", 58, 68], ["cells", "CELL", 72, 77], ["microglia", "CELL", 88, 97], ["macrophage", "CELL", 98, 108], ["L1", "DNA", 3, 5], ["microglia", "CELL_TYPE", 88, 97], ["patient", "SPECIES", 30, 37], ["AQ lesions", "PROBLEM", 58, 68], ["this study", "TEST", 202, 212], ["L1", "ANATOMY", 3, 5], ["brain", "ANATOMY", 38, 43], ["lesions", "OBSERVATION", 61, 68]]], ["Our quantitative immunohistochemistry observations demonstrate that significantly more microglia/macrophages expressed PD-L1 in MS lesions compared with normal control tissues (see Fig. 6 ).", [["microglia", "ANATOMY", 87, 96], ["macrophages", "ANATOMY", 97, 108], ["MS lesions", "ANATOMY", 128, 138], ["tissues", "ANATOMY", 168, 175], ["microglia", "CELL", 87, 96], ["macrophages", "CELL", 97, 108], ["PD-L1", "GENE_OR_GENE_PRODUCT", 119, 124], ["MS lesions", "PATHOLOGICAL_FORMATION", 128, 138], ["tissues", "TISSUE", 168, 175], ["microglia", "CELL_TYPE", 87, 96], ["macrophages", "CELL_TYPE", 97, 108], ["Our quantitative immunohistochemistry observations", "TEST", 0, 50], ["significantly more microglia/macrophages", "PROBLEM", 68, 108], ["MS lesions", "PROBLEM", 128, 138], ["significantly", "OBSERVATION_MODIFIER", 68, 81], ["more microglia", "OBSERVATION_MODIFIER", 82, 96], ["macrophages", "ANATOMY", 97, 108], ["L1", "ANATOMY", 122, 124], ["lesions", "OBSERVATION", 131, 138], ["normal", "OBSERVATION", 153, 159]]], ["Moreover, we detected a greater number of PD-L1-expressing astrocytes per surface area in MS lesions compared with controls (see Fig. 5 ).", [["astrocytes", "ANATOMY", 59, 69], ["surface area", "ANATOMY", 74, 86], ["MS lesions", "ANATOMY", 90, 100], ["PD-L1", "GENE_OR_GENE_PRODUCT", 42, 47], ["astrocytes", "CELL", 59, 69], ["MS lesions", "CANCER", 90, 100], ["L1", "PROTEIN", 45, 47], ["astrocytes", "CELL_TYPE", 59, 69], ["PD", "TEST", 42, 44], ["MS lesions", "PROBLEM", 90, 100], ["greater", "OBSERVATION_MODIFIER", 24, 31], ["L1", "ANATOMY", 45, 47], ["astrocytes", "ANATOMY", 59, 69], ["lesions", "OBSERVATION", 93, 100]]], ["We could not observe detectable PD-L1 on oligodendrocytes in control and MS tissues (see Fig. 7) .", [["oligodendrocytes", "ANATOMY", 41, 57], ["MS tissues", "ANATOMY", 73, 83], ["PD-L1", "GENE_OR_GENE_PRODUCT", 32, 37], ["oligodendrocytes", "CELL", 41, 57], ["MS tissues", "TISSUE", 73, 83], ["PD-L1", "DNA", 32, 37], ["oligodendrocytes", "CELL_TYPE", 41, 57], ["detectable PD", "PROBLEM", 21, 34], ["MS tissues", "PROBLEM", 73, 83], ["L1", "ANATOMY", 35, 37]]], ["It is still possible that human oligodendrocytes could express PD-L1 in human brain in response to stimuli other than those present in MS lesions, as reported in mice infected with a coronavirus (Phares et al., 2009) .DISCUSSIONThe susceptibility of T lymphocytes to PD-L1 or PD-L2-mediated inhibition relies on their expression of PD-1, the inhibitory receptor.", [["oligodendrocytes", "ANATOMY", 32, 48], ["brain", "ANATOMY", 78, 83], ["MS lesions", "ANATOMY", 135, 145], ["T lymphocytes", "ANATOMY", 250, 263], ["coronavirus", "DISEASE", 183, 194], ["human", "ORGANISM", 26, 31], ["oligodendrocytes", "CELL", 32, 48], ["PD-L1", "GENE_OR_GENE_PRODUCT", 63, 68], ["human", "ORGANISM", 72, 77], ["brain", "ORGAN", 78, 83], ["MS lesions", "PATHOLOGICAL_FORMATION", 135, 145], ["mice", "ORGANISM", 162, 166], ["coronavirus", "ORGANISM", 183, 194], ["T lymphocytes", "CELL", 250, 263], ["PD-L1", "GENE_OR_GENE_PRODUCT", 267, 272], ["PD-L2", "GENE_OR_GENE_PRODUCT", 276, 281], ["PD-1", "GENE_OR_GENE_PRODUCT", 332, 336], ["human oligodendrocytes", "CELL_TYPE", 26, 48], ["PD-L1", "DNA", 63, 68], ["T lymphocytes", "CELL_TYPE", 250, 263], ["PD-1", "PROTEIN", 332, 336], ["inhibitory receptor", "PROTEIN", 342, 361], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 72, 77], ["mice", "SPECIES", 162, 166], ["coronavirus", "SPECIES", 183, 194], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 72, 77], ["mice", "SPECIES", 162, 166], ["human oligodendrocytes", "PROBLEM", 26, 48], ["MS lesions", "PROBLEM", 135, 145], ["PD", "TEST", 267, 269], ["PD", "TEST", 276, 278], ["PD", "TEST", 332, 334], ["still possible", "UNCERTAINTY", 6, 20], ["human brain", "ANATOMY", 72, 83], ["lesions", "OBSERVATION", 138, 145]]], ["Less CD8 T cells in the parenchyma of MS lesions expressed detectable PD-1 compared with normal controls (see Fig. 8 ).", [["CD8 T cells", "ANATOMY", 5, 16], ["parenchyma", "ANATOMY", 24, 34], ["MS lesions", "ANATOMY", 38, 48], ["CD8 T", "GENE_OR_GENE_PRODUCT", 5, 10], ["parenchyma", "TISSUE", 24, 34], ["MS lesions", "CANCER", 38, 48], ["PD-1", "GENE_OR_GENE_PRODUCT", 70, 74], ["CD8 T cells", "CELL_TYPE", 5, 16], ["MS lesions", "PROBLEM", 38, 48], ["PD", "TEST", 70, 72], ["CD8 T cells", "OBSERVATION", 5, 16], ["parenchyma", "ANATOMY", 24, 34], ["MS", "OBSERVATION_MODIFIER", 38, 40], ["lesions", "OBSERVATION", 41, 48]]], ["In contrast, we detected PD-11 cells that were not positive for CD8 in MS lesions illustrating the capacity of other PD-11 cells, some being CD4 T lymphocytes (see Fig. 8 ) to infiltrate the CNS of MS patients.", [["PD-11 cells", "ANATOMY", 25, 36], ["MS lesions", "ANATOMY", 71, 81], ["PD-11 cells", "ANATOMY", 117, 128], ["CD4 T lymphocytes", "ANATOMY", 141, 158], ["CNS", "ANATOMY", 191, 194], ["MS", "DISEASE", 198, 200], ["PD-11 cells", "CELL", 25, 36], ["CD8", "GENE_OR_GENE_PRODUCT", 64, 67], ["MS lesions", "CANCER", 71, 81], ["PD-11 cells", "CELL", 117, 128], ["CD4 T lymphocytes", "CELL", 141, 158], ["CNS", "ANATOMICAL_SYSTEM", 191, 194], ["patients", "ORGANISM", 201, 209], ["PD-11 cells", "CELL_LINE", 25, 36], ["CD8", "PROTEIN", 64, 67], ["PD-11 cells", "CELL_LINE", 117, 128], ["CD4 T lymphocytes", "CELL_TYPE", 141, 158], ["patients", "SPECIES", 201, 209], ["PD", "TEST", 25, 27], ["CD8", "PROBLEM", 64, 67], ["MS lesions", "PROBLEM", 71, 81], ["the capacity", "TEST", 95, 107], ["other PD-11 cells", "PROBLEM", 111, 128], ["CD4 T lymphocytes", "TEST", 141, 158], ["infiltrate", "PROBLEM", 176, 186], ["lesions", "OBSERVATION", 74, 81], ["infiltrate", "OBSERVATION", 176, 186], ["CNS", "ANATOMY", 191, 194]]], ["Activated CD4 and CD8 T cells have been shown to cross the blood-brain barrier under both pathological and normal conditions (Vrethem et al., 1998) albeit in much lower number in normal controls.", [["CD4", "ANATOMY", 10, 13], ["CD8 T cells", "ANATOMY", 18, 29], ["blood-brain barrier", "ANATOMY", 59, 78], ["CD4", "GENE_OR_GENE_PRODUCT", 10, 13], ["CD8", "GENE_OR_GENE_PRODUCT", 18, 21], ["blood-", "MULTI-TISSUE_STRUCTURE", 59, 65], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 65, 78], ["Activated CD4 and CD8 T cells", "CELL_TYPE", 0, 29], ["Activated CD4", "TEST", 0, 13], ["CD8 T cells", "TEST", 18, 29], ["the blood", "TEST", 55, 64], ["brain", "ANATOMY", 65, 70], ["normal conditions", "OBSERVATION", 107, 124], ["normal controls", "OBSERVATION", 179, 194]]], ["Thus, the few and scattered CD8 T cells we detected in normal controls were most likely activated T cells expressing PD-1.", [["CD8 T cells", "ANATOMY", 28, 39], ["T cells", "ANATOMY", 98, 105], ["CD8 T cells", "CELL", 28, 39], ["T cells", "CELL", 98, 105], ["PD-1", "GENE_OR_GENE_PRODUCT", 117, 121], ["CD8 T cells", "CELL_TYPE", 28, 39], ["T cells", "CELL_TYPE", 98, 105], ["PD-1", "PROTEIN", 117, 121], ["scattered CD8 T cells", "PROBLEM", 18, 39], ["few", "OBSERVATION_MODIFIER", 10, 13], ["scattered", "OBSERVATION_MODIFIER", 18, 27], ["CD8 T cells", "OBSERVATION", 28, 39], ["most likely", "UNCERTAINTY", 76, 87]]], ["PD-1 levels on CD4 and CD8 T lymphocytes were lower from relapsing compared to remitting MS patients in blood and cerebrospinal fluid samples obtained from relapsing-remitting MS (RRMS) patients (Trabattoni et al., 2009) .", [["CD4", "ANATOMY", 15, 18], ["CD8 T lymphocytes", "ANATOMY", 23, 40], ["blood", "ANATOMY", 104, 109], ["cerebrospinal fluid samples", "ANATOMY", 114, 141], ["MS", "DISEASE", 89, 91], ["relapsing-remitting MS", "DISEASE", 156, 178], ["RRMS", "DISEASE", 180, 184], ["PD-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["CD4", "GENE_OR_GENE_PRODUCT", 15, 18], ["CD8", "GENE_OR_GENE_PRODUCT", 23, 26], ["patients", "ORGANISM", 92, 100], ["blood", "ORGANISM_SUBSTANCE", 104, 109], ["cerebrospinal fluid samples", "ORGANISM_SUBSTANCE", 114, 141], ["patients", "ORGANISM", 186, 194], ["CD4 and CD8 T lymphocytes", "CELL_TYPE", 15, 40], ["patients", "SPECIES", 92, 100], ["patients", "SPECIES", 186, 194], ["PD", "TEST", 0, 2], ["CD4", "TEST", 15, 18], ["CD8 T lymphocytes", "TEST", 23, 40], ["remitting MS", "TEST", 79, 91], ["blood", "TEST", 104, 109], ["cerebrospinal fluid samples", "TEST", 114, 141], ["remitting MS", "PROBLEM", 166, 178], ["blood", "ANATOMY", 104, 109], ["cerebrospinal", "ANATOMY", 114, 127]]], ["These results suggest that during active MS, when an important number of T lymphocytes infiltrates the CNS due to an impaired blood-brain barrier (Sospedra and Martin, 2005) , a smaller proportion of these cells expresses PD-1.", [["T lymphocytes", "ANATOMY", 73, 86], ["CNS", "ANATOMY", 103, 106], ["blood-brain barrier", "ANATOMY", 126, 145], ["cells", "ANATOMY", 206, 211], ["MS", "DISEASE", 41, 43], ["T lymphocytes", "CELL", 73, 86], ["CNS", "ANATOMICAL_SYSTEM", 103, 106], ["blood-", "MULTI-TISSUE_STRUCTURE", 126, 132], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 132, 145], ["cells", "CELL", 206, 211], ["PD-1", "GENE_OR_GENE_PRODUCT", 222, 226], ["T lymphocytes", "CELL_TYPE", 73, 86], ["PD-1", "PROTEIN", 222, 226], ["active MS", "PROBLEM", 34, 43], ["T lymphocytes infiltrates the CNS", "PROBLEM", 73, 106], ["an impaired blood-brain barrier", "PROBLEM", 114, 145], ["CNS", "ANATOMY", 103, 106], ["impaired", "OBSERVATION", 117, 125], ["brain", "ANATOMY", 132, 137]]], ["We can also speculate that CNS infiltrating CD8 T lymphocytes devoid of PD-1 have a functional advantage over their PD-11 counterparts and can locally proliferate since their TCR signalling is not inhibited by local PD-L1.", [["CNS infiltrating CD8 T lymphocytes", "ANATOMY", 27, 61], ["CD8", "GENE_OR_GENE_PRODUCT", 44, 47], ["PD-1", "GENE_OR_GENE_PRODUCT", 72, 76], ["PD-11 counterparts", "CELL", 116, 134], ["TCR", "GENE_OR_GENE_PRODUCT", 175, 178], ["PD-L1", "GENE_OR_GENE_PRODUCT", 216, 221], ["CNS infiltrating CD8 T lymphocytes", "CELL_TYPE", 27, 61], ["TCR", "PROTEIN", 175, 178], ["PD", "TEST", 72, 74], ["CNS", "ANATOMY", 27, 30], ["infiltrating", "OBSERVATION", 31, 43], ["L1", "ANATOMY", 219, 221]]], ["Alternatively, PD-11 T cells could have undergone apoptosis in the MS tissues and thus be less abundant than their PD-1 negative counterparts.", [["PD-11 T cells", "ANATOMY", 15, 28], ["MS tissues", "ANATOMY", 67, 77], ["PD-11 T cells", "CELL", 15, 28], ["MS tissues", "TISSUE", 67, 77], ["PD-1", "GENE_OR_GENE_PRODUCT", 115, 119], ["PD-11 T cells", "CELL_LINE", 15, 28], ["PD", "TEST", 15, 17], ["T cells", "PROBLEM", 21, 28], ["apoptosis in the MS tissues", "PROBLEM", 50, 77], ["their PD", "TEST", 109, 117], ["apoptosis", "OBSERVATION", 50, 59]]], ["Indeed, CD8 T-cell clones have been shown to persist over many years in the CNS of MS patients supporting the notion that these cells have locally encountered their cognate antigen and proliferated (Skulina et al., 2004) .", [["CD8 T-cell clones", "ANATOMY", 8, 25], ["CNS", "ANATOMY", 76, 79], ["cells", "ANATOMY", 128, 133], ["MS", "DISEASE", 83, 85], ["CD8", "GENE_OR_GENE_PRODUCT", 8, 11], ["CNS", "ANATOMICAL_SYSTEM", 76, 79], ["patients", "ORGANISM", 86, 94], ["cells", "CELL", 128, 133], ["CD8 T-cell clones", "CELL_LINE", 8, 25], ["cognate antigen", "PROTEIN", 165, 180], ["patients", "SPECIES", 86, 94]]], ["PD-1 expression by infiltrating immune cells was evaluated in murine models of CNS disorders.", [["infiltrating immune cells", "ANATOMY", 19, 44], ["CNS", "ANATOMY", 79, 82], ["CNS disorders", "DISEASE", 79, 92], ["PD-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["infiltrating immune cells", "CELL", 19, 44], ["murine", "ORGANISM", 62, 68], ["CNS", "ANATOMICAL_SYSTEM", 79, 82], ["infiltrating immune cells", "CELL_TYPE", 19, 44], ["murine", "SPECIES", 62, 68], ["PD", "TREATMENT", 0, 2], ["infiltrating immune cells", "PROBLEM", 19, 44], ["CNS disorders", "PROBLEM", 79, 92], ["infiltrating immune cells", "OBSERVATION", 19, 44], ["CNS", "ANATOMY", 79, 82]]], ["Although in EAE, PD-1 was detected in brain and spinal cord (Salama et al., 2003) no quantification assessment was provided.", [["brain", "ANATOMY", 38, 43], ["spinal cord", "ANATOMY", 48, 59], ["EAE", "DISEASE", 12, 15], ["PD-1", "GENE_OR_GENE_PRODUCT", 17, 21], ["brain", "ORGAN", 38, 43], ["spinal cord", "ORGAN", 48, 59], ["PD", "TEST", 17, 19], ["quantification assessment", "TEST", 85, 110], ["brain", "ANATOMY", 38, 43], ["spinal cord", "ANATOMY", 48, 59]]], ["PD-1 knockout mice demonstrated a greater susceptibility to EAE than their wildtype counterparts (Wang et al., 2010) .", [["EAE", "DISEASE", 60, 63], ["PD-1", "GENE_OR_GENE_PRODUCT", 0, 4], ["mice", "ORGANISM", 14, 18], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["PD", "TEST", 0, 2]]], ["Moreover, in the absence of PD-1, an increased expansion of T lymphocytes in the CNS and an augmented disease severity were observed in transgenic mice overexpressing a myelin gene (Kroner et al., 2009a,b) .", [["T lymphocytes", "ANATOMY", 60, 73], ["CNS", "ANATOMY", 81, 84], ["PD-1", "GENE_OR_GENE_PRODUCT", 28, 32], ["T lymphocytes", "CELL", 60, 73], ["CNS", "ANATOMICAL_SYSTEM", 81, 84], ["mice", "ORGANISM", 147, 151], ["myelin", "GENE_OR_GENE_PRODUCT", 169, 175], ["T lymphocytes", "CELL_TYPE", 60, 73], ["myelin gene", "DNA", 169, 180], ["mice", "SPECIES", 147, 151], ["mice", "SPECIES", 147, 151], ["PD", "TEST", 28, 30], ["an increased expansion of T lymphocytes", "PROBLEM", 34, 73], ["the CNS", "PROBLEM", 77, 84], ["an augmented disease severity", "PROBLEM", 89, 118], ["increased", "OBSERVATION_MODIFIER", 37, 46], ["expansion", "OBSERVATION_MODIFIER", 47, 56], ["T lymphocytes", "OBSERVATION", 60, 73], ["CNS", "ANATOMY", 81, 84], ["augmented", "OBSERVATION_MODIFIER", 92, 101], ["disease", "OBSERVATION", 102, 109]]], ["These mouse models support the hypothesis that PD-1-negative T cells have an elevated capacity to proliferate in the CNS during an ongoing demyelinating disease.DISCUSSIONSeveral lines of evidence support the notion that PD-11 CD8 T lymphocytes are not intrinsically incompetent at migrating to the CNS or to other organ attacked by deleterious autoimmune responses.", [["PD-1-negative T cells", "ANATOMY", 47, 68], ["CNS", "ANATOMY", 117, 120], ["PD-11 CD8 T lymphocytes", "ANATOMY", 221, 244], ["CNS", "ANATOMY", 299, 302], ["organ", "ANATOMY", 315, 320], ["mouse", "ORGANISM", 6, 11], ["PD-1", "GENE_OR_GENE_PRODUCT", 47, 51], ["T cells", "CELL", 61, 68], ["CNS", "ANATOMICAL_SYSTEM", 117, 120], ["CD8", "GENE_OR_GENE_PRODUCT", 227, 230], ["CNS", "ANATOMICAL_SYSTEM", 299, 302], ["organ", "ORGAN", 315, 320], ["PD-1-negative T cells", "CELL_LINE", 47, 68], ["CD8 T lymphocytes", "CELL_TYPE", 227, 244], ["mouse", "SPECIES", 6, 11], ["mouse", "SPECIES", 6, 11], ["PD", "TEST", 47, 49], ["T cells", "PROBLEM", 61, 68], ["an elevated capacity", "PROBLEM", 74, 94], ["the CNS", "PROBLEM", 113, 120], ["an ongoing demyelinating disease.DISCUSSIONSeveral lines", "PROBLEM", 128, 184], ["PD", "TEST", 221, 223], ["CD8 T lymphocytes", "PROBLEM", 227, 244], ["intrinsically incompetent", "PROBLEM", 253, 278], ["deleterious autoimmune responses", "PROBLEM", 333, 365], ["elevated capacity", "OBSERVATION", 77, 94], ["CNS", "ANATOMY", 117, 120], ["demyelinating", "OBSERVATION_MODIFIER", 139, 152], ["incompetent", "OBSERVATION", 267, 278]]], ["A greater number of HIV-specific CD8 T cells were found to express PD-1 in the cerebrospinal fluid compared with their peripheral blood counterparts in HIV patients (Sadagopal et al., 2010) .", [["CD8 T cells", "ANATOMY", 33, 44], ["cerebrospinal fluid", "ANATOMY", 79, 98], ["peripheral blood", "ANATOMY", 119, 135], ["HIV", "ORGANISM", 20, 23], ["CD8 T cells", "CELL", 33, 44], ["PD-1", "GENE_OR_GENE_PRODUCT", 67, 71], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 79, 98], ["peripheral blood", "ORGANISM_SUBSTANCE", 119, 135], ["HIV", "ORGANISM", 152, 155], ["patients", "ORGANISM", 156, 164], ["CD8 T cells", "CELL_TYPE", 33, 44], ["PD-1", "PROTEIN", 67, 71], ["HIV", "SPECIES", 152, 155], ["patients", "SPECIES", 156, 164], ["HIV", "SPECIES", 20, 23], ["HIV", "SPECIES", 152, 155], ["HIV-specific CD8 T cells", "PROBLEM", 20, 44], ["PD", "TEST", 67, 69], ["the cerebrospinal fluid", "TEST", 75, 98], ["greater", "OBSERVATION_MODIFIER", 2, 9], ["cerebrospinal", "ANATOMY", 79, 92], ["fluid", "OBSERVATION", 93, 98]]], ["Analysis of most tissues from chronically infected mice with lymphochoriomeningitis virus illustrated that the brain contained the highest levels of PD-1 compared with other organs (Blackburn et al., 2010) .", [["tissues", "ANATOMY", 17, 24], ["brain", "ANATOMY", 111, 116], ["organs", "ANATOMY", 174, 180], ["tissues", "TISSUE", 17, 24], ["mice", "ORGANISM", 51, 55], ["lymphochoriomeningitis virus", "ORGANISM", 61, 89], ["brain", "ORGAN", 111, 116], ["PD-1", "GENE_OR_GENE_PRODUCT", 149, 153], ["organs", "ORGAN", 174, 180], ["mice", "SPECIES", 51, 55], ["mice", "SPECIES", 51, 55], ["lymphochoriomeningitis virus", "SPECIES", 61, 89], ["most tissues", "PROBLEM", 12, 24], ["chronically infected mice", "PROBLEM", 30, 55], ["lymphochoriomeningitis virus", "PROBLEM", 61, 89], ["PD", "TEST", 149, 151], ["most tissues", "OBSERVATION_MODIFIER", 12, 24], ["chronically", "OBSERVATION_MODIFIER", 30, 41], ["infected", "OBSERVATION", 42, 50], ["brain", "ANATOMY", 111, 116], ["highest", "OBSERVATION_MODIFIER", 131, 138], ["levels", "OBSERVATION_MODIFIER", 139, 145], ["organs", "ANATOMY", 174, 180]]], ["Similarly, analysis of mice infected with a neurotropic virus (strain JHM of mouse hepatitis virus) established that virus specific CD8 T cells in the CNS bore greater PD-1 levels compared with their peripheral counterparts (Phares et al., 2009 ).", [["CD8 T cells", "ANATOMY", 132, 143], ["CNS", "ANATOMY", 151, 154], ["hepatitis virus", "DISEASE", 83, 98], ["mice", "ORGANISM", 23, 27], ["neurotropic virus", "ORGANISM", 44, 61], ["strain JHM", "ORGANISM", 63, 73], ["mouse hepatitis virus", "ORGANISM", 77, 98], ["CD8 T cells", "CELL", 132, 143], ["CNS", "ANATOMICAL_SYSTEM", 151, 154], ["PD-1", "GENE_OR_GENE_PRODUCT", 168, 172], ["CD8 T cells", "CELL_TYPE", 132, 143], ["mice", "SPECIES", 23, 27], ["mouse", "SPECIES", 77, 82], ["hepatitis virus", "SPECIES", 83, 98], ["mice", "SPECIES", 23, 27], ["neurotropic virus", "SPECIES", 44, 61], ["mouse hepatitis virus", "SPECIES", 77, 98], ["mice infected", "PROBLEM", 23, 36], ["a neurotropic virus", "PROBLEM", 42, 61], ["mouse hepatitis virus", "PROBLEM", 77, 98], ["CNS", "ANATOMY", 151, 154]]], ["Raptopoulou et al. observed that T lymphocytes that have infiltrated the target organ (synovial tissue and fluid) of rheumatoid arthritis patients were enriched in PD-11 cells compared with healthy tissues (Raptopoulou et al., 2010) .", [["T lymphocytes", "ANATOMY", 33, 46], ["organ", "ANATOMY", 80, 85], ["synovial tissue", "ANATOMY", 87, 102], ["fluid", "ANATOMY", 107, 112], ["PD-11 cells", "ANATOMY", 164, 175], ["tissues", "ANATOMY", 198, 205], ["rheumatoid arthritis", "DISEASE", 117, 137], ["T lymphocytes", "CELL", 33, 46], ["organ", "ORGAN", 80, 85], ["synovial tissue", "TISSUE", 87, 102], ["fluid", "ORGANISM_SUBSTANCE", 107, 112], ["patients", "ORGANISM", 138, 146], ["PD-11 cells", "CELL", 164, 175], ["tissues", "TISSUE", 198, 205], ["T lymphocytes", "CELL_TYPE", 33, 46], ["PD-11 cells", "CELL_LINE", 164, 175], ["patients", "SPECIES", 138, 146], ["T lymphocytes", "PROBLEM", 33, 46], ["rheumatoid arthritis", "PROBLEM", 117, 137], ["lymphocytes", "ANATOMY", 35, 46], ["organ", "ANATOMY", 80, 85], ["synovial tissue", "OBSERVATION", 87, 102], ["fluid", "OBSERVATION_MODIFIER", 107, 112], ["rheumatoid", "OBSERVATION_MODIFIER", 117, 127], ["arthritis", "OBSERVATION", 128, 137], ["healthy tissues", "OBSERVATION_MODIFIER", 190, 205]]], ["Thus, PD-11 T lymphocytes could be detected in human CNS and other organs targeted by autoimmune diseases supporting the notion that our results demonstrating the absence of PD-1 on most infiltrating CD8 T lymphocytes in MS lesions is novel and unique.DISCUSSIONIn summary, our novel observations revealed the presence of PD-L1 on CNS cells in an inflamed environment in vitro and in MS lesions.", [["PD-11 T lymphocytes", "ANATOMY", 6, 25], ["CNS", "ANATOMY", 53, 56], ["organs", "ANATOMY", 67, 73], ["infiltrating CD8 T lymphocytes", "ANATOMY", 187, 217], ["MS lesions", "ANATOMY", 221, 231], ["CNS cells", "ANATOMY", 331, 340], ["MS lesions", "ANATOMY", 384, 394], ["autoimmune diseases", "DISEASE", 86, 105], ["PD-11 T lymphocytes", "CELL", 6, 25], ["human", "ORGANISM", 47, 52], ["CNS", "ANATOMICAL_SYSTEM", 53, 56], ["organs", "ORGAN", 67, 73], ["PD-1", "GENE_OR_GENE_PRODUCT", 174, 178], ["CD8 T lymphocytes", "CELL", 200, 217], ["MS lesions", "CANCER", 221, 231], ["PD-L1", "GENE_OR_GENE_PRODUCT", 322, 327], ["CNS cells", "CELL", 331, 340], ["MS lesions", "CANCER", 384, 394], ["T lymphocytes", "CELL_TYPE", 12, 25], ["infiltrating CD8 T lymphocytes", "CELL_TYPE", 187, 217], ["PD-L1", "DNA", 322, 327], ["CNS cells", "CELL_TYPE", 331, 340], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["PD", "TEST", 6, 8], ["autoimmune diseases", "PROBLEM", 86, 105], ["PD", "TEST", 174, 176], ["MS lesions", "PROBLEM", 221, 231], ["our novel observations", "TEST", 274, 296], ["PD-L1 on CNS cells", "PROBLEM", 322, 340], ["MS lesions", "PROBLEM", 384, 394], ["lesions", "OBSERVATION", 224, 231], ["L1", "ANATOMY", 325, 327], ["CNS cells", "ANATOMY", 331, 340], ["inflamed", "OBSERVATION", 347, 355], ["lesions", "OBSERVATION", 387, 394]]], ["We also demonstrate that this molecule has the capacity to modulate CD8 T-cell responses by dampening proliferation and cytokine production.", [["CD8 T-cell", "ANATOMY", 68, 78], ["CD8", "GENE_OR_GENE_PRODUCT", 68, 71], ["cytokine", "PROTEIN", 120, 128], ["the capacity", "PROBLEM", 43, 55], ["dampening proliferation", "PROBLEM", 92, 115], ["cytokine production", "PROBLEM", 120, 139], ["dampening", "OBSERVATION_MODIFIER", 92, 101], ["proliferation", "OBSERVATION_MODIFIER", 102, 115], ["cytokine production", "OBSERVATION", 120, 139]]], ["The local expression of PD-L1 by tissue cells has been shown to play a crucial role in inhibiting T-cell responses in different mouse models.", [["tissue cells", "ANATOMY", 33, 45], ["T-cell", "ANATOMY", 98, 104], ["PD-L1", "GENE_OR_GENE_PRODUCT", 24, 29], ["tissue cells", "CELL", 33, 45], ["T-cell", "CELL", 98, 104], ["mouse", "ORGANISM", 128, 133], ["PD-L1", "DNA", 24, 29], ["mouse", "SPECIES", 128, 133], ["mouse", "SPECIES", 128, 133], ["tissue cells", "PROBLEM", 33, 45], ["L1", "ANATOMY", 27, 29]]], ["Whilst PD-L1 expression by islet cells protects from detrimental autoimmune CD4 T cell attack in a diabetes model (Keir et al., 2006) , PD-L1 expression by nonhematogenous cells diminished viral clearance and organ immunopathology mediated by CD8 T lymphocytes in a chronic infection model (Mueller et al., 2010) .", [["islet cells", "ANATOMY", 27, 38], ["autoimmune CD4 T cell", "ANATOMY", 65, 86], ["nonhematogenous cells", "ANATOMY", 156, 177], ["organ", "ANATOMY", 209, 214], ["CD8 T lymphocytes", "ANATOMY", 243, 260], ["diabetes", "DISEASE", 99, 107], ["chronic infection", "DISEASE", 266, 283], ["PD-L1", "GENE_OR_GENE_PRODUCT", 7, 12], ["islet cells", "CELL", 27, 38], ["CD4 T cell", "CELL", 76, 86], ["PD-L1", "GENE_OR_GENE_PRODUCT", 136, 141], ["nonhematogenous cells", "CELL", 156, 177], ["organ", "ORGAN", 209, 214], ["CD8 T lymphocytes", "CELL", 243, 260], ["L1", "DNA", 10, 12], ["islet cells", "CELL_TYPE", 27, 38], ["nonhematogenous cells", "CELL_TYPE", 156, 177], ["CD8 T lymphocytes", "CELL_TYPE", 243, 260], ["detrimental autoimmune CD4 T cell attack", "PROBLEM", 53, 93], ["a diabetes model", "PROBLEM", 97, 113], ["PD", "TEST", 136, 138], ["nonhematogenous cells", "PROBLEM", 156, 177], ["diminished viral clearance", "PROBLEM", 178, 204], ["organ immunopathology", "PROBLEM", 209, 230], ["a chronic infection model", "PROBLEM", 264, 289], ["L1 expression", "OBSERVATION_MODIFIER", 10, 23], ["islet cells", "OBSERVATION", 27, 38], ["autoimmune CD4 T cell attack", "OBSERVATION", 65, 93], ["L1", "ANATOMY", 139, 141], ["viral clearance", "OBSERVATION", 189, 204], ["chronic", "OBSERVATION_MODIFIER", 266, 273], ["infection", "OBSERVATION", 274, 283]]], ["Thus, human CNS cells can achieve the same capacity of abrogating T-cell responses.", [["CNS cells", "ANATOMY", 12, 21], ["T-cell", "ANATOMY", 66, 72], ["human", "ORGANISM", 6, 11], ["CNS cells", "CELL", 12, 21], ["T-cell", "CELL", 66, 72], ["human CNS cells", "CELL_TYPE", 6, 21], ["human", "SPECIES", 6, 11], ["human", "SPECIES", 6, 11], ["human CNS cells", "TREATMENT", 6, 21]]], ["Finally, the lack of PD-1 on numerous infiltrating CD8 T cells suggests that these cells will not receive an inhibitory signal from the PD-L1 expressing CNS cells, astrocytes, or microglia/macrophages.", [["infiltrating CD8 T cells", "ANATOMY", 38, 62], ["cells", "ANATOMY", 83, 88], ["CNS cells", "ANATOMY", 153, 162], ["astrocytes", "ANATOMY", 164, 174], ["microglia", "ANATOMY", 179, 188], ["macrophages", "ANATOMY", 189, 200], ["PD-1", "GENE_OR_GENE_PRODUCT", 21, 25], ["CD8 T cells", "CELL", 51, 62], ["cells", "CELL", 83, 88], ["PD-L1", "GENE_OR_GENE_PRODUCT", 136, 141], ["CNS cells", "CELL", 153, 162], ["astrocytes", "CELL", 164, 174], ["microglia", "CELL", 179, 188], ["macrophages", "CELL", 189, 200], ["PD-1", "PROTEIN", 21, 25], ["infiltrating CD8 T cells", "CELL_TYPE", 38, 62], ["PD-L1 expressing CNS cells", "CELL_TYPE", 136, 162], ["astrocytes", "CELL_TYPE", 164, 174], ["microglia", "CELL_TYPE", 179, 188], ["macrophages", "CELL_TYPE", 189, 200], ["PD", "TEST", 21, 23], ["numerous infiltrating CD8 T cells", "PROBLEM", 29, 62], ["these cells", "PROBLEM", 77, 88], ["an inhibitory signal", "TEST", 106, 126], ["the PD", "TEST", 132, 138], ["astrocytes", "PROBLEM", 164, 174], ["microglia/macrophages", "PROBLEM", 179, 200], ["infiltrating", "OBSERVATION_MODIFIER", 38, 50], ["CD8 T cells", "OBSERVATION", 51, 62], ["L1", "ANATOMY", 139, 141], ["CNS cells", "ANATOMY", 153, 162], ["microglia", "ANATOMY", 179, 188]]], ["Strategies aimed at boosting PD-1 levels on activated autoreactive human T cells could be a new promising therapeutic approach since PD-L1 is already increased in the target organ.", [["T cells", "ANATOMY", 73, 80], ["organ", "ANATOMY", 174, 179], ["PD-1", "GENE_OR_GENE_PRODUCT", 29, 33], ["human", "ORGANISM", 67, 72], ["T cells", "CELL", 73, 80], ["PD-L1", "GENE_OR_GENE_PRODUCT", 133, 138], ["organ", "ORGAN", 174, 179], ["autoreactive human T cells", "CELL_TYPE", 54, 80], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 67, 72], ["PD", "TEST", 29, 31], ["activated autoreactive human T cells", "TREATMENT", 44, 80], ["PD-L1", "TREATMENT", 133, 138], ["L1", "ANATOMY", 136, 138], ["increased", "OBSERVATION", 150, 159]]]], "PMC7152297": [["Hepatitis A ::: Viral Infections of the Liver and Bile DuctHepatitis A virus (HAV) is an RNA virus in the Picornaviridae family.", [["Liver", "ANATOMY", 40, 45], ["Hepatitis", "DISEASE", 0, 9], ["Viral Infections", "DISEASE", 16, 32], ["Liver", "ORGAN", 40, 45], ["Bile DuctHepatitis A virus", "ORGANISM", 50, 76], ["HAV", "ORGANISM", 78, 81], ["DuctHepatitis A virus", "SPECIES", 55, 76], ["Bile DuctHepatitis A virus", "SPECIES", 50, 76], ["HAV", "SPECIES", 78, 81], ["Viral Infections of the Liver", "PROBLEM", 16, 45], ["Bile DuctHepatitis A virus (HAV", "PROBLEM", 50, 81], ["an RNA virus", "PROBLEM", 86, 98], ["Infections", "OBSERVATION", 22, 32], ["Liver", "ANATOMY", 40, 45], ["Bile", "ANATOMY", 50, 54], ["virus", "OBSERVATION", 71, 76], ["RNA virus", "OBSERVATION", 89, 98]]], ["Although the incidence of HAV infection has fallen dramatically since the introduction of vaccines, it still causes approximately 60,000 infections per year and occasionally causes dramatic outbreaks with fulminant hepatitis and death.1 Fecal-oral transmission is facilitated by extensive viral shedding in feces during the 3- to 6-week incubation period, which reaches a maximum just before the onset of hepatocellular injury.1 An increasing incidence has been noted among urban homosexual men.", [["oral", "ANATOMY", 243, 247], ["feces", "ANATOMY", 307, 312], ["hepatocellular", "ANATOMY", 405, 419], ["HAV infection", "DISEASE", 26, 39], ["infections", "DISEASE", 137, 147], ["hepatitis", "DISEASE", 215, 224], ["death", "DISEASE", 229, 234], ["hepatocellular injury", "DISEASE", 405, 426], ["HAV", "ORGANISM", 26, 29], ["oral", "ORGANISM_SUBDIVISION", 243, 247], ["feces", "ORGANISM_SUBSTANCE", 307, 312], ["hepatocellular", "ORGAN", 405, 419], ["men", "ORGANISM", 491, 494], ["men", "SPECIES", 491, 494], ["HAV", "SPECIES", 26, 29], ["HAV infection", "PROBLEM", 26, 39], ["vaccines", "TREATMENT", 90, 98], ["fulminant hepatitis", "PROBLEM", 205, 224], ["death", "PROBLEM", 229, 234], ["extensive viral shedding in feces", "PROBLEM", 279, 312], ["hepatocellular injury", "PROBLEM", 405, 426], ["HAV", "OBSERVATION_MODIFIER", 26, 29], ["infection", "OBSERVATION", 30, 39], ["fallen", "OBSERVATION_MODIFIER", 44, 50], ["dramatically", "OBSERVATION_MODIFIER", 51, 63], ["infections", "OBSERVATION", 137, 147], ["dramatic", "OBSERVATION_MODIFIER", 181, 189], ["outbreaks", "OBSERVATION_MODIFIER", 190, 199], ["fulminant", "OBSERVATION_MODIFIER", 205, 214], ["hepatitis", "OBSERVATION", 215, 224], ["Fecal", "ANATOMY", 237, 242], ["extensive", "OBSERVATION_MODIFIER", 279, 288], ["viral", "OBSERVATION_MODIFIER", 289, 294], ["shedding", "OBSERVATION", 295, 303], ["hepatocellular", "ANATOMY", 405, 419], ["injury", "OBSERVATION", 420, 426], ["increasing", "OBSERVATION_MODIFIER", 432, 442]]], ["An effective vaccine has been developed.Hepatitis A ::: Viral Infections of the Liver and Bile DuctThe signs and symptoms of hepatitis A are related to patient age.", [["Liver", "ANATOMY", 80, 85], ["Bile Duct", "ANATOMY", 90, 99], ["Hepatitis", "DISEASE", 40, 49], ["hepatitis A", "DISEASE", 125, 136], ["Liver", "ORGAN", 80, 85], ["Bile Duct", "MULTI-TISSUE_STRUCTURE", 90, 99], ["patient", "ORGANISM", 152, 159], ["patient", "SPECIES", 152, 159], ["hepatitis A", "SPECIES", 125, 136], ["An effective vaccine", "TREATMENT", 0, 20], ["Viral Infections of the Liver", "PROBLEM", 56, 85], ["Bile Duct", "PROBLEM", 90, 99], ["symptoms", "PROBLEM", 113, 121], ["hepatitis A", "PROBLEM", 125, 136], ["effective", "OBSERVATION_MODIFIER", 3, 12], ["vaccine", "OBSERVATION", 13, 20], ["Infections", "OBSERVATION", 62, 72], ["Liver", "ANATOMY", 80, 85], ["Bile Duct", "ANATOMY", 90, 99], ["signs", "OBSERVATION_MODIFIER", 103, 108], ["hepatitis", "OBSERVATION", 125, 134]]], ["In children younger than 3 years, more than 80% of infections are clinically silent, whereas in adolescents and adults, more than 75% of cases are symptomatic.2 Symptoms include fever, malaise, abdominal pain, and jaundice.", [["abdominal", "ANATOMY", 194, 203], ["infections", "DISEASE", 51, 61], ["fever", "DISEASE", 178, 183], ["abdominal pain", "DISEASE", 194, 208], ["jaundice", "DISEASE", 214, 222], ["children", "ORGANISM", 3, 11], ["abdominal", "ORGANISM_SUBDIVISION", 194, 203], ["children", "SPECIES", 3, 11], ["adolescents", "SPECIES", 96, 107], ["infections", "PROBLEM", 51, 61], ["symptomatic", "PROBLEM", 147, 158], ["Symptoms", "PROBLEM", 161, 169], ["fever", "PROBLEM", 178, 183], ["malaise", "PROBLEM", 185, 192], ["abdominal pain", "PROBLEM", 194, 208], ["jaundice", "PROBLEM", 214, 222], ["infections", "OBSERVATION", 51, 61], ["fever", "OBSERVATION", 178, 183], ["malaise", "OBSERVATION", 185, 192], ["abdominal", "ANATOMY", 194, 203], ["pain", "OBSERVATION", 204, 208], ["jaundice", "OBSERVATION", 214, 222]]], ["Marked transaminase elevations are characteristic.", [["transaminase", "SIMPLE_CHEMICAL", 7, 19], ["Marked transaminase elevations", "PROBLEM", 0, 30], ["transaminase elevations", "OBSERVATION", 7, 30]]], ["Approximately 100 cases of HAV-related fulminant liver failure are reported each year, predominantly in adults.2 Chronic infection does not occur.", [["liver", "ANATOMY", 49, 54], ["HAV", "DISEASE", 27, 30], ["fulminant liver failure", "DISEASE", 39, 62], ["Chronic infection", "DISEASE", 113, 130], ["HAV", "ORGANISM", 27, 30], ["liver", "ORGAN", 49, 54], ["HAV", "PROBLEM", 27, 30], ["fulminant liver failure", "PROBLEM", 39, 62], ["Chronic infection", "PROBLEM", 113, 130], ["fulminant", "OBSERVATION_MODIFIER", 39, 48], ["liver", "ANATOMY", 49, 54], ["failure", "OBSERVATION", 55, 62], ["predominantly", "OBSERVATION_MODIFIER", 87, 100], ["Chronic", "OBSERVATION_MODIFIER", 113, 120], ["infection", "OBSERVATION", 121, 130]]], ["However, HAV infection can precipitate autoimmune hepatitis, which can progress to chronic hepatitis with fibrosis or cirrhosis.3, 4, 5, 6", [["HAV infection", "DISEASE", 9, 22], ["autoimmune hepatitis", "DISEASE", 39, 59], ["hepatitis", "DISEASE", 91, 100], ["fibrosis", "DISEASE", 106, 114], ["cirrhosis", "DISEASE", 118, 127], ["3, 4, 5, 6", "CHEMICAL", 128, 138], ["HAV", "ORGANISM", 9, 12], ["HAV", "SPECIES", 9, 12], ["HAV infection", "PROBLEM", 9, 22], ["autoimmune hepatitis", "PROBLEM", 39, 59], ["chronic hepatitis", "PROBLEM", 83, 100], ["fibrosis", "PROBLEM", 106, 114], ["cirrhosis", "PROBLEM", 118, 127], ["infection", "OBSERVATION", 13, 22], ["autoimmune hepatitis", "OBSERVATION", 39, 59], ["chronic", "OBSERVATION_MODIFIER", 83, 90], ["hepatitis", "OBSERVATION", 91, 100], ["fibrosis", "OBSERVATION", 106, 114], ["cirrhosis", "OBSERVATION", 118, 127]]]], "260a4a6c86be9a90a06b3c6505ac78951ea16045": [["IntroductionThe number of patients presenting to the Emergency Department (ED) with meticillin-resistant Staphylococcus aureus (MRSA) infection is increasing [1] , but few studies focus on patients with bacteraemia [2] [3] [4] [5] .", [["meticillin-resistant", "CHEMICAL", 84, 104], ["Staphylococcus aureus (MRSA) infection", "DISEASE", 105, 143], ["bacteraemia", "DISEASE", 203, 214], ["meticillin", "CHEMICAL", 84, 94], ["patients", "ORGANISM", 26, 34], ["meticillin-resistant Staphylococcus aureus", "ORGANISM", 84, 126], ["MRSA", "CANCER", 128, 132], ["patients", "ORGANISM", 189, 197], ["[2] [3] [4] [5]", "SIMPLE_CHEMICAL", 215, 230], ["patients", "SPECIES", 26, 34], ["Staphylococcus aureus", "SPECIES", 105, 126], ["MRSA", "SPECIES", 128, 132], ["patients", "SPECIES", 189, 197], ["Staphylococcus aureus", "SPECIES", 105, 126], ["MRSA", "SPECIES", 128, 132], ["meticillin-resistant Staphylococcus aureus", "PROBLEM", 84, 126], ["MRSA) infection", "PROBLEM", 128, 143], ["bacteraemia", "PROBLEM", 203, 214], ["Staphylococcus aureus", "OBSERVATION", 105, 126]]], ["In Taiwan, the prevalence of MRSA amongst nosocomial staphylococcal infections was ca.", [["MRSA", "DISEASE", 29, 33], ["nosocomial staphylococcal infections", "DISEASE", 42, 78], ["MRSA", "SPECIES", 29, 33], ["MRSA", "SPECIES", 29, 33], ["MRSA", "PROBLEM", 29, 33], ["nosocomial staphylococcal infections", "PROBLEM", 42, 78], ["ca", "PROBLEM", 83, 85], ["MRSA", "OBSERVATION", 29, 33], ["staphylococcal", "OBSERVATION_MODIFIER", 53, 67], ["infections", "OBSERVATION", 68, 78]]], ["60% [6] , and MRSA is an emerging community-acquired pathogen [7] .", [["MRSA", "DISEASE", 14, 18], ["MRSA", "SPECIES", 14, 18], ["MRSA", "PROBLEM", 14, 18], ["MRSA", "OBSERVATION", 14, 18]]], ["In our previous study of patients at the ED with MRSA bacteraemia, patients with true community MRSA bacteraemia were rarely seen [5] ; however, in recent years the number of these patients has been increasing at our hospital [8] .", [["MRSA bacteraemia", "DISEASE", 49, 65], ["MRSA bacteraemia", "DISEASE", 96, 112], ["patients", "ORGANISM", 25, 33], ["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 181, 189], ["patients", "SPECIES", 25, 33], ["MRSA", "SPECIES", 49, 53], ["patients", "SPECIES", 67, 75], ["MRSA", "SPECIES", 96, 100], ["patients", "SPECIES", 181, 189], ["MRSA", "SPECIES", 49, 53], ["MRSA bacteraemia", "PROBLEM", 49, 65], ["true community MRSA bacteraemia", "PROBLEM", 81, 112], ["bacteraemia", "OBSERVATION", 54, 65], ["MRSA bacteraemia", "OBSERVATION", 96, 112], ["increasing", "OBSERVATION_MODIFIER", 199, 209]]], ["Concern about MRSA bacteraemia is due to its poor response to glycopeptide treat-ment [9, 10] , and many factors are reported to be closely associated with poor response, including severity of illness [10] , type of infection [11] , persistence of bacteraemia [12] and, notably, increased minimum inhibitory concentrations (MICs) of MRSA isolates [13, 14] .IntroductionMany patients with MRSA bacteraemia have complex underlying illnesses and develop bacteraemia during prolonged hospital stay.", [["bacteraemia", "DISEASE", 19, 30], ["illness", "DISEASE", 193, 200], ["infection", "DISEASE", 216, 225], ["bacteraemia", "DISEASE", 248, 259], ["MRSA bacteraemia", "DISEASE", 388, 404], ["bacteraemia", "DISEASE", 451, 462], ["MRSA", "CANCER", 14, 18], ["patients", "ORGANISM", 374, 382], ["MRSA", "SPECIES", 14, 18], ["MRSA", "SPECIES", 333, 337], ["patients", "SPECIES", 374, 382], ["MRSA", "SPECIES", 388, 392], ["MRSA", "SPECIES", 14, 18], ["MRSA bacteraemia", "PROBLEM", 14, 30], ["glycopeptide treat", "TREATMENT", 62, 80], ["illness", "PROBLEM", 193, 200], ["infection", "PROBLEM", 216, 225], ["bacteraemia", "PROBLEM", 248, 259], ["increased minimum inhibitory concentrations", "PROBLEM", 279, 322], ["MRSA isolates", "PROBLEM", 333, 346], ["MRSA bacteraemia", "PROBLEM", 388, 404], ["complex underlying illnesses", "PROBLEM", 410, 438], ["bacteraemia", "PROBLEM", 451, 462], ["MRSA bacteraemia", "OBSERVATION", 14, 30], ["infection", "OBSERVATION", 216, 225], ["bacteraemia", "OBSERVATION", 248, 259], ["bacteraemia", "OBSERVATION", 451, 462]]], ["Thus, we are interested in the outcome of patients with MRSA bacteraemia treated at the ED.", [["bacteraemia", "DISEASE", 61, 72], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["MRSA", "SPECIES", 56, 60], ["MRSA", "SPECIES", 56, 60], ["MRSA bacteraemia", "PROBLEM", 56, 72]]], ["Despite some studies suggesting that blood cultures ordered in the adult ED are rarely clinically useful [15, 16] , MRSA bacteraemia detected at the ED would usually change the antimicrobial agent at our hospital, where empirical glycopeptide use is not recommended [17] .", [["blood cultures", "ANATOMY", 37, 51], ["bacteraemia", "DISEASE", 121, 132], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["MRSA", "ORGANISM", 116, 120], ["MRSA", "SPECIES", 116, 120], ["MRSA", "SPECIES", 116, 120], ["some studies", "TEST", 8, 20], ["blood cultures", "TEST", 37, 51], ["MRSA bacteraemia", "PROBLEM", 116, 132], ["the antimicrobial agent", "TREATMENT", 173, 196], ["empirical glycopeptide", "TREATMENT", 220, 242]]], ["Moreover, bacteraemia recovered at the ED is usually less complicated compared with nosocomial bacteraemia [18] .", [["bacteraemia", "DISEASE", 10, 21], ["nosocomial bacteraemia", "DISEASE", 84, 106], ["bacteraemia", "PROBLEM", 10, 21], ["nosocomial bacteraemia", "PROBLEM", 84, 106], ["bacteraemia", "OBSERVATION", 10, 21]]], ["However, these patients might not receive complete examinations if rapid mortality occurs.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["complete examinations", "TEST", 42, 63], ["rapid mortality", "PROBLEM", 67, 82]]], ["With increasing MRSA bacteraemia aris-ing from the community [4, 8] , we describe the results of our observational study of MRSA bacteraemia at a university hospital ED, focusing on the risk factors for poor patient outcome.Hospital setting and patient selectionNational Taiwan University Hospital (NTUH) is a 2200bed, academically affiliated medical centre providing both primary and tertiary care in northern Taiwan.", [["bacteraemia", "DISEASE", 21, 32], ["bacteraemia", "DISEASE", 129, 140], ["patient", "ORGANISM", 208, 215], ["patient", "ORGANISM", 245, 252], ["MRSA", "SPECIES", 16, 20], ["MRSA", "SPECIES", 124, 128], ["patient", "SPECIES", 208, 215], ["patient", "SPECIES", 245, 252], ["MRSA", "SPECIES", 124, 128], ["increasing MRSA bacteraemia aris", "PROBLEM", 5, 37], ["our observational study", "TEST", 97, 120], ["MRSA bacteraemia", "PROBLEM", 124, 140], ["poor patient outcome", "PROBLEM", 203, 223], ["increasing", "OBSERVATION_MODIFIER", 5, 15], ["MRSA", "OBSERVATION_MODIFIER", 16, 20], ["bacteraemia", "OBSERVATION", 21, 32], ["MRSA bacteraemia", "OBSERVATION", 124, 140]]], ["From January 2001 to May 2002 a prospective study was initiated for all patients aged >16 years with positive S. aureus blood cultures within 48 h of arrival at the ED.", [["blood", "ANATOMY", 120, 125], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["S. aureus", "SPECIES", 110, 119], ["S. aureus", "SPECIES", 110, 119], ["a prospective study", "TEST", 30, 49], ["positive S. aureus blood cultures", "PROBLEM", 101, 134]]], ["The study was discontinued due to the epidemic of severe acute respiratory syndrome and was re-started in July 2004.", [["acute respiratory syndrome", "DISEASE", 57, 83], ["The study", "TEST", 0, 9], ["severe acute respiratory syndrome", "PROBLEM", 50, 83], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory syndrome", "OBSERVATION", 63, 83]]], ["All patients were evaluated using a structured recording form.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12]]], ["To complete the whole picture of MRSA bacteraemia at NTUH ED, data from patients with MRSA bacteraemia were retrospectively collected with the same form from June 2002 to June 2004.", [["bacteraemia", "DISEASE", 38, 49], ["MRSA bacteraemia", "DISEASE", 86, 102], ["patients", "ORGANISM", 72, 80], ["MRSA", "SPECIES", 33, 37], ["patients", "SPECIES", 72, 80], ["MRSA", "SPECIES", 86, 90], ["MRSA", "SPECIES", 33, 37], ["MRSA", "SPECIES", 86, 90], ["MRSA bacteraemia", "PROBLEM", 33, 49], ["MRSA bacteraemia", "PROBLEM", 86, 102], ["MRSA bacteraemia", "OBSERVATION", 33, 49]]], ["Thus, all patients with MRSA bacteraemia presenting to the ED from January 2001 to June 2006 were incorporated in this study.Hospital setting and patient selectionPatients who had been hospitalised for >48 h or discharged from any hospital within 48 h were considered to have nosocomial bacteraemia [5] .", [["MRSA bacteraemia", "DISEASE", 24, 40], ["bacteraemia", "DISEASE", 287, 298], ["patients", "ORGANISM", 10, 18], ["patient", "ORGANISM", 146, 153], ["Patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 10, 18], ["MRSA", "SPECIES", 24, 28], ["patient", "SPECIES", 146, 153], ["Patients", "SPECIES", 163, 171], ["MRSA bacteraemia", "PROBLEM", 24, 40], ["this study", "TEST", 114, 124], ["nosocomial bacteraemia", "PROBLEM", 276, 298], ["MRSA", "OBSERVATION_MODIFIER", 24, 28], ["bacteraemia", "OBSERVATION", 29, 40], ["bacteraemia", "OBSERVATION", 287, 298]]], ["Healthcare-associated bacteraemia included bacteraemia related to receiving haemodialysis, chemotherapy or parenteral nutrition on an outpatient basis, nursing home stay, recent surgery or prior hospitalisation within 1 year [5] .", [["bacteraemia", "DISEASE", 22, 33], ["bacteraemia", "DISEASE", 43, 54], ["bacteraemia", "PROBLEM", 22, 33], ["bacteraemia", "PROBLEM", 43, 54], ["haemodialysis", "TREATMENT", 76, 89], ["chemotherapy", "TREATMENT", 91, 103], ["parenteral nutrition", "TREATMENT", 107, 127], ["recent surgery", "TREATMENT", 171, 185], ["bacteraemia", "OBSERVATION", 22, 33], ["bacteraemia", "OBSERVATION", 43, 54]]], ["Bacteraemia in patients without any of the risk exposures mentioned above was defined as community acquired.Data collectionThe clinical courses and primary sites of bacteraemia were evaluated according to the information supplied by primary care physicians and medical records.", [["primary sites", "ANATOMY", 148, 161], ["Bacteraemia", "DISEASE", 0, 11], ["bacteraemia", "DISEASE", 165, 176], ["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["Bacteraemia", "PROBLEM", 0, 11], ["Data collection", "TEST", 108, 123], ["bacteraemia", "PROBLEM", 165, 176], ["bacteraemia", "OBSERVATION", 165, 176]]], ["Diagnosis of the infection focus of bacteraemia was based on clinical, bacteriological and radiological investigations.", [["infection", "DISEASE", 17, 26], ["bacteraemia", "DISEASE", 36, 47], ["the infection", "PROBLEM", 13, 26], ["bacteraemia", "PROBLEM", 36, 47], ["radiological investigations", "TEST", 91, 118], ["infection", "OBSERVATION", 17, 26], ["bacteraemia", "OBSERVATION", 36, 47]]], ["Infective endocarditis (IE) was defined by modified Duke's criteria [19] ; catheter-related bacteraemia (CRBSI) was defined as a positive semiquantitative tip culture (\u226515 colony-forming units) and/or high clinical suspicion, although differential time to positivity was not applied owing to time to positivity not being routinely recorded; pneumonia was defined as a positive culture for MRSA in purulent sputum samples and the presence of newly developed lung infiltrates; urinary tract infection (UTI) was defined as a positive urine culture and pyuria; orthopaedic infections included osteomyelitis documented by pathology or imaging study with compatible clinical findings, prosthetic joint infection or septic arthritis and/or positive microbiological results obtained according to current suggestions [20] ; and soft tissue infection (STI) was defined as clinical soft tissue inflammation plus bacteraemia.", [["colony", "ANATOMY", 172, 178], ["purulent sputum samples", "ANATOMY", 397, 420], ["lung infiltrates", "ANATOMY", 457, 473], ["urinary tract", "ANATOMY", 475, 488], ["urine", "ANATOMY", 531, 536], ["joint", "ANATOMY", 690, 695], ["soft tissue", "ANATOMY", 819, 830], ["soft tissue", "ANATOMY", 871, 882], ["Infective endocarditis", "DISEASE", 0, 22], ["IE", "DISEASE", 24, 26], ["bacteraemia", "DISEASE", 92, 103], ["CRBSI", "DISEASE", 105, 110], ["pneumonia", "DISEASE", 341, 350], ["MRSA", "DISEASE", 389, 393], ["lung infiltrates", "DISEASE", 457, 473], ["urinary tract infection", "DISEASE", 475, 498], ["UTI", "DISEASE", 500, 503], ["pyuria", "DISEASE", 549, 555], ["infections", "DISEASE", 569, 579], ["osteomyelitis", "DISEASE", 589, 602], ["prosthetic joint infection", "DISEASE", 679, 705], ["septic arthritis", "DISEASE", 709, 725], ["soft tissue infection", "DISEASE", 819, 840], ["STI", "DISEASE", 842, 845], ["inflammation", "DISEASE", 883, 895], ["bacteraemia", "DISEASE", 901, 912], ["lung infiltrates", "PATHOLOGICAL_FORMATION", 457, 473], ["urinary tract", "ORGANISM_SUBDIVISION", 475, 488], ["urine", "ORGANISM_SUBSTANCE", 531, 536], ["joint", "MULTI-TISSUE_STRUCTURE", 690, 695], ["soft tissue", "TISSUE", 819, 830], ["tissue", "TISSUE", 876, 882], ["MRSA", "SPECIES", 389, 393], ["MRSA", "SPECIES", 389, 393], ["Infective endocarditis", "PROBLEM", 0, 22], ["catheter", "TREATMENT", 75, 83], ["bacteraemia", "PROBLEM", 92, 103], ["CRBSI", "TEST", 105, 110], ["a positive semiquantitative tip culture", "PROBLEM", 127, 166], ["high clinical suspicion", "PROBLEM", 201, 224], ["pneumonia", "PROBLEM", 341, 350], ["a positive culture", "TEST", 366, 384], ["MRSA", "PROBLEM", 389, 393], ["purulent sputum samples", "PROBLEM", 397, 420], ["newly developed lung infiltrates", "PROBLEM", 441, 473], ["urinary tract infection", "PROBLEM", 475, 498], ["UTI", "PROBLEM", 500, 503], ["a positive urine culture", "PROBLEM", 520, 544], ["pyuria", "PROBLEM", 549, 555], ["orthopaedic infections", "PROBLEM", 557, 579], ["osteomyelitis", "PROBLEM", 589, 602], ["imaging study", "TEST", 630, 643], ["prosthetic joint infection", "PROBLEM", 679, 705], ["septic arthritis", "PROBLEM", 709, 725], ["positive microbiological results", "PROBLEM", 733, 765], ["soft tissue infection", "PROBLEM", 819, 840], ["clinical soft tissue inflammation", "PROBLEM", 862, 895], ["bacteraemia", "PROBLEM", 901, 912], ["endocarditis", "OBSERVATION", 10, 22], ["bacteraemia", "OBSERVATION", 92, 103], ["pneumonia", "OBSERVATION", 341, 350], ["lung", "ANATOMY", 457, 461], ["infiltrates", "OBSERVATION", 462, 473], ["urinary tract", "ANATOMY", 475, 488], ["infection", "OBSERVATION", 489, 498], ["UTI", "OBSERVATION", 500, 503], ["osteomyelitis", "OBSERVATION", 589, 602], ["prosthetic", "OBSERVATION_MODIFIER", 679, 689], ["joint", "ANATOMY", 690, 695], ["infection", "OBSERVATION", 696, 705], ["septic", "OBSERVATION_MODIFIER", 709, 715], ["arthritis", "OBSERVATION", 716, 725], ["soft tissue", "OBSERVATION_MODIFIER", 819, 830], ["infection", "OBSERVATION", 831, 840], ["soft tissue", "OBSERVATION_MODIFIER", 871, 882], ["inflammation", "OBSERVATION", 883, 895], ["bacteraemia", "OBSERVATION", 901, 912]]], ["If no primary focus could be identified, the bacteraemia was classified as primary.Data collectionThe following data were recorded for each patient: age; sex; underlying illness; severity of illness classified by McCabe-Jackson criteria [21] ; severity of bacteraemia assessed by the Pitt bacteraemia score [22] ; septic shock [22] ; persistent bacteraemia (defined as positive blood culture after 5 days of glycopeptide treatment); installation of foreign body, including prosthetic joint, pacemaker or intravenous/Foley catheter; debridement, including catheter/foreign body removal or surgical debridement of infected tissue; and metastatic infection, which included documented MRSA infection remote from the original site.", [["blood", "ANATOMY", 378, 383], ["body", "ANATOMY", 457, 461], ["joint", "ANATOMY", 484, 489], ["intravenous", "ANATOMY", 504, 515], ["body", "ANATOMY", 572, 576], ["tissue", "ANATOMY", 621, 627], ["bacteraemia", "DISEASE", 45, 56], ["illness", "DISEASE", 191, 198], ["bacteraemia", "DISEASE", 256, 267], ["bacteraemia", "DISEASE", 289, 300], ["septic shock", "DISEASE", 314, 326], ["bacteraemia", "DISEASE", 345, 356], ["infection", "DISEASE", 644, 653], ["MRSA infection", "DISEASE", 681, 695], ["patient", "ORGANISM", 140, 147], ["blood", "ORGANISM_SUBSTANCE", 378, 383], ["body", "ORGANISM_SUBDIVISION", 457, 461], ["joint", "MULTI-TISSUE_STRUCTURE", 484, 489], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 504, 515], ["tissue", "TISSUE", 621, 627], ["patient", "SPECIES", 140, 147], ["MRSA", "SPECIES", 681, 685], ["MRSA", "SPECIES", 681, 685], ["the bacteraemia", "PROBLEM", 41, 56], ["Data collection", "TEST", 83, 98], ["underlying illness", "PROBLEM", 159, 177], ["illness", "PROBLEM", 191, 198], ["bacteraemia", "PROBLEM", 256, 267], ["the Pitt bacteraemia score", "TEST", 280, 306], ["septic shock", "PROBLEM", 314, 326], ["persistent bacteraemia", "PROBLEM", 334, 356], ["blood culture", "TEST", 378, 391], ["glycopeptide treatment", "TREATMENT", 408, 430], ["foreign body", "PROBLEM", 449, 461], ["prosthetic joint", "TREATMENT", 473, 489], ["pacemaker", "TREATMENT", 491, 500], ["intravenous/Foley catheter", "TREATMENT", 504, 530], ["debridement", "TREATMENT", 532, 543], ["catheter", "TREATMENT", 555, 563], ["foreign body removal", "TREATMENT", 564, 584], ["surgical debridement", "TREATMENT", 588, 608], ["infected tissue", "PROBLEM", 612, 627], ["metastatic infection", "PROBLEM", 633, 653], ["MRSA infection", "PROBLEM", 681, 695], ["bacteraemia", "OBSERVATION", 45, 56], ["bacteraemia", "OBSERVATION", 256, 267], ["persistent", "OBSERVATION_MODIFIER", 334, 344], ["bacteraemia", "OBSERVATION", 345, 356], ["foreign body", "OBSERVATION", 449, 461], ["prosthetic joint", "OBSERVATION", 473, 489], ["pacemaker", "ANATOMY", 491, 500], ["Foley catheter", "OBSERVATION", 516, 530], ["debridement", "OBSERVATION", 532, 543], ["catheter", "OBSERVATION", 555, 563], ["surgical debridement", "OBSERVATION", 588, 608], ["infected tissue", "OBSERVATION", 612, 627], ["metastatic", "OBSERVATION_MODIFIER", 633, 643], ["infection", "OBSERVATION", 644, 653], ["MRSA", "OBSERVATION_MODIFIER", 681, 685], ["infection", "OBSERVATION", 686, 695]]], ["Inactive malignancy was not included in the underlying illnesses.", [["malignancy", "DISEASE", 9, 19], ["malignancy", "CANCER", 9, 19], ["Inactive malignancy", "PROBLEM", 0, 19], ["the underlying illnesses", "PROBLEM", 40, 64], ["malignancy", "OBSERVATION", 9, 19], ["illnesses", "OBSERVATION", 55, 64]]], ["For patients not admitted to NTUH, telephone contact was performed to collect the required information.Data collectionUse of glycopeptides prior to knowledge of the blood culture results was defined as empirical therapy.", [["blood culture", "ANATOMY", 165, 178], ["patients", "ORGANISM", 4, 12], ["blood", "ORGANISM_SUBSTANCE", 165, 170], ["patients", "SPECIES", 4, 12], ["Data collection", "TEST", 103, 118], ["glycopeptides", "TREATMENT", 125, 138], ["the blood culture", "TEST", 161, 178], ["empirical therapy", "TREATMENT", 202, 219]]], ["Glycopeptide use (either vancomycin or teicoplanin) is the suggested regimen to treat MRSA infection at our institute, and linezolid is under the control of infectious disease physicians.", [["Glycopeptide", "CHEMICAL", 0, 12], ["vancomycin", "CHEMICAL", 25, 35], ["teicoplanin", "CHEMICAL", 39, 50], ["MRSA infection", "DISEASE", 86, 100], ["linezolid", "CHEMICAL", 123, 132], ["infectious disease", "DISEASE", 157, 175], ["Glycopeptide", "CHEMICAL", 0, 12], ["vancomycin", "CHEMICAL", 25, 35], ["teicoplanin", "CHEMICAL", 39, 50], ["linezolid", "CHEMICAL", 123, 132], ["Glycopeptide", "SIMPLE_CHEMICAL", 0, 12], ["vancomycin", "SIMPLE_CHEMICAL", 25, 35], ["teicoplanin", "SIMPLE_CHEMICAL", 39, 50], ["linezolid", "SIMPLE_CHEMICAL", 123, 132], ["MRSA", "SPECIES", 86, 90], ["MRSA", "SPECIES", 86, 90], ["Glycopeptide use", "TREATMENT", 0, 16], ["vancomycin", "TREATMENT", 25, 35], ["teicoplanin", "TREATMENT", 39, 50], ["MRSA infection", "PROBLEM", 86, 100], ["linezolid", "TREATMENT", 123, 132]]], ["In addition, early initiation of empirical glycopeptide treatment is not encouraged at our institute [17] .", [["empirical glycopeptide treatment", "TREATMENT", 33, 65]]], ["Adjustment of vancomycin dosage to achieve a trough level >10 g/mL is suggested and is monitored by clinical pharmacists.Data collectionSeveral endpoints were used to evaluate the outcome of patients, including in-hospital mortality, 14-day mortality, and mortality excluding patients who died within 3 days, patients with McCabe rapidly fatal disease or patients with mortality not related to MRSA bacteraemia.Microbiology and antimicrobial susceptibilityBlood culture specimens were inoculated into BACTEC or BACTEC PLUS culture bottles using the BACTEC 9000 system (Becton Dickinson, Sparks, MA).", [["Blood culture specimens", "ANATOMY", 456, 479], ["vancomycin", "CHEMICAL", 14, 24], ["bacteraemia", "DISEASE", 399, 410], ["vancomycin", "CHEMICAL", 14, 24], ["vancomycin", "SIMPLE_CHEMICAL", 14, 24], ["patients", "ORGANISM", 191, 199], ["patients", "ORGANISM", 276, 284], ["patients", "ORGANISM", 309, 317], ["patients", "ORGANISM", 355, 363], ["Blood culture specimens", "ORGANISM_SUBSTANCE", 456, 479], ["patients", "SPECIES", 191, 199], ["patients", "SPECIES", 276, 284], ["patients", "SPECIES", 309, 317], ["patients", "SPECIES", 355, 363], ["MRSA", "SPECIES", 394, 398], ["vancomycin dosage", "TREATMENT", 14, 31], ["a trough level", "TEST", 43, 57], ["Data collection", "TEST", 121, 136], ["McCabe rapidly fatal disease", "PROBLEM", 323, 351], ["MRSA bacteraemia", "PROBLEM", 394, 410], ["Microbiology", "TEST", 411, 423], ["antimicrobial susceptibility", "TEST", 428, 456], ["Blood culture specimens", "TEST", 456, 479], ["BACTEC", "TEST", 501, 507], ["MRSA", "OBSERVATION_MODIFIER", 394, 398], ["bacteraemia", "OBSERVATION", 399, 410], ["antimicrobial susceptibility", "OBSERVATION", 428, 456]]], ["Identification of S. aureus was based on the morphology of colonies grown on trypticase soy agar supplemented with sheep blood (BBL Microbiology Systems, Cockeysville, MD), results of Gram staining and a positive slide or tube coagulase test.", [["colonies", "ANATOMY", 59, 67], ["blood", "ANATOMY", 121, 126], ["S. aureus", "ORGANISM", 18, 27], ["sheep", "ORGANISM", 115, 120], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["S. aureus", "SPECIES", 18, 27], ["sheep", "SPECIES", 115, 120], ["S. aureus", "SPECIES", 18, 27], ["sheep", "SPECIES", 115, 120], ["S. aureus", "PROBLEM", 18, 27], ["sheep blood", "TEST", 115, 126], ["Gram staining", "TEST", 184, 197], ["tube coagulase test", "TEST", 222, 241], ["aureus", "OBSERVATION", 21, 27]]], ["Susceptibilities to antimicrobial agents were determined by the standard disk diffusion method [23] .", [["antimicrobial agents", "TREATMENT", 20, 40], ["the standard disk diffusion method", "TEST", 60, 94]]], ["Since 2006, a 30 g cefoxitin disk (BBL Microbiology Systems) was applied to detect MRSA [24] .", [["cefoxitin", "CHEMICAL", 19, 28], ["cefoxitin", "CHEMICAL", 19, 28], ["cefoxitin", "SIMPLE_CHEMICAL", 19, 28], ["MRSA", "SPECIES", 83, 87], ["MRSA", "SPECIES", 83, 87], ["a 30 g cefoxitin disk", "TREATMENT", 12, 33], ["MRSA", "PROBLEM", 83, 87]]], ["Clinical isolates of MRSA were collected and stored at \u221270 \u2022 C in trypticase soy broth (Difco Laboratories, Detroit, MI) supplemented with 15% glycerol.", [["glycerol", "CHEMICAL", 143, 151], ["glycerol", "CHEMICAL", 143, 151], ["MRSA", "CANCER", 21, 25], ["glycerol", "SIMPLE_CHEMICAL", 143, 151], ["MRSA", "SPECIES", 21, 25], ["MRSA", "SPECIES", 21, 25], ["MRSA", "PROBLEM", 21, 25], ["15% glycerol", "TREATMENT", 139, 151], ["MRSA", "OBSERVATION", 21, 25]]], ["The MICs of vancomycin, teicoplanin, linezolid and daptomycin were further determined by the broth microdilution method for all MRSA isolates [25, 26] .Statistical analysisSeveral endpoints of patient outcome were used to evaluate the factors related to poor prognosis amongst patients with MRSA bacteraemia recovered at the ED.", [["vancomycin", "CHEMICAL", 12, 22], ["teicoplanin", "CHEMICAL", 24, 35], ["linezolid", "CHEMICAL", 37, 46], ["daptomycin", "CHEMICAL", 51, 61], ["bacteraemia", "DISEASE", 296, 307], ["vancomycin", "CHEMICAL", 12, 22], ["teicoplanin", "CHEMICAL", 24, 35], ["linezolid", "CHEMICAL", 37, 46], ["daptomycin", "CHEMICAL", 51, 61], ["vancomycin", "SIMPLE_CHEMICAL", 12, 22], ["teicoplanin", "SIMPLE_CHEMICAL", 24, 35], ["linezolid", "SIMPLE_CHEMICAL", 37, 46], ["daptomycin", "SIMPLE_CHEMICAL", 51, 61], ["patient", "ORGANISM", 193, 200], ["patients", "ORGANISM", 277, 285], ["MRSA", "SPECIES", 128, 132], ["patient", "SPECIES", 193, 200], ["patients", "SPECIES", 277, 285], ["MRSA", "SPECIES", 291, 295], ["MRSA", "SPECIES", 128, 132], ["MRSA", "SPECIES", 291, 295], ["vancomycin", "TREATMENT", 12, 22], ["teicoplanin", "TREATMENT", 24, 35], ["linezolid", "TREATMENT", 37, 46], ["daptomycin", "TREATMENT", 51, 61], ["the broth microdilution method", "TREATMENT", 89, 119], ["all MRSA isolates", "TEST", 124, 141], ["MRSA bacteraemia", "PROBLEM", 291, 307]]], ["The mean andResultsFrom January 2001 to June 2006 a total of 177 patients presenting to NTUH ED with MRSA bacteraemia were included.", [["MRSA bacteraemia", "DISEASE", 101, 117], ["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73], ["MRSA", "SPECIES", 101, 105], ["MRSA bacteraemia", "PROBLEM", 101, 117], ["MRSA bacteraemia", "OBSERVATION", 101, 117]]], ["The clinical characteristics of the patients are summarised in CRBSI was the most common type of infection (22.6%), followed by STI (20.9%), primary bacteraemia (15.3%), lower respiratory tract infection (13.6%), orthopaedic infection (9.0%), IE (6.8%), UTI (5.6%), endovascular infection other than IE (5.1%) and biliary infection (1.1%).", [["lower respiratory tract", "ANATOMY", 170, 193], ["biliary", "ANATOMY", 314, 321], ["CRBSI", "DISEASE", 63, 68], ["infection", "DISEASE", 97, 106], ["STI", "DISEASE", 128, 131], ["primary bacteraemia", "DISEASE", 141, 160], ["lower respiratory tract infection", "DISEASE", 170, 203], ["orthopaedic infection", "DISEASE", 213, 234], ["IE", "DISEASE", 243, 245], ["UTI", "DISEASE", 254, 257], ["endovascular infection", "DISEASE", 266, 288], ["IE", "DISEASE", 300, 302], ["biliary infection", "DISEASE", 314, 331], ["patients", "ORGANISM", 36, 44], ["tract", "ORGANISM_SUBDIVISION", 188, 193], ["biliary", "ORGAN", 314, 321], ["patients", "SPECIES", 36, 44], ["CRBSI", "PROBLEM", 63, 68], ["infection", "PROBLEM", 97, 106], ["STI", "TEST", 128, 131], ["primary bacteraemia", "PROBLEM", 141, 160], ["lower respiratory tract infection", "PROBLEM", 170, 203], ["orthopaedic infection", "PROBLEM", 213, 234], ["IE", "TEST", 243, 245], ["UTI", "PROBLEM", 254, 257], ["endovascular infection", "PROBLEM", 266, 288], ["IE", "TEST", 300, 302], ["biliary infection", "PROBLEM", 314, 331], ["most common", "OBSERVATION_MODIFIER", 77, 88], ["infection", "OBSERVATION", 97, 106], ["bacteraemia", "OBSERVATION", 149, 160], ["lower", "ANATOMY_MODIFIER", 170, 175], ["respiratory tract", "ANATOMY", 176, 193], ["infection", "OBSERVATION", 194, 203], ["infection", "OBSERVATION", 225, 234], ["UTI", "OBSERVATION", 254, 257], ["endovascular", "OBSERVATION_MODIFIER", 266, 278], ["infection", "OBSERVATION", 279, 288], ["biliary", "ANATOMY", 314, 321], ["infection", "OBSERVATION", 322, 331]]], ["The most common underlying illnesses were diabetes mellitus (36.7%) and renal insufficiency (24.9%).", [["renal", "ANATOMY", 72, 77], ["diabetes mellitus", "DISEASE", 42, 59], ["renal insufficiency", "DISEASE", 72, 91], ["renal", "ORGAN", 72, 77], ["diabetes mellitus", "PROBLEM", 42, 59], ["renal insufficiency", "PROBLEM", 72, 91], ["illnesses", "OBSERVATION", 27, 36], ["renal", "ANATOMY", 72, 77], ["insufficiency", "OBSERVATION", 78, 91]]], ["An intravenous catheter was used in 31.1% of patients.", [["intravenous", "ANATOMY", 3, 14], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 3, 14], ["patients", "ORGANISM", 45, 53], ["patients", "SPECIES", 45, 53], ["An intravenous catheter", "TREATMENT", 0, 23], ["intravenous catheter", "OBSERVATION", 3, 23]]], ["The in-hospital mortality rate was 33.3% and was associated with increased age, persistent bacteraemia, polymicrobial bacteraemia, fewer debridements, rapidly fatal disease according to the McCabe classification, higher Pitt bacteraemia score, septic shock, lower respiratory tract infection, active malignancy and metastatic infection ( Table 1) .ResultsAnalysis of patients who died within 14 days revealed a similar set of risk factors, as well as lower mortality rate amongst patients with STI-associated bacteraemia.", [["lower respiratory tract", "ANATOMY", 258, 281], ["bacteraemia", "DISEASE", 91, 102], ["bacteraemia", "DISEASE", 118, 129], ["bacteraemia", "DISEASE", 225, 236], ["septic shock", "DISEASE", 244, 256], ["respiratory tract infection", "DISEASE", 264, 291], ["malignancy", "DISEASE", 300, 310], ["infection", "DISEASE", 326, 335], ["STI", "DISEASE", 494, 497], ["bacteraemia", "DISEASE", 509, 520], ["tract", "ORGANISM_SUBDIVISION", 276, 281], ["patients", "ORGANISM", 367, 375], ["patients", "ORGANISM", 480, 488], ["patients", "SPECIES", 367, 375], ["patients", "SPECIES", 480, 488], ["The in-hospital mortality rate", "TEST", 0, 30], ["persistent bacteraemia", "PROBLEM", 80, 102], ["polymicrobial bacteraemia", "PROBLEM", 104, 129], ["fewer debridements", "TREATMENT", 131, 149], ["rapidly fatal disease", "PROBLEM", 151, 172], ["higher Pitt bacteraemia score", "PROBLEM", 213, 242], ["septic shock", "PROBLEM", 244, 256], ["lower respiratory tract infection", "PROBLEM", 258, 291], ["active malignancy", "PROBLEM", 293, 310], ["metastatic infection", "PROBLEM", 315, 335], ["STI", "PROBLEM", 494, 497], ["bacteraemia", "PROBLEM", 509, 520], ["persistent", "OBSERVATION_MODIFIER", 80, 90], ["bacteraemia", "OBSERVATION", 91, 102], ["polymicrobial bacteraemia", "OBSERVATION", 104, 129], ["fewer", "OBSERVATION_MODIFIER", 131, 136], ["debridements", "OBSERVATION", 137, 149], ["rapidly", "OBSERVATION_MODIFIER", 151, 158], ["fatal disease", "OBSERVATION", 159, 172], ["higher", "OBSERVATION_MODIFIER", 213, 219], ["Pitt bacteraemia", "OBSERVATION", 220, 236], ["septic shock", "OBSERVATION", 244, 256], ["lower", "ANATOMY_MODIFIER", 258, 263], ["respiratory tract", "ANATOMY", 264, 281], ["infection", "OBSERVATION", 282, 291], ["active", "OBSERVATION_MODIFIER", 293, 299], ["malignancy", "OBSERVATION", 300, 310], ["metastatic", "OBSERVATION_MODIFIER", 315, 325], ["infection", "OBSERVATION", 326, 335], ["bacteraemia", "OBSERVATION", 509, 520]]], ["Differences in mortality rates amongst different types of infection were significant.", [["infection", "DISEASE", 58, 67], ["mortality rates", "TEST", 15, 30], ["infection", "PROBLEM", 58, 67], ["infection", "OBSERVATION", 58, 67]]], ["For in-hospital mortality, bacteraemia due to lower respiratory tract infection carried the highest mortality (66.7%), whilst bacteraemia secondary to orthopaedic infection carried the lowest (6.3%).", [["lower respiratory tract", "ANATOMY", 46, 69], ["bacteraemia", "DISEASE", 27, 38], ["lower respiratory tract infection", "DISEASE", 46, 79], ["bacteraemia", "DISEASE", 126, 137], ["infection", "DISEASE", 163, 172], ["tract", "ORGANISM_SUBDIVISION", 64, 69], ["bacteraemia", "PROBLEM", 27, 38], ["lower respiratory tract infection", "PROBLEM", 46, 79], ["bacteraemia", "PROBLEM", 126, 137], ["orthopaedic infection", "PROBLEM", 151, 172], ["bacteraemia", "OBSERVATION", 27, 38], ["lower", "ANATOMY_MODIFIER", 46, 51], ["respiratory tract", "ANATOMY", 52, 69], ["infection", "OBSERVATION", 70, 79], ["infection", "OBSERVATION", 163, 172]]], ["The mortality rate amongst different types of infection is shown in Fig. 1 .ResultsTo explore the efficacy of treatment response, patients who died within 3 days of the ED visit (n = 24), with McCabe rapidly fatal disease (n = 9) or mortality not related to MRSA bacteraemia (n = 3) were excluded.", [["infection", "DISEASE", 46, 55], ["MRSA bacteraemia", "DISEASE", 258, 274], ["patients", "ORGANISM", 130, 138], ["patients", "SPECIES", 130, 138], ["MRSA", "SPECIES", 258, 262], ["The mortality rate", "PROBLEM", 0, 18], ["infection", "PROBLEM", 46, 55], ["McCabe rapidly fatal disease", "PROBLEM", 193, 221], ["mortality", "PROBLEM", 233, 242], ["MRSA bacteraemia", "PROBLEM", 258, 274], ["infection", "OBSERVATION", 46, 55], ["MRSA", "OBSERVATION", 258, 262]]], ["After excluding these patients, 141 patients remained.", [["patients", "ORGANISM", 22, 30], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 22, 30], ["patients", "SPECIES", 36, 44]]], ["Fewer risk factors associated with mortality were identified in this group.", [["Fewer risk factors", "PROBLEM", 0, 18], ["mortality", "PROBLEM", 35, 44]]], ["These included increased age, persistent bacteraemia, ultimately fatal disease and non-fatal disease according to the McCabe classification, higher Pitt bacteraemia score, septic shock, lower respiratory tract infection and metastatic infection.", [["lower respiratory tract", "ANATOMY", 186, 209], ["bacteraemia", "DISEASE", 41, 52], ["Pitt bacteraemia", "DISEASE", 148, 164], ["septic shock", "DISEASE", 172, 184], ["respiratory tract infection", "DISEASE", 192, 219], ["infection", "DISEASE", 235, 244], ["tract", "ORGANISM_SUBDIVISION", 204, 209], ["persistent bacteraemia", "PROBLEM", 30, 52], ["ultimately fatal disease", "PROBLEM", 54, 78], ["non-fatal disease", "PROBLEM", 83, 100], ["higher Pitt bacteraemia score", "PROBLEM", 141, 170], ["septic shock", "PROBLEM", 172, 184], ["lower respiratory tract infection", "PROBLEM", 186, 219], ["metastatic infection", "PROBLEM", 224, 244], ["increased", "OBSERVATION_MODIFIER", 15, 24], ["persistent", "OBSERVATION_MODIFIER", 30, 40], ["bacteraemia", "OBSERVATION", 41, 52], ["fatal", "OBSERVATION_MODIFIER", 65, 70], ["disease", "OBSERVATION", 71, 78], ["non-fatal disease", "OBSERVATION", 83, 100], ["higher", "OBSERVATION_MODIFIER", 141, 147], ["Pitt bacteraemia", "OBSERVATION", 148, 164], ["septic shock", "OBSERVATION", 172, 184], ["lower", "ANATOMY_MODIFIER", 186, 191], ["respiratory tract", "ANATOMY", 192, 209], ["infection", "OBSERVATION", 210, 219], ["metastatic", "OBSERVATION_MODIFIER", 224, 234], ["infection", "OBSERVATION", 235, 244]]], ["A logistic regression analysis of mortality in this group revealed that age (P = 0.021; odds ratio (OR) = 1.07, 95% confidence interval (CI) 1.01-1.13), persistent bacteraemia (P = 0.024; OR = 17.52, 95% CI 1.45-211.76), ultimately fatal disease (P = 0.014; OR = 7.99, 95% CI 1.53-41.59) and Pitt bacteraemia score (P = 0.024; OR = 1.33, 95% CI 1.04-1.69) were significant risk factors for mortality.", [["bacteraemia", "DISEASE", 164, 175], ["bacteraemia", "DISEASE", 297, 308], ["A logistic regression analysis", "TEST", 0, 30], ["P", "TEST", 77, 78], ["odds ratio", "TEST", 88, 98], ["CI", "TEST", 137, 139], ["persistent bacteraemia", "PROBLEM", 153, 175], ["P", "TEST", 177, 178], ["CI", "TEST", 204, 206], ["ultimately fatal disease", "PROBLEM", 221, 245], ["P", "TEST", 247, 248], ["CI", "TEST", 273, 275], ["Pitt bacteraemia score", "TEST", 292, 314], ["P", "TEST", 316, 317], ["CI", "TEST", 342, 344], ["significant risk factors", "PROBLEM", 361, 385], ["mortality", "PROBLEM", 390, 399], ["persistent", "OBSERVATION_MODIFIER", 153, 163], ["bacteraemia", "OBSERVATION", 164, 175], ["fatal", "OBSERVATION_MODIFIER", 232, 237], ["disease", "OBSERVATION", 238, 245]]], ["The association of metastatic infection with mortality was of borderline significance (P = 0.057; OR = 4.47, 95% CI 0.96-20.88).", [["infection", "DISEASE", 30, 39], ["metastatic infection", "PROBLEM", 19, 39], ["P", "TEST", 87, 88], ["CI", "TEST", 113, 115], ["metastatic", "OBSERVATION_MODIFIER", 19, 29], ["infection", "OBSERVATION", 30, 39]]], ["Empirical glycopeptide therapy was not associated with decreased mortality.ResultsAll MRSA isolates were susceptible to vancomycin, teicoplanin, linezolid and daptomycin ( Table 3 ).", [["vancomycin", "CHEMICAL", 120, 130], ["teicoplanin", "CHEMICAL", 132, 143], ["linezolid", "CHEMICAL", 145, 154], ["daptomycin", "CHEMICAL", 159, 169], ["vancomycin", "CHEMICAL", 120, 130], ["teicoplanin", "CHEMICAL", 132, 143], ["linezolid", "CHEMICAL", 145, 154], ["daptomycin", "CHEMICAL", 159, 169], ["vancomycin", "SIMPLE_CHEMICAL", 120, 130], ["teicoplanin", "SIMPLE_CHEMICAL", 132, 143], ["linezolid", "SIMPLE_CHEMICAL", 145, 154], ["daptomycin", "SIMPLE_CHEMICAL", 159, 169], ["MRSA", "SPECIES", 86, 90], ["MRSA", "SPECIES", 86, 90], ["Empirical glycopeptide therapy", "TREATMENT", 0, 30], ["decreased mortality", "PROBLEM", 55, 74], ["All MRSA isolates", "TEST", 82, 99], ["vancomycin", "TREATMENT", 120, 130], ["teicoplanin", "TREATMENT", 132, 143], ["linezolid", "TREATMENT", 145, 154], ["daptomycin", "TREATMENT", 159, 169]]], ["The MICs of vancomycin for all MRSA isolates were between 1 g/mL and 2 g/mL.", [["vancomycin", "CHEMICAL", 12, 22], ["MRSA", "CHEMICAL", 31, 35], ["vancomycin", "CHEMICAL", 12, 22], ["vancomycin", "SIMPLE_CHEMICAL", 12, 22], ["MRSA", "SPECIES", 31, 35], ["MRSA", "SPECIES", 31, 35], ["vancomycin", "TREATMENT", 12, 22], ["all MRSA isolates", "PROBLEM", 27, 44]]], ["A detrimental effect of increased vancomycin MICs on patient outcome could not be demonstrated despite separate analyses using the different definitions of outcome.", [["vancomycin", "CHEMICAL", 34, 44], ["vancomycin", "CHEMICAL", 34, 44], ["vancomycin", "SIMPLE_CHEMICAL", 34, 44], ["patient", "ORGANISM", 53, 60], ["patient", "SPECIES", 53, 60], ["increased vancomycin MICs", "TREATMENT", 24, 49], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["vancomycin MICs", "OBSERVATION", 34, 49]]], ["Intravenous linezolid was used in six patients later in the course of hospitalisation (four due to treatment failure with glycopeptides and two due to cytopenia using glycopeptides) and oral linezolid was prescribed for three patients following glycopeptide therapy (oral switch).DiscussionMost studies of MRSA bacteraemia have included nosocomially acquired cases and compared the difference between MRSA and meticillin-susceptible S. aureus (MSSA).", [["Intravenous", "ANATOMY", 0, 11], ["oral", "ANATOMY", 186, 190], ["oral", "ANATOMY", 267, 271], ["linezolid", "CHEMICAL", 12, 21], ["cytopenia", "DISEASE", 151, 160], ["linezolid", "CHEMICAL", 191, 200], ["MRSA bacteraemia", "DISEASE", 306, 322], ["MRSA", "CHEMICAL", 401, 405], ["meticillin", "CHEMICAL", 410, 420], ["linezolid", "CHEMICAL", 12, 21], ["linezolid", "CHEMICAL", 191, 200], ["meticillin", "CHEMICAL", 410, 420], ["linezolid", "SIMPLE_CHEMICAL", 12, 21], ["patients", "ORGANISM", 38, 46], ["oral", "ORGANISM_SUBDIVISION", 186, 190], ["linezolid", "SIMPLE_CHEMICAL", 191, 200], ["patients", "ORGANISM", 226, 234], ["oral", "ORGANISM_SUBDIVISION", 267, 271], ["MRSA", "ORGANISM", 306, 310], ["meticillin-susceptible", "ORGANISM", 410, 432], ["S. aureus", "ORGANISM", 433, 442], ["MSSA", "CANCER", 444, 448], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 226, 234], ["MRSA", "SPECIES", 306, 310], ["MRSA", "SPECIES", 401, 405], ["S. aureus", "SPECIES", 433, 442], ["MRSA", "SPECIES", 306, 310], ["MRSA", "SPECIES", 401, 405], ["S. aureus", "SPECIES", 433, 442], ["MSSA", "SPECIES", 444, 448], ["Intravenous linezolid", "TREATMENT", 0, 21], ["treatment failure", "PROBLEM", 99, 116], ["glycopeptides", "TREATMENT", 122, 135], ["cytopenia", "PROBLEM", 151, 160], ["glycopeptides", "TREATMENT", 167, 180], ["oral linezolid", "TREATMENT", 186, 200], ["glycopeptide therapy", "TREATMENT", 245, 265], ["oral switch)", "TREATMENT", 267, 279], ["MRSA bacteraemia", "PROBLEM", 306, 322], ["nosocomially acquired cases", "PROBLEM", 337, 364], ["MRSA", "PROBLEM", 401, 405], ["meticillin", "TEST", 410, 420], ["susceptible S. aureus", "PROBLEM", 421, 442], ["MSSA", "PROBLEM", 444, 448], ["aureus", "OBSERVATION", 436, 442], ["MSSA", "OBSERVATION", 444, 448]]], ["How- ever, the antimicrobial agents used for MSSA and MRSA are different [10] .", [["MSSA", "CHEMICAL", 45, 49], ["MRSA", "DISEASE", 54, 58], ["MRSA", "SPECIES", 54, 58], ["the antimicrobial agents", "TREATMENT", 11, 35], ["MSSA", "PROBLEM", 45, 49], ["MRSA", "PROBLEM", 54, 58]]], ["In this study, we focused on patients with MRSA bacteraemia recovered at the ED and demonstrated the characteristics and outcome of these patients.", [["bacteraemia", "DISEASE", 48, 59], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 138, 146], ["patients", "SPECIES", 29, 37], ["MRSA", "SPECIES", 43, 47], ["patients", "SPECIES", 138, 146], ["MRSA", "SPECIES", 43, 47], ["this study", "TEST", 3, 13], ["MRSA bacteraemia", "PROBLEM", 43, 59]]], ["The outcome of our patients was more closely associated with the severity of underlying illness and bacteraemia, age and persistent bacteraemia.", [["illness", "DISEASE", 88, 95], ["bacteraemia", "DISEASE", 100, 111], ["bacteraemia", "DISEASE", 132, 143], ["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["underlying illness", "PROBLEM", 77, 95], ["bacteraemia", "PROBLEM", 100, 111], ["persistent bacteraemia", "PROBLEM", 121, 143], ["illness", "OBSERVATION", 88, 95], ["bacteraemia", "OBSERVATION", 100, 111], ["persistent", "OBSERVATION_MODIFIER", 121, 131], ["bacteraemia", "OBSERVATION", 132, 143]]], ["Despite recent studies suggesting that increased MICs of MRSA isolates have a detrimental effect on patient outcome [13, 14] , this is not supported in the current study.", [["MICs", "CHEMICAL", 49, 53], ["MRSA", "CHEMICAL", 57, 61], ["MRSA isolates", "ORGANISM", 57, 70], ["patient", "ORGANISM", 100, 107], ["MRSA", "SPECIES", 57, 61], ["patient", "SPECIES", 100, 107], ["MRSA", "SPECIES", 57, 61], ["recent studies", "TEST", 8, 22], ["increased MICs of MRSA isolates", "PROBLEM", 39, 70], ["the current study", "TEST", 152, 169], ["increased", "OBSERVATION_MODIFIER", 39, 48]]], ["The in-hospital mortality was 33.6% and 32.5% amongst patients with MRSA isolates with a vancomycin MIC of 1 g/mL and 2 g/mL, respectively.", [["vancomycin", "CHEMICAL", 89, 99], ["vancomycin", "CHEMICAL", 89, 99], ["patients", "ORGANISM", 54, 62], ["vancomycin", "SIMPLE_CHEMICAL", 89, 99], ["patients", "SPECIES", 54, 62], ["MRSA", "SPECIES", 68, 72], ["MRSA", "SPECIES", 68, 72], ["MRSA isolates", "PROBLEM", 68, 81], ["a vancomycin MIC", "TREATMENT", 87, 103]]], ["Many factors complicate the evaluation of treatment response in patients with MRSA bacteraemia.", [["bacteraemia", "DISEASE", 83, 94], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["MRSA", "SPECIES", 78, 82], ["MRSA", "SPECIES", 78, 82], ["the evaluation", "TEST", 24, 38], ["treatment response", "TREATMENT", 42, 60], ["MRSA bacteraemia", "PROBLEM", 78, 94], ["MRSA bacteraemia", "OBSERVATION", 78, 94]]], ["One of the most important factors is the wide variation in the severity of underlying illness.", [["underlying illness", "PROBLEM", 75, 93], ["most important", "OBSERVATION_MODIFIER", 11, 25], ["wide", "OBSERVATION_MODIFIER", 41, 45], ["variation", "OBSERVATION_MODIFIER", 46, 55], ["illness", "OBSERVATION", 86, 93]]], ["Patients with rapidly fatal disease carry the highest mortality rates from bacteraemia episodes, which reached 84.6% in this study and 76.2% in a previous one [17] .", [["bacteraemia", "DISEASE", 75, 86], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["rapidly fatal disease", "PROBLEM", 14, 35], ["bacteraemia episodes", "PROBLEM", 75, 95], ["this study", "TEST", 120, 130], ["rapidly", "OBSERVATION_MODIFIER", 14, 21], ["fatal", "OBSERVATION_MODIFIER", 22, 27], ["disease", "OBSERVATION", 28, 35], ["bacteraemia", "OBSERVATION", 75, 86]]], ["Inclusion of these patients in survival analyses will confound the search for important prognostic factors.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["survival analyses", "TEST", 31, 48]]], ["A recent study also found that underlying illness was the most important predictor of 7-day mortality in patients with S. aureus bacteraemia [27] .DiscussionThe type of infection is also clearly correlated with treatment response.", [["illness", "DISEASE", 42, 49], ["S. aureus bacteraemia", "DISEASE", 119, 140], ["infection", "DISEASE", 169, 178], ["patients", "ORGANISM", 105, 113], ["S. aureus", "ORGANISM", 119, 128], ["patients", "SPECIES", 105, 113], ["S. aureus", "SPECIES", 119, 128], ["S. aureus", "SPECIES", 119, 128], ["A recent study", "TEST", 0, 14], ["underlying illness", "PROBLEM", 31, 49], ["S. aureus bacteraemia", "PROBLEM", 119, 140], ["infection", "PROBLEM", 169, 178], ["aureus", "OBSERVATION_MODIFIER", 122, 128], ["bacteraemia", "OBSERVATION", 129, 140], ["infection", "OBSERVATION", 169, 178]]], ["Differences in the type of infection determine the feasibility of source infection control.", [["infection", "DISEASE", 27, 36], ["infection", "DISEASE", 73, 82], ["infection", "PROBLEM", 27, 36], ["infection control", "TREATMENT", 73, 90], ["infection", "OBSERVATION", 27, 36], ["infection", "OBSERVATION", 73, 82]]], ["Pneumonia has been long considered the most difficult type of MRSA infection to treat [28, 29] .", [["Pneumonia", "DISEASE", 0, 9], ["MRSA infection", "DISEASE", 62, 76], ["MRSA", "SPECIES", 62, 66], ["MRSA", "SPECIES", 62, 66], ["Pneumonia", "PROBLEM", 0, 9], ["MRSA infection", "PROBLEM", 62, 76], ["most difficult type", "OBSERVATION_MODIFIER", 39, 58], ["MRSA", "OBSERVATION_MODIFIER", 62, 66], ["infection", "OBSERVATION", 67, 76]]], ["Difficulty in achieving high concentrations of glycopeptides in the lung and in removing the infected tissue might represent equally important obstacles to effective management [29] .", [["lung", "ANATOMY", 68, 72], ["tissue", "ANATOMY", 102, 108], ["lung", "ORGAN", 68, 72], ["tissue", "TISSUE", 102, 108], ["glycopeptides", "TREATMENT", 47, 60], ["the infected tissue", "PROBLEM", 89, 108], ["high concentrations", "OBSERVATION_MODIFIER", 24, 43], ["glycopeptides", "OBSERVATION", 47, 60], ["lung", "ANATOMY", 68, 72], ["infected", "OBSERVATION", 93, 101]]], ["In this study, the mortality rate in patients with orthopaedic infection (6.3%) was substantially lower than in pneumonic patients (66.7%), probably due to relatively lower co-morbidity in these patients and ease of surgical intervention.", [["infection", "DISEASE", 63, 72], ["pneumonic", "DISEASE", 112, 121], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 122, 130], ["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 195, 203], ["this study", "TEST", 3, 13], ["the mortality rate", "TEST", 15, 33], ["orthopaedic infection", "PROBLEM", 51, 72], ["relatively lower co-morbidity", "PROBLEM", 156, 185], ["surgical intervention", "TREATMENT", 216, 237], ["infection", "OBSERVATION", 63, 72], ["lower", "OBSERVATION_MODIFIER", 98, 103], ["pneumonic", "OBSERVATION", 112, 121], ["probably due to", "UNCERTAINTY", 140, 155], ["relatively", "OBSERVATION_MODIFIER", 156, 166], ["lower", "OBSERVATION_MODIFIER", 167, 172], ["co-morbidity", "OBSERVATION", 173, 185], ["surgical", "OBSERVATION", 216, 224]]], ["The spectrum of MRSA bacteraemia can vary from mild to life-threatening disease; however, determining the type of infection is sometimes difficult, especially for patients with early mortality.DiscussionWithout novel molecular methods, patients with MRSA bacteraemia have to survive several days waiting for a positive blood culture, traditional identification of isolates and determination of antimicrobial susceptibility in order to confirm the existence of MRSA.", [["blood", "ANATOMY", 319, 324], ["bacteraemia", "DISEASE", 21, 32], ["infection", "DISEASE", 114, 123], ["MRSA bacteraemia", "DISEASE", 250, 266], ["MRSA", "DISEASE", 460, 464], ["patients", "ORGANISM", 163, 171], ["patients", "ORGANISM", 236, 244], ["blood", "ORGANISM_SUBSTANCE", 319, 324], ["MRSA", "CANCER", 460, 464], ["MRSA", "SPECIES", 16, 20], ["patients", "SPECIES", 163, 171], ["patients", "SPECIES", 236, 244], ["MRSA", "SPECIES", 250, 254], ["MRSA", "SPECIES", 460, 464], ["MRSA", "SPECIES", 16, 20], ["MRSA", "SPECIES", 250, 254], ["MRSA", "SPECIES", 460, 464], ["MRSA bacteraemia", "PROBLEM", 16, 32], ["mild to life-threatening disease", "PROBLEM", 47, 79], ["infection", "PROBLEM", 114, 123], ["early mortality", "PROBLEM", 177, 192], ["MRSA bacteraemia", "PROBLEM", 250, 266], ["a positive blood culture", "PROBLEM", 308, 332], ["isolates", "PROBLEM", 364, 372], ["antimicrobial susceptibility", "PROBLEM", 394, 422], ["MRSA", "PROBLEM", 460, 464], ["MRSA bacteraemia", "OBSERVATION", 16, 32], ["mild", "OBSERVATION_MODIFIER", 47, 51], ["threatening", "OBSERVATION_MODIFIER", 60, 71], ["disease", "OBSERVATION", 72, 79], ["infection", "OBSERVATION", 114, 123], ["MRSA", "OBSERVATION", 460, 464]]], ["It also takes days for vancomycin to take effect.", [["vancomycin", "CHEMICAL", 23, 33], ["vancomycin", "CHEMICAL", 23, 33], ["vancomycin", "SIMPLE_CHEMICAL", 23, 33], ["vancomycin", "TREATMENT", 23, 33]]], ["Some patients in this study died before the culture results were known, as shown by the 3-day mortality rate of 13.6%.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["this study", "TEST", 17, 27], ["the culture", "TEST", 40, 51], ["mortality rate", "TEST", 94, 108]]], ["Recent studies showed that empirical glycopeptides might improve the outcome of patients with MRSA infection [30, 31] .", [["MRSA infection", "DISEASE", 94, 108], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["MRSA", "SPECIES", 94, 98], ["MRSA", "SPECIES", 94, 98], ["Recent studies", "TEST", 0, 14], ["empirical glycopeptides", "TREATMENT", 27, 50], ["MRSA infection", "PROBLEM", 94, 108]]], ["However, amongst the 24 patients who died within 3 days in this study, 6 had rapidly fatal disease and the average Pitt bacteraemia score was 8.46, implying that these patients had advanced disease and the outcome might not be altered by early antimicrobial therapy.DiscussionDuring the study period, linezolid was the only available alternative agent for MRSA infection.", [["bacteraemia", "DISEASE", 120, 131], ["linezolid", "CHEMICAL", 301, 310], ["MRSA infection", "DISEASE", 356, 370], ["linezolid", "CHEMICAL", 301, 310], ["patients", "ORGANISM", 24, 32], ["patients", "ORGANISM", 168, 176], ["linezolid", "SIMPLE_CHEMICAL", 301, 310], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 168, 176], ["MRSA", "SPECIES", 356, 360], ["MRSA", "SPECIES", 356, 360], ["this study", "TEST", 59, 69], ["rapidly fatal disease", "PROBLEM", 77, 98], ["the average Pitt bacteraemia score", "TEST", 103, 137], ["advanced disease", "PROBLEM", 181, 197], ["early antimicrobial therapy", "TREATMENT", 238, 265], ["linezolid", "TREATMENT", 301, 310], ["alternative agent", "TREATMENT", 334, 351], ["MRSA infection", "PROBLEM", 356, 370], ["fatal", "OBSERVATION_MODIFIER", 85, 90], ["disease", "OBSERVATION", 91, 98], ["advanced", "OBSERVATION_MODIFIER", 181, 189], ["disease", "OBSERVATION", 190, 197], ["antimicrobial therapy", "OBSERVATION", 244, 265], ["infection", "OBSERVATION", 361, 370]]], ["Quinupristin/dalfopristin is not marketed in Taiwan [32] .", [["Quinupristin", "CHEMICAL", 0, 12], ["dalfopristin", "CHEMICAL", 13, 25], ["Quinupristin", "CHEMICAL", 0, 12], ["dalfopristin", "CHEMICAL", 13, 25], ["Quinupristin", "SIMPLE_CHEMICAL", 0, 12], ["dalfopristin", "SIMPLE_CHEMICAL", 13, 25], ["dalfopristin", "TREATMENT", 13, 25]]], ["In this study, linezolid was used in only nine patients, four of whom died despite linezolid use.", [["linezolid", "CHEMICAL", 15, 24], ["linezolid", "CHEMICAL", 83, 92], ["linezolid", "CHEMICAL", 15, 24], ["linezolid", "CHEMICAL", 83, 92], ["linezolid", "SIMPLE_CHEMICAL", 15, 24], ["patients", "ORGANISM", 47, 55], ["linezolid", "SIMPLE_CHEMICAL", 83, 92], ["patients", "SPECIES", 47, 55], ["this study", "TEST", 3, 13], ["linezolid", "TREATMENT", 15, 24], ["linezolid use", "TREATMENT", 83, 96], ["linezolid", "OBSERVATION", 83, 92]]], ["As for the role of combination therapy, a high rate of gentamicin resistance was also found amongst MRSA isolates in Taiwan [32] ; despite occasional use of gentamicin amongst our patients, this is not routine in clinical practice.", [["gentamicin", "CHEMICAL", 55, 65], ["gentamicin", "CHEMICAL", 157, 167], ["gentamicin", "CHEMICAL", 55, 65], ["gentamicin", "CHEMICAL", 157, 167], ["gentamicin", "SIMPLE_CHEMICAL", 55, 65], ["gentamicin", "SIMPLE_CHEMICAL", 157, 167], ["patients", "ORGANISM", 180, 188], ["MRSA", "SPECIES", 100, 104], ["patients", "SPECIES", 180, 188], ["MRSA", "SPECIES", 100, 104], ["combination therapy", "TREATMENT", 19, 38], ["a high rate of gentamicin resistance", "TREATMENT", 40, 76], ["MRSA isolates", "PROBLEM", 100, 113], ["gentamicin", "TREATMENT", 157, 167]]], ["Previous reports showed that adding rifampicin is effective as combination therapy for MRSA infection [33] , and resistance of MRSA to rifampicin in Taiwan was not high [32] .", [["rifampicin", "CHEMICAL", 36, 46], ["MRSA infection", "DISEASE", 87, 101], ["MRSA", "CHEMICAL", 127, 131], ["rifampicin", "CHEMICAL", 135, 145], ["rifampicin", "CHEMICAL", 36, 46], ["rifampicin", "CHEMICAL", 135, 145], ["rifampicin", "SIMPLE_CHEMICAL", 36, 46], ["rifampicin", "SIMPLE_CHEMICAL", 135, 145], ["MRSA", "SPECIES", 87, 91], ["MRSA", "SPECIES", 127, 131], ["MRSA", "SPECIES", 87, 91], ["MRSA", "SPECIES", 127, 131], ["rifampicin", "TREATMENT", 36, 46], ["combination therapy", "TREATMENT", 63, 82], ["MRSA infection", "PROBLEM", 87, 101], ["MRSA", "PROBLEM", 127, 131], ["rifampicin", "TREATMENT", 135, 145]]], ["However, this agent is not used in the initial treatment of most patients in our hospital.DiscussionThe increasing rate of MRSA isolates with high vancomycin MICs is a serious and important issue.", [["vancomycin", "CHEMICAL", 147, 157], ["vancomycin", "CHEMICAL", 147, 157], ["patients", "ORGANISM", 65, 73], ["vancomycin", "SIMPLE_CHEMICAL", 147, 157], ["patients", "SPECIES", 65, 73], ["MRSA", "SPECIES", 123, 127], ["MRSA", "SPECIES", 123, 127], ["MRSA isolates", "TREATMENT", 123, 136], ["high vancomycin MICs", "TREATMENT", 142, 162]]], ["An increase in the vancomycin MICs of isolates has been correlated with the rate of treatment failure, although the vancomycin MICs were within the susceptible range [13] .", [["vancomycin", "CHEMICAL", 19, 29], ["vancomycin", "CHEMICAL", 116, 126], ["vancomycin", "CHEMICAL", 19, 29], ["vancomycin", "CHEMICAL", 116, 126], ["vancomycin", "SIMPLE_CHEMICAL", 19, 29], ["vancomycin MICs", "SIMPLE_CHEMICAL", 116, 131], ["An increase", "PROBLEM", 0, 11], ["the vancomycin MICs of isolates", "TREATMENT", 15, 46], ["treatment failure", "PROBLEM", 84, 101], ["the vancomycin MICs", "TREATMENT", 112, 131], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["vancomycin MICs", "OBSERVATION", 19, 34]]], ["However, in this study, despite several endpoints being applied, no correlation of increased vancomycin MICs and poor patient outcome was found.DiscussionA recent study of Soriano et al. [34] showed that an elevated MIC itself did not alter patient mortality, but a vancomycin MIC of 2 g/mL did carry a higher risk of death only in patients receiving empirical therapy.", [["vancomycin", "CHEMICAL", 93, 103], ["MIC", "CHEMICAL", 216, 219], ["vancomycin", "CHEMICAL", 266, 276], ["death", "DISEASE", 318, 323], ["vancomycin", "CHEMICAL", 93, 103], ["vancomycin", "CHEMICAL", 266, 276], ["vancomycin", "SIMPLE_CHEMICAL", 93, 103], ["patient", "ORGANISM", 118, 125], ["patient", "ORGANISM", 241, 248], ["vancomycin", "SIMPLE_CHEMICAL", 266, 276], ["patients", "ORGANISM", 332, 340], ["patient", "SPECIES", 118, 125], ["patient", "SPECIES", 241, 248], ["patients", "SPECIES", 332, 340], ["this study", "TEST", 12, 22], ["increased vancomycin MICs", "TREATMENT", 83, 108], ["an elevated MIC", "PROBLEM", 204, 219], ["a vancomycin MIC", "TREATMENT", 264, 280], ["death", "PROBLEM", 318, 323], ["empirical therapy", "TREATMENT", 351, 368], ["increased", "OBSERVATION_MODIFIER", 83, 92], ["vancomycin MICs", "OBSERVATION", 93, 108], ["elevated", "OBSERVATION", 207, 215]]], ["There may be some explanations for this discrepancy.", [["this discrepancy", "PROBLEM", 35, 51], ["may be", "UNCERTAINTY", 6, 12]]], ["First, the patients studied by Sakoulas et al. were identified because of poor response to vancomycin therapy, whereas this study included all patients with clinically significant MRSA bacteraemia presenting to an ED.", [["vancomycin", "CHEMICAL", 91, 101], ["MRSA bacteraemia", "DISEASE", 180, 196], ["vancomycin", "CHEMICAL", 91, 101], ["patients", "ORGANISM", 11, 19], ["vancomycin", "SIMPLE_CHEMICAL", 91, 101], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 143, 151], ["MRSA", "SPECIES", 180, 184], ["vancomycin therapy", "TREATMENT", 91, 109], ["this study", "TEST", 119, 129], ["clinically significant MRSA bacteraemia", "PROBLEM", 157, 196], ["significant", "OBSERVATION_MODIFIER", 168, 179], ["MRSA bacteraemia", "OBSERVATION", 180, 196]]], ["Second, the distribution of vancomycin MICs of MRSA isolates was relatively homogeneously high in the present study (1-2 g/mL), which might have limited its ability to demonstrate the probable beneficial effect of lower MICs.", [["vancomycin", "CHEMICAL", 28, 38], ["MRSA", "CHEMICAL", 47, 51], ["vancomycin", "CHEMICAL", 28, 38], ["vancomycin", "SIMPLE_CHEMICAL", 28, 38], ["MRSA", "SPECIES", 47, 51], ["MRSA", "SPECIES", 47, 51], ["vancomycin MICs", "TREATMENT", 28, 43], ["MRSA isolates", "PROBLEM", 47, 60], ["the present study", "TEST", 98, 115], ["lower MICs", "TREATMENT", 214, 224], ["vancomycin MICs", "OBSERVATION", 28, 43], ["homogeneously", "OBSERVATION_MODIFIER", 76, 89], ["high", "OBSERVATION_MODIFIER", 90, 94], ["lower MICs", "OBSERVATION", 214, 224]]], ["Third, the percentage of empirical therapy was low in this study and, owing to the limited numbers, we could not reproduce the findings of Soriano et al. [34] .DiscussionIn summary, this study of patients with MRSA bacteraemia treated at an ED found no effect of increased vancomycin MICs of isolates on patient outcome.", [["MRSA bacteraemia", "DISEASE", 210, 226], ["vancomycin", "CHEMICAL", 273, 283], ["vancomycin", "CHEMICAL", 273, 283], ["patients", "ORGANISM", 196, 204], ["vancomycin", "SIMPLE_CHEMICAL", 273, 283], ["patient", "ORGANISM", 304, 311], ["patients", "SPECIES", 196, 204], ["MRSA", "SPECIES", 210, 214], ["patient", "SPECIES", 304, 311], ["MRSA", "SPECIES", 210, 214], ["empirical therapy", "TREATMENT", 25, 42], ["this study", "TEST", 54, 64], ["Soriano et al", "TREATMENT", 139, 152], ["this study", "TEST", 182, 192], ["MRSA bacteraemia", "PROBLEM", 210, 226], ["increased vancomycin MICs", "TREATMENT", 263, 288], ["percentage", "OBSERVATION_MODIFIER", 11, 21]]], ["In patients who had MRSA isolates with relatively high vancomycin MICs, the outcome was more closely associated with the severity of underlying illness and bacteraemia, age and persistent bacteraemia.", [["vancomycin", "CHEMICAL", 55, 65], ["illness", "DISEASE", 144, 151], ["bacteraemia", "DISEASE", 156, 167], ["bacteraemia", "DISEASE", 188, 199], ["vancomycin", "CHEMICAL", 55, 65], ["patients", "ORGANISM", 3, 11], ["vancomycin", "SIMPLE_CHEMICAL", 55, 65], ["patients", "SPECIES", 3, 11], ["MRSA", "SPECIES", 20, 24], ["MRSA", "SPECIES", 20, 24], ["MRSA isolates", "PROBLEM", 20, 33], ["relatively high vancomycin MICs", "TREATMENT", 39, 70], ["underlying illness", "PROBLEM", 133, 151], ["bacteraemia", "PROBLEM", 156, 167], ["persistent bacteraemia", "PROBLEM", 177, 199], ["illness", "OBSERVATION", 144, 151], ["bacteraemia", "OBSERVATION", 156, 167], ["persistent", "OBSERVATION_MODIFIER", 177, 187], ["bacteraemia", "OBSERVATION", 188, 199]]], ["Whether empirical vancomycin therapy or new anti-MRSA agents will improve the outcome of these patients deserves further research.DiscussionFunding: No funding sources.DiscussionCompeting interests: None declared.", [["vancomycin", "CHEMICAL", 18, 28], ["vancomycin", "CHEMICAL", 18, 28], ["vancomycin", "SIMPLE_CHEMICAL", 18, 28], ["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["empirical vancomycin therapy", "TREATMENT", 8, 36], ["new anti-MRSA agents", "TREATMENT", 40, 60], ["No", "UNCERTAINTY", 149, 151]]]], "PMC7110867": [["IntroductionSuite aux crises sanitaires suscit\u00e9es par l\u2019 \u00ab affaire du sang contamin\u00e9 \u00bb, puis par le \u00ab scandale de l\u2019hormone de croissance \u00bb, les responsables de la transfusion en France se sont dot\u00e9s de moyens de pr\u00e9vention tr\u00e8s performants capables de faire de l\u2019acte transfusionnel l\u2019un des plus s\u00fbrs sous l\u2019angle du risque microbiologique.", [["du sang contamin\u00e9", "TREATMENT", 67, 84]]], ["Gr\u00e2ce \u00e0 la combinaison de diff\u00e9rentes mesures (s\u00e9lection et fid\u00e9lisation des donneurs, d\u00e9leucocytation des produits sanguins, pratique syst\u00e9matique du diagnostic g\u00e9nomique viral pour les virus les plus pathog\u00e8nes\u2026), le risque infectieux a \u00e9t\u00e9 r\u00e9duit par un facteur de plus de 1500 au cours des 20 derni\u00e8res ann\u00e9es alors que, dans le m\u00eame temps, le risque d\u2019accident ABO n\u2019a \u00e9t\u00e9 r\u00e9duit que de moiti\u00e9 [1].", [["Gr\u00e2ce \u00e0 la combinaison de diff\u00e9rentes mesures", "TREATMENT", 0, 45], ["et fid\u00e9lisation des donneurs", "TREATMENT", 57, 85], ["d\u00e9leucocytation des", "TREATMENT", 87, 106], ["diagnostic g\u00e9nomique viral pour les virus les", "TREATMENT", 151, 196], ["temps", "TEST", 338, 343], ["ABO", "TEST", 366, 369]]], ["Selon des donn\u00e9es r\u00e9centes de l\u2019Institut national de veille sanitaire, le risque r\u00e9siduel moyen d\u2019infection au cours de la p\u00e9riode 2007\u20132009 serait en France de 1 sur 3 millions de dons pour HIV-1, de 1 sur 6 millions de dons pour HTLV, de 1 sur 10 millions de dons pour le virus de l\u2019h\u00e9patite C (HCV) et de 1 sur 100 000 dons pour le virus de l\u2019h\u00e9patite B (avant instauration du DGV pour ce dernier agent) [2].", [["pour le virus", "PROBLEM", 266, 279], ["pour le virus", "TREATMENT", 327, 340], ["du DGV pour ce dernier agent", "TREATMENT", 377, 405]]], ["Est-ce \u00e0 dire que la question du risque viral vis-\u00e0-vis des produits sanguins labiles (PSL) est d\u00e9finitivement r\u00e9gl\u00e9e en 2011 ?", [["Est", "TEST", 0, 3]]], ["Cela serait sans compter les \u00e9mergences et r\u00e9\u00e9mergences virales qui sont susceptibles de venir compromettre ce fragile \u00e9quilibre et remettre en question la confiance retrouv\u00e9e de l\u2019opinion publique vis-\u00e0-vis de la transfusion.", [["Cela", "TEST", 0, 4], ["vis de la transfusion", "TREATMENT", 204, 225]]], ["L\u2019objet de la pr\u00e9sente revue est de proposer un \u00e9tat de l\u2019art des risques viraux \u2013auxquels nous associerons les agents transmissibles non conventionnels (ATNC ou prions)\u2013 \u00e9mergents qui justifient une veille sanitaire active afin d\u2019anticiper les mesures pouvant pr\u00e9venir de nouvelles infections post-transfusionnelles.Concept d\u2019\u00e9mergence et de r\u00e9\u00e9mergence virale ::: \u00c9mergence virale et risque transfusionnelL\u2019Institute of Medicine of the National Academies (\u00c9tats-Unis) a d\u00e9fini une infection \u00e9mergente comme une infection nouvelle, r\u00e9emergente ou r\u00e9sistante aux th\u00e9rapies courantes dont l\u2019incidence chez l\u2019homme a cru au cours des deux derni\u00e8res d\u00e9cennies ou menace de cro\u00eetre au cours des prochaines ann\u00e9es [3].", [["nouvelles infections", "DISEASE", 273, 293], ["infection", "DISEASE", 483, 492], ["infection nouvelle", "DISEASE", 513, 531], ["\u00e9mergents", "TEST", 171, 180], ["a d\u00e9fini une infection", "PROBLEM", 470, 492], ["infections", "OBSERVATION", 283, 293]]], ["Le saut d\u2019esp\u00e8ce constitue la modalit\u00e9 la plus embl\u00e9matique d\u2019\u00e9mergence avec apparition d\u2019une nouvelle infection jusque-l\u00e0 inconnue (pand\u00e9mie HIV, \u00e9pid\u00e9mie de SARS, variant de la maladie de Creutzfeldt-Jakob [MCJv]\u2026) ; la variabilit\u00e9 des virus (et notamment des virus \u00e0 ARN) peut \u00e9galement susciter l\u2019\u00e9mergence d\u2019un nouvel agent viral comme en font foi les diff\u00e9rentes pand\u00e9mies grippales.", [["infection jusque-l\u00e0 inconnue", "DISEASE", 103, 131], ["SARS", "DISEASE", 159, 163], ["Le saut d\u2019esp\u00e8ce constitue la modalit\u00e9 la plus embl\u00e9matique d\u2019\u00e9mergence avec apparition d\u2019une nouvelle infection jusque-l\u00e0 inconnue (pand\u00e9mie HIV, \u00e9pid\u00e9mie de SARS, variant de la maladie de Creutzfeldt-Jakob [MCJv]\u2026", "SPECIES", 0, 215], ["Le saut", "TEST", 0, 7], ["nouvelle infection", "PROBLEM", 94, 112], ["Creutzfeldt", "TEST", 190, 201], ["la variabilit\u00e9 des virus", "PROBLEM", 219, 243], ["et notamment des virus \u00e0 ARN", "TREATMENT", 245, 273], ["susciter l\u2019\u00e9mergence", "TREATMENT", 290, 310], ["nouvel agent", "TREATMENT", 316, 328]]], ["L\u2019extension d\u2019une infection du fait du d\u00e9placement de son vecteur naturel suite \u00e0 des changements climatiques et \u00e0 l\u2019intensification des d\u00e9placements intercontinentaux est illustr\u00e9e par la diss\u00e9mination r\u00e9cente de plusieurs arboviroses (infections virales transmises par des invert\u00e9br\u00e9s) dans des r\u00e9gions jusque-l\u00e0 \u00e9pargn\u00e9es.", [["infection", "DISEASE", 18, 27], ["infections", "DISEASE", 237, 247], ["L\u2019extension d\u2019une infection", "PROBLEM", 0, 27], ["des changements", "TREATMENT", 82, 97], ["et \u00e0 l\u2019intensification", "TREATMENT", 110, 132], ["des d\u00e9placements", "TREATMENT", 133, 149], ["est illustr\u00e9e par la diss\u00e9mination", "TREATMENT", 168, 202]]], ["Par ailleurs, les nouvelles technologies permettent l\u2019identification de \u00ab nouveaux \u00bb pathog\u00e8nes sans doute pr\u00e9sents depuis tr\u00e8s longtemps mais jusque l\u00e0 m\u00e9connus ; on parle dans ce cas de pseudo-\u00e9mergence dont l\u2019illustration la plus typique est la d\u00e9couverte de HCV, longtemps suspect\u00e9 (agent de l\u2019h\u00e9patite dite non A non B) mais identifi\u00e9 seulement en 1989 gr\u00e2ce \u00e0 l\u2019av\u00e8nement des techniques de biologie mol\u00e9culaire.", [["pseudo", "TEST", 188, 194], ["l\u2019av\u00e8nement des techniques", "TREATMENT", 366, 392]]], ["Le Tableau 1illustre ces diff\u00e9rentes situations d\u2019\u00e9mergence ou de r\u00e9\u00e9mergence virale avec des exemples emprunt\u00e9s au risque transfusionnel.Conditions pour qu\u2019un agent infectieux constitue un risque transfusionnel ::: \u00c9mergence virale et risque transfusionnelTous les agents infectieux \u00e9mergents ou r\u00e9\u00e9mergents ne pr\u00e9sentent pas le m\u00eame risque pour la transfusion des PSL.", [["PSL", "CHEMICAL", 366, 369], ["\u00c9mergence virale et risque transfusionnel", "TREATMENT", 216, 257], ["pour la transfusion des PSL", "TREATMENT", 342, 369]]], ["Les conditions n\u00e9cessaires (mais pas forc\u00e9ment suffisantes) pour une transmission transfusionnelle sont les suivantes : (i) l\u2019agent doit \u00eatre pr\u00e9sent dans le sang (de fa\u00e7on libre ou associ\u00e9 aux cellules sanguines) \u00e0 un stade de l\u2019infection (plus cette phase est prolong\u00e9e, plus le risque transfusionnel est important) ; (ii) cette phase de pr\u00e9sence sanguine doit co\u00efncider avec une p\u00e9riode asymptomatique ou pauci-symptomatique de l\u2019infection de mani\u00e8re \u00e0 permettre au donneur de passer le filtre de la qualification clinique ; (iii) l\u2019agent infectieux doit \u00eatre dot\u00e9 d\u2019un pouvoir pathog\u00e8ne reconnu (ce qui exclut des virus comme GBVc/HGV ou TTV que l\u2019on sait \u00eatre pr\u00e9sents dans le sang mais qui sont orphelins de pathologie, y compris chez les patients immunod\u00e9prim\u00e9s) ; (iv) enfin, l\u2019agent infectieux doit r\u00e9sister aux traitements habituels des PSL (par exemple, de nombreuses bact\u00e9ries sont inactiv\u00e9es par le pouvoir bact\u00e9ricide du s\u00e9rum pendant la phase initiale de conservation des PSL [4]).", [["patients", "ORGANISM", 745, 753], ["patients", "SPECIES", 745, 753], ["l\u2019agent doit \u00eatre pr\u00e9sent dans le sang (de fa\u00e7on libre ou associ\u00e9 aux cellules sanguines) \u00e0 un stade de l\u2019infection (plus cette phase est prolong\u00e9e, plus le risque transfusionnel est important) ; (ii) cette phase de pr\u00e9sence sanguine doit co\u00efncider avec une p\u00e9riode asymptomatique ou pauci-symptomatique de l\u2019infection de mani\u00e8re \u00e0 permettre au donneur de passer le filtre de la qualification clinique ; (iii) l\u2019agent infectieux doit \u00eatre dot\u00e9 d\u2019un pouvoir pathog\u00e8ne reconnu (ce qui exclut des virus comme GBVc/HGV ou TTV que l\u2019on sait \u00eatre pr\u00e9sents dans le sang mais qui sont orphelins de pathologie, y compris chez les patients immunod\u00e9prim\u00e9s", "SPECIES", 124, 768], ["cette phase est prolong\u00e9e", "TREATMENT", 246, 271], ["le risque transfusionnel est", "TREATMENT", 278, 306], ["des virus", "TEST", 614, 623], ["GBVc", "TEST", 630, 634], ["y compris chez les patients immunod\u00e9prim\u00e9s", "TREATMENT", 726, 768], ["du s\u00e9rum pendant la phase", "TREATMENT", 932, 957]]], ["En ce qui concerne le risque de d\u00e9veloppement d\u2019une infection s\u00e9v\u00e8re suite \u00e0 la transmission d\u2019un agent infectieux par voie transfusionnelle, l\u2019\u00e9tat immunitaire du receveur joue \u00e9videmment un r\u00f4le majeur (bien montr\u00e9, par exemple, pour les infections \u00e0 virus West Nile [WNV] ou \u00e0 virus chikungunya [CHIK-V]).Conditions pour qu\u2019un agent infectieux constitue un risque transfusionnel ::: \u00c9mergence virale et risque transfusionnelEn tenant compte des crit\u00e8res pr\u00e9c\u00e9dents et de crit\u00e8res additionnels, l\u2019American Association of Blood Banks a essay\u00e9 de prioriser en quatre niveaux de risque transfusionnel les agents infectieux \u00e9mergents ou r\u00e9\u00e9mergents susceptibles de circuler en Am\u00e9rique du Nord [5] (Tableau 2).Variante de la maladie de Creutzfeldt-Jakob ::: Risque transfusionnel associ\u00e9 aux prionsJusqu\u2019\u00e0 l\u2019\u00e9pid\u00e9mie d\u2019enc\u00e9phalite spongiforme bovine (ESB ou maladie de la vache folle) identifi\u00e9e au Royaume-Uni \u00e0 partir de 1985 et l\u2019adaptation de l\u2019agent causal \u00e0 l\u2019homme, \u00e0 l\u2019origine de la MCJv, les prions humains n\u2019avaient jamais \u00e9t\u00e9 incrimin\u00e9s dans des transmissions par voie sanguine, probablement en raison d\u2019un passage sanguin tr\u00e8s faible, du moins dans les phases pr\u00e9coces de la maladie [6].", [["infection s\u00e9v\u00e8re", "DISEASE", 52, 68], ["infections", "DISEASE", 240, 250], ["chikungunya", "DISEASE", 286, 297], ["bovine", "SPECIES", 841, 847], ["d\u2019une infection", "PROBLEM", 46, 61], ["pour les infections", "PROBLEM", 231, 250], ["\u00c9mergence", "TREATMENT", 386, 395], ["a essay\u00e9 de prioriser en quatre niveaux de risque transfusionnel les agents", "TREATMENT", 535, 610], ["d\u2019enc\u00e9phalite spongiforme bovine", "TREATMENT", 815, 847], ["les prions humains", "TREATMENT", 995, 1013], ["probablement en raison", "TREATMENT", 1088, 1110], ["aux prions", "OBSERVATION", 786, 796]]], ["La MCJv se caract\u00e9rise au contraire par un tropisme fort de l\u2019agent causal pour les leucocytes et les formations lympho\u00efdes (amygdales, rate, plaques de Payer).", [["leucocytes", "CELL_TYPE", 84, 94], ["La MCJv se caract\u00e9rise au contraire par un tropisme fort", "TREATMENT", 0, 56], ["pour les leucocytes et les formations lympho\u00efdes", "PROBLEM", 75, 123]]], ["Il est impossible de d\u00e9montrer le caract\u00e8re infectieux du sang de sujets atteints de MCJv en l\u2019injectant \u00e0 des petits animaux de laboratoires, probablement en raison des charges infectieuses trop faibles et de la barri\u00e8re g\u00e9n\u00e9tique ; en revanche, par l\u2019utilisation de souches variantes de prions adapt\u00e9es au hamster ou \u00e0 la souris, il a \u00e9t\u00e9 montr\u00e9 que l\u2019inoculation par voie sanguine \u00e9tait aussi efficace que celle par voie intrac\u00e9r\u00e9brale et que l\u2019infectiosit\u00e9 du sang total se r\u00e9partissait pour 40 % sur les leucocytes (avec possibilit\u00e9 de relarguer une grande partie de ces prions par lavage des cellules) et pour le reste dans le plasma [7].Variante de la maladie de Creutzfeldt-Jakob ::: Risque transfusionnel associ\u00e9 aux prionsD\u00e8s 2002, des \u00e9tudes exp\u00e9rimentales chez le mouton infect\u00e9 par une souche de prion provenant d\u2019une vache atteinte d\u2019ESB ont montr\u00e9 que cet agent pouvait \u00eatre transmis par voie sanguine \u00e0 un autre animal d\u00e8s la phase d\u2019incubation de la maladie [8].", [["leucocytes", "ORGANISM_SUBSTANCE", 509, 519], ["plasma", "ORGANISM_SUBSTANCE", 633, 639], ["leucocytes", "CELL_TYPE", 509, 519], ["aussi efficace que celle par voie intrac\u00e9r\u00e9brale et que l\u2019infectiosit\u00e9 du sang total se r\u00e9partissait pour 40 % sur les leucocytes (avec possibilit\u00e9 de relarguer une grande partie de ces prions par lavage des cellules) et pour le reste dans le plasma", "SPECIES", 390, 639], ["probablement en raison des charges", "TREATMENT", 143, 177], ["trop", "TEST", 191, 195], ["et de la barri\u00e8re g\u00e9n\u00e9tique", "TREATMENT", 204, 231], ["sanguine", "TEST", 375, 383], ["aussi", "TEST", 390, 395], ["efficace", "TEST", 396, 404], ["et que l\u2019infectiosit\u00e9", "TEST", 439, 460], ["sang total se r\u00e9partissait pour", "TREATMENT", 464, 495], ["sur les leucocytes", "TEST", 501, 519], ["prions par lavage des cellules", "TREATMENT", 576, 606], ["et pour le reste dans le plasma", "TEST", 608, 639], ["des \u00e9tudes", "TREATMENT", 742, 752], ["que cet agent", "TREATMENT", 863, 876], ["\u00eatre", "TEST", 885, 889], ["transmis", "TEST", 890, 898], ["sanguine", "TEST", 908, 916]]], ["Gr\u00e2ce \u00e0 une surveillance syst\u00e9matique des patients ayant re\u00e7u des PSL de sujets identifi\u00e9s secondairement comme atteint de MCJv au Royaume-Uni, le premier cas humain av\u00e9r\u00e9 de transmission sanguine de prion a \u00e9t\u00e9 identifi\u00e9 en 2002 [9] ; trois autres cas ont \u00e9t\u00e9 d\u00e9crits par la suite [10], [11], [12].", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["trois autres cas", "TEST", 236, 252]]], ["Trois des quatre cas publi\u00e9s se sont manifest\u00e9s par des tableaux de MCJv dans un d\u00e9lai de six \u00e0 8,5 ans apr\u00e8s la transfusion ; ils \u00e9taient tous homozygotes MM au codon 129 du g\u00e8ne prp (le support g\u00e9n\u00e9tique de la prot\u00e9ine humaine capable de se commuter en prion), comme l\u2019ensemble des patients atteints de MCJv identifi\u00e9s \u00e0 ce jour.", [["patients", "ORGANISM", 284, 292], ["patients", "SPECIES", 284, 292], ["ans apr\u00e8s la transfusion", "TREATMENT", 100, 124], ["au codon", "TREATMENT", 159, 167], ["du g\u00e8ne prp (le support g\u00e9n\u00e9tique de la prot\u00e9ine humaine", "TREATMENT", 172, 228]]], ["En revanche, le deuxi\u00e8me patient est d\u00e9c\u00e9d\u00e9 d\u2019une pathologie intercurrente cinq ans apr\u00e8s la transfusion \u00e0 risque [10] ; \u00e0 l\u2019autopsie, le prion variant a \u00e9t\u00e9 retrouv\u00e9 dans le syst\u00e8me lympho\u00efde mais pas dans le cerveau ; or ce patient \u00e9tait h\u00e9t\u00e9rozygote MV au codon 129, ce qui est actuellement consid\u00e9r\u00e9 comme un facteur de protection ou au moins de retard pour le d\u00e9veloppement d\u2019une MCJv.", [["patient", "ORGANISM", 25, 32], ["patient", "ORGANISM", 226, 233], ["patient", "SPECIES", 25, 32], ["patient", "SPECIES", 226, 233], ["\u00e9t\u00e9 retrouv\u00e9 dans le syst\u00e8me lympho\u00efde mais pas dans le cerveau ; or ce patient \u00e9tait h\u00e9t\u00e9rozygote MV au codon 129, ce qui est actuellement consid\u00e9r\u00e9 comme un facteur de protection ou au moins de retard pour le d\u00e9veloppement d\u2019une MCJv", "SPECIES", 154, 389], ["pathologie", "TEST", 50, 60], ["MV au codon", "TEST", 253, 264], ["ce qui est actuellement", "TEST", 270, 293]]], ["Enfin, il est important de noter que ces quatre patients avaient tous re\u00e7u des PSL non d\u00e9leucocyt\u00e9s.Variante de la maladie de Creutzfeldt-Jakob ::: Risque transfusionnel associ\u00e9 aux prionsAu Royaume-Uni, le risque de transmission est estim\u00e9 autour de 1 pour 15 000 \u00e0 30 000 dons [9].", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["Risque transfusionnel associ\u00e9 aux prionsAu Royaume-Uni, le risque de transmission est estim\u00e9 autour de 1 pour 15 000 \u00e0 30 000 dons", "SPECIES", 148, 278], ["d\u00e9leucocyt\u00e9s", "PROBLEM", 87, 99]]], ["Le risque r\u00e9siduel en France serait de l\u2019ordre de 1 pour 360000 dons [6] ; la d\u00e9leucocytation des PSL (voir ci-dessous) et l\u2019exclusion du don de sang des sujets pr\u00e9alablement transfus\u00e9s ont constitu\u00e9 deux mesures importantes pour r\u00e9duire ce risque.Chronic wasting disease (CWD) ::: Risque transfusionnel associ\u00e9 aux prionsLa maladie du d\u00e9p\u00e9rissement chronique des cervid\u00e9s est une affection \u00e0 prions qui s\u00e9vit dans les for\u00eats du nord des \u00c9tats-Unis et du Canada.", [["Chronic wasting disease", "DISEASE", 248, 271], ["CWD", "DISEASE", 273, 276], ["Risque transfusionnel associ\u00e9 aux prions", "SPECIES", 282, 322], ["la d\u00e9leucocytation des PSL", "TREATMENT", 75, 101], ["et l\u2019exclusion du don", "TREATMENT", 120, 141], ["sang des sujets pr\u00e9alablement", "TREATMENT", 145, 174], ["ont constitu\u00e9 deux", "TREATMENT", 186, 204], ["Chronic wasting disease", "PROBLEM", 248, 271], ["La maladie du d\u00e9p\u00e9rissement", "TREATMENT", 322, 349], ["est une affection", "TEST", 373, 390], ["wasting", "OBSERVATION", 256, 263], ["aux prions", "OBSERVATION", 312, 322]]], ["Un saut de barri\u00e8re d\u2019esp\u00e8ce ne pouvant \u00eatre \u00e9cart\u00e9, les responsables de la transfusion en Am\u00e9rique du Nord restent en alerte par rapport \u00e0 cette \u00e9pizootie.Infection \u00e0 virus West Nile ::: ArbovirosesDepuis l\u2019\u00e9mergence de cette arbovirose en Am\u00e9rique du Nord entre 1999 et 2005, l\u2019infection \u00e0 WNV constitue le prototype de la pathologie vectorielle susceptible de se transmettre par les PSL et les tissus.", [["Depuis l\u2019\u00e9mergence de cette arbovirose en Am\u00e9rique du Nord entre 1999 et 2005, l\u2019infection \u00e0 WNV constitue le prototype de la pathologie vectorielle susceptible de se transmettre par les PSL et les tissus", "SPECIES", 199, 403], ["Infection", "PROBLEM", 156, 165], ["Arboviroses", "TREATMENT", 188, 199]]], ["End\u00e9mique ou \u00e9pid\u00e9mique dans de nombreuses r\u00e9gions du globe, cette pathologie n\u2019a r\u00e9v\u00e9l\u00e9 sa capacit\u00e9 \u00e0 se transmettre autrement que par des moustiques qu\u2019en 2002 avec la description, au cours de l\u2019\u00e9pid\u00e9mie nord-am\u00e9ricaine, de cas d\u2019infections graves suite \u00e0 la transfusion de d\u00e9riv\u00e9s sanguins ou \u00e0 une transplantation d\u2019organe [13], [14].", [["la transfusion", "TREATMENT", 258, 272], ["globe", "ANATOMY", 54, 59]]], ["Pour limiter ce risque nosocomial, les autorit\u00e9s de sant\u00e9 nord-am\u00e9ricaines ont pr\u00e9conis\u00e9 une recherche d\u2019anticorps et un diagnostic g\u00e9nomique viral chez tous les donneurs, soit en minipools, soit en individuel dans les zones de forte end\u00e9mie.", [["nosocomial", "DISEASE", 23, 33], ["am\u00e9ricaines", "TREATMENT", 63, 74]]], ["Cette strat\u00e9gie relativement co\u00fbt-efficace au d\u00e9but de l\u2019\u00e9pid\u00e9mie (incidence de dons d\u00e9pist\u00e9s positifs : 1,4 sur 10 000 en 2003, 0,44 sur 10 000 en 2004) [5] est remise en question du fait du caract\u00e8re d\u00e9sormais end\u00e9mique de l\u2019infection \u00e0 WNV : en effet, le co\u00fbt d\u2019une ann\u00e9e de vie gagn\u00e9e par cette strat\u00e9gie, ajust\u00e9e sur la qualit\u00e9 de vie (indicateur QALY), a \u00e9t\u00e9 \u00e9valu\u00e9e \u00e0 1,5 million de dollars [15].Infection \u00e0 virus West Nile ::: ArbovirosesDans la zone Europe, on assiste \u00e0 une recrudescence du nombre d\u2019infections \u00e0 WNV, notamment en Europe centrale (Roumanie, Hongrie), en Russie, en Isra\u00ebl, en Turquie, en Gr\u00e8ce continentale (plus de 250 cas de formes neurologiques au cours de l\u2019\u00e9t\u00e9 2010 dans la r\u00e9gion de Salonique) et m\u00eame en Italie.", [["Infection", "PROBLEM", 403, 412]]], ["En 2003, des cas humains et \u00e9quins avaient \u00e9t\u00e9 observ\u00e9s dans le Sud de la France [16] ; si cette situation venait \u00e0 se reproduire, les \u00e9tablissements transfusionnels concern\u00e9s sont op\u00e9rationnels pour mettre en place un diagnostic g\u00e9nomique viral.Dengue ::: ArbovirosesLa dengue repr\u00e9sente sans doute une des priorit\u00e9s \u00e0 venir en mati\u00e8re de risque viral transfusionnel \u00e9mergent : (i) plus de 100 millions de cas sont r\u00e9pertori\u00e9s dans le monde dont 250 000 formes h\u00e9morragiques graves ; (ii) la zone de diffusion de la maladie ne cesse de s\u2019\u00e9tendre, notamment en raison de l\u2019extension de la zone d\u2019influence d\u2019Aedes albopictus, l\u2019un des vecteurs du virus de la dengue (DEN-V) ; (iii) il existe quatre s\u00e9rotypes de DEN-V et l\u2019infection par un s\u00e9rotype ne prot\u00e8ge pas contre les trois autres ; (iv) les vir\u00e9mies mesur\u00e9es chez les donneurs de sang peuvent \u00eatre \u00e9lev\u00e9es de l\u2019ordre de 105 \u00e0 107 ufp/ml [17], [18], et la dur\u00e9e de la vir\u00e9mie est de l\u2019ordre d\u2019une semaine ; (v) il a enfin \u00e9t\u00e9 publi\u00e9 r\u00e9cemment quatre cas de transmission sanguine av\u00e9r\u00e9e suite \u00e0 des transfusions de PSL [19], [20], [21].", [["Dengue", "DISEASE", 246, 252], ["dengue", "DISEASE", 659, 665], ["Dengue", "ORGANISM", 246, 252], ["des cas humains", "TREATMENT", 9, 24], ["si cette situation", "TREATMENT", 88, 106], ["Arboviroses", "TEST", 257, 268], ["h\u00e9morragiques graves", "PROBLEM", 462, 482], ["Aedes albopictus", "PROBLEM", 608, 624], ["du virus de la dengue", "PROBLEM", 644, 665], ["s\u00e9rotypes", "TEST", 699, 708], ["s\u00e9rotype", "TEST", 740, 748], ["et la dur\u00e9e", "TEST", 907, 918], ["a enfin", "TREATMENT", 971, 978], ["des transfusions", "TREATMENT", 1051, 1067]]], ["Le faible nombre de cas transfusionnels rapport\u00e9s en regard du nombre consid\u00e9rable d\u2019infections chaque ann\u00e9e est sans doute \u00e0 relier au fait que l\u2019infection touche essentiellement les zones intertropicales o\u00f9 l\u2019incidence \u00e9lev\u00e9e de l\u2019infection naturelle masque les cas transfusionnels et que beaucoup de formes post-transfusionnelles sont \u00e9galement asymptomatiques (contrairement \u00e0 l\u2019infection par le WNV, l\u2019immunosuppression ne semble pas favoriser les cas graves).Dengue ::: ArbovirosesDeux faits \u00e9pid\u00e9miologiques importants en relation avec la dengue ont concern\u00e9 la France en 2010 : d\u2019une part, une importante \u00e9pid\u00e9mie, principalement \u00e0 s\u00e9rotype 1, a \u00e9t\u00e9 observ\u00e9e dans les Antilles (Martinique, Guadeloupe, Saint-Martin, Saint-Barth\u00e9lemy) au cours de l\u2019\u00e9t\u00e9 [22], au moins comparable \u00e0 celle de 2007 ; d\u2019autre part, deux cas autochtones ont \u00e9t\u00e9 rapport\u00e9s \u00e0 Nice en septembre [23] : ce sont les premiers cas non import\u00e9s de la zone Europe dus \u00e0 cet agent.", [["Dengue", "DISEASE", 465, 471], ["Dengue", "ORGANISM", 465, 471], ["les zones intertropicales", "PROBLEM", 180, 205], ["asymptomatiques", "PROBLEM", 348, 363], ["l\u2019infection par le WNV", "PROBLEM", 381, 403], ["l\u2019immunosuppression", "TEST", 405, 424], ["Arboviroses", "TEST", 476, 487], ["cet agent", "TREATMENT", 946, 955]]], ["Une r\u00e9flexion est engag\u00e9e pour renforcer la surveillance si le virus venait \u00e0 s\u2019implanter durablement sur le territoire m\u00e9tropolitain.Chikungunya ::: ArbovirosesL\u2019\u00e9pid\u00e9mie de CHIK-V qui a s\u00e9vi sur l\u2019\u00eele de la R\u00e9union entre 2005 et 2006 constitue une autre illustration d\u2019\u00e9mergence particuli\u00e8rement r\u00e9ussie.", [["Chikungunya", "DISEASE", 134, 145], ["ArbovirosesL\u2019\u00e9pid\u00e9mie de CHIK-V qui a s\u00e9vi sur l\u2019\u00eele de la R\u00e9union entre 2005 et 2006 constitue une autre illustration d\u2019\u00e9mergence particuli\u00e8rement r\u00e9ussie", "SPECIES", 150, 305], ["Une r\u00e9flexion est", "TEST", 0, 17], ["la surveillance", "TEST", 41, 56], ["si le virus venait", "TREATMENT", 57, 75], ["sur le territoire m\u00e9tropolitain", "TREATMENT", 102, 133], ["Chikungunya", "PROBLEM", 134, 145]]], ["Le 20 janvier 2006, face \u00e0 l\u2019ampleur de l\u2019\u00e9pid\u00e9mie (avec 10 000 \u00e0 40 000 nouveaux cas par semaine), l\u2019\u00c9tablissement fran\u00e7ais du sang a suspendu la collecte de sang total sur l\u2019\u00eele et a mis en place deux mesures qui n\u2019avaient jamais \u00e9t\u00e9 exp\u00e9riment\u00e9es \u00e0 grande \u00e9chelle pour les dons de plaquettes : qualification unitaire par RT-PCR quantitative et inactivation syst\u00e9matique des concentr\u00e9s plaquettaires par le syst\u00e8me Intercept\u00ae susceptible de r\u00e9duire de plus de 5 log10 la charge virale d\u2019un produit sanguin.", [["a suspendu la collecte", "TREATMENT", 133, 155], ["deux", "TEST", 198, 202], ["mesures", "TEST", 203, 210], ["PCR", "TEST", 327, 330], ["et inactivation syst\u00e9matique des", "TREATMENT", 344, 376]]], ["Selon une mod\u00e9lisation de l\u2019Institut national de veille sanitaire (INVS), en consid\u00e9rant que la dur\u00e9e moyenne de la vir\u00e9mie est de 7,5 jours et que 38 % de la population r\u00e9unionnaise a \u00e9t\u00e9 expos\u00e9e au virus (dont environ 6 % de formes asymptomatiques), le nombre de dons positifs \u00e9vit\u00e9s a \u00e9t\u00e9 de 29 au pic de l\u2019\u00e9pid\u00e9mie et de 40 pour l\u2019ensemble de celle-ci [24].Chikungunya ::: ArbovirosesEn d\u00e9finitive, aucun cas de contamination transfusionnelle n\u2019a \u00e9t\u00e9 r\u00e9ellement observ\u00e9 ni \u00e0 la R\u00e9union ni ailleurs dans le monde.", [["Chikungunya", "DISEASE", 361, 372], ["Chikungunya", "ORGANISM", 361, 372], ["en consid\u00e9rant que la dur\u00e9e moyenne de la vir\u00e9mie est", "TREATMENT", 74, 127], ["a \u00e9t\u00e9 expos\u00e9e au virus (dont environ", "TREATMENT", 183, 219], ["ArbovirosesEn", "TREATMENT", 377, 390]]], ["Pourtant le risque de transmission sanguine est av\u00e9r\u00e9 par plusieurs cas de contaminations de travailleurs de laboratoires et par un cas de contamination d\u2019une infirmi\u00e8re au cours d\u2019un pr\u00e9l\u00e8vement de sang chez un patient infect\u00e9 [25], [26].Chikungunya ::: ArbovirosesL\u2019\u00e9pid\u00e9mie de chikungunya continue de d\u00e9ferler vers l\u2019Est (Inde, Indon\u00e9sie, Malaisie, Sri Lanka, Singapour\u2026) avec un tr\u00e8s grand nombre de formes symptomatiques, mais sans manifestations tr\u00e8s graves, contrairement aux deux arboviroses pr\u00e9c\u00e9dentes.", [["Chikungunya", "DISEASE", 239, 250], ["chikungunya", "DISEASE", 280, 291], ["Chikungunya", "ORGANISM", 239, 250], ["patient", "SPECIES", 212, 219], ["Pourtant le risque", "TREATMENT", 0, 18], ["au cours d\u2019un pr\u00e9l\u00e8vement", "TREATMENT", 170, 195], ["ArbovirosesL", "TREATMENT", 255, 267], ["mais sans manifestations tr\u00e8s graves", "PROBLEM", 427, 463]]], ["Au cours de l\u2019\u00e9t\u00e9 2007, un foyer de 250 cas a \u00e9t\u00e9 observ\u00e9 dans la province de Ravenne, au nord-est de l\u2019Italie, suite au retour d\u2019Inde d\u2019un voyageur infect\u00e9 lors d\u2019une piq\u00fbre de moustique dans ce pays [27].Chikungunya ::: ArbovirosesEn septembre 2010, les deux premiers cas fran\u00e7ais non import\u00e9s de chikungunya ont \u00e9t\u00e9 rapport\u00e9s chez des adolescentes de la r\u00e9gion de Fr\u00e9jus [23].Chikungunya ::: ArbovirosesSuite \u00e0 des importations en provenance d\u2019Asie de pneumatiques rechap\u00e9s charg\u00e9s de larves, le vecteur Aedes albopictus est d\u00e9sormais largement implant\u00e9 sur tout le pourtour m\u00e9diterran\u00e9en (sa zone d\u2019influence en France s\u2019\u00e9tend jusqu\u2019\u00e0 Montpellier \u00e0 l\u2019est et \u00e0 l\u2019agglom\u00e9ration lyonnaise au nord), cr\u00e9ant une situation propice \u00e0 la diffusion de CHIK-V comme de DEN-V en cas d\u2019importation de ces agents par le biais de sujets infect\u00e9s.", [["Chikungunya", "DISEASE", 206, 217], ["Chikungunya", "DISEASE", 379, 390], ["Au", "CHEMICAL", 0, 2], ["Chikungunya", "ORGANISM", 206, 217], ["Aedes albopictus est d\u00e9sormais largement implant\u00e9 sur tout le pourtour m\u00e9diterran\u00e9en (sa zone d\u2019influence en France s\u2019\u00e9tend jusqu\u2019\u00e0 Montpellier \u00e0 l\u2019est et \u00e0 l\u2019agglom\u00e9ration lyonnaise au nord", "SPECIES", 507, 697], ["ArbovirosesEn septembre", "TREATMENT", 222, 245], ["Chikungunya", "PROBLEM", 379, 390], ["ArbovirosesSuite \u00e0 des", "TREATMENT", 395, 417], ["V en cas d\u2019importation de ces agents", "TREATMENT", 767, 803], ["le", "ANATOMY", 496, 498]]], ["Concernant la surveillance entomologique pratiqu\u00e9e suite aux cas autochtones de dengue et de chikungunya survenus presque simultan\u00e9ment dans deux zones voisines du sud-est de la France en septembre 2010, il est int\u00e9ressant de noter que seulement deux moustiques ont \u00e9t\u00e9 trouv\u00e9s infect\u00e9s par CHIK-V alors que 180 \u00e9taient infect\u00e9s par DEN-V, ce qui montre le caract\u00e8re bien plus \u00e9pid\u00e9miog\u00e8ne du premier virus que du second.Autres arboviroses ::: ArbovirosesLes principaux arbovirus pr\u00e9sentant un risque transfusionnel potentiel ou av\u00e9r\u00e9s sont pr\u00e9sent\u00e9s dans le Tableau 3.", [["chikungunya survenus presque simultan\u00e9ment dans deux zones voisines du sud-est de la France en septembre 2010, il est int\u00e9ressant de noter que seulement deux moustiques ont \u00e9t\u00e9 trouv\u00e9s infect\u00e9s par CHIK-V alors que 180 \u00e9taient infect\u00e9s par DEN-V, ce qui montre le caract\u00e8re bien plus \u00e9pid\u00e9miog\u00e8ne du premier virus", "SPECIES", 93, 406], ["deux", "TEST", 246, 250], ["CHIK", "TEST", 291, 295], ["ArbovirosesLes", "TEST", 444, 458]]], ["Bien qu\u2019il n\u2019existe aucun cas d\u00e9crit de transmission transfusionnelle, la proximit\u00e9 phylog\u00e9n\u00e9tique de ce virus avec WNV et leurs similitudes \u00e9pid\u00e9miologiques (m\u00eame vecteur, m\u00eame r\u00e9servoir aviaire, m\u00eames h\u00f4tes accidentels : homme et cheval) plaident pour une vigilance autour de cet agent.Autres arboviroses ::: ArbovirosesL\u2019enc\u00e9phalite \u00e0 tique s\u00e9vit dans toute l\u2019Europe centrale (y compris l\u2019Alsace pour la France, l\u2019Allemagne, la Suisse et l\u2019Autriche), la Russie et l\u2019Asie (jusqu\u2019au Japon).", [["ArbovirosesL\u2019enc\u00e9phalite \u00e0 tique s\u00e9vit dans toute l\u2019Europe centrale (y compris l\u2019Alsace pour la France, l\u2019Allemagne, la Suisse et l\u2019Autriche", "SPECIES", 311, 451], ["la", "TEST", 71, 73], ["ArbovirosesL\u2019enc\u00e9phalite", "TEST", 311, 335], ["Allemagne", "TEST", 417, 426]]], ["Un vaccin est disponible dans les r\u00e9gions de forte end\u00e9mie.Human herpes virus 8 (HHV-8) ::: Autres viroses \u00e9mergentes en transfusionHHV-8 est l\u2019agent causal du sarcome de Kaposi.", [["Human herpes virus", "DISEASE", 59, 77], ["Kaposi", "DISEASE", 171, 177], ["Human herpes virus 8", "ORGANISM", 59, 79], ["HHV-8", "ORGANISM", 81, 86], ["Kaposi", "ORGANISM", 171, 177], ["Human herpes virus", "SPECIES", 59, 77], ["Human herpes virus", "SPECIES", 59, 77], ["HHV", "SPECIES", 81, 84], ["Autres viroses \u00e9mergentes en transfusionHHV-8 est l\u2019agent causal du sarcome", "SPECIES", 92, 167], ["Human herpes virus", "TEST", 59, 77], ["Autres viroses", "TREATMENT", 92, 106], ["HHV", "TEST", 132, 135], ["Kaposi", "OBSERVATION", 171, 177]]], ["Il se transmet principalement par voie sexuelle et sa pr\u00e9valence a \u00e9t\u00e9 estim\u00e9e entre 2 et 4 % chez les donneurs de sang aux \u00c9tats-Unis et \u00e0 2 % chez les donneurs fran\u00e7ais [29], [30].", [["Il se transmet principalement", "TREATMENT", 0, 29], ["a \u00e9t\u00e9 estim\u00e9e entre", "TREATMENT", 65, 84], ["Unis et \u00e0", "TREATMENT", 130, 139]]], ["Sa transmission par voie sanguine a \u00e9t\u00e9 discut\u00e9e au cours d\u2019une transfusion de sang et d\u2019une transplantation r\u00e9nale [31], [32] ; elle a \u00e9t\u00e9 bien \u00e9tablie par une \u00e9tude prospective men\u00e9e au Kenya et ayant montr\u00e9 un taux de s\u00e9roconversion, dans un d\u00e9lai de trois \u00e0 dix semaines apr\u00e8s un acte transfusionnel, significativement plus \u00e9lev\u00e9 dans le groupe transfus\u00e9 que dans le groupe non transfus\u00e9 [33].", [["transfusion de sang et d\u2019une transplantation", "TREATMENT", 64, 108]]], ["Cependant, aucune infection clinique n\u2019a \u00e9t\u00e9 observ\u00e9e.", [["infection", "DISEASE", 18, 27], ["Cependant", "TREATMENT", 0, 9], ["aucune infection", "PROBLEM", 11, 27], ["infection", "OBSERVATION", 18, 27]]], ["Cette derni\u00e8re observation, conjugu\u00e9e \u00e0 la faible incidence du portage, a conduit \u00e0 ne prendre aucune mesure particuli\u00e8re de pr\u00e9vention en dehors de la d\u00e9leucocytation des PSL [3].Erythrovirus B19 (ex-parvovirus B19) ::: Autres viroses \u00e9mergentes en transfusionCe petit virus non envelopp\u00e9, tr\u00e8s r\u00e9sistant dans le milieu ext\u00e9rieur et responsable du m\u00e9gal\u00e9ryth\u00e8me \u00e9pid\u00e9mique chez l\u2019enfant, d\u2019infections cong\u00e9nitales par transmission transplacentaire et de pouss\u00e9es de d\u00e9globulinisation aigu\u00ebs chez les sujets porteurs d\u2019an\u00e9mies constitutionnelles, a un fort tropisme pour les cellules my\u00e9lo\u00efdes.", [["ex-parvovirus B19", "DISEASE", 198, 215], ["Erythrovirus B19", "ORGANISM", 180, 196], ["ex-parvovirus B19", "ORGANISM", 198, 215], ["Erythrovirus B19", "SPECIES", 180, 196], ["Erythrovirus B19", "SPECIES", 180, 196], ["B19", "SPECIES", 212, 215], ["a conduit", "TREATMENT", 72, 81], ["Erythrovirus", "TEST", 180, 192], ["Autres viroses \u00e9mergentes", "TREATMENT", 221, 246], ["petit virus", "PROBLEM", 264, 275]]], ["La plupart des fabricants de ces produits utilisent des tests mol\u00e9culaires pour exclure les produits contamin\u00e9s par cet agent [3].Virus de l\u2019h\u00e9patite A (HAV) et de l\u2019h\u00e9patite E (HEV) ::: Autres viroses \u00e9mergentes en transfusionCes deux agents non envelopp\u00e9s, principalement diss\u00e9min\u00e9s par voie f\u00e9cale-orale, pr\u00e9sentent une courte vir\u00e9mie au cours de laquelle ils peuvent \u00eatre transmis par transfusion [37], [38], [39], [40], [41].", [["Virus de l\u2019h\u00e9patite A", "ORGANISM", 130, 151], ["HAV", "ORGANISM", 153, 156], ["HEV", "SPECIES", 178, 181], ["La plupart des", "TREATMENT", 0, 14], ["des tests", "TEST", 52, 61], ["contamin\u00e9s par cet agent", "TREATMENT", 101, 125], ["Autres viroses \u00e9mergentes", "TREATMENT", 187, 212]]], ["Les infections sont habituellement asymptomatiques chez le receveur.", [["Les infections", "PROBLEM", 0, 14], ["infections", "OBSERVATION", 4, 14]]], ["N\u00e9anmoins, HEV est end\u00e9mique en France, notamment dans le r\u00e9servoir porcin, et l\u2019infection par cet agent, potentiellement grave chez l\u2019immunod\u00e9prim\u00e9 (par exemple apr\u00e8s transplantation h\u00e9patique ou r\u00e9nale) et la femme enceinte, est consid\u00e9r\u00e9e comme \u00e9mergente (pour des revues sur cet agent, voir [42], [43]).", [["N\u00e9anmoins", "TREATMENT", 0, 9], ["notamment dans le r\u00e9servoir porcin", "TREATMENT", 40, 74], ["et l\u2019infection par cet agent", "TREATMENT", 76, 104], ["grave chez l\u2019immunod\u00e9prim\u00e9", "TREATMENT", 122, 148], ["par exemple apr\u00e8s transplantation", "TREATMENT", 150, 183]]], ["C\u2019est pourquoi une vigilance est de rigueur vis-\u00e0-vis du risque transfusionnel, notamment chez des sujets transplant\u00e9s [44], [45], [46].Variants de HIV-1\u00a0et de HBV ::: Autres viroses \u00e9mergentes en transfusionLes virus HIV-1 et HBV se caract\u00e9risent par leur capacit\u00e9 \u00e0 \u00e9voluer sous forme de quasi-esp\u00e8ce caract\u00e9ris\u00e9e par l\u2019\u00e9mergence de mutants au fil de l\u2019histoire clinique du patient.", [["HIV-1", "ORGANISM", 148, 153], ["HBV", "ORGANISM", 160, 163], ["patient", "ORGANISM", 376, 383], ["HIV", "SPECIES", 148, 151], ["patient", "SPECIES", 376, 383], ["C\u2019est", "TEST", 0, 5], ["Autres viroses", "TREATMENT", 168, 182], ["HIV", "TEST", 218, 221], ["et HBV se caract\u00e9risent par leur capacit\u00e9", "TREATMENT", 224, 265]]], ["Certaines mutations peuvent s\u2019accompagner d\u2019une non-reconnaissance par les tests diagnostiques traditionnels [47].", [["Certaines mutations", "TREATMENT", 0, 19]]], ["Pour l\u2019HBV, il existe en outre des cas d\u2019h\u00e9patite B dite occulte o\u00f9 seuls les marqueurs mol\u00e9culaires sont positifs [48], [49].", [["Pour l\u2019HBV", "TREATMENT", 0, 10], ["HBV", "OBSERVATION", 7, 10]]], ["Le diagnostic g\u00e9nomique viral appliqu\u00e9 \u00e0 tous les dons de sang pour la d\u00e9tection du g\u00e9nome de ces deux agents (en combinaison avec celui de HCV) est susceptible de r\u00e9duire consid\u00e9rablement les risques de faux-n\u00e9gatif par les tests s\u00e9rologiques.Virus grippal A/H5N1 ::: Autres viroses \u00e9mergentes en transfusionLe variant grippal A/H5N1 qui est responsable d\u2019une v\u00e9ritable pand\u00e9mie aviaire depuis une dizaine d\u2019ann\u00e9e a caus\u00e9 \u00e0 ce jour plus de 500 infections humaines document\u00e9es virologiquement, avec une mortalit\u00e9 d\u2019environ 60 % [50].", [["infections", "DISEASE", 445, 455], ["Virus grippal A/H5N1", "ORGANISM", 244, 264], ["Virus grippal A/H5N1", "SPECIES", 244, 264], ["Autres viroses \u00e9mergentes en transfusionLe variant grippal A/H5N1 qui est responsable d\u2019une v\u00e9ritable pand\u00e9mie aviaire depuis une dizaine d\u2019ann\u00e9e", "SPECIES", 269, 414], ["Le diagnostic", "TEST", 0, 13], ["deux agents", "TREATMENT", 98, 109], ["en combinaison avec celui", "TREATMENT", 111, 136]]], ["Le sc\u00e9nario d\u2019une adaptation durable du virus \u00e0 notre esp\u00e8ce justifie une vigilance extr\u00eame.", [["Le sc\u00e9nario", "TREATMENT", 0, 11], ["du virus", "OBSERVATION", 37, 45]]], ["M\u00eame si la dur\u00e9e tr\u00e8s courte de la vir\u00e9mie ne semble pas faire peser un risque important sur l\u2019acte transfusionnel [51], la d\u00e9sorganisation de la transfusion sanguine provoqu\u00e9e par une pand\u00e9mie grippale de tr\u00e8s grandes ampleur et gravit\u00e9 a \u00e9t\u00e9 anticip\u00e9e dans les \u00ab plans pand\u00e9miques \u00bb pr\u00e9par\u00e9s par de nombreux pays [3], [52].R\u00e9trovirus simiens ::: Autres viroses \u00e9mergentes en transfusionDes chasseurs ou des personnes expos\u00e9s professionnellement \u00e0 des primates non humains ont \u00e9t\u00e9 identifi\u00e9s comme porteurs d\u2019anticorps contre certains r\u00e9trovirus simiens et notamment le Simian foamy virus (SFV) [53].", [["Simian foamy virus", "DISEASE", 571, 589], ["Simian foamy virus", "ORGANISM", 571, 589], ["Simian foamy virus", "SPECIES", 571, 589], ["Simian foamy virus", "SPECIES", 571, 589], ["la d\u00e9sorganisation de la transfusion sanguine", "TREATMENT", 121, 166], ["Autres viroses \u00e9mergentes", "TREATMENT", 348, 373], ["ou des", "TREATMENT", 402, 408], ["humains ont \u00e9t\u00e9", "TREATMENT", 466, 481], ["d\u2019anticorps", "TEST", 508, 519]]], ["Par ailleurs, le d\u00e9veloppement d\u2019un tourisme de masse dans des r\u00e9gions exotiques o\u00f9 vivent des singes h\u00e9bergeant de nombreux r\u00e9trovirus constitue un risque de contamination accidentelle non n\u00e9gligeable : le risque d\u2019infection par SFV a \u00e9t\u00e9 estim\u00e9 \u00e0 0,3 % pour les quelque 700 000 touristes visitant chaque ann\u00e9e les r\u00e9serves de singes de l\u2019\u00eele de Bali [54].", [["Par ailleurs", "TREATMENT", 0, 12], ["a \u00e9t\u00e9 estim\u00e9", "TREATMENT", 234, 246], ["le", "ANATOMY", 14, 16]]], ["M\u00eame s\u2019il n\u2019a jamais \u00e9t\u00e9 rapport\u00e9 de transmission transfusionnelle de cet agent, il ne faut pas n\u00e9gliger, par analogie avec l\u2019origine simienne de la pand\u00e9mie HIV, l\u2019hypoth\u00e8se de son adaptation durable \u00e0 l\u2019esp\u00e8ce humaine, ce qui ne manquerait pas d\u2019impacter la s\u00e9curit\u00e9 transfusionnelle.Autres virus ::: Autres viroses \u00e9mergentes en transfusionLa liste des virus poss\u00e9dant un risque transfusionnel th\u00e9orique pourrait s\u2019allonger presqu\u2019ind\u00e9finiment tant sont nombreux les virus transmissibles par voie sanguine, qu\u2019il s\u2019agisse des centaines d\u2019esp\u00e8ces d\u2019arbovirus infestant la plan\u00e8te, des papillomavirus, du coronavirus du SRAS (dont la circulation a compl\u00e8tement cess\u00e9 apr\u00e8s une br\u00e8ve \u00e9mergence en 2002\u20132003), du virus de la variole (qui pourrait \u00eatre \u00ab ressuscit\u00e9 \u00bb dans le cadre d\u2019une op\u00e9ration de bioterrorisme), des virus des fi\u00e8vres h\u00e9morragiques (Ebola, Lassa, Marburg, ar\u00e9navirus du nouveau monde, fi\u00e8vre de la vall\u00e9e du Rift, fi\u00e8vre jaune, fi\u00e8vre h\u00e9morragique d\u2019Omsk, fi\u00e8vre h\u00e9morragique de Crim\u00e9e-Congo, maladie de la for\u00eat de Kyasanur), voire de virus actuellement orphelins de pouvoir pathog\u00e8ne comme GBVc/HGV ou TTV/SEN-V.Tests biologiques cibl\u00e9s de d\u00e9pistage ::: N\u00e9cessit\u00e9 de mesures de contr\u00f4lesCes tests sont principalement d\u00e9di\u00e9s aux virus \u00ab majeurs \u00bb (HIV, HBV, HCV, HTLV).", [["Ebola, Lassa", "DISEASE", 852, 864], ["HIV, HBV, HCV, HTLV", "DISEASE", 1268, 1287], ["Autres virus", "ORGANISM", 286, 298], ["papillomavirus", "ORGANISM", 587, 601], ["HIV", "ORGANISM", 1268, 1271], ["HBV", "ORGANISM", 1273, 1276], ["HCV", "ORGANISM", 1278, 1281], ["HTLV", "ORGANISM", 1283, 1287], ["Autres virus", "SPECIES", 286, 298], ["du coronavirus du SRAS (dont la circulation a compl\u00e8tement cess\u00e9 apr\u00e8s une br\u00e8ve \u00e9mergence en 2002\u20132003), du virus de la variole (qui pourrait \u00eatre \u00ab ressuscit\u00e9 \u00bb dans le cadre d\u2019une op\u00e9ration de bioterrorisme", "SPECIES", 603, 812], ["pouvoir pathog\u00e8ne comme GBVc/HGV ou TTV/SEN-V.", "SPECIES", 1087, 1133], ["HIV", "SPECIES", 1268, 1271], ["HBV", "SPECIES", 1273, 1276], ["HCV", "SPECIES", 1278, 1281], ["Autres viroses \u00e9mergentes", "TREATMENT", 303, 328], ["en transfusionLa liste des virus", "TREATMENT", 329, 361], ["transfusionnel", "TEST", 382, 396], ["th\u00e9orique", "TEST", 397, 406], ["sanguine", "TEST", 500, 508], ["qu\u2019il s\u2019agisse des", "TREATMENT", 510, 528], ["la plan\u00e8te", "TREATMENT", 571, 581], ["du coronavirus du SRAS", "PROBLEM", 603, 625], ["du virus de la variole (qui pourrait \u00eatre", "TREATMENT", 709, 750], ["Ces tests", "TEST", 1208, 1217], ["principalement", "TEST", 1223, 1237], ["HIV", "PROBLEM", 1268, 1271], ["HBV", "PROBLEM", 1273, 1276], ["HCV", "PROBLEM", 1278, 1281]]], ["D\u2019abord de type immunologique (avec d\u00e9tection d\u2019anticorps et, si possible, d\u2019antig\u00e8nes s\u00e9riques), ils sont \u00e9galement mol\u00e9culaires (diagnostic g\u00e9nomique viral) en France pour HIV, HCV et, r\u00e9cemment, HBV.", [["HCV", "ORGANISM", 179, 182], ["HBV", "ORGANISM", 198, 201], ["HCV", "SPECIES", 179, 182], ["HBV", "SPECIES", 198, 201], ["D\u2019abord de type immunologique", "PROBLEM", 0, 29], ["avec d\u00e9tection d\u2019anticorps", "TREATMENT", 31, 57], ["diagnostic g\u00e9nomique viral)", "TREATMENT", 131, 158], ["HCV et", "TREATMENT", 179, 185], ["HBV", "PROBLEM", 198, 201]]], ["Ces derniers permettent de r\u00e9duire la fen\u00eatre s\u00e9rologique et d\u2019\u00e9largir le d\u00e9pistage aux virus variants non reconnus par les tests immunologiques.", [["Ces derniers", "TEST", 0, 12]]], ["Un article r\u00e9cent [55] vient de montrer l\u2019apport de la d\u00e9tection mol\u00e9culaire de HBV chez les donneurs de sang (y compris ceux vaccin\u00e9s contre l\u2019h\u00e9patite B) pour pr\u00e9venir la contamination des receveurs par de telles souches variantes.Tests biologiques cibl\u00e9s de d\u00e9pistage ::: N\u00e9cessit\u00e9 de mesures de contr\u00f4lesDe nombreux virus \u00e9mergents peuvent \u00eatre identifi\u00e9s par des tests sp\u00e9cifiques, qu\u2019ils soient s\u00e9rologiques ou mol\u00e9culaires.", [["vient de montrer l\u2019apport de la d\u00e9tection mol\u00e9culaire", "TREATMENT", 23, 76], ["y compris ceux vaccin\u00e9s", "TREATMENT", 111, 134], ["pour pr\u00e9venir la contamination des", "TREATMENT", 156, 190]]], ["A priori, n\u2019importe quel agent \u00e9mergent peut faire l\u2019objet d\u2019un tel d\u00e9pistage.", [["n\u2019importe quel agent", "TREATMENT", 10, 30]]], ["En pratique, il faut n\u00e9anmoins \u00eatre capable d\u2019adapter la technique (parfois r\u00e9serv\u00e9e \u00e0 des centres de r\u00e9f\u00e9rence) \u00e0 un d\u00e9pistage de masse, ce qui ne va pas sans poser des probl\u00e8mes \u00e0 la fois organisationnels et \u00e9conomiques [15].Tests biologiques cibl\u00e9s de d\u00e9pistage ::: N\u00e9cessit\u00e9 de mesures de contr\u00f4lesPour le prion responsable de la MCJv, des tests biologiques sont en cours de d\u00e9veloppement, mais leur manque de sensibilit\u00e9 et l\u2019absence de test de confirmation standardis\u00e9 rendent leur mise en \u0153uvre encore hasardeuse [6].", [["la technique", "TREATMENT", 54, 66], ["Pour le prion", "TEST", 302, 315], ["des tests biologiques", "TEST", 340, 361]]], ["La publication toute r\u00e9cente d\u2019un test capable de d\u00e9tecter l\u2019agent variant de la MCJv dans le sang de sujets atteints de cette pathologie [56] laisse esp\u00e9rer que nous disposerons dans le futur d\u2019un test suffisamment sensible pour \u00eatre utilis\u00e9 en d\u00e9pistage transfusionnel de routine.Techniques de d\u00e9leucocytation ::: N\u00e9cessit\u00e9 de mesures de contr\u00f4lesLa mesure a \u00e9t\u00e9 impl\u00e9ment\u00e9e en France de fa\u00e7on syst\u00e9matique d\u00e8s 1998 ; elle permet une r\u00e9duction du nombre de leucocytes en dessous de 106 par unit\u00e9 de sang.", [["leucocytes", "CELL_TYPE", 459, 469], ["La publication toute", "TEST", 0, 20], ["sang", "OBSERVATION", 501, 505]]], ["Cette technique s\u2019est av\u00e9r\u00e9e tr\u00e8s efficace pour \u00e9liminer les virus principalement intracellulaires et notamment le cytom\u00e9galovirus, le virus d\u2019Epstein-Barr, HHV-8 et les r\u00e9trovirus (HIV et HTLV) [57].", [["HIV et HTLV", "ORGANISM", 182, 193], ["av\u00e9r\u00e9e tr\u00e8s efficace pour \u00e9liminer les virus principalement intracellulaires et notamment le cytom\u00e9galovirus, le virus d\u2019Epstein-Barr, HHV-8 et les r\u00e9trovirus (HIV et HTLV)", "SPECIES", 22, 194], ["Cette technique", "TEST", 0, 15], ["s\u2019est", "TEST", 16, 21], ["tr\u00e8s", "TEST", 29, 33], ["efficace", "TEST", 34, 42], ["pour \u00e9liminer les virus principalement", "TEST", 43, 81], ["intracellulaires", "TEST", 82, 98], ["et notamment", "TEST", 99, 111], ["le cytom\u00e9galovirus", "TEST", 112, 130], ["le virus", "PROBLEM", 132, 140], ["HHV", "TEST", 157, 160], ["et les r\u00e9trovirus", "PROBLEM", 163, 180], ["le virus", "ANATOMY", 132, 140]]], ["La d\u00e9leucocytation permet aussi de minorer le risque prion d\u2019un facteur d\u2019environ 50 % [58], sans parler de son int\u00e9r\u00eat pour r\u00e9duire le risque d\u2019immunisation HLA ou d\u2019infection par des bact\u00e9ries ou des protozoaires.Techniques d\u2019inactivation pour le plasma ::: Inactivation non sp\u00e9cifique des pathog\u00e8nes ::: N\u00e9cessit\u00e9 de mesures de contr\u00f4lesLes techniques d\u00e9di\u00e9es exclusivement au plasma comprennent : (i) des traitements physicochimiques comme l\u2019utilisation de solvants-d\u00e9tergents capables d\u2019inactiver les virus envelopp\u00e9s par destruction des lipides constitutifs de l\u2019enveloppe, (ii) des traitements par des colorants \u00e0 base de ph\u00e9nothiazine comme le bleu de m\u00e9thyl\u00e8ne qui, lorsqu\u2019ils sont photoactiv\u00e9s par la lumi\u00e8re visible, entra\u00eenent une oxydation de la guanine des g\u00e9nomes viraux, et (iii) des techniques physiques de nanofiltration qui \u00e9liminent les organismes de taille sup\u00e9rieure \u00e0 celle des pores du nanofiltre.", [["plasma", "ORGANISM_SUBSTANCE", 249, 255], ["plasma", "ORGANISM_SUBSTANCE", 380, 386], ["La d\u00e9leucocytation permet", "TREATMENT", 0, 25], ["facteur d\u2019environ", "TREATMENT", 64, 81], ["HLA ou d\u2019infection par des", "TREATMENT", 158, 184], ["des traitements physicochimiques", "TREATMENT", 405, 437], ["les virus envelopp\u00e9s par destruction", "PROBLEM", 502, 538], ["des traitements par des colorants", "TREATMENT", 585, 618], ["entra\u00eenent une oxydation de la guanine des", "TREATMENT", 728, 770], ["et (iii) des techniques", "TREATMENT", 787, 810], ["de nanofiltration qui \u00e9liminent les organismes", "TREATMENT", 821, 867], ["du nanofiltre", "TREATMENT", 907, 920]]], ["Les deux premi\u00e8res techniques sont utilis\u00e9es en routine dans les centres de pr\u00e9paration de plasma en France.Techniques d\u2019inactivation convenant au plasma et aux concentr\u00e9s plaquettaires ::: Inactivation non sp\u00e9cifique des pathog\u00e8nes ::: N\u00e9cessit\u00e9 de mesures de contr\u00f4lesTrois techniques n\u00e9cessitant une photoactivation par des ultraviolets conviennent, avec des variantes, \u00e0 la fois au plasma et aux concentr\u00e9s plaquettaires ; il s\u2019agit (i) du proc\u00e9d\u00e9 Intercept\u00ae de Cerus Corporation (Concord, Ca, \u00c9tats-Unis) qui utilise un d\u00e9riv\u00e9 du psoral\u00e8ne, l\u2019amotosalen, comme principe actif, (ii) du proc\u00e9d\u00e9 Mirasol\u00ae de CaridianBCT Biotechnologies (Lakewood, Co, \u00c9tats-Unis) qui utilise la riboflavine (ou vitamine B2) comme principe actif, et (iii) du proc\u00e9d\u00e9 Theraflex UV\u00ae de MacoPharma (Tourcoing, France) qui, par la simple combinaison d\u2019une irradiation par les ultraviolets et d\u2019une intense agitation, produit la formation d\u2019anneaux cyclobutyl.", [["Ca", "CHEMICAL", 494, 496], ["Mirasol\u00ae", "CHEMICAL", 598, 606], ["Theraflex UV\u00ae de MacoPharma", "CHEMICAL", 751, 778], ["agitation", "DISEASE", 886, 895], ["cyclobutyl", "CHEMICAL", 928, 938], ["cyclobutyl", "CHEMICAL", 928, 938], ["plasma", "ORGANISM_SUBSTANCE", 91, 97], ["plasma", "ORGANISM_SUBSTANCE", 147, 153], ["Trois techniques", "TREATMENT", 270, 286], ["une photoactivation par des ultraviolets", "TREATMENT", 299, 339], ["du psoral\u00e8ne", "TREATMENT", 532, 544], ["l\u2019amotosalen", "TREATMENT", 546, 558], ["Co", "TEST", 649, 651], ["\u00c9tats", "TEST", 653, 658], ["la riboflavine", "TREATMENT", 677, 691], ["ou vitamine B2", "TREATMENT", 693, 707], ["par la simple combinaison d\u2019une irradiation par les ultraviolets", "TREATMENT", 804, 868], ["intense agitation", "PROBLEM", 878, 895]]], ["Ces proc\u00e9d\u00e9s sont actifs contre une large gamme de pathog\u00e8nes, incluant des virus nus et envelopp\u00e9s, des bact\u00e9ries et des protozoaires.", [["Ces proc\u00e9d\u00e9s", "TEST", 0, 12], ["des bact\u00e9ries et des protozoaires", "TREATMENT", 101, 134]]], ["Le rendement en plaquettes est sensiblement diminu\u00e9, notamment avec l\u2019amotosalen, mais celles-ci semblent conserver leurs propri\u00e9t\u00e9s d\u2019activation, d\u2019adh\u00e9sion et d\u2019agr\u00e9gation.", [["Le rendement", "TEST", 0, 12]]], ["Le syst\u00e8me Intercept\u00ae a \u00e9t\u00e9 test\u00e9 avec satisfaction pour l\u2019inactivation des concentr\u00e9s plaquettaires lors de l\u2019\u00e9pid\u00e9mie de CHIK-V \u00e0 la R\u00e9union.Techniques d\u2019inactivation des concentr\u00e9s de globules rouges ::: Inactivation non sp\u00e9cifique des pathog\u00e8nes ::: N\u00e9cessit\u00e9 de mesures de contr\u00f4lesLes proc\u00e9d\u00e9s d\u2019inactivation des concentr\u00e9s de globules rouges font encore l\u2019objet d\u2019essais cliniques.", [["a \u00e9t\u00e9 test\u00e9", "TEST", 22, 33]]], ["Trois approches utilisant des agents bloquants des acides nucl\u00e9iques sont en cours d\u2019\u00e9valuation assez avanc\u00e9e : la premi\u00e8re repose sur la riboflavine (Caridian), la deuxi\u00e8me sur une \u00e9thyl\u00e8neimine binaire, l\u2019Inactine\u2122 (PEN110) de la soci\u00e9t\u00e9 Vitex (Prestons, NSW, Australie), et la troisi\u00e8me sur un agent alkylant d\u00e9nomm\u00e9 S3003 ou amustaline (Cerus), dont l\u2019activation ne se fait pas par irradiation mais par exposition \u00e0 un pH acide.Techniques d\u2019inactivation des concentr\u00e9s de globules rouges ::: Inactivation non sp\u00e9cifique des pathog\u00e8nes ::: N\u00e9cessit\u00e9 de mesures de contr\u00f4lesLe rapport b\u00e9n\u00e9fice-risque de ces diff\u00e9rentes strat\u00e9gies d\u2019inactivation fait l\u2019objet d\u2019\u00e9tudes dont les r\u00e9sultats seront bient\u00f4t publi\u00e9s.ConclusionsAu cours des 20 derni\u00e8res ann\u00e9es, la s\u00e9curit\u00e9 en transfusion sanguine a fait de tr\u00e8s grands progr\u00e8s vis-\u00e0-vis du risque infectieux et notamment du risque viral.", [["des agents bloquants des acides nucl\u00e9iques", "CHEMICAL", 26, 68], ["amustaline", "CHEMICAL", 329, 339], ["Au", "CHEMICAL", 723, 725], ["la deuxi\u00e8me sur une \u00e9thyl\u00e8neimine binaire", "TREATMENT", 162, 203], ["l\u2019Inactine\u2122 (PEN110", "TREATMENT", 205, 224], ["et la troisi\u00e8me sur un agent", "TREATMENT", 274, 302], ["pas par irradiation", "TREATMENT", 378, 397], ["ann\u00e9es", "TEST", 749, 755], ["la s\u00e9curit\u00e9 en transfusion", "TREATMENT", 757, 783], ["PE", "OBSERVATION", 218, 220]]], ["L\u2019am\u00e9lioration continue de la qualit\u00e9 conduit \u00e0 toujours accro\u00eetre la vigilance dans ce domaine.", [["L\u2019am\u00e9lioration", "TEST", 0, 14]]], ["Si de tr\u00e8s nombreux virus peuvent \u00eatre consid\u00e9r\u00e9s comme \u00e9mergents, deux risques sont particuli\u00e8rement \u00e0 prendre en consid\u00e9ration en France m\u00e9tropolitaine : les arbovirus \u00e9mergents et l\u2019agent de la MCJv.ConclusionsL\u2019extension du p\u00e9rim\u00e8tre de diffusion d\u2019Aedes albopictus en Europe justifie une surveillance accrue qui s\u2019est mat\u00e9rialis\u00e9e par les recommandations de la circulaire no DGS/RI1/2010/163 du 17 mai 2010 relative aux modalit\u00e9s de mise en \u0153uvre du plan anti-diss\u00e9mination du chikungunya et de la dengue en m\u00e9tropole [62].", [["Si", "CHEMICAL", 0, 2], ["ConclusionsL\u2019extension du p\u00e9rim\u00e8tre de diffusion d\u2019Aedes albopictus en Europe justifie une surveillance accrue qui s\u2019est mat\u00e9rialis\u00e9e par les recommandations de la circulaire no DGS/RI1/2010/163 du 17 mai 2010 relative aux modalit\u00e9s de mise en \u0153uvre du plan anti-diss\u00e9mination du chikungunya et de la dengue en m\u00e9tropole", "SPECIES", 202, 522], ["les arbovirus \u00e9mergents", "TREATMENT", 156, 179]]], ["Le faible nombre de cas transfusionnels r\u00e9pertori\u00e9s \u00e0 ce jour ne doit pas rassurer \u00e0 bon compte si l\u2019on prend en consid\u00e9ration le fait que ces deux agents pourraient toucher des populations totalement r\u00e9ceptives ; \u00e0 cet \u00e9gard, l\u2019implantation du WNV en Am\u00e9rique du nord et les nouveaux risques transfusionnels qui en ont d\u00e9coul\u00e9 peuvent servir de mod\u00e8le.ConclusionsEn ce qui concerne le risque prion, m\u00eame s\u2019il semble quantitativement faible, il justifie les efforts conjugu\u00e9s des sp\u00e9cialistes europ\u00e9ens pour d\u00e9velopper des outils de d\u00e9pistage fiables et performants de l\u2019agent de la MCJv dans les produits sanguins.ConclusionsEn parall\u00e8le, il appara\u00eet indispensable de d\u00e9velopper des traitements non sp\u00e9cifiques des PSL susceptibles d\u2019inactiver les agents infectieux \u2013 quelle qu\u2019en soit la nature \u2013 qui sont potentiellement pr\u00e9sents dans le sang des donneurs.", [["r\u00e9pertori\u00e9s", "TEST", 40, 51], ["ce", "TEST", 54, 56], ["sang des", "OBSERVATION", 841, 849]]]], "1ae41b47e692f87a2a73f1a02ac6c908b26d94bf": [["IntroductionThis document aims to formalize a minimum level of management for patients with thoracic malignancies during the COVID-19 pandemic.", [["thoracic malignancies", "ANATOMY", 92, 113], ["thoracic malignancies", "DISEASE", 92, 113], ["patients", "ORGANISM", 78, 86], ["thoracic malignancies", "CANCER", 92, 113], ["patients", "SPECIES", 78, 86], ["a minimum level of management", "TREATMENT", 44, 73], ["thoracic malignancies", "PROBLEM", 92, 113], ["the COVID", "TEST", 121, 130], ["pandemic", "PROBLEM", 134, 142], ["thoracic", "ANATOMY", 92, 100], ["malignancies", "OBSERVATION", 101, 113]]], ["The objectives are to reduce the risk of infection among particularly vulnerable patients and save human medical and paramedical resources as well as material resources like operating theaters, ventilators and hospital beds.", [["infection", "DISEASE", 41, 50], ["patients", "ORGANISM", 81, 89], ["human", "ORGANISM", 99, 104], ["patients", "SPECIES", 81, 89], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["infection", "PROBLEM", 41, 50], ["paramedical resources", "TREATMENT", 117, 138], ["ventilators", "TREATMENT", 194, 205], ["infection", "OBSERVATION", 41, 50]]], ["The goal is to handle thoracic cancer patients in a concerted and, above all, in a standardized manner.", [["thoracic cancer", "ANATOMY", 22, 37], ["thoracic cancer", "DISEASE", 22, 37], ["thoracic cancer", "CANCER", 22, 37], ["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["handle thoracic cancer", "PROBLEM", 15, 37], ["thoracic", "ANATOMY", 22, 30], ["cancer", "OBSERVATION", 31, 37]]], ["They must be tailored to our institutions and fluctuating resources during the COVID-19 epidemic.", [["the COVID", "TEST", 75, 84]]], ["The proposals are based on those of the French High Council for Public Health, on published data on thoracic oncology outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients.", [["thoracic", "ANATOMY", 100, 108], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["COVID", "TEST", 141, 146], ["thoracic", "ANATOMY", 100, 108]]], ["Symptomatic and/or COVID-19+ patients are not discussed in this document.", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["Symptomatic", "PROBLEM", 0, 11], ["COVID", "TEST", 19, 24]]], ["They are managed by specific departments.General considerations and measuresPatients are to come to appointments for treatment purposes only once they receive confirmation the day before through remote consultation.", [["Patients", "ORGANISM", 76, 84], ["Patients", "SPECIES", 76, 84], ["treatment purposes", "TREATMENT", 117, 135]]], ["On arrival on the day of their appointment, they are checked for any fever and/or symptoms that might have appeared since the previous day and then enter the treatment and follow-up units unaccompanied.", [["fever", "DISEASE", 69, 74], ["any fever", "PROBLEM", 65, 74], ["symptoms", "PROBLEM", 82, 90]]], ["If they have symptoms, they will be referred to a specific COVID unit.General considerations and measuresPatients in other situations will be seen through remote consultation.", [["Patients", "ORGANISM", 105, 113], ["COVID unit", "DNA", 59, 69], ["Patients", "SPECIES", 105, 113], ["symptoms", "PROBLEM", 13, 21]]], ["Whenever possible, home hospital care should be the preferred option.", [["home hospital care", "TREATMENT", 19, 37]]], ["Patients with metastatic or locally advanced lung cancer are at risk of serious infection because they may be immunocompromised (corticosteroids, chemotherapy) or suffer from concomitant lung disease or ischemic heart disease.", [["lung cancer", "ANATOMY", 45, 56], ["lung", "ANATOMY", 187, 191], ["heart", "ANATOMY", 212, 217], ["lung cancer", "DISEASE", 45, 56], ["infection", "DISEASE", 80, 89], ["lung disease", "DISEASE", 187, 199], ["ischemic heart disease", "DISEASE", 203, 225], ["Patients", "ORGANISM", 0, 8], ["lung cancer", "CANCER", 45, 56], ["lung", "ORGAN", 187, 191], ["heart", "ORGAN", 212, 217], ["Patients", "SPECIES", 0, 8], ["metastatic or locally advanced lung cancer", "PROBLEM", 14, 56], ["serious infection", "PROBLEM", 72, 89], ["immunocompromised", "PROBLEM", 110, 127], ["corticosteroids", "TREATMENT", 129, 144], ["chemotherapy", "TREATMENT", 146, 158], ["concomitant lung disease", "PROBLEM", 175, 199], ["ischemic heart disease", "PROBLEM", 203, 225], ["metastatic", "OBSERVATION_MODIFIER", 14, 24], ["locally", "OBSERVATION_MODIFIER", 28, 35], ["advanced", "OBSERVATION_MODIFIER", 36, 44], ["lung", "ANATOMY", 45, 49], ["cancer", "OBSERVATION", 50, 56], ["serious", "OBSERVATION_MODIFIER", 72, 79], ["infection", "OBSERVATION", 80, 89], ["may be", "UNCERTAINTY", 103, 109], ["immunocompromised", "OBSERVATION", 110, 127], ["concomitant", "OBSERVATION_MODIFIER", 175, 186], ["lung", "ANATOMY", 187, 191], ["disease", "OBSERVATION", 192, 199], ["ischemic", "OBSERVATION_MODIFIER", 203, 211], ["heart", "ANATOMY", 212, 217], ["disease", "OBSERVATION", 218, 225]]], ["As with other immunocompromised patients, if visits by lung cancer patients to outpatient services cannot be avoided, the following measures must be taken:General considerations and measuresdouble-barrier protection: when patients enter the unit, they must be given a surgical mask which they must wear throughout their stay.General considerations and measureshealthcare personnel must wear a surgical mask throughout the day (1 mask/4 hours).General considerations and measureshealthcare personnel must repeatedly disinfect their hands using an alcoholbased solution.", [["lung cancer", "ANATOMY", 55, 66], ["lung cancer", "DISEASE", 55, 66], ["patients", "ORGANISM", 32, 40], ["lung cancer", "CANCER", 55, 66], ["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 222, 230], ["patients", "SPECIES", 32, 40], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 222, 230], ["lung cancer", "PROBLEM", 55, 66], ["measuresdouble-barrier protection", "TREATMENT", 182, 215], ["a surgical mask", "TREATMENT", 266, 281], ["a surgical mask", "TREATMENT", 391, 406], ["measureshealthcare personnel", "TREATMENT", 470, 498], ["an alcoholbased solution", "TREATMENT", 543, 567], ["lung", "ANATOMY", 55, 59], ["cancer", "OBSERVATION", 60, 66]]], ["The diaphragms of stethoscopes and sensors of pulse oxymeters must also be disinfected using an alcohol-based solution or alcohol wipes.General considerations and measuresThe patient's healthcare wishes must be discussed with the patient and recorded in the medical file.Patients with non-small cell lung cancer in the surgical phase of careThese patients receive curative treatment.", [["diaphragms", "ANATOMY", 4, 14], ["non-small cell lung cancer", "ANATOMY", 285, 311], ["alcohol", "CHEMICAL", 96, 103], ["alcohol", "CHEMICAL", 122, 129], ["non-small cell lung cancer", "DISEASE", 285, 311], ["alcohol", "CHEMICAL", 96, 103], ["alcohol", "CHEMICAL", 122, 129], ["diaphragms", "MULTI-TISSUE_STRUCTURE", 4, 14], ["alcohol", "SIMPLE_CHEMICAL", 96, 103], ["alcohol", "SIMPLE_CHEMICAL", 122, 129], ["patient", "ORGANISM", 175, 182], ["patient", "ORGANISM", 230, 237], ["Patients", "ORGANISM", 271, 279], ["non-small cell lung cancer", "CANCER", 285, 311], ["patients", "ORGANISM", 347, 355], ["patient", "SPECIES", 175, 182], ["patient", "SPECIES", 230, 237], ["Patients", "SPECIES", 271, 279], ["patients", "SPECIES", 347, 355], ["stethoscopes", "TREATMENT", 18, 30], ["sensors of pulse oxymeters", "TREATMENT", 35, 61], ["an alcohol-based solution", "TREATMENT", 93, 118], ["non-small cell lung cancer", "PROBLEM", 285, 311], ["curative treatment", "TREATMENT", 364, 382], ["diaphragms", "ANATOMY", 4, 14], ["non-small cell", "OBSERVATION", 285, 299], ["lung", "ANATOMY", 300, 304], ["cancer", "OBSERVATION", 305, 311], ["surgical phase", "OBSERVATION_MODIFIER", 319, 333]]], ["Their survival rate is more than 50% at 5 years [1] . proposed that surgical resection be postponed for stage I and even some stage II N0 tumors, either by putting surgery off (for up to 6 weeks) or by offering stereotactic radiotherapy as a treatment alternative with a reduced number of sessions (1 to 3) to limit the number of visits patients need to make.", [["stage II N0 tumors", "ANATOMY", 126, 144], ["tumors", "DISEASE", 138, 144], ["stage II N0 tumors", "CANCER", 126, 144], ["patients", "ORGANISM", 337, 345], ["patients", "SPECIES", 337, 345], ["survival rate", "TEST", 6, 19], ["surgical resection", "TREATMENT", 68, 86], ["stage I", "PROBLEM", 104, 111], ["some stage II N0 tumors", "PROBLEM", 121, 144], ["surgery", "TREATMENT", 164, 171], ["stereotactic radiotherapy", "TREATMENT", 211, 236], ["a treatment alternative", "TREATMENT", 240, 263], ["surgical resection", "OBSERVATION", 68, 86], ["stage II", "OBSERVATION_MODIFIER", 126, 134], ["N0", "OBSERVATION_MODIFIER", 135, 137], ["tumors", "OBSERVATION", 138, 144]]], ["This will depend on the limited availability of this technique during the lockdown period.", [["this technique", "TREATMENT", 48, 62]]], ["We suggest that bronchoscopy not be performed in patients whose surgery is postponed as outlined above.", [["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["bronchoscopy", "TREATMENT", 16, 28], ["surgery", "TREATMENT", 64, 71]]], ["Finally, for patients about to undergo surgery, a systematic screening for COVID by viral PCR and a systematic chest CT scan are discussed in order to avoid operating on asymptomatic COVID patients.Postoperative radiotherapyPatients currently undergoing treatment will finish their course.", [["COVID", "DISEASE", 183, 188], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 189, 197], ["surgery", "TREATMENT", 39, 46], ["a systematic screening", "TEST", 48, 70], ["viral PCR", "TEST", 84, 93], ["a systematic chest CT scan", "TEST", 98, 124], ["asymptomatic COVID patients", "TREATMENT", 170, 197], ["Postoperative radiotherapyPatients", "TREATMENT", 198, 232], ["treatment", "TREATMENT", 254, 263], ["chest", "ANATOMY", 111, 116]]], ["Given the uncertainty surrounding the utility of radiotherapy in this setting, no new patient is to begin adjuvant radiation treatment for pN2 disease.Patients with locally advanced non-small cell lung cancer undergoing chemoradiotherapyThese patients receive curative treatment.", [["non-small cell lung cancer", "ANATOMY", 182, 208], ["non-small cell lung cancer", "DISEASE", 182, 208], ["patient", "ORGANISM", 86, 93], ["Patients", "ORGANISM", 151, 159], ["non-small cell lung cancer", "CANCER", 182, 208], ["patients", "ORGANISM", 243, 251], ["patient", "SPECIES", 86, 93], ["Patients", "SPECIES", 151, 159], ["patients", "SPECIES", 243, 251], ["radiotherapy", "TREATMENT", 49, 61], ["adjuvant radiation treatment", "TREATMENT", 106, 134], ["pN2 disease", "PROBLEM", 139, 150], ["locally advanced non-small cell lung cancer", "PROBLEM", 165, 208], ["chemoradiotherapy", "TREATMENT", 220, 237], ["curative treatment", "TREATMENT", 260, 278], ["locally", "OBSERVATION_MODIFIER", 165, 172], ["advanced", "OBSERVATION_MODIFIER", 173, 181], ["non-small cell", "OBSERVATION", 182, 196], ["lung", "ANATOMY", 197, 201], ["cancer", "OBSERVATION", 202, 208], ["chemoradiotherapy", "OBSERVATION", 220, 237]]], ["Their survival rate is more than 50% at 3 or even 5 years [2] .", [["Their survival rate", "TEST", 0, 19]]], ["These patients are known to be more at risk of developing severe respiratory complications requiring critical care.", [["respiratory", "ANATOMY", 65, 76], ["respiratory complications", "DISEASE", 65, 90], ["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["developing severe respiratory complications", "PROBLEM", 47, 90], ["critical care", "TREATMENT", 101, 114], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["respiratory complications", "OBSERVATION", 65, 90]]], ["Patients currently undergoing treatment will finish their course.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["treatment", "TREATMENT", 30, 39]]], ["For patients currently undergoing chemotherapy, carboplatin is preferable to cisplatin since it is faster to administer and has lower toxicity.", [["carboplatin", "CHEMICAL", 48, 59], ["cisplatin", "CHEMICAL", 77, 86], ["toxicity", "DISEASE", 134, 142], ["carboplatin", "CHEMICAL", 48, 59], ["cisplatin", "CHEMICAL", 77, 86], ["patients", "ORGANISM", 4, 12], ["carboplatin", "SIMPLE_CHEMICAL", 48, 59], ["cisplatin", "SIMPLE_CHEMICAL", 77, 86], ["patients", "SPECIES", 4, 12], ["chemotherapy", "TREATMENT", 34, 46], ["carboplatin", "TREATMENT", 48, 59], ["cisplatin", "TREATMENT", 77, 86], ["lower toxicity", "PROBLEM", 128, 142]]], ["Regarding patients currently on durvalumab, the proposal being considered is 1/ double the dose to 1500mg once every 4 weeks or 2/ space administration out to once every 4 weeks.", [["durvalumab", "CHEMICAL", 32, 42], ["durvalumab", "CHEMICAL", 32, 42], ["patients", "ORGANISM", 10, 18], ["durvalumab", "SIMPLE_CHEMICAL", 32, 42], ["patients", "SPECIES", 10, 18], ["durvalumab", "TREATMENT", 32, 42]]], ["Initiating treatment in new patients must be discussed in MDT meetings.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["treatment", "TREATMENT", 11, 20]]], ["Since consolidation with durvalumab offers significant survival benefit, treatment must be administered if reasonable safety conditions can be met.Oncogenic alterationsThese patients receive palliative care.", [["durvalumab", "CHEMICAL", 25, 35], ["durvalumab", "CHEMICAL", 25, 35], ["durvalumab", "SIMPLE_CHEMICAL", 25, 35], ["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182], ["consolidation", "PROBLEM", 6, 19], ["durvalumab", "TREATMENT", 25, 35], ["treatment", "TREATMENT", 73, 82], ["Oncogenic alterations", "PROBLEM", 147, 168], ["palliative care", "TREATMENT", 191, 206], ["consolidation", "OBSERVATION", 6, 19]]], ["Their survival rate is more than 50% at 3 or even 5 or 7 years [3] .", [["survival rate", "TEST", 6, 19]]], ["The general plan is to continue any targeted therapy currently being Some of these treatments may have cytopenic effects.", [["any targeted therapy", "TREATMENT", 32, 52], ["these treatments", "TREATMENT", 77, 93], ["cytopenic effects", "PROBLEM", 103, 120]]], ["Care must be taken to monitor CBCs, particularly regarding neutropenia.No oncogenic alterations: first-lineThese patients are known to be more at risk of developing severe respiratory complications requiring critical care.", [["respiratory", "ANATOMY", 172, 183], ["neutropenia", "DISEASE", 59, 70], ["respiratory complications", "DISEASE", 172, 197], ["patients", "ORGANISM", 113, 121], ["patients", "SPECIES", 113, 121], ["CBCs", "TEST", 30, 34], ["neutropenia", "PROBLEM", 59, 70], ["oncogenic alterations", "PROBLEM", 74, 95], ["first-line", "TREATMENT", 97, 107], ["developing severe respiratory complications", "PROBLEM", 154, 197], ["critical care", "TREATMENT", 208, 221], ["oncogenic", "OBSERVATION_MODIFIER", 74, 83], ["alterations", "OBSERVATION", 84, 95], ["severe", "OBSERVATION_MODIFIER", 165, 171], ["respiratory complications", "OBSERVATION", 172, 197]]], ["These patients receive palliative care.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["palliative care", "TREATMENT", 23, 38]]], ["Their survival rate is around 50% at 2 years [4] .No oncogenic alterations: first-lineFor patients who are currently receiving treatment:No oncogenic alterations: first-line-Induction immunotherapy +/-chemotherapy: patients currently receiving treatment finish their course up to 4 cycles.No oncogenic alterations: first-line-Maintenance chemotherapy: the risk-benefit ratio will be assessed case-bycase so that we can propose either spacing out or discontinuing maintenance therapy.No oncogenic alterations: first-line-Pembrolizumab immunotherapy: it is proposed 1/ that administration be halted in responders who have been on treatment for more than 1 year, and 2/ that the dose of Pembrolizumab be doubled to 400mg once every 6 weeks after the initial assessment in patients with controlled disease who are in their first year of treatment.No oncogenic alterations: first-lineThe administration interval of immunotherapy may be doubled and the dose administered at each treatment doubled or space administration out to once every 6No oncogenic alterations: first-lineweeks.", [["Pembrolizumab", "CHEMICAL", 520, 533], ["Pembrolizumab", "CHEMICAL", 684, 697], ["Pembrolizumab", "CHEMICAL", 520, 533], ["Pembrolizumab", "CHEMICAL", 684, 697], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 215, 223], ["Pembrolizumab", "SIMPLE_CHEMICAL", 520, 533], ["Pembrolizumab", "SIMPLE_CHEMICAL", 684, 697], ["patients", "ORGANISM", 769, 777], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 215, 223], ["patients", "SPECIES", 769, 777], ["survival rate", "TEST", 6, 19], ["oncogenic alterations", "PROBLEM", 53, 74], ["treatment", "TREATMENT", 127, 136], ["oncogenic alterations", "PROBLEM", 140, 161], ["first-line", "TREATMENT", 163, 173], ["Induction immunotherapy", "TREATMENT", 174, 197], ["chemotherapy", "TREATMENT", 201, 213], ["treatment", "TREATMENT", 244, 253], ["oncogenic alterations", "PROBLEM", 292, 313], ["first-line", "TREATMENT", 315, 325], ["Maintenance chemotherapy", "TREATMENT", 326, 350], ["maintenance therapy", "TREATMENT", 463, 482], ["oncogenic alterations", "PROBLEM", 486, 507], ["first-line", "TREATMENT", 509, 519], ["Pembrolizumab immunotherapy", "TREATMENT", 520, 547], ["treatment", "TREATMENT", 628, 637], ["Pembrolizumab", "TREATMENT", 684, 697], ["the initial assessment", "TEST", 743, 765], ["controlled disease", "PROBLEM", 783, 801], ["treatment", "TREATMENT", 833, 842], ["oncogenic alterations", "PROBLEM", 846, 867], ["first-line", "TREATMENT", 869, 879], ["The administration interval of immunotherapy", "TREATMENT", 879, 923], ["space administration", "TREATMENT", 994, 1014], ["oncogenic", "OBSERVATION_MODIFIER", 292, 301], ["alterations", "OBSERVATION", 302, 313], ["oncogenic", "OBSERVATION_MODIFIER", 486, 495], ["alterations", "OBSERVATION", 496, 507], ["oncogenic", "OBSERVATION_MODIFIER", 846, 855], ["alterations", "OBSERVATION", 856, 867]]], ["If an initial assessment after 2 months of treatment confirms a response or tumor control, assessments need only be performed once every 4 months.", [["tumor", "ANATOMY", 76, 81], ["tumor", "DISEASE", 76, 81], ["tumor", "CANCER", 76, 81], ["an initial assessment", "TEST", 3, 24], ["treatment", "TREATMENT", 43, 52], ["tumor control", "TREATMENT", 76, 89], ["assessments", "TEST", 91, 102], ["tumor", "OBSERVATION", 76, 81]]], ["However, J o u r n a l P r e -p r o o f 9 a remote consultation and lab tests must be conducted every month.", [["a remote consultation", "TEST", 42, 63], ["lab tests", "TEST", 68, 77]]], ["Any sign of toxicity, such as colitis or lung disease, requires the patient to be called in and hospitalized.No oncogenic alterations: first-lineInitiating treatment in new patients must be discussed in MDT meetings.No oncogenic alterations: second and subsequent linesThese patients are known to be more at risk of developing severe respiratory complications requiring critical care.", [["lung", "ANATOMY", 41, 45], ["respiratory", "ANATOMY", 334, 345], ["toxicity", "DISEASE", 12, 20], ["colitis", "DISEASE", 30, 37], ["lung disease", "DISEASE", 41, 53], ["respiratory complications", "DISEASE", 334, 359], ["colitis", "PATHOLOGICAL_FORMATION", 30, 37], ["lung", "ORGAN", 41, 45], ["patient", "ORGANISM", 68, 75], ["patients", "ORGANISM", 173, 181], ["patients", "ORGANISM", 275, 283], ["patient", "SPECIES", 68, 75], ["patients", "SPECIES", 173, 181], ["patients", "SPECIES", 275, 283], ["toxicity", "PROBLEM", 12, 20], ["colitis", "PROBLEM", 30, 37], ["lung disease", "PROBLEM", 41, 53], ["oncogenic alterations", "PROBLEM", 112, 133], ["first-line", "TREATMENT", 135, 145], ["treatment", "TREATMENT", 156, 165], ["oncogenic alterations", "PROBLEM", 219, 240], ["second and subsequent lines", "TREATMENT", 242, 269], ["developing severe respiratory complications", "PROBLEM", 316, 359], ["critical care", "TREATMENT", 370, 383], ["sign of", "UNCERTAINTY", 4, 11], ["toxicity", "OBSERVATION", 12, 20], ["colitis", "OBSERVATION", 30, 37], ["lung", "ANATOMY", 41, 45], ["disease", "OBSERVATION", 46, 53], ["oncogenic", "OBSERVATION_MODIFIER", 112, 121], ["alterations", "OBSERVATION", 122, 133], ["oncogenic", "OBSERVATION_MODIFIER", 219, 228], ["alterations", "OBSERVATION", 229, 240], ["severe", "OBSERVATION_MODIFIER", 327, 333], ["respiratory complications", "OBSERVATION", 334, 359]]], ["These patients receive palliative care.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["palliative care", "TREATMENT", 23, 38]]], ["Their median survival is around 1 year [5] .No oncogenic alterations: second and subsequent linesFor patients who are currently receiving treatment:No oncogenic alterations: second and subsequent lines-Chemotherapy: discuss the appropriateness of continuing treatment.No oncogenic alterations: second and subsequent lines-Immunotherapy: it is proposed 1/ that administration be halted in responders who have been on treatment for more than 1 year, and 2/ that doses be doubled in patients with stable disease who are in their first year of treatment: Nivolumab to 480mg every 4 weeks, and Pembrolizumab to 400mg every 6 weeks after initial assessment.", [["Nivolumab", "CHEMICAL", 551, 560], ["Pembrolizumab", "CHEMICAL", 589, 602], ["patients", "ORGANISM", 101, 109], ["patients", "ORGANISM", 480, 488], ["Nivolumab", "SIMPLE_CHEMICAL", 551, 560], ["Pembrolizumab", "SIMPLE_CHEMICAL", 589, 602], ["patients", "SPECIES", 101, 109], ["patients", "SPECIES", 480, 488], ["oncogenic alterations", "PROBLEM", 47, 68], ["treatment", "TREATMENT", 138, 147], ["oncogenic alterations", "PROBLEM", 151, 172], ["second and subsequent lines", "TREATMENT", 174, 201], ["Chemotherapy", "TREATMENT", 202, 214], ["continuing treatment", "TREATMENT", 247, 267], ["oncogenic alterations", "PROBLEM", 271, 292], ["second and subsequent lines", "TREATMENT", 294, 321], ["Immunotherapy", "TREATMENT", 322, 335], ["treatment", "TREATMENT", 416, 425], ["Nivolumab", "TREATMENT", 551, 560], ["Pembrolizumab", "TREATMENT", 589, 602], ["initial assessment", "TEST", 632, 650], ["oncogenic", "OBSERVATION_MODIFIER", 47, 56], ["alterations", "OBSERVATION", 57, 68], ["oncogenic", "OBSERVATION_MODIFIER", 271, 280], ["alterations", "OBSERVATION", 281, 292]]], ["Atezolizumab could be administered at 1200mg every 4 (unstead of 3)No oncogenic alterations: second and subsequent linesweeks [6] .Initiating further lines of treatment must be discussed in MDT meetings.Patients with small cell lung cancerThese patients are known to be more at risk of developing severe respiratory complications requiring critical care.", [["small cell lung cancer", "ANATOMY", 217, 239], ["respiratory", "ANATOMY", 304, 315], ["Atezolizumab", "CHEMICAL", 0, 12], ["small cell lung cancer", "DISEASE", 217, 239], ["respiratory complications", "DISEASE", 304, 329], ["Atezolizumab", "CHEMICAL", 0, 12], ["Atezolizumab", "SIMPLE_CHEMICAL", 0, 12], ["Patients", "ORGANISM", 203, 211], ["small cell lung cancer", "CANCER", 217, 239], ["patients", "ORGANISM", 245, 253], ["Patients", "SPECIES", 203, 211], ["patients", "SPECIES", 245, 253], ["Atezolizumab", "TREATMENT", 0, 12], ["oncogenic alterations", "PROBLEM", 70, 91], ["further lines of treatment", "TREATMENT", 142, 168], ["small cell lung cancer", "PROBLEM", 217, 239], ["developing severe respiratory complications", "PROBLEM", 286, 329], ["critical care", "TREATMENT", 340, 353], ["small", "OBSERVATION_MODIFIER", 217, 222], ["cell", "OBSERVATION", 223, 227], ["lung", "ANATOMY", 228, 232], ["cancer", "OBSERVATION", 233, 239], ["severe", "OBSERVATION_MODIFIER", 297, 303], ["respiratory complications", "OBSERVATION", 304, 329]]], ["These patients receive palliative care.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["palliative care", "TREATMENT", 23, 38]]], ["Their median survival is around 1 year [8] .Patients with small cell lung cancerFirst-line and ongoing treatments must be continued.", [["small cell lung cancerFirst-line", "ANATOMY", 58, 90], ["Patients", "ORGANISM", 44, 52], ["small cell lung cancerFirst-line", "CELL", 58, 90], ["Patients", "SPECIES", 44, 52], ["small cell lung cancerFirst-line", "TREATMENT", 58, 90], ["ongoing treatments", "TREATMENT", 95, 113], ["small", "OBSERVATION_MODIFIER", 58, 63], ["cell", "OBSERVATION", 64, 68], ["lung", "ANATOMY", 69, 73], ["cancerFirst", "OBSERVATION", 74, 85], ["line", "OBSERVATION_MODIFIER", 86, 90]]], ["Initiating treatment in new patients must be discussed in MDT meetings.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["treatment", "TREATMENT", 11, 20]]], ["Second-line and ongoing treatments must be continued.", [["Second-line", "TREATMENT", 0, 11], ["ongoing treatments", "TREATMENT", 16, 34], ["line", "OBSERVATION", 7, 11]]], ["Initiating further lines of treatment must be discussed in MDT meetings.", [["further lines of treatment", "TREATMENT", 11, 37]]], ["Atezolizumab must be offered according to the recommendations in the current extended Temporary Authorization for Use, particularly regarding PS criteria.Patients with small cell lung cancerHowever, Atezolizumab could be administered at 1200mg every 4 (unstead of 3)Patients with small cell lung cancerweeks [6] .", [["small cell lung", "ANATOMY", 168, 183], ["small cell lung cancerweeks", "ANATOMY", 280, 307], ["Atezolizumab", "CHEMICAL", 0, 12], ["Atezolizumab", "CHEMICAL", 199, 211], ["Atezolizumab", "CHEMICAL", 0, 12], ["Atezolizumab", "CHEMICAL", 199, 211], ["Atezolizumab", "SIMPLE_CHEMICAL", 0, 12], ["Patients", "ORGANISM", 154, 162], ["small cell lung", "CANCER", 168, 183], ["Atezolizumab", "SIMPLE_CHEMICAL", 199, 211], ["Patients", "ORGANISM", 266, 274], ["small cell lung", "CANCER", 280, 295], ["Patients", "SPECIES", 154, 162], ["Patients", "SPECIES", 266, 274], ["Atezolizumab", "TREATMENT", 0, 12], ["small cell lung cancerHowever", "PROBLEM", 168, 197], ["Atezolizumab", "TREATMENT", 199, 211], ["small cell lung cancerweeks", "PROBLEM", 280, 307], ["small", "OBSERVATION_MODIFIER", 168, 173], ["cell", "OBSERVATION", 174, 178], ["lung", "ANATOMY", 179, 183], ["cancerHowever", "OBSERVATION", 184, 197], ["small cell", "OBSERVATION", 280, 290], ["lung", "ANATOMY", 291, 295]]], ["More recently, Durvalumab also obtained its Temporary Authorization for Use in this indication.Patients with small cell lung cancerCarboplatin is preferable to cisplatin since it is faster to administer and has lower toxicity.", [["small cell lung", "ANATOMY", 109, 124], ["cisplatin", "CHEMICAL", 160, 169], ["toxicity", "DISEASE", 217, 225], ["Durvalumab", "CHEMICAL", 15, 25], ["cisplatin", "CHEMICAL", 160, 169], ["Durvalumab", "SIMPLE_CHEMICAL", 15, 25], ["Patients", "ORGANISM", 95, 103], ["small cell lung cancerCarboplatin", "CANCER", 109, 142], ["cisplatin", "SIMPLE_CHEMICAL", 160, 169], ["Patients", "SPECIES", 95, 103], ["small cell lung cancerCarboplatin", "PROBLEM", 109, 142], ["cisplatin", "TREATMENT", 160, 169], ["lower toxicity", "PROBLEM", 211, 225], ["small", "OBSERVATION_MODIFIER", 109, 114], ["cell", "OBSERVATION", 115, 119], ["lung", "ANATOMY", 120, 124], ["cancerCarboplatin", "OBSERVATION", 125, 142], ["lower", "OBSERVATION_MODIFIER", 211, 216], ["toxicity", "OBSERVATION", 217, 225]]], ["G-CSF growth factors must be administered in all cases.Patients with small cell lung cancerJ o u r n a l P r e -p r o o f 11Patients with mesotheliomaThese patients are known to be more at risk of developing severe respiratory complications requiring critical care.", [["small cell lung", "ANATOMY", 69, 84], ["mesothelioma", "ANATOMY", 138, 150], ["respiratory", "ANATOMY", 215, 226], ["mesothelioma", "DISEASE", 138, 150], ["respiratory complications", "DISEASE", 215, 240], ["G-CSF growth factors", "GENE_OR_GENE_PRODUCT", 0, 20], ["Patients", "ORGANISM", 55, 63], ["mesothelioma", "CANCER", 138, 150], ["patients", "ORGANISM", 156, 164], ["G-CSF growth factors", "PROTEIN", 0, 20], ["Patients", "SPECIES", 55, 63], ["patients", "SPECIES", 156, 164], ["CSF growth factors", "PROBLEM", 2, 20], ["small cell lung cancerJ", "PROBLEM", 69, 92], ["mesothelioma", "PROBLEM", 138, 150], ["developing severe respiratory complications", "PROBLEM", 197, 240], ["critical care", "TREATMENT", 251, 264], ["small cell", "OBSERVATION", 69, 79], ["lung", "ANATOMY", 80, 84], ["cancerJ", "OBSERVATION", 85, 92], ["mesothelioma", "OBSERVATION", 138, 150], ["severe", "OBSERVATION_MODIFIER", 208, 214], ["respiratory complications", "OBSERVATION", 215, 240]]], ["These patients receive palliative care.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["palliative care", "TREATMENT", 23, 38]]], ["Their median survival is between 15 and 18 months [9] .Patients with mesotheliomaFirst-line and ongoing treatments must be continued.", [["Patients", "ORGANISM", 55, 63], ["Patients", "SPECIES", 55, 63], ["mesotheliomaFirst-line", "TREATMENT", 69, 91], ["ongoing treatments", "TREATMENT", 96, 114], ["line", "OBSERVATION", 87, 91]]], ["Initiating treatment in new patients must be discussed in MDT meetings.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["treatment", "TREATMENT", 11, 20]]], ["Ongoing second-line treatments must be continued.", [["Ongoing second-line treatments", "TREATMENT", 0, 30], ["line treatments", "OBSERVATION", 15, 30]]], ["Initiating further lines of treatment must be discussed in MDT meetings.Patients with mesotheliomaImmunotherapy: it is proposed 1/ that administration be halted in responders who have been on treatment for more than 1 year, and 2/ that doses be doubled after the initial assessment in patients in their first year of treatment (Nivolumab to 480mg every 4 weeks).", [["mesotheliomaImmunotherapy", "DISEASE", 86, 111], ["Nivolumab", "CHEMICAL", 328, 337], ["Patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 285, 293], ["Patients", "SPECIES", 72, 80], ["patients", "SPECIES", 285, 293], ["further lines of treatment", "TREATMENT", 11, 37], ["mesotheliomaImmunotherapy", "TREATMENT", 86, 111], ["treatment", "TREATMENT", 192, 201], ["the initial assessment", "TEST", 259, 281], ["treatment", "TREATMENT", 317, 326], ["Nivolumab", "TREATMENT", 328, 337]]], ["Bevacizumab maintenance therapy may be halted.Patient with thymic malignanciesThese patients are known to be more at risk of developing severe respiratory complications requiring critical care, particularly in cases of concomitant myasthenia gravis.Patient with thymic malignanciesComplex situations should be discussed with the coordinating physician from the RYTHMIC thymic malignancy network.", [["thymic malignancies", "ANATOMY", 59, 78], ["respiratory", "ANATOMY", 143, 154], ["thymic malignancies", "ANATOMY", 262, 281], ["thymic malignancy network", "ANATOMY", 369, 394], ["Bevacizumab", "CHEMICAL", 0, 11], ["thymic malignancies", "DISEASE", 59, 78], ["respiratory complications", "DISEASE", 143, 168], ["myasthenia gravis", "DISEASE", 231, 248], ["thymic malignancies", "DISEASE", 262, 281], ["malignancy", "DISEASE", 376, 386], ["Bevacizumab", "CHEMICAL", 0, 11], ["Bevacizumab", "SIMPLE_CHEMICAL", 0, 11], ["thymic malignancies", "CANCER", 59, 78], ["patients", "ORGANISM", 84, 92], ["thymic malignancies", "CANCER", 262, 281], ["thymic malignancy network", "MULTI-TISSUE_STRUCTURE", 369, 394], ["Patient", "SPECIES", 46, 53], ["patients", "SPECIES", 84, 92], ["Patient", "SPECIES", 249, 256], ["Bevacizumab maintenance therapy", "TREATMENT", 0, 31], ["thymic malignancies", "PROBLEM", 59, 78], ["severe respiratory complications", "PROBLEM", 136, 168], ["critical care", "TREATMENT", 179, 192], ["concomitant myasthenia gravis", "PROBLEM", 219, 248], ["thymic malignanciesComplex situations", "PROBLEM", 262, 299], ["thymic", "ANATOMY", 59, 65], ["malignancies", "OBSERVATION", 66, 78], ["severe", "OBSERVATION_MODIFIER", 136, 142], ["respiratory complications", "OBSERVATION", 143, 168], ["myasthenia gravis", "OBSERVATION", 231, 248], ["thymic", "ANATOMY", 262, 268], ["malignancies", "OBSERVATION", 269, 281], ["thymic", "ANATOMY", 369, 375], ["malignancy", "OBSERVATION", 376, 386]]], ["The discussion should focus on the size of the tumor, histological type and general health of the patient.", [["tumor", "ANATOMY", 47, 52], ["tumor", "DISEASE", 47, 52], ["tumor", "CANCER", 47, 52], ["patient", "ORGANISM", 98, 105], ["patient", "SPECIES", 98, 105], ["the tumor", "PROBLEM", 43, 52], ["size", "OBSERVATION_MODIFIER", 35, 39], ["tumor", "OBSERVATION", 47, 52]]], ["Another proposal is to postpone surgical resection of stage I and stage II tumors.", [["stage II tumors", "ANATOMY", 66, 81], ["tumors", "DISEASE", 75, 81], ["stage II tumors", "CANCER", 66, 81], ["surgical resection", "TREATMENT", 32, 50], ["stage I", "PROBLEM", 54, 61], ["stage II tumors", "PROBLEM", 66, 81], ["resection", "OBSERVATION", 41, 50], ["stage I", "OBSERVATION_MODIFIER", 54, 61], ["stage II", "OBSERVATION_MODIFIER", 66, 74], ["tumors", "OBSERVATION", 75, 81]]], ["Ongoing first-line treatments must be continued.", [["Ongoing first-line treatments", "TREATMENT", 0, 29], ["line treatments", "OBSERVATION", 14, 29]]], ["Initiating treatment in new patients must be discussed in MDT meetings.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["treatment", "TREATMENT", 11, 20]]], ["Ongoing second-line treatments must be continued.", [["Ongoing second-line treatments", "TREATMENT", 0, 30], ["line treatments", "OBSERVATION", 15, 30]]], ["Initiating further lines of treatment must be discussed in MDT meetings.Patients in clinical trialsSituation should be examined case-by-case depending on the study and type of patients involved.", [["Patients", "ORGANISM", 72, 80], ["patients", "ORGANISM", 176, 184], ["Patients", "SPECIES", 72, 80], ["patients", "SPECIES", 176, 184], ["further lines of treatment", "TREATMENT", 11, 37], ["the study", "TEST", 154, 163]]], ["A clear benefit and rare settings with no treatment alternatives must be prioritized.", [["rare settings", "TREATMENT", 20, 33], ["treatment alternatives", "TREATMENT", 42, 64], ["clear", "OBSERVATION", 2, 7]]], ["Special attention should be paid to trials in neoadjuvant settings or involving chemoradiotherapy in which access to surgery or radiotherapy on a particular date is not guaranteed.", [["neoadjuvant settings", "TREATMENT", 46, 66], ["chemoradiotherapy", "TREATMENT", 80, 97], ["surgery", "TREATMENT", 117, 124], ["radiotherapy", "TREATMENT", 128, 140]]]]}